right
ventricular
rv
dysfunct
strongli
independ
predict
outcom
peopl
myxomat
mitral
valv
diseas
mmvd
purpos
prospect
pilot
studi
assess
rv
systol
function
rvsf
dog
differ
stage
mmvd
hypothes
rvsf
would
differ
among
stage
diseas
decreas
decompens
mmvd
clientown
dog
mmvd
previous
receiv
cardiovascular
medic
without
moderateorsever
pulmonari
hypertens
elig
enrol
dog
present
acut
congest
heart
failur
receiv
singl
dose
furosemid
prior
echocardiographi
five
valid
indic
rvsf
measur
tricuspid
annular
plane
systol
excurs
taps
fraction
area
chang
later
tricuspid
annular
longitudin
peak
systol
veloc
longitudin
global
strain
strain
strain
rate
rv
free
wall
group
compar
use
oneway
anova
sidak
test
frequenc
case
cardiac
remodel
fall
outsid
previouslyestablish
refer
interv
compar
use
fisher
exact
test
thirtyf
dog
stage
mmvd
recruit
base
statist
power
analysi
n
n
c
n
dog
stage
higher
valu
taps
strain
p
compar
stage
taps
compar
stage
c
p
taps
exceed
refer
limit
dog
compar
stage
c
p
studi
indic
compens
mmvd
remodel
associ
hyperdynam
rvsf
cardiac
decompens
taps
strain
often
normal
result
demonstr
rvsf
differ
across
stage
mmvd
aim
evalu
safeti
efficaci
highpressur
balloon
valvuloplasti
hpbvp
treatment
canin
pulmon
stenosi
twentyf
dog
sever
valvular
ps
echocardiographicallyderiv
transpulmon
peakmaximum
pressur
gradient
edpg
mmhg
recruit
patient
underw
complet
echocardiographi
hour
balloon
valvuloplasti
bvp
perform
use
highpressur
balloon
atla
gold
pta
dilat
cathet
rate
burst
pressur
rang
mmhg
balloon
size
mm
cm
length
pulmon
valv
annulu
diamet
multipli
mean
size
factor
ae
determin
balloon
size
procedur
success
defin
posthpbvp
edpg
reduct
least
reduct
least
moder
categori
ps
mmhg
optim
result
defin
postprocedur
edpg
mmhg
initi
median
iqr
edpg
dog
mmhg
postop
median
mmhg
hpbvp
produc
median
pressur
gradient
reduct
procedur
success
rate
dog
optim
result
achiev
dog
signific
correl
pressur
gradient
reduct
valv
morpholog
type
type
ii
sever
right
ventricular
hypertrophi
pulmon
valv
annulu
diamet
test
variabl
significantli
correl
pressur
gradient
reduct
p
patient
experienc
suicid
right
ventricl
patient
surviv
procedur
find
suggest
hpbvp
appeal
treatment
option
routin
case
sever
ps
consid
procedur
success
rate
high
number
optim
result
studi
compar
hpbvp
tradit
bvp
warrant
purpos
studi
determin
beattobeat
pattern
judg
geometr
heart
rate
variabl
hrv
compat
hypothesi
impuls
exit
block
mechan
sinu
node
dysfunct
snd
dog
twentyfour
dog
snd
ages
match
control
dog
studi
geometr
hrv
assess
use
poincar
e
plot
tachogram
holter
record
autonom
tone
assess
use
time
frequenc
domain
hrv
comput
model
design
assess
beattobeat
behavior
input
includ
sinusoid
oscil
vagal
tone
period
respir
slowli
vari
compon
sleepwak
cycl
randomli
vari
nois
oscil
sinu
node
variat
depend
vagal
tone
random
compon
base
previou
exit
block
probabl
exit
block
threshold
depend
vagal
tone
snd
dog
higher
indic
hrv
control
dog
contrast
control
dog
record
snd
dog
show
beattobeat
cluster
approxim
multipl
depend
input
control
snd
dog
beattobeat
pattern
could
mimick
model
comput
model
verifi
pattern
repres
exit
block
frame
b
c
snd
dog
poincar
e
plot
fail
reveal
inher
sinu
node
rate
bpm
control
dog
instead
shortest
interv
faster
bpm
multipl
bifurc
rate
slow
beattobeat
pattern
snd
dog
consist
block
sinu
node
support
hypothesi
impuls
block
exit
pathway
sinu
node
myocardium
place
rna
later
frozen
batch
analysi
rest
heart
formalinfix
histopatholog
rna
extract
gexp
express
profil
softwar
use
design
primer
multiplex
qrtpcr
perform
quantifi
thrombomodulin
gene
express
multiplex
result
normal
ribosom
protein
result
express
median
rang
compar
group
use
kruskalw
mann
whitney
test
differ
sex
p
age
group
p
median
age
month
month
normal
cat
month
month
chf
cat
month
month
ate
cat
normal
thrombomodulin
concentr
ate
group
compar
chf
group
normal
group
p
although
signific
differ
thrombomodulin
express
identifi
investig
larger
sampl
size
would
justifi
purpos
studi
use
genomewid
associ
studi
gwa
precis
nuclear
runon
sequenc
proseq
identifi
novel
gene
candid
express
profil
link
dmvd
small
breed
dog
blood
sampl
control
dmvd
clientown
dog
kg
use
gwa
tissu
sampl
anterior
mitral
valv
leaflet
avail
dmvd
control
dog
western
blot
proseq
analysi
dmvd
dog
murmur
mitral
regurgit
associ
leaflet
thicken
andor
prolaps
echocardiographi
control
dog
year
age
murmur
abnorm
echocardiographi
gwa
perform
genom
dna
use
custom
singl
nucleotid
polymorph
snp
genotyp
array
contain
marker
result
analyz
calcul
odd
ratio
p
valu
snp
gene
interest
identifi
overlap
primer
pair
design
incorpor
exon
segment
base
pair
length
polymeras
chain
reaction
pcr
perform
use
touchdown
program
sanger
sequenc
perform
total
sampl
dmvd
control
sequenc
align
perform
use
clustal
omega
softwar
total
control
dmvd
valv
avail
western
blot
analysi
sampl
probe
antibodi
recogn
alphacatenin
betacatenin
isoform
normal
gapdh
signal
proseq
perform
one
control
one
dmvd
valv
order
directli
detect
chang
gene
transcript
express
genomewid
map
rna
polymeras
data
analyz
genom
wide
upordown
regul
use
panther
classif
system
pantherdborg
gene
group
base
biolog
function
gwa
reveal
strongest
associ
signal
chromosom
p
near
gene
code
alphacatenin
fine
map
detect
mutat
within
code
region
gene
howev
western
blot
analysi
reveal
decreas
normal
alphacatenin
level
decreas
betacatenin
isoform
compar
control
sampl
proseq
experi
reveal
clear
signal
regulatori
enhanc
upstream
alphacatenin
near
highest
associ
signal
proseq
data
addit
reveal
genomewid
express
profil
gene
significantli
upordown
regul
p
bonferroni
correct
dmvd
sampl
chang
note
gene
function
wound
heal
regul
muscl
contract
muscl
structur
develop
studi
identifi
candid
gene
code
alphacatenin
essenti
protein
adheren
junction
modul
canon
wnt
pathway
although
mutat
detect
within
code
region
gene
within
upstream
enhanc
western
blot
reveal
decreas
level
alphacatenin
phosphoryl
form
betacatenin
dmvd
valv
preliminari
data
may
support
presenc
mutat
locat
within
noncod
region
control
transcript
investig
warrant
sought
investig
whether
maps
taps
associ
surviv
time
cat
hcm
medic
record
search
cat
diagnos
hcm
echocardiographi
lv
wall
thick
mm
imag
adequ
qualiti
measur
maps
taps
surviv
inform
includ
cat
show
clinic
sign
chf
aortic
thromboembol
concurr
chf
syncop
exert
dyspnoea
maps
taps
measur
anatom
mmode
atrioventricular
annular
level
lv
free
wall
mapsefw
interventricular
septum
mapseiv
right
ventricular
wall
taps
cat
mapsefw
mm
median
surviv
time
mst
day
vs
day
mapsefw
mm
p
cat
mapseiv
mm
mst
day
vs
day
mapseiv
mm
p
cat
taps
mm
mst
day
vs
day
taps
mm
lower
maps
taps
associ
wors
surviv
suggest
systol
longitudin
dysfunct
prognost
valu
cat
hcm
echocardiograph
assess
aortic
root
rotat
dog
congenit
heart
diseas
nr
wyatt
ba
scansen
colorado
state
univers
veterinari
teach
hospit
fort
collin
co
usa
colorado
state
univers
fort
collin
co
usa
rotat
aortic
root
defin
abnorm
posit
aortic
valvar
sinus
rel
surround
cardiac
structur
describ
children
congenit
heart
diseas
dog
children
tetralog
fallot
tof
show
clockwis
aortic
root
rotat
increas
preval
coronari
arteri
anomali
coronari
arteri
anomali
also
common
brachycephal
dog
pulmonari
valv
stenosi
ps
studi
evalu
aortic
root
rotat
dog
normal
heart
ps
subaort
stenosi
sa
tof
aortic
root
rotat
normocephal
compar
brachycephal
ps
dog
also
investig
echocardiogram
retrospect
evalu
normal
n
ps
sa
tof
dog
theta
defin
angl
interatri
septum
commissur
left
coronari
noncoronari
sinus
rho
angl
interatri
septum
commissur
right
coronari
left
coronari
sinus
angl
measur
triplic
accur
assess
left
atrial
la
size
integr
evalu
leftsid
cardiac
diseas
dog
provid
risk
stratif
develop
leftsid
congest
heart
failur
chf
thorac
radiograph
routin
use
subject
assess
presenc
sever
left
atrial
enlarg
lae
primari
aim
studi
assess
interread
agreement
subject
radiograph
lae
reader
differ
level
experi
expertis
second
aim
compar
subject
degre
radiograph
lae
echocardiograph
measur
la
size
retrospect
studi
identifi
dog
underw
thorac
radiograph
echocardiogram
day
oregon
state
univers
veterinari
teach
hospit
thorac
radiograph
view
anonym
review
boardcertifi
cardiologist
boardcertifi
radiologist
small
anim
rotat
intern
radiograph
evalu
presenc
absenc
lae
sever
lae
present
mild
moder
sever
presenc
absenc
predefin
subject
lae
criteria
later
project
includ
elev
left
caudal
mainstem
bronchu
loss
normal
gentl
curvatur
caudal
margin
cardiac
silhouett
straighten
caudodors
margin
cardiac
silhouett
increas
height
caudodors
border
heart
ventrodors
dorsoventr
project
criteria
includ
diverg
splay
princip
bronchi
doubl
opac
sign
oclock
posit
cardiac
silhouett
evid
left
auricular
enlarg
oclock
posit
echocardiograph
la
size
evalu
object
left
atrialtoaort
ratio
la
ao
la
volum
via
monoplan
modifi
simpson
method
disc
mod
la
volum
lav
index
bodi
weight
mlkg
object
measur
la
size
stratifi
categori
normal
la
ao
lav
mild
la
ao
lav
moder
la
ao
lav
sever
enlarg
la
ao
lav
interread
agreement
radiograph
lae
evalu
assess
linearli
weight
kappa
k
intraclass
correl
icc
sensit
se
specif
sp
identifi
vari
degre
echocardiograph
lae
radiograph
assess
use
la
ao
lav
dog
includ
median
weight
kg
rang
kg
median
age
year
old
rang
year
echocardiograph
diagnos
includ
normal
n
chronic
degen
valv
diseas
n
dilat
cardiomyopathi
n
pulmon
stenosi
n
lefttoright
patent
ductu
arteriosu
n
subaort
stenosi
n
singl
case
cardiac
diseas
agreement
presenc
absenc
radiograph
lae
excel
reader
icc
interread
agreement
degre
radiograph
lae
rang
moder
substanti
k
depend
combin
reader
distinct
subject
lae
criteria
interread
agreement
rang
fair
good
icc
strongest
interread
agreement
increas
height
caudodors
heart
margin
splay
mainstem
bronchi
enlarg
left
auricl
agreement
specialist
higher
agreement
reader
individu
criterion
except
elev
left
caudal
mainstem
bronchu
overal
strong
agreement
method
echocardiograph
lae
stratif
agreement
lav
subject
lae
almost
perfect
k
la
ao
moder
agreement
lav
k
agreement
subject
radiograph
lae
object
echocardiograph
lae
moder
vari
slightli
echocardiograph
method
classif
lav
k
la
ao
k
sensit
specif
thorac
radiograph
identifi
lae
slightli
better
use
lav
la
ao
lav
se
sp
la
ao
se
sp
result
studi
confirm
hypothesi
interread
agreement
radiograph
classif
lae
strong
even
across
specialti
disciplin
level
experi
variabl
agreement
reader
applic
distinct
subject
criteria
lae
studi
indic
increas
height
caudodors
heart
margin
splay
mainstem
bronchi
enlarg
left
auricl
consist
criteria
use
cardiologist
radiologist
intern
identifi
lae
subject
radiograph
lae
sever
moder
agreement
echocardiograph
lae
sever
regardless
object
la
size
measur
howev
lav
subject
lae
show
stronger
agreement
la
ao
heartfatti
acid
bind
protein
hfabp
produc
primarili
cardiomyocyt
mainli
respons
fatti
acid
homeostasi
propos
earli
sensit
biomark
human
cardiac
diseas
potenti
use
cardiac
biomark
veterinari
medicin
yet
investig
studi
aim
assess
hfabp
prospect
biomark
canin
cardiac
diseas
compar
cardiac
troponini
ctni
twentyon
healthi
dog
control
dog
degen
mitral
valv
diseas
mvd
dog
dilat
cardiomyopathi
dcm
variou
cardiac
diseas
stage
studi
serum
measur
hfabp
ctni
routin
bloodwork
echocardiographi
perform
initi
present
dog
month
diseas
dog
follow
month
verifi
surviv
level
record
initi
present
show
significantli
elev
hfabp
highest
level
found
acvim
stage
c
diseas
regardless
caus
follow
stage
b
control
ctni
differ
stage
c
b
control
unabl
differenti
stage
b
control
dcm
patient
higher
hfabp
ctni
level
mvd
patient
ctni
indistinguish
mvd
dog
control
reduct
hfabp
ctni
follow
period
also
observ
initi
present
among
dcm
stage
c
dog
hfabp
signific
predictor
death
multivari
studi
perform
studi
show
potenti
valu
hfabp
cardiac
marker
differenti
stage
diseas
type
dog
valvuloplasti
bvp
identif
ca
report
use
highslic
cardiacg
comput
tomographi
angiographi
cta
howev
util
access
nongat
cta
unknown
purpos
studi
evalu
feasibl
nongat
cta
identifi
ca
anesthet
bulldog
sever
pulmon
stenosi
ps
prior
bvp
prospect
observ
studi
bulldog
bulldog
mix
sever
ps
recruit
full
echocardiogram
perform
diagnos
ps
dog
place
gener
anesthesia
nongat
slice
cta
perform
cta
review
boardcertifi
radiologist
cardiologist
coronari
anatomi
identifi
normal
coronari
arteri
anatomi
note
cta
right
ventricular
outflow
tract
angiogram
perform
evalu
levophas
confirm
normal
coronari
anatomi
prior
bvp
dog
prepulmon
ca
recov
anesthesia
bvp
perform
five
bulldog
bulldog
cross
enrol
dog
clear
interpret
imag
nongat
cta
coronari
anomali
identifi
dog
base
nongat
cta
consist
anomali
three
dog
normal
coronari
anatomi
base
nongat
cta
confirm
levophas
angiographi
success
bvp
perform
without
incid
dog
conclud
nongat
cta
repres
access
noninvas
method
diagnos
ca
bulldog
ps
atrial
thrombosi
known
complic
cat
hypertroph
cardiomyopathi
hcm
slow
blood
flow
endotheli
damag
hypercoagul
caus
enlarg
left
atrium
la
cardiac
dysfunct
suspect
involv
thrombu
format
howev
cat
hcm
la
enlarg
develop
cat
differ
cat
without
known
therefor
compar
myocardi
transcript
cytokin
interleukin
il
tumour
necrosi
factora
interferonc
transform
growth
factor
tgf
b
matrix
metalloproteinas
mmp
tissu
inhibitor
metalloproteinas
timp
atria
ventricular
sampl
cat
hcm
cat
hcm
use
quantit
real
time
pcr
cat
clinic
patient
diagnosi
diseas
obtain
echocardiographi
cat
hcm
show
gener
higher
atrial
ventricular
marker
transcript
appli
cat
hcm
tgfb
cat
hcm
exhibit
also
significantli
lower
atrial
lower
ventricular
transcript
atria
ventricular
sampl
respect
cat
hcm
without
result
suggest
differ
remodel
process
primarili
ventricl
cat
hcm
might
contribut
cardiac
dysfunct
format
cat
hcm
lower
report
associ
increas
left
ventricular
hypertrophi
fibrosi
dysfunct
studi
aim
describ
echocardiograph
find
healthi
adult
tiger
determin
differ
echocardiograph
variabl
sedat
medetomidin
revers
atipamezol
eight
adult
tiger
panthera
tigri
exot
cat
sanctuari
includ
tiger
underw
complet
echocardiograph
examin
oper
follow
sedat
medetomidin
midazolam
ketamin
induct
gener
anesthesia
follow
complet
first
exam
medetomidin
revers
atipamezol
second
echocardiograph
examin
perform
minut
later
oper
measur
test
statist
differ
two
examin
gender
weight
one
tiger
exclud
analysi
due
find
ventricular
septal
defect
leav
total
tiger
physiolog
regurgit
tricuspid
pulmon
valv
seen
tiger
statist
signific
differ
left
ventricular
intern
dimens
enddiastol
base
weight
interventricular
septum
thick
endsystol
pre
postecho
fraction
shorten
left
ventricular
intern
dimens
endsystol
approach
reach
statist
signific
pre
postecho
conclus
physiolog
tricuspid
pulmon
regurgit
common
find
healthi
adult
tiger
echocardiograph
measur
obtain
studi
use
refer
futur
examin
adult
tiger
effect
medetomidin
measur
specif
left
ventricular
intern
dimens
enddiastol
interventricular
septum
thick
endsystol
taken
account
platelet
function
test
may
use
identifi
clopidogrel
resist
occur
cat
plateletwork
pw
consist
detect
clopidogrel
effect
normal
cat
use
adp
agonist
canin
pw
studi
arachidon
acid
aa
use
agonist
adp
detect
clopidogrel
effect
data
cat
platelet
function
analyz
pfa
inconsist
detect
clopidogrel
effect
normal
cat
use
collagenadp
cartridg
also
occur
human
prompt
develop
innov
cartridg
consist
detect
clopidogrel
effect
human
dog
object
studi
investig
pwaa
cat
nine
normal
cat
cat
cardiovascular
diseas
studi
normal
hematocrit
platelet
count
blood
sampl
collect
jugular
venipunctur
normal
cat
show
pwaa
aggreg
agg
closur
time
ct
second
cat
cardiovascular
diseas
one
test
perform
cat
alreadi
receiv
clopidogrel
pwaa
agg
n
ct
second
n
b
cat
prior
start
clopidogrel
pwaa
agg
n
ct
second
n
cat
one
test
repeat
receiv
clopidogrel
pwaa
agg
n
ct
second
n
test
differ
normal
cat
cat
treat
clopidogrel
signific
p
pw
aa
agonist
pfa
cartridg
may
highli
sensit
detect
clopidogrel
effect
cat
fujii
h
sunahara
k
sugimoto
uehara
wakao
azabu
univers
sagamihara
kanagawa
japan
azabu
univers
sagamiharashi
kanagawa
japan
object
elucid
influenc
chang
diastol
aortic
pressur
aortic
complianc
fraction
shorten
fs
dog
undergo
patent
ductu
arteriosu
pda
occlus
own
dog
underw
percutan
pda
occlus
retrospect
use
studi
dog
evalu
use
echocardiographi
cathet
measur
direct
blood
pressur
pda
occlus
diamet
descend
aorta
measur
use
digit
fluoroscop
cine
loop
pda
occlus
systol
blood
pressur
chang
howev
puls
pressur
significantli
decreas
p
diastol
blood
pressur
dap
significantli
increas
p
univari
analysi
n
low
postop
fs
associ
older
age
p
increas
postop
diastol
blood
pressur
decreas
puls
pressur
p
multivari
analysi
n
low
postop
fs
associ
older
age
p
decreas
postop
puls
pressur
p
diamet
descend
aorta
significantli
increas
systol
diastol
p
aortic
fs
significantli
decreas
p
pda
occlus
conclus
left
ventricl
might
abl
contract
pda
occlus
increas
dap
decreas
aortic
complianc
ie
aortic
valv
strongli
close
aorta
rapidli
dilat
like
ruptur
balloon
due
trap
larg
amount
blood
aorta
canin
ha
case
identifi
time
period
also
experienc
chf
eight
dog
chronic
mitral
valv
diseas
dilat
cardiomyopathi
five
dog
experienc
chf
first
inject
docp
known
preexist
heart
diseas
median
time
docp
chf
day
rang
day
hadocpchf
case
match
histor
control
chf
without
ha
match
age
breed
sex
cardiac
diagnosi
year
diagnosi
number
time
interv
document
chf
episod
surviv
chf
evalu
group
median
surviv
onset
chf
day
control
vs
day
hadocp
group
differ
signific
p
number
time
interv
chf
episod
likewis
differ
group
small
number
case
larg
variabl
paramet
measur
limit
abil
identifi
differ
group
despit
neg
find
small
retrospect
studi
studi
relationship
docp
administr
chf
seem
warrant
oculocardiac
reflex
heart
physiolog
respons
digit
compress
eyebal
produc
neg
chronotrop
inotrop
respons
healthi
subject
studi
investig
autonom
imbal
dog
chf
due
myxomat
mitral
valv
diseas
mmvd
mean
individu
respons
vagal
maneuv
fiftytwo
clientown
mmvd
dog
stage
twelv
healthi
dog
admit
regular
cardiac
evalu
recruit
prospect
observ
studi
everi
dog
ecg
record
minut
last
minut
globe
compress
orbit
use
digit
pressur
minuterecord
twenti
rr
interv
use
calcul
mean
rr
interv
standard
deviat
rr
interv
root
mean
squar
success
differ
rr
interv
vasovag
tonu
index
eyebal
compress
approxim
twenti
second
compress
start
percent
chang
everi
surrog
calcul
although
signific
differ
document
vvti
p
surrog
behav
differ
stage
c
dog
compar
anim
figur
explan
might
parasympathet
withdraw
chf
addit
subtl
sympathet
activ
due
discomfort
like
suppress
dog
preserv
vagal
respons
also
sustain
increas
sympathet
activ
rather
transit
sympathet
activ
might
involv
distinct
respons
ocr
symptomat
dog
compar
asymptomat
one
peopl
qt
prolong
instabl
known
relat
ventricular
arrhythmia
sinc
dog
myxomat
mitral
valv
diseas
prone
develop
ventricular
arrhythmia
studi
investig
whether
indic
deriv
qt
interv
could
use
predict
increas
likelihood
arrhythmia
regardless
clinic
sign
clientown
mmvd
dog
stage
admit
cardiac
evalu
recruit
prospect
crosssect
studi
everi
dog
underw
echocardiogram
ecg
record
fifti
consecut
qt
interv
measur
dog
qt
correct
heart
rate
use
calcul
averag
qt
qta
qt
varianc
qtv
total
instabl
ti
short
term
sti
long
term
lti
instabl
signific
differ
asymptomat
symptomat
anim
document
everi
paramet
p
higher
valu
found
stage
c
dog
signific
differ
also
exist
qta
auc
found
qta
sti
use
discrimin
dog
without
ventricular
arrhythmia
figur
dog
qta
sti
shown
slightli
moder
prone
develop
ventricular
arrhythmia
respect
also
auc
document
everi
qt
index
use
distinguish
anim
remodel
nonremodel
heart
qta
qtv
best
discrimin
dog
c
dog
respect
increas
qt
instabl
shown
symptomat
patient
qt
indic
might
translat
prognost
surrog
arrhythmia
chf
mmvd
dog
brachycephal
syndrom
character
primari
secondari
upper
respiratori
tract
abnorm
may
result
signific
upper
airway
obstruct
cardiovascular
hemodynam
chang
may
also
present
howev
unlik
upper
respiratori
abnorm
intens
studi
pauciti
inform
regard
cardiovascular
hemodynam
chang
relat
syndrom
purpos
one
evalu
anim
select
two
distinct
group
control
group
cg
compris
beagl
mean
age
year
brachycephal
group
bg
consist
french
bulldog
brachycephal
syndrom
age
year
thorac
radiograph
arteri
blood
ga
analysi
echocardiograph
examin
perform
data
submit
normal
test
statist
differ
group
assess
use
ttest
p
bg
present
p
ae
mmhg
p
co
ae
mmhg
cg
ae
mmhg
ae
mmhg
respect
p
vh
index
bg
ae
higher
compar
cg
ae
p
bg
show
better
perform
mmode
regard
lvid
ae
mm
fs
ae
compar
cg
ae
mm
ae
respect
p
laao
ratio
also
higher
bg
ae
cg
ae
p
base
result
brachycephal
dog
present
sign
cardiorespiratori
disord
demonstr
lower
p
valu
furthermor
heart
silhouett
consid
bigger
cg
higher
vh
index
sign
rightsid
cardiac
remodel
howev
signific
variat
observ
echocardiograph
examin
could
indic
sign
cardiac
remodel
group
best
perform
obtain
bg
base
lvid
fs
variabl
could
explain
catecholamin
releas
sinc
chemic
restrain
examin
procedur
anim
stress
examin
tabl
believ
sinc
anim
bg
group
young
adult
mean
age
year
enough
time
manifest
complic
includ
cardiovascular
hematolog
relat
syndrom
belief
age
thu
progress
condit
rightsid
cardiac
remodel
alter
blood
ga
arteri
blood
pressur
would
evid
even
depend
sever
develop
precapillari
pulmonari
arteri
hypertens
may
also
occur
result
suggest
brachycephal
syndrom
may
effect
cardiovascular
system
therefor
encourag
need
thorough
investig
better
understand
cardiovascular
chang
relat
brachycephal
syndrom
order
distinguish
specif
heart
condit
especi
attain
predispos
dog
breed
mitral
valv
myxomat
degen
diseas
mvmd
main
heart
diseas
dog
whose
evolut
lead
signific
secondari
hemodynam
chang
activ
cardiac
neurohormon
compensatori
mechan
pharmacolog
stress
dobutamin
perform
aim
detect
possibl
chang
myocardi
reserv
systol
dysfunct
usual
detect
convent
echocardiograph
exam
therefor
might
help
veterinarian
earli
diagnosi
disord
thu
establish
prognosi
appropri
treatment
patient
purpos
beagl
male
femal
older
year
old
evalu
anim
select
group
control
group
compris
anim
group
compos
dog
mvmd
second
group
anim
left
ventricular
intern
diamet
ratio
diastol
index
aorta
dive
ao
less
third
group
anim
dive
ao
echocardiographi
perform
pharmacolog
stress
dobutamin
protocol
pharmacolog
stress
continu
infus
lgkgminut
minut
follow
lgkgminut
minut
result
base
differ
pre
post
pharmacolog
stress
valu
shorten
fraction
fs
eject
fraction
ef
variabl
obtain
mean
group
compar
statist
analysi
perform
varianc
analysi
follow
tukey
test
regard
fs
statist
differ
p
among
ae
ae
respect
howev
ae
ae
ae
ae
show
statist
differ
along
ef
variabl
statist
differ
among
ae
ae
ae
ae
differ
ae
ae
base
result
possibl
infer
pharmacolog
stress
test
dobutamin
evid
chang
systol
function
anim
mild
cardiac
remodel
compar
howev
anim
sever
remodel
systol
function
differ
compar
group
suggest
systol
dysfunct
myxomat
mitral
valv
diseas
mmvd
common
heart
diseas
dog
lead
valv
heart
failur
congest
heart
failur
evalu
myocardi
function
twodimension
speckl
track
shown
effect
method
earli
identif
ventricular
dysfunct
safe
feasibl
evalu
myocardi
function
dog
suspect
form
latent
myocardi
dysfunct
evidenc
convent
echocardiograph
examin
stress
echocardiographi
dobutamin
commonli
indic
detect
cardiac
dysfunct
asymptomat
patient
evalu
myocardi
contractil
reserv
viabil
pharmacolog
stress
test
perform
dobutamin
evalu
myocardi
function
via
twodimension
speckl
track
healthi
dog
differ
stage
mmvm
studi
includ
beagl
dog
distribut
group
select
accord
intern
diamet
left
ventricl
diastol
aortic
ratio
divedao
group
constitut
group
control
healthi
dog
without
mmvd
group
ii
dog
mmvd
dive
ao
ratio
lower
group
iii
dog
mmvd
divedao
ratio
higher
anim
submit
echocardiograph
examin
perform
singl
oper
evalu
perform
dobutamin
infus
dobutamin
dilut
glucos
solut
follow
progress
scheme
lgkgminut
consecut
minut
lgkgminut
consecut
minut
lgkgminut
consecut
minut
imag
analyz
use
syngo
veloc
vector
imag
vvi
algorithm
optic
flow
algorithm
siemen
data
submit
normal
test
repeat
measur
analysi
varianc
tukey
test
aim
studi
evalu
adapt
involv
left
ventricl
across
gestat
process
diastol
function
use
tissu
doppler
echocardiographi
anim
pregnant
bitch
healthi
age
year
weigh
kg
heart
rate
blood
pressur
clinic
evalu
perform
well
echocardiographi
mmode
spectral
tissu
doppler
estrou
ez
everi
day
pregnanc
pd
day
post
partum
pp
variabl
evalu
submit
statist
analysi
heart
rate
hr
p
systol
blood
pressur
sap
p
show
signific
chang
pregnanc
paramet
undergon
signific
chang
ef
p
fs
p
avvmax
pvmax
wave
e
lat
influenc
gestat
period
p
chang
could
explain
cubic
regress
model
e
p
ivrt
relat
lat
also
suffer
influenc
pregnanc
nonparametr
residu
distribut
pregnanc
produc
chang
matern
hemodynam
also
influenc
diastol
function
myocardi
contractil
increas
result
improv
systol
perform
diastol
function
chang
significantli
reveal
compliant
ventricl
physiolog
respons
increas
volum
metabol
requir
due
gestat
pulmonari
hypertens
ph
hemodynam
pathophysiolog
condit
defin
increas
systol
pulmonari
arteri
pressur
greater
mmhg
classic
condit
lead
right
ventricular
dysfunct
associ
poor
outcom
especi
patient
chronic
congest
heart
failur
unfortun
right
ventricular
function
dog
pulmonari
arteri
hypertens
poorli
investig
thu
aim
present
studi
assess
right
ventricular
systol
function
dog
tricuspid
regurgit
pulmonari
hypertens
echocardiograph
evalu
purpos
one
evalu
dog
echocardiograph
diagnosi
tricuspid
regurgit
ph
calcul
transtricuspid
gradient
regurgit
bernoulli
modifi
equat
ad
assum
right
atrial
pressur
anim
select
group
poscapillari
ph
group
compos
dog
myxomat
mitral
valv
diseas
clinic
echocardiograph
congest
sign
precapillari
ph
group
includ
dog
pulmonari
diseas
group
subdivid
mild
ph
group
includ
dog
pulmonari
arteri
pressur
gradient
estim
mmhg
moderatesever
ph
group
compris
anim
pulmonari
arteri
pressur
gradient
mmhg
precapillari
mild
group
compos
dog
precapillari
ph
moderatesever
group
dog
poscapillari
ph
mild
group
dog
poscapillari
ph
moderatesever
group
dog
ph
group
compris
anim
year
kg
pulmonari
arteri
pressur
estim
mmhg
anim
receiv
antihypertens
treatment
time
examin
control
group
clinic
healthi
dog
echocardiograph
abnorm
year
old
weight
kg
echocardiograph
evalu
rv
perform
dog
follow
recommend
guidelin
echocardiograph
assess
right
heart
endors
european
associ
echocardiographi
paramet
assess
tricuspid
annular
plane
systol
excurs
taps
acquir
place
mmode
cursor
tricuspid
annulu
measur
amount
longitudin
motion
annulu
peak
systol
apic
window
taps
vari
accord
patient
weight
index
aortic
diamet
tapseidx
data
submit
normal
test
analysi
group
perform
one
way
anova
test
p
mean
compar
tukey
test
statist
differ
control
precapillari
moderatesever
group
p
poscapillari
moderatesever
control
group
p
evalu
tapseidx
paramet
result
summar
tabl
lassbio
compound
develop
laboratori
evalu
synthesi
bioactiv
substanc
lassbio
feder
univers
rio
de
janeiro
ufrj
made
substrat
safrol
compound
extract
sassafra
oil
found
brazilian
plant
cinnamonwhit
ocotea
pretiosa
inodil
effect
compound
demonstr
bioassay
use
isol
intact
aortic
ring
whole
heart
fraction
myocardi
rat
suggest
mechan
action
vasodilatori
effect
relat
inhibit
phosphodiesteras
inotrop
effect
increas
ca
uptak
sarcoplasm
reticulum
rat
experiment
induc
myocardi
infarct
lassbio
decreas
collagen
deposit
presum
regul
inflamm
mediat
addit
increas
cardiac
lusitrop
decreas
left
ventricular
fill
pressur
modul
action
serca
protein
increas
ca
uptak
sarcoplasm
reticulum
induc
myocardi
relax
improv
diastol
function
previou
studi
perform
author
healthi
beagl
dog
oral
administr
compound
lower
blood
pressur
without
caus
hypotens
toxic
effect
increas
shorten
fraction
face
need
test
compound
nonrod
mammal
myocardi
diseas
propos
studi
verifi
action
lassbio
mgkg
n
cardiovascular
paramet
new
zealand
rabbit
dilat
cardiomyopathi
induc
doxorubicin
use
pimobendan
mgkg
n
posit
control
treatment
administ
everi
hour
day
dcm
induc
intraven
administr
mgkg
doxorubicin
twice
week
three
week
weekli
thereaft
fs
less
achiev
anim
evalu
weekli
electrocardiographi
echocardiographi
blood
pressur
measur
chest
xray
biomark
renal
hepat
function
myocardi
injuri
studi
approv
ethic
committe
anim
use
feder
univers
goia
ufg
protocol
number
data
submit
analysi
varianc
compar
mean
tukey
test
adopt
signific
condit
lassbio
increas
systol
function
increas
fs
second
week
improv
diastol
function
superior
manner
pimobendan
maintain
e
ratio
e
reduc
ivrt
without
alter
arteri
pressur
produc
proarrhythmogen
toxic
effect
also
reduc
serum
concentr
creatinin
howev
prevent
evolut
congest
condit
sinc
two
anim
present
pulmonari
edema
effus
thu
preclin
vitro
vivo
test
stage
lassbio
conclud
test
rodent
nonrod
mammal
healthi
induc
dcm
posit
inodil
lusitrop
effect
therefor
conclud
lassbio
promis
compound
need
use
clinic
trial
individu
natur
occur
dcm
complet
necessari
trial
rise
drug
allow
increas
exist
therapeut
protocol
pulmon
stenosi
ps
one
common
congenit
heart
defect
dog
affect
variou
canin
breed
includ
english
french
bulldog
fb
ps
extens
describ
english
bulldog
howev
best
knowledg
specif
studi
dedic
ps
fb
object
prospect
observ
studi
therefor
document
epidemiolog
clinic
echocardiograph
featur
risk
factor
death
fb
ps
studi
popul
consist
fb
case
least
obstruct
lesion
observ
commonli
valvular
supravalvular
use
colorflow
doppler
mode
echocardiographi
median
dopplerderiv
peak
transvalvular
pulmonari
gradient
dg
high
mmhg
lowerupp
quartil
mmhg
dg
mmhg
fb
among
fb
followup
avail
die
death
cardiacrel
cd
median
age
year
univari
analys
age
per
year
p
clinic
sign
present
p
dg
per
mmhg
p
right
ventricl
dilat
p
moder
sever
tricuspid
regurgit
p
rightsid
congest
heart
failur
p
significantli
associ
time
cd
adjust
age
dg
tricuspid
regurgit
remain
significantli
associ
time
cd
p
conclus
ps
fb
commonli
sever
complex
tricuspid
regurgit
independ
predictor
cd
accur
measur
integr
devic
select
size
minim
complic
associ
minim
invas
transcathet
closur
patent
ductu
arteriosu
pda
particular
regard
minim
ductal
diamet
mdd
devic
ratio
depend
method
measur
standard
measur
typic
obtain
two
dimension
angiographi
echocardiographi
aim
studi
character
pda
dimens
includ
mdd
ampulla
diamet
mm
mdd
morpholog
base
right
later
angiographi
transthorac
echocardiographi
tte
right
left
imag
window
biplan
transesophag
echocardiographi
tee
studi
popul
consist
dog
lefttoright
shunt
pda
minim
invas
closur
surgic
ligat
see
tabl
tte
angiograph
mdd
measur
acquir
orient
tee
measur
smallest
perpendicular
measur
dog
ratio
ab
indic
circular
mm
differ
b
shape
ampulla
mdd
realtim
tee
document
dynam
chang
pulmonari
ostium
dimens
throughout
cardiac
cycl
dog
angiographi
perform
prior
catheterbas
closur
morpholog
classifi
type
iia
type
iib
type
iii
subsequ
ligat
similar
krichenko
type
dog
circular
mdd
tee
classifi
type
iia
angiographi
median
amplatz
canin
duct
occlud
acdo
size
use
dog
rang
median
rang
cdo
mdd
ratio
angiographi
tee
median
rang
cdo
proxim
disc
ampulla
ratio
angiographi
tee
measur
deem
accur
includ
tee
use
make
devic
select
individu
case
complic
occur
dog
conclus
tee
provid
clear
cross
section
imag
pda
pulmonari
ostium
document
ellipt
shape
mdd
major
minor
axi
similar
locat
angiograph
tee
measur
could
contribut
devic
size
base
standard
tee
angiograph
imag
acdo
overs
approxim
time
mdd
previous
report
proxim
disc
ampulla
ratio
alway
least
receiv
carperitid
present
pulmonari
edema
enokizono
n
kanno
h
suzuki
yamada
k
matsuura
japan
small
anim
medic
center
tokorozawa
saitama
japan
nihon
univers
fujisawa
kanagawa
japan
anim
cardiovascular
thorac
surgeri
center
sayama
saitama
japan
anim
cardiovascular
thorac
surgeri
fuchuu
tokyo
japan
anim
cardiovascular
thorac
surgeri
center
sayamashi
saitama
japan
purpos
studi
clarifi
treatment
effect
carperitid
veterinari
case
nine
dog
present
pulmonari
edema
due
mitral
valv
insuffici
treat
continu
infus
carperitid
lgkgmin
dog
hypotens
exclud
studi
blood
sampl
perform
twice
administr
carperitid
pre
administr
carperitid
post
neurohumor
factor
atrial
natriuret
peptid
anp
ntermin
pro
btype
natriuret
peptid
ntprobnp
aldosteron
level
measur
time
point
measur
report
mm
median
rang
angiographi
tte
right
tte
left
tee
tee
mdd
b
ampulla
diamet
b
two
perpendicular
measur
obtain
cross
section
view
addit
chest
radiographi
echocardiographi
blood
pressur
measur
perform
depend
specif
case
seven
dog
show
improv
posttreat
although
case
show
improv
anp
level
increas
posttreat
case
mean
ae
standard
deviat
pre
ae
vs
post
ae
ntprobnp
level
increas
case
decreas
case
pre
ae
vs
post
ae
aldosteron
level
increas
one
case
pre
ae
vs
post
ae
addit
left
atrial
aortic
root
ratio
laao
ewav
vertebr
heart
score
vh
blood
pressur
decreas
carperitid
human
anp
agent
expect
higher
anp
level
posttreat
observ
decreas
ntprobnp
level
case
treat
hour
thought
due
time
lag
halflif
period
ntprobnp
stretch
stimul
ventricular
muscl
reflect
blood
concentr
ntprobnp
addit
ventricular
muscl
stretch
inhibit
decreas
left
atrial
pressur
follow
administr
carperitid
last
hour
lastli
decreas
aldosteron
level
thought
due
inhibitori
effect
carperitid
reninangiotensinaldosteron
system
studi
suggest
carperitid
administr
effect
sinc
pulmonari
edema
improv
aldosteron
suppress
myocardi
remodel
canin
dilat
cardiomyopathi
dcm
gasparini
fonfara
u
hetzel
kipar
univers
zurich
zurich
zurich
switzerland
univers
guelph
guelph
canada
institut
veterinari
patholog
vetsuiss
faculti
univers
zurich
switzerland
zurich
zurich
switzerland
dilat
cardiomyopathi
dcm
one
common
cardiac
diseas
dog
howev
pathogenesi
still
well
understood
base
detail
histolog
transcript
assess
myocardium
dcm
present
studi
aim
investig
involv
remodel
process
pathogenesi
dcm
myocardium
dog
dcm
examin
histolog
immunohistolog
alongsid
quantit
revers
transcriptas
pcr
qpcr
cytokin
remodel
marker
perform
four
case
relat
transcript
six
dog
noncardiac
diseas
laser
microdissect
subsequ
qpcr
serv
confirm
cardiomyocyt
sourc
marker
histolog
examin
confirm
occurr
degen
myocardi
chang
fatti
infiltrationdegen
type
attenu
wavi
fiber
type
also
reveal
gener
increas
interstiti
cell
addit
focal
lesion
observ
compris
accumul
fibroblastlik
cell
mild
fibrosi
edema
neovascular
degener
cardiomyocyt
major
interstiti
cell
appear
macrophag
origin
often
found
express
intracellular
adhes
molecul
transform
growth
factor
tgf
b
vascular
endotheli
growth
factor
also
cardiomyocyt
express
frequent
transcript
matrix
metalloproteinas
mmp
tissu
inhibitor
mmp
timp
lysyl
oxidas
tumor
necrosi
factor
tnf
significantli
increas
cardiomyocyt
shown
transcrib
relev
marker
result
confirm
remodel
process
major
compon
pathogenesi
canin
dcm
suggest
cardiomyocyt
least
contribut
pathogen
process
atrial
fibril
af
common
arrhythmia
dog
usual
associ
rapid
ventricular
respons
rate
typic
manag
pharmacolog
rate
control
retrospect
studi
aim
assess
effect
heart
rate
hr
surviv
time
dog
af
fortysix
dog
site
af
least
one
hour
holter
record
includ
record
review
mean
heart
rate
meanhr
hour
averag
minimum
hr
minhr
minut
averag
maximum
hr
maxhr
minut
averag
record
time
adequ
rate
control
presum
adjust
rate
control
therapi
made
longterm
outcom
ascertain
primari
studi
endpoint
caus
mortal
dog
structur
heart
diseas
congest
heart
failur
receiv
antiarrhythm
drug
meanhr
bpm
rang
bpm
minhr
bpm
rang
bpm
maxhr
bpm
rang
bpm
sex
age
weight
cardiac
diagnosi
studi
site
signific
impact
surviv
everi
bpm
increas
meanhr
risk
allcaus
mortal
increas
hazard
ratio
ci
p
median
surviv
time
dog
meanhr
bpm
n
significantli
longer
day
rang
dog
meanhr
bpm
n
day
rang
day
p
meanhr
independ
associ
surviv
time
p
multivari
regress
result
suggest
aggress
rate
control
dog
af
lead
reduc
mortal
prospect
studi
target
meanhr
bpm
lower
indic
studi
aim
evalu
left
atrial
volum
lav
dog
differ
stage
chronic
mitral
valv
diseas
cmvd
evalu
associ
valu
congest
heart
failur
chf
hypothesi
lav
increas
sever
cmvd
use
detect
chf
dog
cmvd
eighti
dog
includ
prospect
crosssect
clinic
studi
group
accord
stage
cmvd
propos
american
colleg
veterinari
intern
medicin
c
base
clinic
sign
echocardiograph
evalu
left
atrial
volum
calcul
use
biplan
arealength
method
left
apic
two
four
chamber
view
end
ventricular
systol
lav
index
bodi
weight
lavkg
show
high
valu
p
compar
group
mlkg
p
mlkg
p
mlkg
p
analysi
roc
curv
chf
diagnosi
show
area
curv
lav
kg
lavkg
mlkg
optim
cutoff
identifi
detect
chf
dog
cmvd
sensit
specif
addit
lav
greater
cutoff
increas
probabl
detect
chf
increas
diagnost
capac
pretest
allow
decis
treat
chf
conclus
left
atrial
volum
increas
sever
cmvd
help
detect
chf
dog
solubl
fraction
circul
isoform
member
receptor
famili
induc
cardiomyocyt
cardiac
fibroblast
undergo
mechan
strain
make
promis
biomark
fibrosi
cardiac
remodel
wide
studi
human
medicin
character
import
prognost
biomark
independ
mortal
predictor
howev
studi
determin
refer
valu
evalu
influenc
gender
age
healthi
dog
therefor
studi
aim
measur
serum
level
healthi
dog
order
determin
normal
valu
studi
popul
evalu
influenc
gender
age
biomark
concentr
futur
assess
dog
heart
diseas
purpos
prospect
crosssect
clinic
studi
conduct
includ
sampl
healthi
smalltomedium
size
dog
male
femal
adult
differ
age
signific
differ
serum
level
male
femal
p
age
group
studi
popul
p
refer
valu
found
serum
level
healthi
dog
rang
pgml
ci
mean
valu
pgml
influenc
gender
age
group
serum
level
assess
dog
popul
possibl
suggest
refer
rang
biomark
healthi
dog
solubl
fraction
consid
cardiac
biomark
induc
mechan
stretch
cardiomyocyt
fibroblast
biomark
prognost
valu
human
cardiolog
consid
import
independ
mortal
predictor
howev
studi
assess
dog
still
lack
therefor
studi
aim
determin
util
compar
ntprobnp
cardiac
troponin
ctni
assess
dog
chronic
mitral
valv
diseas
cmvd
purpos
dog
differ
stage
cmvd
submit
clinic
exam
laboratori
test
cardiolog
exam
measur
ntprobnp
ctni
result
demonstr
higher
dog
chf
compar
nonchf
dog
howev
dog
stratifi
accord
cmvd
stage
possibl
differenti
stage
base
concentr
ntprobnp
ctni
higher
chf
dog
well
advanc
stage
cmvd
correl
ntprobnp
ctni
analysi
roc
curv
chf
diagnosi
show
area
curv
auc
ntprobnp
ctni
prognosi
assess
concentr
higher
pgml
indic
higher
mortal
compar
group
lower
valu
result
suggest
perform
standalon
diagnost
test
limit
inferior
studi
biomark
howev
seem
use
independ
prognost
marker
mortal
predictor
dog
cmvd
chronic
valvular
heart
diseas
cvhd
common
morbid
great
relev
intern
medicin
small
anim
scope
present
studi
evalu
main
diagnos
perform
period
cardiolog
unit
teach
hospit
period
studi
dog
attend
gender
balanc
male
femal
mongrel
dog
poodl
repres
anim
mean
age
patient
month
sought
unit
preanesthet
evalu
exclud
preanesthet
evalu
cvhd
account
diagnos
healthi
dog
congenit
anomali
arrhythmia
pericardi
effus
retrospect
review
medic
record
dog
mmvd
perform
clientown
fortyeight
dog
includ
studi
everi
dog
present
evalu
heart
diseas
dog
mmvd
accord
mitral
regurgit
mr
sever
mild
n
moder
n
sever
group
n
healthi
age
weightmatch
control
convent
echocardiograph
paramet
includ
fraction
shorten
fs
eject
fraction
ef
e
veloc
ea
ratio
ee
ratio
left
atrium
aorta
ratio
laao
endsystol
volum
index
bodi
surfac
area
bmode
edvi
b
enddiastol
volum
index
bodi
surfac
area
bmode
esvi
b
pw
tdi
paramet
record
left
atrial
speckl
track
imag
includ
global
peak
atrial
longitudin
strain
pal
global
peak
atrial
contractil
strain
pac
acquir
twodimension
cine
loop
apic
fourchamb
view
global
pal
increas
mild
mr
group
reduc
moder
mr
group
reduc
sever
mr
group
global
pac
reduc
moder
sever
mr
group
global
pal
pac
correl
laao
edvi
b
esvi
b
fs
ef
e
veloc
ee
dog
diastol
dysfunct
reduc
global
pal
plot
left
atrial
size
ste
repeat
reproduc
tool
import
role
manag
advanc
heart
diseas
dog
left
atrial
size
paramet
may
underestim
sever
diseas
endstag
heart
diseas
sought
determin
acut
effect
sotalol
administ
oral
left
ventricular
lv
systol
function
ventricular
ectopi
dog
ventricular
tachyarrhythmia
dog
n
diagnos
stabl
ventricular
tachyarrhythmia
prospect
enrol
dog
echocardiogram
ecg
hour
postsotalol
systol
function
assess
sinu
rhythm
via
fraction
shorten
fs
lv
shorten
area
lvsa
modifi
simpson
eject
fraction
ef
number
ventricular
prematur
complex
vpc
tabul
ventricular
arrhythmia
grade
vpc
singl
vpc
acceler
idioventricular
rhythm
bigeminytrigemini
coupletstriplet
ventricular
tachycardia
ront
phenomenon
echocardiograph
ecg
measur
perform
blind
fashion
number
complex
grade
indic
lv
systol
function
sinu
heart
rate
compar
use
pair
ttest
wilcoxon
signedrank
test
baselin
heart
rate
fs
lvsa
ef
significantli
p
decreas
postsotalol
ae
mgkg
po
mean
percent
chang
ae
sd
ae
ae
ae
ae
respect
median
iqr
vs
arrhythmia
grade
vs
also
significantli
p
decreas
postsotalol
reduct
lv
systol
function
postsotalol
rel
mild
dog
percent
chang
postsotalol
may
exceed
previous
report
withinday
coeffici
variat
echocardiograph
lv
systol
function
indic
base
ecg
sotalol
acut
improv
ventricular
ectopi
chronic
mitral
valvular
diseas
cmvd
common
acquir
canin
heart
diseas
character
result
volum
overload
firstli
lead
left
atrial
enlarg
occasion
dog
cmvd
concomit
renal
insuffici
found
patholog
interact
exist
cardiovascular
diseas
renal
disord
recent
defin
cardiovascularren
disord
cvrd
veterinari
medicin
although
mechan
cvrd
yet
fulli
understood
cardiac
diseas
renal
dysfunct
recogn
import
determin
prognosi
tool
evalu
cardiac
function
speckletrack
echocardiographi
ste
newer
techniqu
allow
accur
assess
left
atrial
la
well
left
ventricular
lv
function
present
studi
aim
evalu
la
lv
function
use
ste
assess
correl
class
cardiac
renal
diseas
investig
correl
among
class
renal
diseas
echocardiograph
variabl
laboratori
variabl
differ
stage
cmvd
dog
cmvd
dog
concomit
renal
disord
fortyon
clientown
dog
cmvd
includ
dog
underw
physic
examin
blood
work
radiograph
abdomin
ultrasound
urinalysi
electrocardiogram
echocardiographi
dog
categor
accord
american
colleg
veterinari
intern
medicin
acvim
consensu
statement
intern
renal
interest
societi
iri
stage
system
mmode
doppler
examin
perform
convent
echocardiographi
use
ste
strain
circumferenti
radial
longitudin
motion
lv
twist
la
volum
la
strain
assess
systol
twist
increas
moder
stage
acvim
c
class
decreas
sever
stage
acvim
class
dog
advanc
stage
increas
circumferenti
radial
strain
wherea
decreas
longitudin
strain
compar
earlier
stage
la
maxim
minim
volum
increas
left
atrial
activ
empti
index
lafacact
peak
la
strain
rate
atrial
contract
decreas
sever
higher
concentr
serum
creatinin
serum
urea
found
acvim
class
iri
stage
statist
signific
correl
acvim
class
sever
echocardiograph
variabl
includ
earli
diastol
untwist
rate
ea
studi
signific
correl
among
iri
stage
serum
creatinin
concentr
echocardiograph
variabl
acvim
class
shown
find
suggest
connect
chronic
mitral
valv
diseas
renal
disord
prospect
random
doubl
blind
studi
purpos
evalu
echocardiograph
paramet
dog
chronic
mitral
valv
degener
cmvd
stage
c
treat
pimobendan
amlodipin
addit
convent
therapi
use
pimobendan
stage
c
dog
well
establish
debat
due
appar
preserv
myocardi
inotrop
patient
amlodipin
vasodil
drug
inotrop
effect
usual
use
stage
dog
ten
dog
random
group
eleven
group
b
group
treat
furosemid
enalapril
maleat
group
dog
also
receiv
pimobendan
mgkg
bid
group
b
one
amlodipin
mgkg
bid
dog
evalu
begin
medic
thirti
day
later
sixti
day
observ
chang
echodopplercardiograph
electrocardiograph
examin
well
systol
blood
pressur
signific
differ
electrocardiograph
systol
blood
pressur
measur
group
echodopplercardiograph
examin
show
statist
signific
differ
speed
em
wave
group
amlodipin
group
speed
wave
time
paramet
may
indic
chang
earli
myocardi
relax
first
prospect
random
doubl
blind
studi
compar
pimobendan
amlodipin
stage
c
cmvd
dog
despit
rel
small
sampl
size
find
studi
conclud
superior
one
drug
anoth
use
glucocorticoid
veterinari
patient
heart
diseas
present
limit
due
concern
possibl
precipit
congest
heart
failur
object
studi
investig
previous
propos
mechan
glucocorticoid
could
caus
progress
heart
diseas
dog
includ
fluid
retent
mineralocorticoid
effect
transient
hyperglycemia
caus
intravascular
fluid
shift
increas
afterload
due
system
hypertens
direct
cardiac
remodel
prospect
clinic
trial
clinic
healthi
dog
allerg
dermat
n
given
antiinflammatori
dose
oral
prednison
mgkgday
day
follow
taper
washout
period
hemodynam
biochem
echocardiograph
variabl
measur
prior
prednison
administr
day
postwashout
match
control
popul
evalu
concurr
hypothes
prednison
administr
would
caus
chang
measur
variabl
time
point
linear
mix
model
use
compar
chang
variabl
baselin
treatment
group
result
demonstr
signific
chang
sodiumpotassium
ratio
blood
glucos
echocardiograph
variabl
signific
increas
blood
pressur
baselin
occur
treatment
group
compar
control
group
p
expect
chang
hematolog
biochem
variabl
due
prednison
administr
neutrophilia
eosinopenia
isosthenuria
elev
alp
alt
occur
treatment
group
overal
studi
demonstr
antiinflammatori
dose
glucocorticoid
clinic
healthi
dog
potenti
impact
cardiac
function
caus
elev
blood
pressur
thu
increas
afterload
effect
ultrafiltr
cardiopulmonari
bypass
dog
undergo
mitral
valv
plasti
k
matsuura
yamada
enokizono
h
suzuki
nagakubo
n
kanno
anim
cardiovascular
thorac
surgeri
center
sayamashi
saitama
japan
anim
cardiovascular
thorac
surgeri
fuchuu
tokyo
japan
japan
small
anim
medic
center
tokorozawa
saitama
japan
anim
cardiovascular
thorac
surgeri
center
sayama
saitama
japan
univers
tokyo
sayama
saitama
japan
nihon
univers
fujisawa
kanagawa
japan
cardiopulmonari
bypass
cpb
necessari
perform
mitral
valv
plasti
mvp
dog
ultrafiltr
uf
major
advantag
reduc
amount
blood
transfus
remov
variou
cytokin
human
medicin
perform
mvp
dog
spontan
mitral
valv
regurgit
mr
cpb
investig
effect
ultrafiltr
twentytwo
dog
diagnos
sever
mr
underw
mvp
cpb
includ
depend
whether
ultrafiltr
use
divid
nonuf
group
uf
group
perform
cuf
convent
ultrafiltr
muf
modifi
ultrafiltr
lowest
hematocrit
ht
valu
ht
end
cpb
group
compar
averag
lowest
ht
oper
nonuf
n
group
uf
group
n
signific
differ
observ
two
group
averag
ht
end
cpb
nonuf
group
uf
group
thu
averag
ht
significantli
higher
uf
group
p
also
analyz
case
low
bodi
weight
kg
less
separ
case
nonuf
group
low
bodi
weight
case
uf
group
lowest
ht
ht
end
cpb
significantli
higher
uf
group
notabl
averag
ht
cpb
higher
uf
group
nonuf
group
amount
cardioplegia
suffici
produc
cardiac
arrest
vari
depend
specif
case
often
result
excess
hemodilut
sinc
help
drain
excess
fluid
circumst
cuf
thought
contribut
differ
ht
studi
addit
muf
residu
blood
extracorpor
circuit
return
patient
bodi
result
ht
end
cpb
higher
uf
group
nonuf
group
conclud
uf
cpb
increas
lowest
ht
valu
cpb
increas
ht
end
cpb
dog
undergo
mvp
differ
particularli
notic
small
dog
morita
k
nakamura
osuga
k
morishita
n
sasaki
h
ohta
takiguchi
hokkaido
univers
sapporo
hokkaido
japan
depart
veterinari
clinic
scienc
hokkaido
univers
sapporo
hokkaido
japan
right
ventricular
rv
dysfunct
dyssynchroni
associ
decreas
cardiac
function
clinic
worsen
human
patient
precapillari
pulmonari
hypertens
ph
howev
report
avail
rv
function
dyssynchroni
dog
precapillari
ph
object
retrospect
studi
investig
rv
morpholog
chang
function
dyssynchroni
assess
echocardiographi
dog
precapillari
ph
medic
record
retrospect
review
clientown
dog
dog
precapillari
ph
healthi
dog
rv
morpholog
variabl
includ
rv
intern
diamet
enddiastol
rvidd
rv
enddiastol
area
rveda
rv
wall
thick
enddiastol
rvwtd
echocardiograph
indic
rv
function
includ
rv
strain
speckl
track
echocardiographi
dyssynchroni
index
standard
deviat
time
peak
longitudin
strain
rv
rvsd
speckl
track
echocardiographi
evalu
addit
relationship
echocardiograph
variabl
qr
durat
rvsd
valid
dog
precapillari
ph
dog
precapillari
ph
larger
rvidd
rveda
rvwtd
lower
rv
strain
higher
rvsd
compar
healthi
dog
posit
correl
rvsd
rvidd
rveda
tr
veloc
rvidd
r
p
rveda
r
p
tr
veloc
r
p
rvwtd
qr
durat
relat
rvsd
conclus
dog
precapillari
ph
rv
dysfunct
dyssynchroni
rv
dyssynchroni
may
caus
rv
dilat
elev
pulmonari
arteri
pressur
dog
precapillari
ph
brachiocephal
syndrom
bs
result
combin
anatom
abnorm
predispos
breed
includ
stenot
nare
elong
soft
palat
among
other
sign
bs
includ
laryng
stridor
rale
exercis
intoler
higher
risk
heat
stroke
cyanosi
vomit
pulmonari
hypertens
right
ventricl
congest
heart
failur
english
bulldog
report
natur
model
studi
sleep
obstruct
apnea
syndrom
peopl
breed
show
alter
like
snore
fragil
sleep
hypoxemia
addit
upper
respiratori
tract
obstruct
inflamm
known
direct
effect
cardiovascular
system
healthrel
qualiti
life
hrqol
aim
studi
compar
qualiti
life
right
ventricular
global
function
correct
surgeri
upper
respiratori
tract
obstruct
longitudin
prospect
studi
patient
clinic
evid
upper
airway
obstruct
candid
correct
palatoplasti
pp
rhinoplasti
rp
recruit
decemb
decemb
evalu
hrqol
spanish
version
fetch
tm
questionnair
use
tm
global
right
ventricular
function
evalu
paramet
tricuspid
annular
plane
systol
excurs
taps
curvilinear
relationship
taps
weight
follow
correl
equat
use
taps
weight
maxim
veloc
wave
e
earli
diastol
wave
tricuspid
annulu
evalu
tissu
doppler
addit
systol
time
interv
index
myocardi
perform
rvimp
evalu
spectral
signal
transtricuspid
pulmonari
blood
flow
patient
evalu
day
surgeri
month
afterward
student
ttest
wilcoxon
rank
test
use
compar
parametr
nonparametr
variabl
respect
result
consid
statist
signific
pvalu
twenti
dog
differ
brachiocephal
breed
sign
upper
airway
obstruct
recruit
differ
found
surgeri
total
score
obtain
tm
instrument
ae
vs
ae
p
sampl
taps
valu
reduc
compar
establish
refer
rang
dog
popul
research
ae
cm
vs
refer
rang
cm
addit
differ
taps
obtain
day
month
correct
surgeri
ae
vs
ae
p
maximum
veloc
wave
tricuspid
annulu
surgeri
ae
cm
surgeri
ae
cm
statist
signific
differ
pvalu
valu
e
earli
wave
veloc
similar
procedur
ae
cm
vs
ae
cm
afterward
p
rvimp
ae
surgeri
similar
intervent
ae
pvalu
preeject
time
pep
ae
ms
surgeri
markedli
diminish
postrecoveri
ae
ms
pvalu
conclus
correct
surgeri
upper
airway
obstruct
may
releas
right
ventricl
increas
afterload
stabil
systol
function
valu
howev
appar
improv
qualiti
life
patient
undergo
intervent
restrict
cardiomyopathi
rcm
second
common
felin
primari
cardiomyopathi
howev
data
avail
regard
prognost
variabl
larg
felin
rcm
popul
aim
retrospect
studi
therefor
analyz
clinic
cours
cat
diagnos
rcm
alfort
cardiolog
unit
identifi
factor
associ
cardiac
death
cd
rcm
diagnosi
base
follow
echocardiograph
criteria
left
atrial
la
biatrial
enlarg
associ
normal
mildli
alter
left
ventricl
lv
cat
mildli
alter
lv
also
restrict
lv
fill
pattern
median
surviv
time
cd
adjust
hazard
ratio
hr
estim
kaplanmei
method
multivari
cox
model
respect
studi
popul
consist
cat
rcm
rcm
cat
symptomat
time
diagnosi
dyspnea
relat
congest
heart
failur
cat
fiftyeight
rcm
cat
followup
avail
die
cd
repres
death
caus
median
surviv
time
diagnosi
cd
day
independ
age
biatrial
enlarg
arrhythmia
risk
cd
increas
la
aorta
ao
ratio
presenc
sever
la
enlarg
la
ao
ratio
increas
confid
interv
ci
p
ci
p
respect
conclus
cd
common
rcm
cat
la
enlarg
significantli
associ
decreas
surviv
time
arteri
thromboemboli
ate
devast
consequ
heart
diseas
cat
although
antiplatelet
medic
clopidogrel
shown
superior
efficaci
aspirin
prevent
cardiogen
ate
cat
treatment
failur
clopidogrel
still
occur
human
treatment
failur
often
attribut
variat
metabol
clopidogrel
clopidogrel
activ
metabolit
cam
primari
object
project
quantifi
variat
plasma
cam
concentr
cat
determin
differ
correl
variabl
clopidogrel
metabol
andor
bodi
weight
thirtyf
cat
screen
healthi
cat
enrol
singl
oral
dose
mg
clopidogrel
administ
cat
blood
collect
hour
postadministr
plasma
concentr
clopidogrel
cam
clopidogrel
acid
major
inact
metabolit
measur
use
high
perform
liquid
chromatographi
tandem
mass
spectrometri
signific
correl
appreci
percentag
drug
circul
cam
cam
indic
extent
clopidogrel
metabol
cam
cam
concentr
simpl
linear
regress
r
p
multipl
linear
regress
includ
weight
covari
r
p
signific
correl
seen
weight
cam
concentr
simpl
linear
regress
r
p
multipl
linear
regress
includ
cam
covari
r
p
one
cat
high
cam
high
cam
concentr
four
cat
low
cam
low
cam
concentr
identifi
substanti
variat
circul
cam
concentr
exist
cat
variat
could
attribut
individu
differ
clopidogrel
metabol
cam
novel
serum
biomark
associ
fibrosi
inflamm
heart
failur
human
patient
howev
studi
determin
refer
valu
evalu
influenc
gender
age
healthi
dog
studi
aim
establish
refer
interv
healthi
dog
popul
evalu
influenc
gender
age
biomark
concentr
prospect
cross
section
clinic
studi
conduct
includ
sampl
healthi
smalltomedium
size
dog
male
femal
adult
differ
age
consid
gene
homolog
approxim
http
wwwncbinlmnihgovhomologen
canin
human
human
elisa
kit
kitrd
quantikin
elisa
fenix
usa
canin
dog
eiaab
wuhan
eiaab
scienc
china
test
concentr
recoveri
healthi
dog
obtain
canin
kit
significantli
lower
low
repeat
reproduc
compar
human
kit
suggest
lower
sensit
canin
kit
use
refer
valu
obtain
human
ngml
p
signific
differ
serum
level
male
femal
p
age
group
year
year
studi
popul
p
evalu
biolog
variat
biomark
show
concentr
unaffect
age
gender
data
suggest
refer
rang
biomark
human
healthi
dog
chronic
mitral
valv
degener
cmvd
highli
preval
heart
diseas
seen
mainli
older
small
breed
dog
order
follow
progress
heart
failur
hf
appli
biomark
identifi
preclin
cardiac
diseas
progress
decompens
human
patient
studi
aim
establish
util
new
biomark
isol
associ
type
b
natriuret
propeptid
ntprobnp
cardiac
troponin
estim
short
term
prognosi
dog
hf
caus
cmvd
design
prospect
crosssect
clinic
studi
longitudin
arm
one
hundr
thirti
nine
dog
distribut
among
five
group
rigor
select
criteria
accord
acvim
cmvd
stage
control
group
stage
healthi
small
breed
dog
predispos
cmvd
dog
stage
dog
stage
dog
stage
c
dog
stage
recruit
veterinari
teach
hospit
group
c
second
blood
sampl
day
measur
obtain
human
ntprobnp
ctni
refer
valu
obtain
group
human
ngml
p
conclud
magnitud
variat
observ
allow
detect
differ
stage
cmvd
capabl
identifi
patient
hf
compar
measur
biomark
ntprobnp
ctni
alreadi
establish
canin
hf
evalu
although
assess
standard
echocardiographi
longitudin
myocardi
fiber
play
activ
role
ventricular
contract
longitudin
strain
lst
tissu
motion
annular
displac
tmad
techniqu
evalu
fiber
tmad
investig
dog
calcul
dislodg
virtual
point
automat
determin
mitral
septal
later
annulu
toward
left
ventricular
apex
one
report
advantag
tmad
lst
possibl
calcul
use
imag
suitabl
strain
analysi
well
reduc
process
time
prospect
crosssect
observ
studi
twentyseven
healthi
dog
kg
underw
echocardiogram
apic
imag
obtain
allow
calcul
tmad
lst
obtain
imag
data
underw
shapirowilk
test
check
normal
distribut
result
shown
tabl
similar
tmad
lst
calcul
imag
differ
exist
male
femal
lst
posit
correl
exist
global
lst
combin
lst
bodi
weight
interestingli
tmad
correl
significantli
ventricular
arrhythmia
va
alreadi
demonstr
concern
dog
myxomat
mitral
valv
diseas
mmvd
coupl
interv
ci
prematur
index
pi
figur
shown
accur
differenti
benign
malign
va
human
be
va
known
associ
increas
risk
either
evolv
sign
heart
failur
die
suddenli
studi
investig
ci
pi
perform
dog
mmvd
retrospect
crosssect
investig
includ
dog
either
symptomat
stage
cd
n
asymptomat
stage
n
mmvd
review
electrocardiograph
trace
calcul
ci
pi
eight
dog
also
compar
indic
obtain
holter
record
standard
ecg
trace
statist
differ
exist
ci
p
pi
p
even
though
ci
pi
determin
anim
enrol
studi
vpc
characterist
compar
symptomat
asymptomat
dog
holter
record
avail
n
pi
differ
p
symptomat
ae
asymptomat
ae
dog
ci
consid
similar
p
also
symptomat
dog
polymorph
vpc
p
supraventricular
arrhythmia
p
asymptomat
anim
conclus
vpc
dog
symptomat
mmvd
prematur
commonli
associ
supraventricular
arrhythmia
polymorph
ventricular
prematur
complex
asymptomat
anim
pulmon
stenosi
one
common
congenit
cardiac
defect
dog
occur
concurr
type
aberr
coronari
arteri
anatomi
commonli
report
english
bulldog
boxer
comput
tomographi
angiographi
cta
allow
noninvas
assess
coronari
arteri
anatomi
three
dimension
model
improv
understand
visual
complex
cardiac
anatomi
hypothesi
cta
use
evalu
presenc
anatomi
anomal
coronari
arteri
dog
pulmon
stenosi
model
anomal
normal
coronari
arteri
creat
use
special
softwar
print
retrospect
studi
cta
imag
coronari
arteri
dog
confirm
coronari
arteri
anomali
dog
normal
coronari
arteri
anatomi
segment
use
two
differ
model
softwar
program
print
use
printer
normal
aberr
coronari
arteri
could
visual
use
cta
segment
use
softwar
program
case
singl
coronari
ostium
right
aortic
sinu
gave
rise
normal
right
main
circumpulmonari
left
main
coronari
arteri
visual
branch
follow
normal
anatom
cours
normal
case
normal
coronari
arteri
anatomi
print
model
excel
qualiti
allow
direct
visual
normal
abnorm
coronari
anatomi
cta
effect
identif
coronari
arteri
anomali
nongat
cta
suitabl
creat
printabl
model
model
increas
understand
complex
anatomi
normal
anomal
coronari
arteri
cardiac
diseas
especi
dilat
cardiomyopathi
common
dog
quantit
analysi
left
ventricular
deform
twodimension
speckl
track
echocardiographi
provid
better
diagnosi
purpos
studi
specifi
radial
strain
strain
rate
valu
left
ventricl
twodimension
speckletrack
echocardiographi
turkish
kangal
dog
studi
group
b
consist
dog
dilat
cardiomyopathi
dog
valv
diseas
respect
control
group
c
consist
healthi
dog
mean
age
ae
ae
ae
year
group
b
c
respect
significantli
p
differ
right
parastern
shortaxi
view
left
ventricl
level
papillari
muscl
use
determin
radial
strain
strain
rate
twodimension
speckletrack
echocardiographi
result
studi
reveal
group
significantli
p
differ
group
c
group
b
howev
signific
differ
group
c
group
b
twodimension
speckl
track
echocardiographi
reveal
decreas
left
ventricular
myocardi
systol
perform
dog
dilat
cardiomyopathi
similar
strain
strain
rate
healthi
dog
dog
valv
diseas
therefor
procedur
appli
detect
dilat
cardiomyopathi
dog
cardiac
diseas
ctbase
anatom
featur
larg
airway
heart
volum
dog
differ
bodi
size
uehara
fujii
k
sugimoto
h
sunahara
aoki
azabu
univers
sagamihara
kanagawa
japan
chronic
valvular
heart
diseas
commonli
seen
smallbre
dog
cough
common
clinic
sign
hypothes
anatom
featur
heart
larg
airway
differ
influenc
bodi
size
would
relat
cough
heart
enlarg
purpos
studi
compar
rel
heart
volum
anatom
featur
larg
airway
differ
bodi
size
use
ct
scan
retrospect
analys
perform
medic
record
dog
without
heart
lung
diseas
underw
ct
scan
dog
n
divid
group
basi
bodi
weight
small
kg
medium
kg
larg
kg
follow
paramet
calcul
use
osirix
thorac
volum
heart
volum
rel
heart
volum
thorac
volum
heart
length
distanc
main
stem
bronchi
vertebra
tracheal
diamet
angl
bronchu
rel
heart
volum
significantli
larg
small
dog
ae
medium
dog
ae
compar
larg
dog
ae
rel
distanc
main
stem
bronchi
vertebra
significantli
short
small
dog
ae
compar
medium
ae
larg
dog
ae
signific
differ
angl
bronchu
among
group
find
reveal
small
dog
larg
heart
rel
thorax
distanc
heart
vertebra
rel
short
compar
larger
dog
anatom
featur
may
potenti
predispos
occurr
cough
longterm
outcom
irish
wolfhound
dog
preclin
cardiomyopathi
treat
pimobendan
methyldigoxin
benazepril
vollmar
p
fox
privat
practic
bonn
wissen
germani
anim
medic
center
new
york
ny
usa
dilat
cardiomyopathi
dcm
common
caus
morbid
mortal
irish
wolfhound
iw
clinic
data
report
treatment
efficaci
limit
aim
evalu
longterm
pimobendan
benazepril
methyldigoxin
therapi
iw
preclin
dcm
retrospect
open
label
cohort
studi
evalu
iw
receiv
pimobendan
n
mgkg
po
h
benazepril
n
mgkg
po
q
h
methyldigoxin
n
mgkg
po
q
h
methyldigoxinbenazepril
n
pimobendanbenazepril
n
year
time
event
estim
kaplan
meier
method
first
onset
chf
cardiac
death
allcaus
mortal
use
pairwis
comparison
group
pool
data
iw
echocardiograph
followup
dichotom
base
upon
improv
fs
lv
endsystol
lv
enddiastol
dimens
refer
rang
respond
vs
echo
improv
nonrespond
compar
cardiac
surviv
time
chf
significantli
differ
group
p
time
cardiac
death
longer
benazeprilvsmethyldigoxin
p
pimobendanvsmethyldigoxin
p
benazeprilvspimobendanbenazepril
p
pimobendanvspimobendanbenazepril
p
methyldigoxinbenazeprilvspimobendanbenazepril
p
respect
surviv
allcaus
mortal
significantli
longer
pimobendanvsmethyldigoxin
benazeprilvspimobendanbenazepril
respect
p
time
cardiac
death
longest
respond
year
vs
year
p
time
allcaus
death
differ
p
larger
prospect
blind
studi
need
clarifi
clinic
benefit
drug
seven
dog
diagnos
chf
noncardiac
nc
caus
cough
commonli
dynam
airway
diseas
dog
chf
greater
number
bline
compar
nc
dog
p
site
contain
bline
p
use
cutoff
criterion
least
site
contain
bline
sensit
specif
lu
diagnos
chf
respect
diagnost
accuraci
higher
among
subset
dog
heart
murmur
n
sensit
specif
dog
moder
sever
left
atrial
enlarg
n
sensit
specif
notabl
dog
nc
cough
treat
previous
diuret
due
prior
chf
misdiagnosi
lu
use
predict
chf
caus
cough
studi
popul
particularli
among
dog
concurr
heart
diseas
lu
potenti
valuabl
diagnost
tool
identifi
avoid
misdiagnosi
chf
cough
dog
defin
commonli
occur
cytogenet
abnorm
canin
choroid
plexu
tumor
cpt
essenti
understand
oncogenesi
definit
appropri
therapeut
strategi
use
illumina
hd
snp
array
determin
copi
number
alter
cna
allel
imbal
histolog
confirm
spontan
canin
choroid
plexu
tumor
sampl
papillomascpp
carcinomascpc
recurr
cpp
tumor
match
normal
tissu
copi
number
call
allel
event
determin
match
pair
analysi
use
biodiscoveri
nexu
copi
number
tm
softwar
hierarch
cluster
aberr
profil
distinguish
cpp
cpc
choroid
plexu
tumor
character
highli
recurr
singl
copi
whole
chromosom
loss
specif
loss
involv
chromosom
seen
tumor
pattern
predominantli
whole
chromosom
loss
similar
find
human
cpc
compar
cpp
sever
recurr
chromosom
loss
dog
tumor
synten
commonli
report
region
within
whole
chromosom
loss
human
cpt
highli
recurr
loss
dog
cpt
encompass
key
tumor
suppressor
gene
gene
associ
chromosom
instabl
includ
vhl
strikingli
high
preval
specif
cna
canin
tumor
support
biolog
relev
cpt
oncogenesi
progress
characterist
cna
whole
chromosom
loss
reflect
common
oncogen
mechan
human
canin
cpt
compar
cytogenet
detail
analysi
candid
gene
within
ortholog
region
may
provid
insight
novel
common
pathway
choroid
plexu
tumor
biolog
implant
use
surgic
vertebr
stabil
typic
place
bicort
due
theoret
increas
pullout
strength
construct
stiff
bicort
implant
howev
increas
risk
imping
region
neurovascular
structur
recent
studi
involv
cervic
vertebra
suggest
monocort
pinscrew
plate
construct
test
bend
biomechan
equival
bicort
construct
data
directli
compar
pullout
strength
implant
type
method
canin
lumbar
vertebra
full
factori
design
use
assess
pullout
strength
mm
mm
posit
profil
pin
mmg
cortic
screw
mm
lock
screw
insert
monocort
bicort
predril
hole
lumbar
vertebra
canin
cadav
similar
bodi
weight
size
implant
distract
mechan
test
system
direct
along
long
axi
constant
rate
mm
screwpin
pullout
displac
load
data
acquir
hz
effect
implant
insert
depth
implant
pullout
assess
repeat
measur
anova
account
cadav
vertebra
pullout
strength
greater
bicort
n
n
monocort
implant
n
n
regardless
implant
type
signific
differ
pullout
strength
implant
type
vertebra
howev
may
due
low
sampl
number
data
provid
evid
bicort
implant
placement
greater
factor
natur
implant
respect
pullout
strength
lumbar
vertebr
bodi
implant
test
purpos
studi
determin
pharmacokinet
profil
side
effect
follow
singl
dose
mg
extend
releas
levetiracetam
xrl
healthi
cat
seven
healthi
cat
weigh
kg
includ
health
determin
normal
physic
neurolog
examin
pcv
tp
serum
biochemistri
evalu
xrl
administ
per
os
food
time
time
blood
collect
occur
hour
via
jugular
cathet
serum
levetiracetam
quantit
high
perform
liquid
chromatographi
use
techniqu
previous
valid
cat
data
report
mean
sd
c
max
lg
ml
adjust
c
max
lgml
max
minut
mrt
minut
clss
compens
f
c
hour
ug
ml
c
hour
lgml
v
adjust
f
lkg
dose
adjust
auc
lg
h
ml
cat
levetiracetam
concentr
minimum
human
interv
hour
cat
maintain
levetiracetam
concentr
interv
hour
advers
effect
note
throughout
studi
period
cat
maintain
normal
neurolog
examin
conclus
side
effect
appear
minim
mean
concentr
hour
minimum
human
therapeut
interv
lgml
suggest
daili
dose
may
possibl
howev
individu
peak
trough
serum
concentr
consid
administ
daili
osteosarcoma
common
primari
vertebr
tumor
dog
howev
previou
studi
examin
outcom
surgic
decompress
tumor
limit
goal
studi
determin
surviv
time
decompress
surgeri
alon
combin
adjunct
therapi
definit
radiat
chemotherapi
record
collect
retrospect
six
academ
privat
practic
institut
review
data
regard
surgic
procedur
neurolog
function
adjunct
therapi
surviv
sixteen
case
includ
receiv
decompress
surgeri
case
dog
treat
chemotherapi
dog
treat
chemotherapi
definit
radiat
therapi
dog
either
improv
neurolog
follow
surgeri
remain
stabl
neurolog
improv
pain
control
larg
breed
dog
averag
age
year
median
surviv
time
dog
treat
surgeri
alon
n
day
rang
one
outlier
still
aliv
year
surgeri
alon
one
dog
treat
chemotherapi
surviv
day
dog
treat
radiat
therapi
chemotherapi
n
median
surviv
time
day
rage
case
follow
avail
dog
euthan
due
recurr
primari
tumor
return
origin
clinic
sign
conclus
result
studi
indic
overal
surviv
time
surgic
decompress
alon
poor
adjunct
therapi
appear
prolong
surviv
case
primari
vertebr
osteosarcoma
decompress
surgeri
common
challeng
csf
analysi
timedepend
rapid
degrad
nucleat
cell
degrad
lead
inabl
accur
interpret
csf
diagnos
diseas
institut
treatment
csf
addit
fetal
calf
serum
hydroxyethyl
starch
hetastarch
use
delay
cell
degrad
alter
microprotein
level
purpos
research
determin
readili
avail
less
expens
hydroxyethyl
starch
vetstarch
tm
effect
preserv
csf
nucleat
cell
morpholog
without
alter
microprotein
level
csf
sampl
collect
dog
undergo
neurolog
workup
date
target
sampl
size
sampl
divid
aliquot
one
aliquot
analyz
immedi
control
remain
three
aliquot
receiv
one
stabil
agent
salin
fetal
calf
serum
vetstarch
tm
storag
sampl
analyz
hour
total
nucleat
cell
count
microprotein
cell
morpholog
score
record
morpholog
score
indic
observ
cellular
degener
score
indic
sever
degener
sampl
store
vetstarch
tm
fetal
calf
serum
exhibit
improv
morpholog
score
median
respect
compar
store
salin
studi
perform
identifi
mutat
caus
progress
neurodegen
diseas
shiba
inu
dog
storag
bodi
autofluoresc
two
relat
shiba
inu
dog
suspect
neuron
ceroid
lipofuscinosi
ncl
base
clinic
sign
antemortem
diagnost
diseas
progress
autofluoresc
storag
materi
histopatholog
whole
genom
sequenc
wg
gener
dna
one
affect
dog
use
previous
describ
techniqu
data
screen
potenti
causal
mutat
known
ncl
gene
candid
variant
found
howev
wg
contain
novel
homozyg
delet
conserv
codon
hexb
gene
encod
beta
subunit
betahexosaminidas
delet
found
wg
unaffect
dog
variou
breed
affect
shiba
inu
also
homozyg
variant
mutat
hexb
implic
gangliosidosi
sandhoff
diseas
human
dog
breed
betahexosaminidas
activ
measur
brain
tissu
one
affect
dog
use
previous
describ
synthet
substrat
activ
two
differ
substrat
markedli
reduc
compar
normal
dog
consist
sandhofflik
diseas
hexb
defici
thu
conclud
hexb
mutat
dog
caus
gangliosidosi
led
clinic
sign
knowledg
first
report
gangliosidosisassoci
storag
materi
autofluoresc
studi
also
demonstr
util
wg
effici
diagnosi
potenti
herit
diseas
veterinari
medicin
identifi
mutat
abolish
hexb
activ
shiba
inu
dog
easili
access
valid
biomark
glioma
need
aid
diagnosi
therapeut
monitor
exosom
extracellular
membran
vesicl
nm
releas
cell
microenviron
may
carri
signatur
cell
origin
hypothes
integrin
target
cyclic
nonapeptid
deriv
screen
human
canin
glioma
cell
would
identifi
canin
glioma
cell
line
cell
line
deriv
exosom
vitro
three
glioma
cell
line
use
valid
target
peptid
live
cell
use
flow
cytometri
immunofluoresc
label
peptid
canin
glioma
cell
deriv
exosom
isol
serum
free
media
use
exoquick
precipit
centrifug
character
use
nanoparticl
track
analysi
nta
technolog
nanosight
peptid
conjug
quantum
dot
nonglioma
target
peptid
use
neg
control
cell
line
label
peptid
label
exosom
isol
media
collect
cell
line
confirm
nta
analysi
immunocytochemistri
quantum
dot
conjug
label
exosom
demonstr
peptid
express
cell
surfac
canin
glioma
cell
demonstr
use
integrin
specif
peptid
target
consist
human
cell
line
express
dog
tumour
sampl
importantli
integrin
surfac
marker
also
express
cell
deriv
exosom
character
bind
exosom
csf
serum
therefor
ration
strategi
defin
access
biomark
glioma
vivo
mening
meningoenceph
meningoencephalomyel
mmemem
inflammatori
condit
may
immun
infecti
origin
perceiv
increas
condit
specialti
referr
practic
led
two
investig
studi
first
studi
retrospect
survey
mri
diagnos
made
period
assess
increas
preval
andor
tempor
trend
second
studi
prospect
studi
possibl
immun
infecti
caus
mme
mem
diagnos
practic
first
studi
monthli
incid
mmemem
calcul
studi
period
use
comput
search
immun
immuno
mening
meningoenceph
meningoencephalomyel
within
record
mri
diagnos
total
mri
annot
possibl
case
possibl
season
trend
seen
occur
aprilseptemb
second
studi
dog
consid
mmemem
case
base
mri
andor
csf
result
median
age
year
year
median
weight
kg
kg
breed
repres
infecti
diseas
one
bartonella
anaplasma
ehrlichia
identifi
via
routin
test
dog
vaccin
histori
avail
dog
case
receiv
one
vaccin
within
day
onset
clinic
sign
multival
bordetella
vaccin
commonli
administ
window
follow
leptospira
vaccin
number
vaccin
administ
recent
differ
dog
vaccin
caus
season
increas
mmemem
identifi
immun
origin
may
play
role
mediat
dog
undefin
mechan
relat
immunolog
booster
multival
monoval
vaccin
noninvas
prognost
indic
minim
dog
absent
pelvic
limb
deeppain
percept
result
acut
thoracolumbar
intervertebr
disc
herniat
examin
dog
present
one
veterinari
hospit
paraplegia
absent
pelvic
limb
deeppain
percept
undergo
mri
purpos
correl
mri
find
dog
clinic
outcom
medic
record
review
identifi
dog
meet
criteria
dog
includ
mri
studi
compris
sagitt
transvers
imag
cover
region
acut
disc
herniat
within
region
confirm
surgeri
necropsi
surviv
dog
prospect
follow
followup
neurolog
examin
week
postop
mri
studi
review
two
boardcertifi
radiologist
blind
outcom
fiftytwo
dog
met
inclus
criteria
outcom
data
avail
twelv
develop
myelomalacia
fail
recov
deeppain
percept
recov
deeppain
percept
voluntari
pelvic
limb
movement
week
postop
estim
rel
intramedullari
hyperintens
length
sagitt
plane
wellcorrel
observ
r
p
median
length
averag
hyperintens
differ
among
outcom
group
dog
hyperintens
bodi
length
good
recoveri
dog
develop
myelomalacia
hyperintens
bodi
length
conclud
sagitt
length
intramedullari
hyperintens
associ
acut
thoracolumbar
disc
herniat
dog
absent
deeppain
percept
appar
mri
scan
correl
likelihood
function
recoveri
develop
ascendingdescend
myelomalacia
object
clinic
studi
evalu
effect
dietari
supplement
medium
chain
triglycerid
oil
mct
proprietari
brain
nutrient
blend
bpb
contain
dha
epa
enhanc
level
b
vitamin
antioxid
arginin
pet
dog
cognit
dysfunct
syndrom
cd
previou
studi
shown
diet
supplement
mct
bpb
enhanc
learn
memori
problemsolv
abil
senior
dog
particip
veterinari
clinic
screen
senior
dog
sign
cd
determin
senior
canin
behavior
health
questionnair
includ
six
categori
disorient
alter
social
interact
sleepwak
cycl
disturb
loss
hous
train
anxieti
alter
activ
dog
screen
rule
potenti
medic
caus
randomli
enrol
one
three
diet
group
dog
per
group
control
mct
mct
mct
dog
sign
reevalu
day
day
categori
cd
sign
significantli
p
fisher
least
signific
differ
test
improv
dog
given
mct
oil
bpb
diet
end
studi
contrast
control
diet
significantli
improv
disorient
social
interact
score
mct
diet
observ
produc
signific
improv
dog
whose
owner
posit
feedback
diet
suggest
possibl
palat
issu
find
support
use
mct
bpb
supplement
diet
treatment
clinic
sign
senior
dog
sign
consist
cd
previou
epidemiolog
studi
use
valid
scale
provid
use
inform
chang
behaviour
cognit
compet
senior
dog
howev
usual
present
limit
nt
includ
inform
overal
health
statu
dog
target
preselect
popul
senior
dog
thu
miss
inform
age
group
comparison
could
made
behaviour
measur
focus
specif
behaviour
chang
link
age
process
oppos
impact
cognit
impair
could
overal
adapt
function
studi
design
explor
impact
age
process
popul
own
dog
includ
inform
overal
health
statu
overal
adapt
physic
social
environ
onlin
questionnair
made
avail
dog
owner
social
media
select
group
veterinari
clinic
avoid
agerel
selectionbia
studi
present
onlin
tool
dog
owner
estim
overal
level
adapt
dog
environ
particip
given
score
dog
call
global
function
score
question
divid
section
demograph
data
includ
age
weight
valid
scale
assess
cognit
dysfunct
canin
cognit
dysfunct
rate
scale
salvin
et
al
physic
health
condit
worri
owner
well
dog
perform
wide
rang
common
situat
interact
peopl
famili
member
dog
estim
preval
mild
moder
sever
case
cognit
dysfunct
two
method
use
firstli
score
cognit
dysfunct
rate
scale
calcul
accord
author
scheme
secondli
twostep
cluster
analysi
perform
cognit
function
score
kruskalw
use
explor
differ
cognit
dysfunct
score
weight
group
compar
global
function
score
gf
age
group
two
thousand
one
hundr
fourteen
valid
questionnair
obtain
dog
older
n
overal
preval
cognit
dysfunct
popul
sever
case
cognit
dysfunct
detect
year
age
howev
global
function
score
increas
age
declin
lowest
score
seen
dog
age
report
preval
cognit
dysfunct
owner
rank
last
list
health
condit
report
owner
includ
arthriti
tumour
hair
loss
deaf
breath
problem
owner
ask
rate
serious
list
health
condit
cognit
dysfunct
rank
third
behind
cancer
heart
diseas
arthriti
older
owner
rank
cognit
dysfunct
seriou
younger
owner
find
indic
although
cognit
dysfunct
common
often
detect
owner
may
due
combin
lack
knowledg
sign
condit
fals
percept
less
seriou
health
problem
need
tackl
want
improv
take
treatment
condit
global
function
score
indic
dog
everyday
perform
pet
offer
ad
inform
could
refin
help
earli
detect
cognit
dysfunct
age
gold
standard
treatment
recommend
veterinari
human
patient
intracrani
infect
includ
surgic
drainag
antibiot
therapi
purpos
retrospect
case
seri
describ
clinic
mri
find
well
medic
treatment
protocol
dog
confirm
presum
intracrani
bacteri
infect
treat
without
surgic
intervent
five
dog
treat
success
juli
may
describ
medic
treatment
decis
base
upon
diagnos
intracrani
bacteri
infect
andor
owner
reluct
surgic
intervent
mri
imag
patient
review
boardcertifi
veterinari
neurologist
radiologist
success
defin
posttreat
mri
confirm
resolut
primari
lesion
surviv
time
greater
month
past
discontinu
treatment
without
relaps
clinic
sign
dog
receiv
enrofloxacin
combin
second
antimicrobi
frequent
amoxicillinclavulan
acid
prednison
also
prescrib
variabl
dosag
durat
treatment
anim
includ
initi
period
intraven
medic
dog
treat
oral
medic
treatment
durat
rang
week
month
initi
clinic
sign
vari
sever
mild
neurolog
deficit
note
examin
sever
clinic
sign
alter
mental
statu
evid
increas
intracrani
pressur
four
dog
aliv
time
manuscript
composit
month
diagnosi
remain
dog
die
unrel
caus
month
diagnosi
conclud
medic
treatment
without
surgeri
feasibl
option
patient
presum
intracrani
infect
earli
aggress
therapi
broadspectrum
antibiot
recommend
clinic
sever
affect
outcom
group
dog
medic
record
dog
age
year
mue
receiv
cytarabin
review
mri
csf
find
use
confirm
diagnosi
mue
data
report
meansd
median
rang
appropri
student
ttest
wilcoxon
rank
sum
use
comparison
correl
assess
spearman
rank
correl
simpl
linear
regress
dog
receiv
least
cri
treatment
cytarabin
fourteen
dog
also
receiv
least
sq
treatment
number
cri
treatment
per
dog
median
surviv
dog
median
day
surviv
affect
age
diagnosi
p
durat
clinic
sign
p
sex
p
posit
signific
correl
number
cri
treatment
surviv
r
p
number
sq
treatment
affect
surviv
time
r
p
dog
relaps
posit
signific
correl
number
cri
treatment
longest
period
clinic
sign
relaps
r
p
dog
mue
may
live
longer
longer
period
time
clinic
relaps
increas
number
cytarabin
cri
treatment
mutat
gene
previous
associ
hereditari
myotonia
sever
speci
pig
aim
studi
character
hereditari
myotonia
pig
caus
gene
mutat
five
pig
litter
present
clinic
myotonia
two
nonmyoton
pig
submit
clinic
examin
electromyographi
emg
muscl
biopsi
hematoxylin
eosin
molecular
investig
muscl
blood
sampl
respect
use
rna
dna
extract
rtpcr
pcrsequenc
reaction
align
obtain
sequenc
clinic
affect
clinic
normal
ncbi
refer
pig
sequenc
genbank
perform
affect
anim
present
muscl
hypertrophi
stiff
action
myotonia
episod
especi
startl
warmup
phenomenon
observ
emg
affect
anim
evidenc
spontan
myoton
discharg
characterist
sound
dystroph
muscl
abnorm
observ
affect
anim
base
pair
bp
delet
c
correspond
exon
mrna
use
dna
absenc
bp
fragment
g
includ
aforement
exon
intron
entir
intron
partial
verifi
silico
analysi
suggest
mrna
delet
result
chlorid
voltageg
channel
protein
without
amino
acid
pedigre
analysi
indic
autosom
recess
mode
inherit
form
hereditari
myotonia
associ
gene
partial
delet
anim
speci
yet
report
diseas
studi
evalu
disposit
dog
epilepsi
object
studi
evalu
pharmacokinet
levxr
epilept
dog
administ
alon
concurr
a
popul
pharmacokinet
approach
nonlinear
mix
effect
model
nlme
use
examin
variat
sourc
variat
popul
eighteen
clientown
dog
mainten
therapi
levxr
group
l
n
levxr
phenobarbit
group
lp
n
levxr
zonisamid
group
lz
n
enrol
drug
examin
steadi
state
concentr
blood
sampl
collect
hour
morn
dose
levxr
administ
food
lp
group
significantli
lower
c
max
compar
l
lz
group
ae
vs
ae
ae
lg
ml
respect
significantli
lower
auc
ae
vs
ae
ae
respect
significantli
higher
clf
ae
vs
ae
ae
lkghour
respect
demonstr
concurr
administr
phenobarbit
significantli
lower
lev
concentr
epilept
dog
elimin
halflif
similar
among
group
l
ae
hour
lp
ae
hour
lz
ae
hour
shorter
previous
report
healthi
dog
find
warrant
consider
util
levxr
treatment
epilepsi
dog
frequent
occur
noninfecti
inflammatori
lesion
canin
spine
steroidrespons
meningitisarter
srma
pure
myeliti
rare
diseas
dog
although
meningomyel
unknown
caus
granulomat
meningomyel
common
diagnos
canin
case
noninfecti
myeliti
respons
glucocorticoid
treatment
well
describ
report
describ
clinic
diagnost
featur
steroidrespons
myeliti
srm
differ
srma
five
dog
five
dog
srm
identifi
retrospect
signal
histori
bodi
temperatur
neurolog
sign
diagnost
workup
treatment
prognosi
analyz
affect
breed
smallto
mediums
miniatur
pinscher
n
maltes
n
toy
poodl
n
cocker
spaniel
n
mean
age
dog
year
rang
year
paraspin
hyperesthesia
paresi
paralysi
acut
observ
accord
affect
region
spinal
cord
howev
dog
nonfebril
one
dog
neutrophil
leukocytosi
hematolog
analysi
magnet
reson
imag
mri
dog
reveal
diffus
spinal
lesion
flairhyperintens
isointens
signal
intens
differ
region
cervic
n
thoracolumbar
n
lumbosacr
n
multifoc
n
spinal
parenchyma
contrast
enhanc
detect
mening
four
dog
cerebrospin
fluid
csf
pleocytosi
mononuclear
n
mix
n
serum
csf
level
creactiv
protein
crp
immunoglobulin
iga
within
respect
normal
limit
except
two
dog
elev
serum
crp
dog
test
posit
csf
infecti
diseas
presumpt
diagnosi
noninfecti
inflammatori
myeliti
establish
base
clinic
sign
mr
scan
csf
analysi
laboratori
test
treatment
initi
prednisolon
mgkgday
oral
immunosuppress
dose
taper
accord
followup
result
mean
durat
immunosuppress
therapi
day
rang
day
medic
ceas
four
dog
improv
spinal
lesion
confirm
dog
neurolog
evalu
csf
analysi
mr
followup
scan
clinic
sign
recur
discontinu
glucocorticoid
type
myeliti
present
case
consid
steroidrespons
gener
srma
character
fever
neck
pain
neutrophilia
increas
level
iga
crp
neutrophil
pleocytosi
contrast
enhanc
mening
mr
scan
present
case
featur
srma
mononuclear
mix
pleocytosi
diffus
spinal
lesion
mr
imag
excel
respons
glucocorticoid
commonli
note
dog
object
studi
evalu
pharmacokinet
pk
cytarabin
ca
subcutan
sc
administr
dog
meningoencephalomyel
unknown
etiolog
mue
twelv
clientown
dog
month
year
old
weigh
kg
receiv
singl
sc
dose
ca
mgm
treatment
mue
spars
sampl
techniqu
use
collect
pharmacokinet
data
four
sampl
collect
dog
cover
time
period
minut
administr
dog
concurr
oral
prednison
dose
mgkgday
plasma
ca
concentr
measur
hplc
pharmacokinet
paramet
estim
use
nonlinear
mix
effect
model
nlme
plasma
drug
concentr
rang
lgml
popul
estim
cv
elimin
halflif
tmax
cytarabin
dog
h
h
respect
volum
distribut
per
fraction
absorb
lkg
mean
plasma
concentr
ca
dog
lgml
time
point
studi
pharmacokinet
ca
dog
mue
singl
mgm
sc
inject
dog
similar
previous
report
moder
variabl
popul
estim
small
clinic
popul
dog
purpos
studi
identifi
present
complaint
neurolog
find
diagnosi
outcom
dog
cat
cavern
sinu
syndrom
css
medic
record
review
inclus
criteria
neurolog
sign
consist
css
advanc
imag
andor
post
mortem
examin
thirteen
dog
cat
includ
twelv
dog
receiv
advanc
imag
post
mortem
examin
perform
cat
dog
dog
year
mean
year
differ
breed
cat
male
neuter
domest
shorthair
year
respect
present
complaint
includ
mydriasi
n
behavior
chang
n
hyporexia
n
ptosi
n
ataxia
n
pain
n
weak
n
lethargi
n
one
epiphora
ocular
swell
polydipsia
seizur
facial
muscl
atrophi
dysphagia
head
tilt
neurolog
sign
includ
ophthalmoparesisplegia
n
reducedabs
pupillari
light
respons
n
mydriasi
n
reducedabs
corneal
sensat
n
ptosi
n
reduc
facial
sensat
n
enophthalmo
n
thirteen
patient
mass
lesion
within
cavern
sinu
neoplast
histopatholog
median
surviv
time
patient
treat
radiat
therapi
day
rang
patient
receiv
medic
treatment
day
rang
day
nontreat
patient
day
rang
day
conclus
mydriasi
ophthalmoplegia
common
sign
css
mass
lesion
common
caus
surviv
time
may
improv
radiat
therapi
potassium
bromid
kbr
antiepilept
drug
wide
use
seizur
control
dog
diet
high
content
clhave
shown
decreas
serum
brconcentr
dog
howev
numer
relationship
dietari
clintak
serum
brconcentr
current
remain
unknown
therefor
aim
present
studi
quantifi
serum
brconcentr
dog
fed
diet
differ
content
cland
reveal
underli
relationship
order
contribut
therapeut
drug
monitor
kbr
steadyst
serum
brconcentr
measur
use
gold
chlorid
method
dog
treat
kbr
content
cl
per
g
measur
use
mohr
method
calcul
ingredi
label
provid
manufactur
regress
analysi
use
evalu
relationship
daili
clintak
mgkgday
serum
brconcentr
per
dose
lgml
per
mgkg
dog
higher
clintak
lower
serum
brconcentr
strong
neg
correl
observ
daili
clintak
mgkgday
serum
brconcentr
per
dose
lgml
per
mgkg
p
result
suggest
import
consid
dietari
content
clfor
kbrtreat
dog
may
also
assist
select
kbr
dose
appropri
diet
clinician
dog
treat
kbr
canin
central
nervou
system
tumor
develop
deepli
within
brain
parenchyma
preclud
surgic
resect
limit
therapeut
option
novel
bloodbrain
barrier
penetr
proapoptot
small
molecul
activ
orphan
drug
statu
treatment
human
glioblastoma
multiform
frequent
overexpress
malignantli
transform
tissu
provid
opportun
select
induc
apoptosi
cancer
cell
dysregul
upstream
apoptot
circuitri
studi
evalu
vitro
activ
panel
brain
tumor
cell
feasibl
combin
convent
therapi
dog
spontan
brain
cancer
immunohistochem
character
perform
normal
canin
brain
canin
human
intracrani
neoplasm
murin
canin
human
glioma
cell
line
evalu
express
vitro
sensit
radiat
monotherapi
dog
spontaneouslyaris
glioma
meningioma
treat
oral
combin
convent
therapi
determin
toler
serial
clinic
mri
outcom
assess
overexpress
canin
intracrani
neoplasm
high
grade
human
astrocytoma
rel
normal
brain
tissu
immort
canin
human
murin
glioma
cell
line
show
vitro
sensit
radiat
monotherapi
biolog
relev
exposur
six
dog
glioma
meningioma
receiv
combinatori
therapi
achiev
object
respons
complet
respons
partial
respons
stabl
diseas
show
therapeut
promis
treatment
canin
intracrani
neoplasia
well
high
grade
human
astrocytoma
investig
therapeut
approach
combin
radiat
therapi
andor
temozolomid
elucid
therapeut
potenti
murin
model
canin
patient
canin
bcell
lymphoma
common
hematolog
malign
clinic
heterogen
diseas
littl
progress
made
improv
remiss
durat
surviv
primari
goal
studi
correl
modifi
histopatholog
subclassif
flow
cytometri
fc
clinic
outcom
hypothes
histolog
distinct
subclassif
would
uniqu
cell
surfac
marker
determin
fc
subcategori
diseas
would
variabl
outcom
treat
standard
treatment
protocol
prospect
studi
dog
multicentr
bcell
lymphoma
treat
chop
chemotherapi
protocol
flint
anim
cancer
center
six
specialti
clinic
patient
lymph
node
biopsi
fc
collect
prior
therapi
outcom
correl
patient
characterist
treatment
histopatholog
subclassif
fc
featur
total
dog
enrol
flow
cytometri
diagnosi
bcell
lymphoma
consist
histopatholog
diagnosi
case
seventyseven
percent
dog
diagnos
diffus
larg
bcell
lymphoma
dlbcl
phenotyp
differ
subcategori
lymphoma
detect
fc
panel
dlbcl
fell
minimum
forward
light
scatter
valu
indic
cell
size
establish
fc
may
use
rule
diseas
median
overal
surviv
time
mst
dlbcl
day
statist
signific
compar
histopatholog
subgroup
combin
day
p
prognost
factor
identifi
univari
analysi
signific
median
progress
free
surviv
time
andor
mst
includ
cell
size
fc
presenc
lymphocytosi
presenc
hypercalcemia
need
dose
reduct
experienc
complet
remiss
best
respons
therapi
complet
chop
studi
need
determin
factor
may
allow
patient
stratif
eventu
modifi
therapi
improv
outcom
canin
osteosarcoma
osa
highli
aggress
mesenchym
cancer
account
canin
bone
tumor
osa
commonli
aris
long
bone
larg
breed
dog
patient
thought
micrometastas
diagnosi
standard
care
treatment
canin
osa
consist
amput
follow
chemotherapi
median
surviv
time
rang
day
develop
metastat
diseas
limit
longterm
surviv
patient
aliv
two
year
diagnosi
treatment
macroscop
metastasi
unreward
given
therapi
focus
prevent
metastat
diseas
epiderm
growth
factor
receptor
tyrosin
kinas
express
human
cancer
prostat
breast
ovari
stomach
colon
express
report
human
pediatr
osteosarcoma
increas
express
correl
aggress
biolog
behavior
increas
risk
metastasi
contrari
membran
express
seen
carcinoma
express
osa
princip
cytoplasm
canin
patient
one
previou
retrospect
studi
report
express
primari
tumor
sampl
suggest
express
correl
decreas
surviv
therefor
hypothes
express
canin
osa
denot
aggress
diseas
phenotyp
evalu
hypothesi
review
medic
record
osa
patient
suffici
formalinfix
tumor
tissu
avail
immunohistochem
ihc
analysi
sampl
least
malign
cell
stain
posit
classifi
base
criteria
primari
tumor
sampl
addit
metastat
lesion
total
dog
evalu
lesion
correl
express
primari
tumor
express
metastat
foci
sampl
score
base
percentag
neoplast
cell
stain
distribut
score
intens
stain
weak
moder
strong
combin
score
obtain
multipli
distribut
score
intens
score
base
combin
score
patient
group
negativelow
combin
score
intermedi
high
greater
categori
express
time
progress
ttp
overal
surviv
os
analysi
determin
whether
express
prognost
signific
ttp
os
dog
negativelow
medium
high
combin
herneu
score
determin
dog
treat
standard
care
amput
chemotherapi
n
includ
analysi
median
ttp
os
dog
negativelow
express
n
day
respect
compar
ttp
os
day
respect
dog
intermedi
express
n
ttp
os
dog
high
express
n
day
day
respect
previous
report
acvim
origin
data
set
show
correl
express
ttp
os
howev
report
patient
underw
standard
care
amput
chemotherapi
includ
ttp
os
analysi
reveal
trend
toward
shorter
ttp
os
dog
tumor
highli
express
prospect
studi
requir
determin
whether
statist
signific
correl
exist
statu
patient
outcom
nevertheless
taken
togeth
data
show
major
canin
osa
express
dog
tumor
high
combin
score
tendenc
toward
earlier
metastasi
decreas
os
data
support
evalu
target
immunotherapi
prevent
possibl
treatment
metastat
osa
osteosarcoma
osa
common
bone
tumor
children
dog
howev
despit
aggress
treatment
littl
improv
surviv
time
achiev
either
dog
peopl
past
year
microrna
mirna
small
noncod
rna
regul
gene
express
play
fundament
role
cancer
laboratori
previous
identifi
uniqu
mirna
express
signatur
associ
canin
osa
found
express
significantli
decreas
canin
osa
tumor
compar
normal
canin
osteoblast
data
concord
recent
studi
demonstr
function
tumorsuppressor
gene
human
osa
loss
associ
poor
prognosi
human
osa
patient
hypothes
loss
gener
pattern
gene
dysregul
contribut
pathogenesi
canin
osa
express
evalu
primari
canin
osa
tumor
osa
cell
line
normal
canin
osteoblast
cell
applic
inc
use
taqman
mirna
assay
investig
effect
osa
cell
behavior
canin
abram
cell
line
stabli
transduc
empti
control
lentivir
construct
system
bioscienc
cell
prolifer
cell
cycl
cell
invas
migrat
evalu
rna
sequenc
canin
cell
overexpress
perform
chang
gene
express
valid
use
realtim
pcr
real
time
pcr
demonstr
express
level
significantli
lower
primari
canin
osa
tumor
osa
cell
line
compar
normal
canin
osteoblast
furthermor
express
found
significantli
decreas
distant
metastas
compar
primari
osa
tumor
suggest
loss
directli
involv
metastat
process
address
effect
osa
cell
behavior
canin
abram
cell
line
express
low
basal
level
transduc
lentivir
construct
result
high
level
transform
canin
abram
cell
line
overexpress
reduc
cellular
invas
migrat
effect
cell
prolifer
cell
cycl
transcript
profil
cell
overexpress
demonstr
dysregul
sever
gene
includ
downregul
put
target
gene
associ
cellular
invas
consist
find
enhanc
express
gene
correl
decreas
express
primari
canin
osa
tumor
taken
togeth
find
suggest
may
play
import
role
regul
osa
invas
loss
vivo
may
promot
aggress
behavior
canin
osa
retrospect
review
case
includ
cat
surviv
surgeri
known
two
week
postop
statu
data
collect
includ
anatom
site
surgic
margin
surgic
complic
chemotherapi
postop
longterm
outcom
within
includ
case
affect
site
small
intestin
n
larg
intestin
n
stomach
n
complet
margin
n
unrel
anatom
site
lymphoma
thirti
cat
surviv
hospit
discharg
cat
surviv
sutur
remov
approxim
two
week
surgeri
report
caus
postop
death
includ
periton
sepsi
persist
worsen
clinic
sign
overal
mst
cat
surviv
sutur
remov
day
ci
mst
cat
larg
intestin
mass
significantli
longer
cat
small
intestin
stomach
mass
cat
assess
day
day
day
p
cat
surviv
sutur
remov
day
day
day
p
adjunct
system
chemotherapi
n
complet
surgic
margin
significantli
affect
surviv
seriou
complic
overal
uncommon
follow
resect
gastrointestin
lymphoma
major
case
found
surviv
periop
period
given
significantli
longer
surviv
time
cat
larg
intestin
lymphoma
may
reason
recommend
surgic
remov
cat
solitari
lymphoma
tumor
locat
purpos
studi
solicit
data
regard
current
clinic
use
toceranib
dog
gastrointestin
stromal
tumor
gist
provid
initi
assess
biolog
activ
american
colleg
veterinari
intern
medicin
oncolog
small
anim
intern
medicin
listserv
use
solicit
data
pertain
case
toceranib
use
treat
canin
gist
case
data
dog
histopathog
confirm
gist
receiv
particip
institut
dog
undergo
treatment
surgic
excis
prior
toceranib
exclud
clinic
benefit
cb
observ
complet
respons
cr
evid
diseas
ned
partial
respons
pr
stabl
diseas
sd
dog
microscop
diseas
experienc
cb
ned
cr
pr
sd
gross
diseas
experienc
cb
median
durat
treatment
dog
experienc
cb
week
time
data
submiss
respond
dog
still
receiv
treatment
addit
experienc
continu
ned
follow
complet
prescrib
therapi
dog
cb
median
toceranib
dose
mgkg
given
three
day
per
week
treatment
welltoler
experienc
advers
event
major
grade
gastrointestin
toxic
biolog
activ
toceranib
evid
studi
dog
howev
prospect
studi
need
refin
role
toceranib
treatment
gist
microscop
gross
diseas
set
regulatori
cell
treg
play
integr
role
suppress
inflamm
mainten
immunolog
toler
addit
treg
infiltr
varieti
tumor
tissu
therebi
suppress
antitumor
immun
howev
data
associ
tumorinfiltr
treg
prognosi
dog
variou
tumor
limit
purpos
studi
examin
number
tumorinfiltr
treg
associ
prognosi
dog
solid
tumor
studi
includ
canin
tumor
surgic
excis
veterinari
medic
center
univers
tokyo
may
decemb
basi
histopatholog
follow
diagnos
determin
squamou
cell
carcinoma
dog
hepatocellular
carcinoma
dog
oral
malign
melanoma
dog
lung
adenocarcinoma
dog
transit
cell
carcinoma
dog
normal
tissu
sampl
obtain
healthi
dog
treg
normal
tumor
tissu
examin
immunohistochemistri
cell
clear
lymphocyt
morpholog
distinct
nuclear
stain
unstain
cytoplasm
classifi
treg
treg
quantifi
differ
compart
intratumor
peritumor
area
surviv
analysi
case
classifi
high
low
densiti
treg
accord
median
treg
number
tumor
overal
surviv
compar
case
high
treg
number
low
treg
number
use
logrank
test
compar
normal
tissu
number
intratumor
peritumor
treg
tumor
tissu
significantli
increas
dog
squamou
cell
carcinoma
p
oral
malign
melanoma
p
lung
adenocarcinoma
p
transit
cell
carcinoma
p
signific
differ
observ
treg
normal
liver
hepatocellular
carcinoma
overal
surviv
case
high
number
intratumor
treg
significantli
shorter
case
low
number
intratumor
treg
dog
lung
adenocarcinoma
p
squamou
cell
carcinoma
p
transit
cell
carcinoma
p
dog
hepatocellular
carcinoma
oral
malign
melanoma
number
treg
significantli
relat
prognosi
studi
demonstr
treg
infiltr
variou
canin
tumor
tissu
higher
number
intratumor
treg
associ
neg
outcom
dog
lung
adenocarcinoma
squamou
cell
carcinoma
transit
cell
carcinoma
suggest
tumorinfiltr
treg
contribut
suppress
antitumor
immun
dog
well
human
osteosarcoma
common
primari
bone
malign
dog
base
favor
find
infect
canin
limbspar
patient
stagnant
surviv
time
despit
plethora
adjuv
chemotherapi
option
promis
recent
preclin
human
immunotherapi
outcom
novel
immunotherapi
approach
becom
attract
treatment
option
hypothes
cell
infus
made
peripher
blood
mononuclear
cell
pbmc
activ
stimul
prolifer
ex
vivo
exposur
superantigen
could
safe
administ
healthi
dog
dog
osteosarcoma
addit
evalu
safeti
cours
lowdos
human
follow
cell
infus
four
dog
use
healthi
dog
studi
femal
hound
male
mongrel
three
dog
spontan
occur
osteosarcoma
enrol
initi
phase
iii
clinic
trial
univers
missouri
two
underw
cours
autolog
vaccin
leukapheresi
one
also
receiv
ex
vivoactiv
cell
healthi
dog
underw
leukapheresi
isol
pbmc
cell
select
grown
ex
vivo
use
imdm
media
superantigen
follow
cultur
superantigen
remov
product
infus
dog
premed
also
receiv
five
subcutan
dose
dog
vital
analyz
aerobicanaerob
cultur
perform
cytokin
analyz
minim
side
effect
note
healthi
dog
vital
show
normal
variat
studi
gastrointestin
sign
often
note
random
emesi
document
three
four
dog
proinflammatori
cytokin
ifnc
tnfa
antiinflammatori
cytokin
produc
although
signific
inflammatorytyp
symptom
note
healthi
dog
clinic
patient
discharg
day
leukapheresi
procedur
clinic
patient
receiv
ex
vivoactiv
cell
premed
experienc
sever
inflammatori
respons
becam
septic
dog
recov
still
aliv
month
diagnosi
sign
metastasi
cancer
therapi
base
encourag
safeti
data
healthi
canin
patient
adopt
cell
transfer
approach
potenti
chang
treatment
recommend
outcom
dog
diagnos
osteosarcoma
phase
iii
clinic
trial
ongo
determin
amput
inde
safe
result
similar
enhanc
efficaci
compar
surgeri
chemotherapi
exosom
small
lipid
vesicl
mediat
celltocel
commun
cancer
cell
exploit
exosom
promot
metastasi
evad
host
immun
respons
facilit
angiogenesi
present
effect
osteosarcoma
osa
exosom
healthi
osteoblast
studi
first
studi
investig
proteom
composit
canin
osa
exosom
impact
osteoblast
hypothes
osa
exosom
carri
uniqu
cargo
manipul
healthi
osteoblast
result
alter
bone
turnov
exosom
extract
osa
po
hmpo
co
healthi
osteoblast
cnob
supernat
size
concentr
exosom
valid
via
nanoparticl
track
analysi
exosom
proteom
content
determin
mass
spectrometri
valid
western
blot
vitro
assay
perform
cocultur
osa
exosom
cnob
treat
cnob
untreat
cnob
exosom
untreat
cnob
also
subject
proteom
analysi
fluoresc
calcif
assay
assess
hydroxyapatit
deposit
perform
osa
cell
osteoblast
alon
osteoblast
treat
osa
exosom
osa
exosom
contain
protein
comparison
cnob
deriv
exosom
osa
exosom
reveal
addit
protein
associ
ossif
gelsolin
osteocalcin
vitamin
bind
protein
cnob
treat
osa
exosom
show
upregul
protein
downregul
protein
compar
untreat
cnob
osa
cell
exhibit
osteoblast
characterist
fluoresc
calcif
assay
cnob
challeng
osa
exosom
secret
hydroxyapatit
increas
significantli
p
find
demonstr
osa
exosom
contain
proosteoblast
cargo
promot
healthi
osteoblast
increas
bone
deposit
studi
provid
preliminari
understand
role
osasecret
exosom
impact
bone
microenviron
increas
express
program
cell
death
ligand
note
subset
human
lymphoma
recent
target
antibodi
therapi
purpos
studi
measur
express
canin
diffus
larg
bcell
lymphoma
dlbcl
util
quantit
real
time
polymeras
chain
reaction
qpcr
determin
express
correl
progress
free
surviv
pf
biorepositori
maintain
purdu
compar
oncolog
program
search
rna
sampl
histopathologicallyconfirm
case
canin
dlbcl
diagnos
archiv
lymph
node
biopsi
sampl
process
trizol
reagent
dog
retriev
pair
rna
sampl
lymph
node
clinic
healthi
dog
retriev
serv
control
multiplex
qpcr
perform
use
taqman
probe
primer
canin
gapdh
data
analyz
use
ddct
method
calcul
fold
chang
express
dlbcl
rel
normal
lymph
node
fortytwo
dog
met
inclus
criteria
median
progress
free
surviv
time
day
rang
day
express
dlbcl
sampl
rang
fold
differ
measur
normal
canin
lymph
node
dog
fold
chang
less
fold
chang
compar
normal
lymph
node
averag
express
dichotom
fold
chang
greater
less
found
significantli
associ
pf
use
logrank
test
howev
model
continu
express
found
neg
correl
pf
univari
multivari
cox
proport
hazard
model
find
demonstr
variabl
express
canin
dlbcl
higher
express
correl
reduc
pf
affect
dog
introduct
monocarboxyl
transport
mct
transport
lactic
acid
across
plasma
membran
provid
mechan
tumor
cell
meet
bioenerget
need
glycolysi
varieti
microenviron
object
work
explor
therapeut
potenti
modul
cellular
metabol
inhibit
canin
osteosarcoma
ultim
goal
provid
proof
principl
data
support
futur
clinic
studi
materi
method
express
canin
osteosarcoma
assess
qrtpcr
western
blot
ihc
prolifer
apoptosi
oxygen
consumpt
evalu
use
shrna
small
molecul
inhibitor
direct
metformin
doxorubicin
evalu
abil
synerg
small
molecul
inhibitor
result
express
higher
level
rel
canin
osteosarcoma
cell
line
small
molecul
inhibitor
direct
significantli
decreas
cell
prolifer
synergist
activ
observ
cell
treat
doxorubicin
metformin
presenc
small
molecul
inhibitor
conclus
express
canin
osteosarcoma
drug
combin
synergist
activ
necessari
realiz
full
potenti
inhibit
transit
cell
carcinoma
tcc
common
neoplasia
urinari
tract
dog
tend
local
invas
moder
metastat
rate
system
medic
therapi
combin
nonsteroid
antiinflammatori
drug
nsaid
chemotherapeut
agent
current
mainstay
treatment
receptor
tyrosin
kinas
rtk
play
import
role
promot
cell
growth
differenti
regul
cell
function
rtk
inhibitor
palladia
use
anecdot
treat
tcc
goal
studi
evalu
archiv
normal
urinari
bladder
tcc
cystiti
bladder
sampl
express
palladia
target
pdgfrb
stem
cell
factor
receptor
kit
formalinfix
paraffin
waxembed
sampl
canin
urinari
bladder
transit
cell
carcinoma
canin
urinari
bladder
cystiti
normal
canin
urinari
bladder
obtain
univers
tennesse
depart
pathobiolog
histolog
archiv
use
studi
stain
pdgfrb
kit
carri
use
standard
immunohistochem
procedur
develop
use
formalin
fix
tissu
stain
intens
evalu
repres
section
overal
stain
intens
score
entir
section
immunohistochem
stain
cell
stain
evalu
ten
field
given
score
final
score
product
calcul
multipli
intens
score
immunohistochem
stain
score
signific
number
tcc
sampl
express
pdgfrb
compar
cystiti
normal
bladder
sampl
larg
number
tcc
sampl
also
mild
moder
stain
kit
compar
cystiti
normal
bladder
sampl
differ
statist
signific
base
proof
target
studi
investig
warrant
determin
clinic
respons
tcc
palladia
chemotherapyinduc
vomit
inappet
civi
common
advers
event
experienc
cancer
patient
howev
incid
recommend
treatment
follow
administr
specif
chemotherapeut
establish
dog
aim
studi
assess
perceiv
emetogen
inappet
potenti
chemotherapeut
evalu
clinic
use
antiemet
appetit
stimul
dog
receiv
chemotherapi
survey
issu
american
colleg
veterinari
intern
medicin
oncolog
small
anim
intern
medicin
listserv
assess
perceiv
incid
clinic
manag
acut
delay
civi
associ
chemotherapeut
defin
vcogctca
eightyf
complet
survey
evalu
respons
oncologist
privat
practic
practic
medic
oncolog
oral
chemotherapeut
evalu
associ
minimallow
risk
acut
delay
vomit
independ
vcog
grade
inject
chemotherapeut
associ
moderatehigh
risk
caus
clinic
signific
acut
delay
vomit
includ
cisplatin
dacarbazin
epirubicin
paclitaxel
streptozocin
nine
antiemet
evalu
maropit
ondansetron
frequent
administ
inappet
follow
chemotherapi
administr
commonli
treat
maropit
mirtazapin
perceiv
incid
manag
civi
dog
wide
differ
dog
receiv
chemotherapeut
current
perceiv
lower
potenti
civi
may
also
benefit
clinic
treatment
antiemet
andor
appetit
stimul
research
understand
true
incid
clinic
impact
civi
contribut
develop
guidelin
appropri
manag
effect
dog
cutan
lymphoma
repres
skin
tumor
dog
classifi
epitheliotrop
nonepitheliotrop
unlik
anatom
form
lymphoma
cutan
lymphoma
low
respons
treatment
dog
nonepitheliotrop
lymphoma
lower
surviv
time
compar
dog
epitheliotrop
form
resist
neoplast
cell
cytotox
drug
major
caus
failur
chemotherapi
cancer
one
multipl
drug
resist
mechan
mdr
activ
drug
efflux
mediat
atpbind
cassett
superfamili
abc
among
transport
pglycoprotein
aim
studi
investig
immunoexpress
cutan
epitheliotrop
nonepitheliotrop
lymphoma
immunohistochemistri
perform
paraffinembed
tumor
sampl
cutan
lymphoma
dog
nonepitheliotrop
epitheliotrop
use
marker
immunophenotyp
antibodi
enzo
life
scienc
found
epitheliotrop
tcell
bcell
nonepitheliotrop
tcell
bcell
lymphoma
two
sampl
epitheliotrop
lymphoma
neg
median
percentag
label
cell
wherea
nonepitheliotrop
lymphoma
case
posit
median
percentag
label
cell
statist
analysi
show
signific
differ
express
marker
p
conclus
major
case
cutan
lymphoma
express
pglycoprotein
subtyp
nonepitheliotrop
show
higher
label
cell
epitheliotrop
intestin
lymphoma
main
anatom
form
lymphoma
diagnos
cat
cell
prolifer
indic
express
mitot
index
may
import
assess
clinic
behavior
tumor
determin
degre
malign
object
studi
determin
express
mitot
index
intestin
lymphoma
cat
relat
overal
surviv
time
fortyseven
sampl
cat
intestin
lymphoma
studi
immunohistochem
perform
analysi
made
count
infiltr
lymphocyt
tumor
microenviron
mitot
index
rank
mild
moder
high
evalu
microscop
field
result
show
signific
differ
immunohistochem
express
b
tcell
lymphoma
p
median
respect
observ
compar
histolog
type
lymphoblast
lymphocyt
median
respect
p
regard
mitot
index
two
cat
lymphoblast
bcell
one
lymphoblast
tcell
lymphoma
show
high
express
three
anim
show
moder
express
major
case
anim
mild
express
conclus
express
better
prolif
marker
compar
mitot
index
cat
intestin
lymphoma
higher
express
observ
anim
affect
lymphoblast
bcell
relat
low
therapeut
respons
shorter
surviv
time
typic
caus
growthhormon
gh
secret
pituitari
adenoma
thought
common
caus
felin
diabet
mellitu
medic
pituitari
inhibit
challeng
human
cat
condit
could
relat
variabl
express
somatostatin
sstr
dopamin
dr
receptor
express
five
differ
sstr
subtyp
five
differ
subtyp
dr
predomin
dr
subtyp
human
pituitari
pasireotid
somatostatin
analogu
high
bind
affin
effect
control
gh
secret
felin
acromegal
somatostatin
analogu
high
bind
affin
octreotid
lanreotid
aim
studi
document
receptor
express
felin
somatotrophinoma
compar
healthi
felin
pituitari
utilis
novel
customis
multiplex
rtqpcr
assay
investig
express
profil
somatostatin
dopamin
receptor
ghsecret
pituitari
adenoma
pituitari
adenoma
rna
extract
ghsecret
adenoma
eight
control
cat
follow
multiplex
rtqpcr
analys
multipl
gene
includ
somatostatin
receptor
dopamin
receptor
growth
hormon
receptor
growth
hormon
secretagogu
receptor
housekeep
normalis
gene
express
acromegal
cat
vs
control
cat
undetect
express
upregul
acromegal
vs
control
p
p
increas
ci
increas
ci
increas
ci
gene
express
significantli
differ
tumor
normal
pituitari
tissu
within
hypersomatotrop
group
exhibit
moder
neg
correl
pituitari
volum
r
p
rsquar
felin
ghsecret
adenoma
express
sstr
similar
human
ghsecret
adenoma
higher
express
howev
higher
express
vs
human
may
explain
greater
biochem
respons
pasireotid
octreotid
decreas
express
larger
tumour
may
mechan
allow
uncheck
adenoma
growth
receptor
express
profil
felin
ghsecret
adenoma
help
search
improv
medic
manag
option
felin
hypersomatotrop
acth
stimul
test
use
cosyntropin
mcgkg
iv
prefer
method
diagnosi
hypoadrenocortic
previou
studi
shown
maxim
stimul
adren
gland
use
mcgkg
cosyntropin
normal
dog
studi
evalu
efficaci
lower
dose
dog
suspect
hypoadrenocortic
object
compar
mcgkg
lowdos
mcgkg
highdos
cosyntropin
iv
determin
dose
result
similar
adrenocort
respons
test
prospect
perform
dog
suspect
hypoadrenocortic
dog
suspect
hypoadrenocortic
receiv
mcgkg
cosyntropin
iv
follow
four
hour
later
mcgkg
cosyntropin
iv
preliminari
studi
confirm
valid
perform
two
acth
stimul
test
day
blood
sampl
obtain
preand
one
hour
postacth
dose
measur
total
cortisol
measur
use
previous
valid
radioimmunoassay
detect
differ
cortisol
concentr
cosyntropin
dose
mcgkg
time
point
baselin
data
analyz
use
pair
ttest
equival
test
commerci
statist
comput
program
signific
set
p
level
twelv
dog
includ
administr
acth
dose
caus
signific
increas
cortisol
concentr
p
signific
differ
detect
postacth
cortisol
concentr
mean
postacth
cortisol
concentr
highdos
significantli
greater
mean
postacth
cortisol
concentr
obtain
lowdos
onetail
p
valu
p
use
equival
test
result
two
test
equival
p
therefor
mcgkg
iv
dose
cosyntropin
caus
maxim
adren
respons
standard
mcgkg
iv
dose
dog
suspect
hypoadrenocortic
lower
dose
suffici
acth
stimul
test
patient
suspect
hypoadrenocortic
veterinaryspecif
enzymelink
immunoassay
elisa
snap
cortisol
test
kit
idexx
usa
avail
veterinarian
inhous
diagnosi
manag
canin
hypoand
hyperadrenocortic
howev
analyt
perform
assay
report
peerreview
literatur
purpos
studi
investig
precis
elisa
agreement
elisa
two
chemiluminesc
assay
ca
two
refer
laboratori
clinic
implic
identifi
bia
store
frozen
canin
serum
sampl
use
elisa
precis
prospect
evalu
measur
three
canin
serum
pool
low
medium
high
cortisol
concentr
respect
triplic
five
consecut
day
prospect
method
comparison
studi
perform
measur
cortisol
concentr
sixtythre
independ
canin
serum
sampl
use
elisa
two
ca
method
compar
use
pearson
correl
passingbablok
regress
blandaltman
analys
clinic
implic
identifi
bia
investig
use
error
grid
withinlaboratori
coeffici
variat
low
medium
high
concentr
pool
respect
constant
proport
bias
elisa
ca
method
present
concentr
good
overal
correl
ca
r
r
despit
identifi
bias
clinic
agreement
result
sampl
clinic
agreement
elisa
ca
case
clinic
disagr
would
occur
case
equivoc
result
report
elisa
confirm
refer
laboratori
radioiodin
treatment
choic
felin
hyperthyroid
safeti
efficaci
dose
determin
cat
remain
controversi
goal
achiev
euthyroid
state
one
treatment
avoid
persist
hyperthyroid
hypothyroid
method
dose
determin
abl
consist
achiev
goal
test
hypothesi
radioiodin
dose
determin
base
thyroid
scintigraphi
would
associ
reduct
hypothyroid
without
increas
persist
hyperthyroid
month
post
radioiodin
treatment
compar
fix
dose
purpos
studi
compar
novel
method
radioiodin
dose
determin
util
thyroid
scintigraphi
novel
dose
group
standard
fix
dose
method
fix
dose
group
treatment
hyperthyroid
cat
specif
studi
focus
determin
radioiodin
dose
measur
thyroid
gland
size
percent
tco
uptak
use
thyroid
scintigraphi
hyperthyroid
diagnos
cat
find
serum
concentr
refer
interv
characterist
diagnost
hyperthyroid
nuclear
scintigraphi
scintigraphi
perform
obtain
imag
minut
iv
administr
mci
tco
cat
novel
dose
group
percent
dose
uptak
calcul
draw
region
interest
around
thyroid
gland
lobe
divid
correct
count
cpm
thyroid
gland
tco
dose
cpm
cat
percent
dose
uptak
calcul
receiv
mci
mci
mci
respect
administ
subcutan
thyroid
size
assess
ratio
thyroid
roi
size
pixel
salivari
roi
size
pixel
ts
cat
ts
ratio
calcul
receiv
mci
mci
mci
dose
given
first
determin
measur
percent
dose
uptak
thyroid
size
fell
higher
dose
categori
percent
uptak
dose
increas
accordingli
cat
fix
dose
group
receiv
mean
mci
subcutan
cat
evalu
month
treatment
determin
function
statu
thyroid
gland
hypothyroid
defin
serum
concentr
refer
interv
persist
hyperthyroid
defin
serum
concentr
refer
interv
month
post
treatment
fiftyeight
cat
includ
novel
dose
group
fix
dose
group
consist
cat
treat
prior
novel
dose
group
univari
analysi
use
chisquar
fisher
exact
analysi
use
determin
associ
dose
determin
method
outcom
level
signific
set
p
hypothyroid
develop
cat
fix
dose
group
compar
novel
dose
group
p
persist
hyperthyroid
occur
cat
fix
dose
group
compar
cat
novel
dose
group
p
result
studi
show
statist
differ
number
cat
remain
persist
hyperthyroid
becom
hypothyroid
month
post
radioiodin
treatment
use
novel
modifi
fix
dose
protocol
compar
standard
fix
dose
protocol
studi
investig
novel
radioiodin
dose
determin
need
incorpor
addit
dose
addit
mci
mci
mci
describ
studi
blood
glucos
concentr
frequent
measur
dog
mani
diseas
associ
hypoglycemia
hyperglycemia
diabet
mellitu
use
whole
blood
serum
plasma
affect
result
use
human
glucomet
serum
plasma
yield
accur
result
tauk
et
al
j
vet
med
assoc
purpos
studi
investig
correl
glucos
concentr
canin
whole
blood
serum
plasma
measur
zoeti
parsippani
nj
veterinari
glucomet
glucos
concentr
measur
biochem
analyz
prospect
studi
blood
sampl
collect
dog
reason
present
absolut
entranc
criteria
sampl
diabet
dog
sought
immedi
follow
blood
draw
blood
place
heparin
tube
submiss
laboratori
drop
blood
analyz
specif
design
studi
blood
also
use
fill
heparin
capillari
tube
nonheparin
capillari
tube
capillari
tube
centrifug
within
minut
collect
acquir
serum
nonheparin
tube
plasma
heparin
tube
obtain
glucos
concentr
measur
within
minut
follow
blood
draw
blood
submit
auburn
univers
clinic
patholog
lab
determin
glucos
concentr
autom
biochem
analyz
blood
glucos
concentr
whole
blood
serum
plasma
measur
compar
blood
glucos
concentr
measur
autom
analyz
lin
concord
correl
coeffici
pc
blandaltman
plot
use
determin
correl
agreement
result
obtain
differ
sampl
type
glucos
concentr
whole
blood
measur
strongli
correl
glucos
concentr
measur
biochem
analyz
pc
compar
serum
plasma
glucos
concentr
pc
canin
serum
plasma
respect
mean
differ
glucos
concentr
whole
blood
serum
plasma
measur
glucos
concentr
determin
biochem
analyz
mgdl
respect
find
suggest
use
accuraci
reliabl
glucos
measur
obtain
may
increas
use
whole
blood
compar
serum
plasma
thu
use
whole
blood
would
allow
correct
assess
diagnosi
necessari
appropri
therapeut
intervent
optim
irradi
schedul
canin
adrenocorticotrop
hormon
acth
secret
pituitari
tumor
defin
respons
evalu
criteria
establish
aim
studi
evalu
timerel
clinic
magnet
reson
imag
mri
respons
dog
suffer
pituitari
hyperadrenocortic
measur
mass
mri
treat
stereotact
radiotherapi
rt
singl
institut
prospect
singl
arm
observ
studi
conduct
dog
naiv
endocrin
treatment
suffer
pituitari
hyperadrenocortic
diagnos
standard
laboratori
imag
test
irradi
mv
linac
use
volumetr
modul
arc
therapi
dose
gy
deliv
fraction
altern
day
basi
concomit
administr
trilostan
start
tumor
endocrin
respons
evalu
repeat
mri
pituitari
adren
gland
month
basal
acthstimul
cortisol
serial
measur
dose
trilostan
achiev
eucortisol
record
dog
enrol
median
pituitari
tumor
volum
cmc
rang
cmc
mean
basal
stimul
cortisol
diagnosi
mcgdl
mcgdl
mean
initi
dose
trilostan
h
complet
regress
tumor
observ
dog
month
median
month
partial
regress
end
studi
progress
observ
normal
thick
adren
gland
observ
dog
month
median
month
eucortisol
obtain
except
dog
trilostan
progress
taper
withdrawn
month
median
month
radio
toxic
encount
rt
schedul
use
studi
allow
optim
tumor
endocrin
control
gradual
progress
respons
observ
start
volumetr
respons
pituitari
tumor
delay
sever
month
treatment
respons
adren
gland
ultim
reduct
serum
cortisol
level
achiev
pattern
respons
must
taken
consider
follow
evalu
adjust
dose
trilostan
establish
evalu
criteria
insulin
glargin
uml
toujeo
insulin
detemir
levemir
synthet
longact
insulin
analog
associ
minim
intraand
interpati
variabl
episod
hypoglycemia
peopl
toujeo
predict
longer
act
compar
glargin
uml
lantu
peopl
purpos
studi
assess
pharmacokinet
pharmacodynam
toujeo
compar
levemir
healthi
dog
eight
healthi
purposebr
dog
receiv
nmolkg
levemir
toujeo
ukg
ukg
respect
sc
inject
two
differ
day
least
one
week
apart
random
order
endogen
exogen
insulin
measur
hourli
mercodia
isoinsulin
mercodia
canin
insulin
elisa
blood
glucos
bg
measur
everi
minut
glucos
administ
intraven
variabl
rate
goal
maintain
bg
within
baselin
bg
isoglycem
clamp
glucos
infus
rate
declin
endogen
insulin
use
defin
exogen
insulin
action
median
onset
action
significantli
delay
toujeo
compar
levemir
hour
hour
vs
hour
hour
p
signific
differ
peak
toujeo
might
better
suit
levemir
oncedaili
insulin
dog
base
long
durat
action
peakless
timeact
profil
daytoday
variabl
insulin
action
still
assess
formul
baselin
cortisol
concentr
routin
use
screen
dog
hypoadrenocortic
hoc
result
hypothes
exposur
unpleas
auditori
stimulu
prior
sampl
collect
would
trigger
cortisol
product
increas
concentr
nmoll
cutoff
healthi
dog
twentyeight
healthi
clientown
dog
evalu
median
age
year
rang
year
median
weight
kg
rang
kg
dog
inelig
inclus
receiv
shortor
longact
glucocorticoid
within
previou
day
respect
dog
randomli
assign
control
n
test
brief
nois
n
long
nois
n
group
dog
owner
wait
seclud
area
minut
brief
nois
dog
expos
sound
wetdri
vacuum
minut
start
period
long
nois
dog
expos
random
burst
wetdri
vacuum
nois
minut
blood
collect
adjac
room
sampl
process
immedi
serum
frozen
prior
submiss
median
cortisol
concentr
three
group
similar
control
nmoll
rang
nmoll
brief
nois
nmoll
rang
nmoll
long
nois
nmoll
rang
nmoll
figur
expos
dog
unpleas
nois
stimulu
minut
prior
sampl
collect
increas
serum
cortisol
concentr
unlik
improv
specif
baselin
cortisol
determin
screen
test
hoc
identifi
predictor
felin
diabet
remiss
aid
veterinarian
advis
diabet
cat
prognosi
might
provid
insight
etiolog
felin
diabet
remiss
previou
investig
often
studi
referr
patient
util
rel
small
sampl
size
wherea
examin
larger
divers
popul
might
identifi
new
predictor
studi
aim
document
remiss
rate
among
larg
cohort
diabet
cat
examin
uk
primarycar
veterinari
practic
identifi
predictor
remiss
observ
retrospect
cohort
studi
conduct
use
electron
patient
record
data
collect
vetcompass
companion
anim
surveil
programm
septemb
august
cat
newlydiagnos
diabet
mellitu
dm
identifi
occurr
remiss
record
cumul
probabl
remiss
assess
use
kaplanmei
estim
predictor
remiss
identifi
use
multivari
timedepend
cox
proport
hazard
model
mortal
within
day
dm
diagnosi
predictor
death
also
assess
use
kaplanmei
estim
multivari
binari
logist
regress
respect
signific
set
averag
valu
given
median
interquartil
rang
five
hundr
eightythre
cat
male
femal
unknown
sex
recruit
practic
five
hundr
seventeen
crossbr
burmes
n
common
pure
breed
median
age
year
median
bodyweight
kg
median
followup
time
day
oneyear
cumul
probabl
remiss
confid
interv
ci
multivari
analysi
reveal
glucocorticoid
therapi
day
diagnosi
hazard
ratio
hr
ci
p
burmes
breed
compar
crossbr
statu
hr
ci
p
independ
predictor
remiss
cumul
probabl
surviv
day
diagnosi
ci
lack
medic
antihyperglycem
therapi
odd
ratio
ci
p
lower
bodyweight
kg
diagnosi
ci
p
independ
associ
increas
odd
death
within
day
dm
diagnosi
probabl
remiss
lower
often
document
referr
popul
high
mortal
follow
dm
diagnosi
owner
reluct
pursu
medic
therapi
present
substanti
barrier
achiev
greater
diabet
remiss
rate
primarycar
practic
increas
likelihood
diabet
remiss
previous
identifi
burmes
cat
could
result
differ
pathogenesi
dm
burmes
compar
breed
type
warrant
investig
longact
insulin
treatment
recommend
felin
diabet
mellitu
dm
insulin
glargin
frequent
propos
offer
greatest
efficaci
likelihood
diabet
remiss
howev
recent
systemat
review
identifi
unbias
adequ
power
longterm
comparison
insulin
type
lack
oneyear
prospect
random
clinic
trial
conduct
compar
glycem
control
remiss
rate
associ
glargin
lantu
sanofi
humanrecombin
pzi
pzir
prozinc
boehring
ingelheim
therapi
diabet
cat
recentlydiagnos
diabet
cat
durat
week
month
recruit
dedic
felin
dm
clinic
cat
transit
lowcarbohydr
diet
day
first
examin
overweight
cat
bodi
condit
score
receiv
calor
intak
aim
weight
loss
cat
exclud
prerecruit
screen
identifi
ketoacidosi
clinic
pancreat
glucocorticoidprogestogen
administr
hyperthyroid
hypersomatotrop
condit
caus
like
insulin
resist
diabet
control
assess
use
fructosamin
valid
diabet
clinic
score
dc
mean
blood
glucos
mbg
blood
glucos
curv
bgc
twicedaili
bid
insulin
dose
ukg
pet
owner
qualiti
life
assess
use
valid
diaqolpet
score
cat
random
receiv
bid
glargin
pzir
underw
oneyear
standard
reexamin
program
insulin
dose
adjust
accord
singl
nadirl
protocol
base
bgc
result
twosampl
ttest
mannwhitney
utest
assess
differ
mbg
fructosamin
bid
insulin
dose
diaqolpet
score
dc
group
baselin
month
proport
cat
enter
remiss
compar
use
kaplanmei
product
limit
estim
log
rank
test
predictor
remiss
identifi
use
multivari
cox
proport
hazard
model
signific
set
p
fortysix
cat
recruit
signific
differ
mbg
fructosamin
bid
insulin
dose
diaqolpet
score
dc
identifi
group
time
point
eight
glarginetr
cat
five
pzirtreat
cat
achiev
remiss
p
baselin
bodyweight
kg
hazard
ratio
hr
confid
interv
ci
p
baselin
felin
bodi
mass
index
hr
ci
p
weight
loss
time
point
hr
ci
p
identifi
possibl
associ
remiss
univari
analysi
criterion
p
multivari
analysi
reveal
minimum
weight
loss
time
point
signific
predictor
remiss
hr
ci
p
current
studi
unpreced
term
size
control
bia
reveal
glargin
pzir
produc
compar
glycem
control
detect
differ
remiss
rate
among
recruit
cat
clinician
consid
implement
control
weight
loss
program
prioriti
overweight
diabet
cat
order
promot
remiss
effect
hyperadrenocortic
hac
bone
dog
controversi
aim
studi
investig
effect
bone
turnov
assess
intact
whole
parathyroid
hormon
pth
concentr
marker
osteoblast
osteocalcin
oc
osteoclast
carboxytermin
crosslink
telopeptid
type
collagen
ictp
activ
blood
sampl
collect
dog
hac
hospit
control
popul
intact
whole
pth
irma
scantibodi
oc
elisa
immunodiagnost
system
ictp
ria
orion
diagnostica
measur
use
commerci
human
kit
data
report
median
rang
differ
group
assess
mann
whitney
test
intact
whole
pth
concentr
significantli
higher
p
case
dog
hac
pgml
pgml
respect
compar
control
dog
pgml
pgml
respect
median
oc
concentr
dog
hac
significantli
differ
control
dog
ngml
ngml
respect
median
ictp
concentr
dog
hac
significantli
lower
p
control
dog
ngml
ngml
respect
whole
intact
pth
concentr
higher
dog
hac
appear
associ
decreas
bone
format
increas
bone
resorpt
assess
oc
ictp
measur
respect
sever
assay
avail
measur
intact
parathyroid
hormon
ipth
concentr
report
compar
assay
dog
intact
pth
concentr
measur
use
immunoradiometr
assay
irma
scantibodi
chemiluminesc
assay
clia
immulit
design
human
use
canin
specif
enzymelink
immunosorb
assay
elisa
immutop
sampl
duplic
assess
use
techniqu
within
hour
sampl
respect
avail
comparison
irma
elisa
irma
clia
correl
elisa
irma
good
r
ci
p
blandaltman
differ
plot
reveal
bia
elisa
result
greater
irma
valu
mean
ae
sd
ae
ci
use
clia
sampl
ipth
concentr
report
limit
detect
assay
pgml
remain
nine
dog
detect
low
concentr
rang
pgml
comparison
valu
higher
irma
rang
pgml
clia
recommend
measur
canin
ipth
valu
undetect
may
relat
antibodi
use
within
assay
nonisotop
elisa
confer
advantag
irma
regard
eas
use
yield
higher
valu
would
impact
clinic
decisionmak
addit
high
preval
duplic
error
gel
format
impact
reliabl
whilst
technic
demand
irma
prove
reliabl
robust
method
evalu
abnorm
total
calcium
tca
valu
necessarili
impli
hypohypercalcemia
base
measur
ioniz
calcium
mica
unfortun
mica
readili
avail
practic
dog
increas
decreas
tca
multivari
adapt
regress
spline
model
use
predict
mica
creatinin
albumin
tca
phosphoru
sodium
potassium
chlorid
alkalin
phosphatas
alp
triglycerid
age
sensit
specif
predict
ioniz
calcium
pica
compar
correct
tca
true
hyperhypocalcemia
mcnemar
test
impact
miss
biochemistri
valu
predict
model
accuraci
assess
replac
miss
biochemistri
variabl
midrefer
interv
valu
accuraci
consid
alter
pica
becam
significantli
differ
mica
wilcoxon
test
dog
elev
tca
truli
hypercalcem
base
mica
sensit
pica
correct
tca
equival
detect
hypercalcemia
p
specif
pica
significantli
higher
specif
correct
tca
diagnos
hypercalcemia
p
dog
decreas
tca
truli
hypocalcem
base
mica
sensit
pica
significantli
higher
sensit
correct
tca
detect
hypocalcemia
p
specif
pica
correct
tca
equival
diagnos
hypocalcemia
p
without
miss
valu
pica
significantli
differ
mica
p
triglycerid
phosphoru
sodium
alp
could
miss
without
alter
pica
accuraci
dog
abnorm
tca
valu
true
hyperhypocalcemia
may
assess
pica
even
triglycerid
phosphoru
sodium
alp
measur
avail
hyperthyroid
decreas
bodi
muscl
mass
serum
creatinin
concentr
confound
diagnosi
concurr
chronic
kidney
diseas
ckd
serum
symmetr
dimethylarginin
sdma
concentr
influenc
lesser
extent
muscl
mass
might
better
biomark
ckd
hyperthyroid
studi
aim
evalu
serum
sdma
concentr
hyperthyroid
cat
without
azotem
ckd
hyperthyroid
euthyroid
without
azotem
ckd
control
cat
year
old
includ
hyperthyroid
cat
receiv
antithyroid
medic
monitor
azotemia
serum
creatinin
concentr
mgdl
three
month
follow
period
hyperthyroid
cat
azotem
treatment
follow
includ
hyperthyroidckd
group
kruskalw
dunn
multipl
comparison
test
use
compar
baselin
serum
creatinin
sdma
concentr
sdma
measur
idexx
laboratori
control
hyperthyroidckd
hyperthyroid
nonazotem
group
median
rang
valu
present
serum
creatinin
concentr
control
mgdl
n
hyperthyroid
group
significantli
differ
howev
serum
creatinin
significantli
higher
hyperthyroidckd
group
mgdl
n
hyperthyroid
nonazotem
group
mgdl
n
p
serum
sdma
concentr
significantli
p
differ
control
lgdl
hyperthyroidckd
lgdl
hyperthyroid
nonazotem
group
lgdl
serum
sdma
concentr
distinguish
hyperthyroid
cat
without
azotem
ckd
influenc
hyperthyroid
serum
sdma
concentr
warrant
investig
obes
frequent
nutrit
disord
dog
associ
sever
metabol
alter
repres
risk
factor
sever
system
comorbid
howev
controversi
adipos
tissu
contribut
complic
canin
speci
present
studi
aim
evalu
subcutan
viscer
adipos
tissu
ten
obes
femal
dog
ten
femal
dog
eutroph
bodi
condit
regard
adipocyt
size
presenc
leukocyt
infiltr
studi
conduct
routin
anim
veterinari
hospit
anim
submit
complet
clinic
examin
classif
base
bodi
condit
score
blood
exam
exclud
concomit
diseas
fragment
subcutan
viscer
adipos
tissu
obtain
elect
ovariosalpingohisterectomi
procedur
sampl
stain
hematoxylineosin
analyz
zeiss
microscop
softwar
observ
obes
dog
present
remark
larger
adipocyt
size
compar
anim
ideal
bodi
condit
signific
level
student
ttest
likewis
note
presenc
significantli
higher
leukocyt
infiltr
obes
anim
signific
level
kruskalw
test
compar
anim
normal
bodi
condit
leukocyt
infiltr
detect
howev
size
adipocyt
leukocyt
infiltr
obes
anim
differ
significantli
viscer
subcutan
adipos
tissu
sampl
conclud
therefor
obes
dog
relat
increas
adipocyt
presenc
leukocyt
infiltr
possibl
state
studi
differ
fat
deposit
differenti
metabol
endocrin
level
could
interfer
specif
way
inher
process
obes
diabet
patient
obes
frequent
nutrit
disord
dog
cat
result
oxid
stress
evalu
oxid
stress
perform
process
lipid
peroxid
malon
one
abund
aldehyd
evalu
method
call
test
substanc
react
thiobarbitur
acid
tbar
object
present
studi
evalu
oxid
stress
measur
tbar
present
sampl
obes
dog
weight
loss
program
work
carri
routin
anim
veterinari
hospit
pontif
cathol
univers
parana
locat
parana
brazil
anim
submit
complet
clinic
examin
blood
count
biochemistri
urinalysi
systol
blood
pressur
measur
subsequ
classifi
obes
bodi
scale
bodi
mass
index
percentag
bodi
fat
anim
divid
group
prediet
group
postdiet
ten
obes
anim
select
submit
hypocalor
diet
loss
program
tbar
perform
use
elisa
techniqu
anim
group
present
tbar
valu
refer
valu
statist
signific
reduct
valu
group
group
p
base
result
conclud
obes
dog
present
higher
product
lipid
peroxid
anim
ideal
bodi
scale
lead
develop
oxid
stress
elev
tbar
concentr
one
import
endocrin
test
diagnosi
control
hyperadrenocortic
hac
dog
acth
stimul
object
studi
evalu
efficaci
corticotropin
induc
cortisol
product
dog
possibl
use
altern
tetracosactrin
synacthen
current
use
drug
adren
challeng
test
mainli
latin
america
thirti
acth
stimul
test
perform
dog
divid
group
control
anim
femal
male
healthi
mean
age
ae
year
treatment
anim
femal
male
previous
hyperadrenocortic
diagnos
mean
age
ae
year
anim
control
word
first
challeng
synacthen
acthelea
dog
trilostano
mgkgday
acth
stimul
test
initi
hour
postpil
administr
per
manufactur
instruct
first
stimul
test
perform
use
synacthen
drug
elect
induc
cortisol
respons
second
separ
day
period
use
acthelea
blood
sampl
obtain
inject
minut
postacth
first
assess
cortisol
basal
concentr
control
group
csynba
celeaba
treat
group
ttosynba
ttoeleapo
second
collect
assess
cortisol
concentr
postacth
control
group
csynpo
celeapo
treat
group
ttosynpo
ttoeleapo
dose
mlkg
synacthen
mlkg
acthelea
iv
serum
cortisol
concentr
measur
provetbr
hormon
laboratori
use
previous
valid
radioimmunoassay
mp
biomed
result
express
mediums
ae
sem
control
group
result
obtain
baselin
valu
ae
lgdl
csynba
ae
lgdl
celeaba
p
postacth
valu
ae
lgdl
csynpo
ae
lgdl
celeapo
p
signific
differ
mean
baselin
poststimul
control
group
compar
result
among
drug
treat
group
baselin
valu
ae
lgdl
ttosynba
ae
lgdl
ttoeleaba
p
acth
valu
ae
lg
dl
ttosynpo
ae
lgdl
ttoeleapo
p
therefor
signific
differ
observ
valu
obtain
compar
use
two
drug
appli
test
accord
result
obtain
studi
conclud
acthelea
effect
stimul
product
cortisol
dog
use
option
acth
stimul
test
particularli
place
synacthen
avail
human
show
metabol
chang
chemotherapi
due
action
mechan
chemotherapi
drug
andor
concomit
corticosteroid
therapi
health
consequ
aim
studi
evalu
similar
chang
dog
laboratori
test
dog
diagnos
cutan
mastocytoma
treat
small
anim
surgeri
depart
faculdad
de
medicina
veterin
aria
e
zootecnia
universidad
de
paulo
submit
differ
chemotherapi
protocol
tumor
excis
analyz
compar
level
triglycerid
cholesterol
fast
glucos
patient
submit
chemotherapi
accord
protocol
intraven
ivinblastin
mgm
weekli
session
fortnightli
session
metronom
dose
oral
iilomustin
mg
sid
week
associ
oral
prednison
mgkg
sid
intraven
synthet
iiiphosphoethanolamin
mgm
weekli
session
without
glucocorticoid
measur
perform
period
three
period
monthli
protocol
ii
weekli
protocol
iii
day
complet
chemotherapi
c
nineteen
dog
assess
femal
eight
male
mean
age
year
hypertriglyceridemia
elev
serum
glucos
observ
dog
treat
chemotherapi
associ
glucocorticoid
studi
chang
necessari
recent
decad
preval
felin
hyperthyroid
fht
increas
significantli
worldwid
current
major
endocrin
diseas
caus
high
morbid
middleag
cat
due
lack
studi
endocrin
diseas
brazil
retrospect
studi
store
serum
sampl
cat
older
eight
year
treat
veterinari
hospit
anhembi
morumbi
univers
paulo
brazil
carri
januari
januari
regardless
main
complaint
led
treat
servic
thyroid
function
evalu
total
thyroxin
measur
total
cat
serum
sampl
sent
privat
laboratori
measur
radioimmunoassay
ria
assess
serum
sampl
confirm
felin
hyperthyroid
within
normal
rang
normal
valu
suggest
sick
euthyroid
syndrom
sampl
valu
close
upper
limit
valu
rais
possibl
cat
fht
whose
comorbid
time
blood
collect
reduc
valu
blood
serum
conclud
even
though
preval
fht
assess
group
shown
discreet
clinic
suspicion
part
differenti
diagnosi
cat
age
eight
year
endoand
exogen
hypercortisolemia
well
known
associ
insulin
resist
dog
howev
type
chang
level
hormon
involv
maintain
blood
glucos
level
dog
hypercortisolemia
unknown
object
studi
assess
whether
insulin
sensit
factor
regul
blood
glucos
level
dog
alter
chronic
administr
hydrocortison
six
laboratori
dog
receiv
hydrocortison
mgkg
oral
everi
hour
day
variabl
serial
examin
day
hydrocortison
administr
insulin
sensit
evalu
homeostat
model
assess
homa
insulin
sensit
viscer
fat
quantifi
comput
tomographi
hydrocortison
administr
homa
insulin
sensit
significantli
decreas
although
fast
glucos
concentr
maintain
within
refer
rang
viscer
fat
mass
significantli
increas
addit
homa
insulin
sensit
significantli
correl
viscer
fat
mass
chang
serum
concentr
leptin
adiponectin
insulin
glucosedepend
insulinotroph
polypeptid
gip
pancreat
polypeptid
glucagon
ghrelin
signific
except
kclike
chemokin
differ
concentr
inflammatori
cytokin
signific
correl
viscer
fat
mass
leptin
adiponectin
ghrelin
gip
insulin
concentr
homa
insulin
sensit
signific
result
suggest
insulin
sensit
decreas
hydrocortison
administr
like
associ
increas
viscer
fat
mass
chang
serum
concentr
hormon
regul
glucos
level
dog
studi
clarifi
result
natur
occur
hyperadrenocortic
dog
need
persist
hyperton
diabet
dog
c
perez
brandt
schermerhorn
kansa
state
univers
manhattan
ks
usa
tonic
function
serum
concentr
effect
osmol
sodium
na
chlorid
cl
glucos
glu
major
endogen
osmol
affect
tonic
glu
contribut
significantli
hyperglycem
state
pathophysiolog
consequ
hyperton
ht
complet
understood
persist
ht
may
affect
diseas
progress
diabet
human
mani
diabet
dog
experi
persist
hyperglycemia
role
ht
dog
investig
studi
object
evalu
diabet
dog
evid
persist
ht
retrospect
evalu
perform
compar
pertin
solut
concentr
tonic
indic
insulintr
diabet
dog
dd
n
dog
nondiabet
dog
ndd
n
data
analysi
comparison
group
made
use
student
test
correl
perform
use
spearman
rho
test
roc
analysi
use
studi
relationship
mean
corpuscular
volum
differ
dmcv
fructosamin
dd
tonic
vs
mosml
p
glu
vs
mgdl
p
elev
na
cl
decreas
compar
ndd
ht
tonic
mosml
occur
frequent
dd
vs
ndd
dmcv
marker
ht
significantli
increas
dd
vs
fl
ndd
increas
dmcv
predict
elev
fructosamin
lmoll
sensit
specif
result
show
stabl
insulintr
diabet
dog
frequent
ht
glu
major
osmol
contribut
ht
dd
increas
dmcv
modest
predictor
serum
fructosamin
suggest
latter
indirect
marker
hyperton
dd
conclus
dog
moderatepoor
glycem
control
show
evid
persist
ht
although
addit
studi
need
investig
role
persist
ht
possibl
consequ
diabet
dog
imbal
vitamin
statu
recent
suggest
associ
diseas
progress
human
pancreat
date
howev
studi
investig
associ
vitamin
statu
acut
pancreat
ap
dog
therefor
purpos
studi
examin
differ
concentr
serum
oh
healthi
dog
vs
ap
dog
determin
correl
oh
ioniz
calcium
ica
creactiv
protein
crp
level
prospect
observ
cohort
studi
includ
clientown
dog
newli
diagnos
ap
otherwis
healthi
dog
similar
bodycondit
score
circul
concentr
serum
oh
blood
ica
serum
crp
measur
serum
oh
blood
ica
concentr
significantli
lower
serum
crp
concentr
significantli
higher
dog
ap
healthi
dog
signific
differ
concentr
serum
oh
ap
survivor
nonsurvivor
differ
concentr
blood
ica
serum
crp
ap
survivor
nonsurvivor
signific
concentr
oh
posit
correl
concentr
ica
albumin
dog
ap
convers
neg
correl
observ
serum
concentr
crp
ica
ap
group
studi
found
dog
ap
exhibit
decreas
oh
level
might
result
inflammatori
respons
rather
caus
ap
moreov
alter
serum
oh
concentr
might
associ
diseas
sever
mortal
dog
ap
high
preval
cholestat
diseas
includ
gall
bladder
mucocel
gbm
report
dog
naturallyoccur
pituitarydepend
hyperadrenocortic
differ
exist
clinic
featur
dog
pdh
concurr
cholestat
diseas
also
manag
dog
trilostan
studi
clientown
dog
naturallyoccur
pdh
analyz
dog
treat
trilostan
least
month
studi
good
clinic
respons
determin
owner
statist
comparison
clinic
sign
result
routin
blood
test
basal
postacth
cortisol
concentr
optim
trilostan
dosag
made
dog
separ
follow
group
ultrasonograph
imag
normal
ultrasound
nou
group
cholestasi
group
gbm
group
gbm
group
sever
clinic
sign
significantli
differ
total
serum
cholesterol
concentr
postacth
stimul
cortisol
concentr
time
diagnosi
dog
weigh
kg
significantli
higher
preval
cholestat
diseas
dog
p
optim
trilostan
dosag
gbm
cholestasi
group
time
dosag
nou
group
respect
p
gall
bladder
diseas
associ
cholestat
diseas
correl
pdh
dog
clinic
featur
drug
manag
find
may
associ
hypercholesterolemia
unidentifi
genet
factor
hydrophob
natur
trilostan
hypothyroid
common
endocrinopathi
dog
howev
diagnosi
hypothyroid
may
difficult
nonthyroid
ill
nti
medic
might
affect
result
thyroid
function
test
object
studi
evalu
use
thyrotropin
tsh
stimul
test
diagnos
hypothyroid
casecontrol
prospect
studi
includ
dog
clientown
dog
suspect
alter
thyroid
function
dog
receiv
oral
hydrocortison
day
tsh
stimul
test
perform
dog
base
result
test
clientown
dog
divid
group
follow
dog
hypothyroid
dog
nti
dog
without
hypothyroid
mean
basal
serum
concentr
dog
hydrocortison
administr
similar
dog
hypothyroid
lgdl
lgdl
respect
mean
basal
serum
concentr
dog
nti
dog
without
hypothyroid
lgdl
lgdl
respect
mean
postrhtsh
concentr
dog
administ
hydrocortison
dog
nti
dog
without
hypothyroid
increas
lgdl
lgdl
lgdl
respect
postrhtsh
concentr
dog
hypothyroid
remain
lgdl
peak
postrhtsh
concentr
dog
administ
hydrocortison
occur
hour
stimul
dog
nti
dog
without
hypothyroid
occur
hour
inject
rhtsh
result
indic
tsh
stimul
test
use
rhtsh
could
use
method
diagnos
hypothyroid
even
dog
receiv
longterm
highdos
hydrocortison
clinic
practic
tsh
stimul
test
valuabl
diagnosi
hypothyroid
dog
varieti
nti
hyperadrenocortic
dog
administ
glucocorticoid
adrenocorticotrop
hormon
acth
stimul
test
excel
tool
assess
adren
gland
function
dog
among
variou
present
acth
avail
test
depot
tetracosactid
synacthen
depot
econom
advantag
countri
volum
concentr
ampoul
ml
advantag
depend
reus
surplu
volum
ampoul
indic
dose
dog
ml
per
dog
aim
evalu
effect
freez
biolog
activ
depot
tetracosactid
stimul
adren
gland
healthi
dog
thirteen
healthi
adult
dog
submit
acth
stimul
test
mldogim
four
time
interv
two
month
test
month
first
stimul
test
done
everi
dog
first
aliquot
fresh
refriger
ampoul
open
time
applic
remain
three
aliquot
store
plastic
syring
unit
protect
light
sampl
determin
serum
cortisol
radioimmunoassay
obtain
one
two
hour
administr
acth
sampl
thaw
analyz
duplic
anova
serum
cortisol
level
differ
significantli
p
freez
sampl
time
conclud
depot
tetracosactid
store
plastic
syring
six
month
without
interf
biolog
stabil
hormon
portabl
blood
glucos
meter
pbgm
wide
use
use
control
blood
glucos
level
howev
accuraci
pbgm
question
repeatedli
factor
interfer
blood
glucos
measur
identifi
object
studi
evalu
factor
associ
deviat
measur
obtain
pbgm
blood
glucos
refer
rang
dog
prospect
studi
includ
clientown
dog
present
veterinari
medic
center
variou
diseas
includ
diabet
mellitu
blood
sampl
n
collect
jugular
vein
blood
glucos
concentr
measur
pbgm
ipet
onetouch
ultra
cerapet
vetmat
optium
xceed
compar
measur
refer
method
accuraci
evalu
accord
iso
statist
agreement
pbgm
measur
determin
spearman
correl
analysi
passingbablok
regress
analysi
wilcoxon
signedrank
test
blandaltman
plot
error
grid
analysi
mannwhitney
kruskalw
test
perform
assess
variabl
expect
affect
glucos
measur
spearman
correl
analysi
reveal
high
correl
valu
obtain
pbgm
refer
method
howev
blandaltman
plot
show
deviat
pbgm
valu
refer
rang
increas
actual
glucos
concentr
increas
decreas
pack
cell
volum
pcv
result
overestim
underestim
blood
glucos
valu
ipet
onetouch
ultra
respect
hypertriglyceridemia
result
overestim
glucos
valu
ipet
cerapet
vetmat
hyperproteinemia
result
overestim
glucos
valu
onetouch
ultra
optium
xceed
error
grid
analysi
reveal
onetouch
ultra
cerapet
optium
xceed
adequ
base
minimum
accuraci
criteria
iso
result
suggest
hypertriglyceridemia
hyperproteinemia
decreas
pcv
significantli
affect
result
obtain
variou
pbgm
clarif
caus
error
glucos
measur
lead
accur
assess
diseas
appropri
glucos
control
treatment
diabet
dog
previou
studi
shown
relationship
mucos
bacteria
host
respons
cat
inflammatori
bowel
diseas
ibd
lymphoma
lsa
howev
earlier
studi
investig
specif
microbi
etiolog
factor
select
recruit
mucos
tumorinfiltr
immun
cell
may
promot
tumor
progress
object
present
studi
investig
relationship
proinflammatori
microbiota
includ
fusobacterium
spp
helicobact
spp
enterobacteriacea
mucos
cell
cat
small
cell
lsa
vs
ibd
retrospect
analysi
cat
diagnos
intestin
lsa
n
ibd
n
perform
follow
detail
diagnost
evalu
confirm
histopatholog
diagnosi
mucos
microbiota
endoscop
intestin
biopsi
ibd
lsa
cat
evalu
fluoresc
situ
hybrid
fish
target
rrna
gene
select
proinflammatori
microbiota
host
respons
microbi
dysbiosi
studi
use
immunohistochemistri
identifi
cell
gastrointestin
mucosa
express
intestin
nfkb
result
indic
ibd
lsa
cat
middl
age
older
chronic
gastrointestin
sign
sever
month
durat
analysi
fish
show
mucos
bacteria
eub
uncommonli
observ
duodenum
diseas
cat
number
mucos
bacteroid
spp
clostridium
spp
increas
p
ibd
cat
compar
cat
lsa
convers
total
number
fusobacterium
spp
increas
p
colon
tissu
cat
lsa
vs
ibd
lsa
median
rang
ibd
median
rang
moreov
number
fusobacterium
spp
found
within
adher
mucu
colon
cat
lsa
increas
p
rel
mucos
compart
mucos
cell
express
nfkb
increas
p
intestin
cat
lsa
vs
ibd
suggest
presenc
proinflammatori
microenviron
conclus
alter
exist
composit
mucos
microbiota
cat
lsa
ibd
intestin
cat
lsa
select
enrich
bacteri
speci
includ
fusobacterium
spp
microbiota
may
trigger
recruit
tumorinfiltr
immun
cell
contribut
proinflammatori
environ
conduc
intestin
lsa
progress
diarrhea
sequela
gastrointestin
hyperperm
common
complic
antibiot
therapi
akkermansia
muciniphila
mucindegrad
bacterium
posit
associ
gastrointestin
epitheli
health
decreas
permeabl
object
studi
measur
effect
akkermansia
administr
marker
gastrointestin
permeabl
follow
antibiot
administr
eight
healthi
purposebr
dog
random
receiv
either
akkermansia
cfukg
n
vehicl
n
day
follow
cours
metronidazol
washout
dog
crossedov
altern
treatment
addit
washout
experi
repeat
amoxicillinclavulan
fecal
akkermansia
qpcr
plasma
concentr
measur
elisa
lipopolysaccharid
glucagonlik
peptid
measur
baselin
postantibiot
posttreat
vehicl
akkermansia
antibiot
absolut
delta
concentr
compar
timepoint
use
repeat
measur
anova
akkermansia
detect
fece
dog
follow
supplement
delta
metronidazol
significantli
lower
vehicl
ng
ml
vs
akkermansia
ngml
p
concentr
tend
decreas
amoxicillinclavulan
p
postprandi
concentr
pm
ml
higher
preprandi
pmml
concentr
advers
sideeffect
signific
biomark
alter
note
akkermansia
muciniphila
pcr
detect
suggest
success
gastrointestin
transit
follow
oral
supplement
dog
effect
gastrointestin
epithelium
base
plasma
alter
studi
need
determin
impact
dog
natur
occur
diseas
dysbiosi
thought
play
major
role
pathogenesi
intestin
diseas
treatment
intestin
diseas
may
involv
use
antimicrobi
effect
microbiota
fulli
understood
sever
antibiot
shown
promot
dysbiosi
aim
studi
prospect
evalu
impact
tylosin
administr
fecal
microbiota
healthi
dog
ten
healthi
pet
dog
randomli
assign
one
group
doubleblind
fashion
dog
treat
oral
tylosin
mgkg
dog
treat
placebo
capsul
given
hr
day
dog
maintain
usual
diet
fecal
sampl
collect
day
fecal
score
rang
note
daili
drug
administr
addit
fecal
sampl
collect
day
fecal
sampl
assess
use
qpcr
bacteri
group
faecalibacterium
turicibact
e
coli
streptococcu
blautia
c
hiranoni
fusobacterium
result
analyz
bacteri
group
also
compil
mathemat
singl
numer
valu
dysbiosi
index
di
paramet
compar
use
friedman
test
follow
dunn
posttest
pvalu
consid
statist
signific
none
dog
either
group
develop
diarrhea
di
increas
significantli
day
median
rang
compar
day
p
tylosin
treatment
di
remain
significantli
increas
day
p
day
p
abund
faecalibacterium
significantli
decreas
tylosin
treatment
signific
chang
abund
bacteri
group
di
note
dog
receiv
placebo
tylosin
profound
effect
fecal
microbiota
dog
persist
least
month
studi
warrant
determin
dysbiosi
secondari
antimicrobi
administr
increas
patient
risk
develop
diseas
intestin
otherwis
futur
pancreat
may
caus
extrahepat
bile
duct
obstruct
secondari
local
inflamm
vicin
common
bile
duct
date
limit
evid
support
optim
treatment
condit
purpos
studi
describ
clinic
present
outcom
dog
develop
extrahepat
bile
duct
obstruct
secondari
pancreat
assess
factor
associ
surviv
retrospect
review
medic
record
matthew
j
ryan
veterinari
hospit
univers
pennsylvania
perform
case
includ
clinic
sign
ultrasonograph
find
consist
pancreat
extrahepat
bile
duct
obstruct
suspect
base
ultrasonograph
common
bile
duct
dilat
greater
mm
presenc
hyperbilirubinemia
case
exclud
anoth
caus
bile
duct
obstruct
identifi
medic
record
incomplet
medic
record
search
physic
examin
find
clinicopatholog
data
diagnost
imag
find
treatment
outcom
refer
veterinarian
contact
necessari
inform
regard
surviv
median
surviv
time
determin
use
kaplanmei
product
limit
method
cox
multivari
surviv
method
employ
determin
factor
associ
surviv
time
follow
diagnosi
complet
medic
record
avail
dog
dog
manag
medic
dog
manag
surgic
overal
median
surviv
time
day
ci
dog
year
age
older
azotemia
greater
hazard
death
ci
p
compar
dog
younger
year
old
without
azotemia
dog
temperatur
greater
admiss
greater
hazard
death
ci
p
dog
bodi
temperatur
less
admiss
dog
without
gallbladd
distens
ultrasound
greater
hazard
death
ci
p
compar
dog
gallbladd
distens
dog
extrahepat
bile
duct
obstruct
secondari
pancreat
age
year
older
azotemia
admiss
bodi
temperatur
greater
admiss
lack
gallbladd
distens
ultrasound
associ
increas
risk
death
medic
vs
surgic
manag
total
bilirubin
admiss
chang
total
bilirubin
hospit
magnitud
increas
liver
enzym
activ
significantli
associ
outcom
group
dog
canin
inflammatori
bowel
diseas
ibd
believ
multifactori
diseas
due
abnorm
immun
respons
intestin
microb
genet
suscept
individu
proinflammatori
cytokin
previous
shown
elev
biopsi
dog
food
respons
diseas
small
number
case
purpos
studi
investig
duoden
level
protein
larger
number
dog
differ
clinic
sever
ibd
duoden
biopsi
ten
dog
mild
ibd
canin
chronic
enteropathi
clinic
activ
index
ccecai
moder
ibd
ccecai
sever
ibd
ccecai
dog
proteinlos
enteropathi
ple
well
healthi
beagl
dog
includ
studi
biopsi
sampl
weigh
prior
manipul
sampl
homogen
hz
minut
homogen
buffer
pb
contain
proteas
inhibitor
cocktail
tissu
homogen
centrifug
rcf
minut
supernat
frozen
day
elisa
quantif
protein
express
determin
use
commerci
avail
caninespecif
elisa
kingfish
biotech
inc
follow
manufactur
assay
instruct
sampl
analys
duplic
median
express
pgmlmg
tissu
rang
sever
ibd
group
rang
moder
sever
ibd
group
rang
mild
sever
ibd
group
rang
ple
group
rang
healthi
control
dog
statist
signific
differ
express
ibd
dog
healthi
control
p
result
studi
support
previou
find
may
involv
pathogenesi
canin
ibd
criteria
develop
world
small
anim
veterinari
associ
wsava
commonli
use
assess
felin
intestin
biopsi
specimen
howev
histolog
characterist
intestin
biopsi
specimen
collect
healthi
cat
well
character
use
score
system
aim
studi
describ
histolog
find
endoscop
deriv
intestin
biopsi
specimen
clinic
healthi
cat
twelv
clinic
healthi
clientown
cat
underw
gastroduodenoscopi
veterinari
medic
teach
hospit
texa
univers
anim
use
protocol
ca
tissu
specimen
collect
stomach
cat
duodenum
cat
evalu
accord
wsava
criteria
boardcertifi
pathologist
mra
blind
health
statu
cat
median
age
cat
year
minmax
year
sampl
qualiti
report
good
case
histolog
evalu
stomach
reveal
lymphoplasmacyt
infiltr
specimen
evalu
grade
minim
cat
minim
mild
cat
mild
cat
mild
moder
cat
moder
cat
histolog
evalu
duoden
biopsi
reveal
evid
lymphoplasmacyt
infiltr
cat
describ
minim
mild
cat
mild
cat
mild
moder
cat
moder
cat
assess
duoden
specimen
cat
diagnos
diffus
lowgrad
lymphoma
architectur
chang
present
gastric
duoden
section
consist
fibrosi
cat
gastric
specimen
lacteal
dilat
cat
crypt
abscess
cat
fibrosi
cat
crypt
hyperplasia
cat
duoden
specimen
conclus
intestin
biopsi
clinic
healthi
cat
commonli
show
mucos
chang
consid
abnorm
evalu
accord
wsava
guidelin
cholestyramin
bile
acid
sequestr
act
gastrointestin
tract
bind
bile
acid
thu
prevent
reabsorpt
human
patient
inflammatori
bowel
diseas
ibd
cholestyramin
often
use
treat
individu
symptom
diarrhea
preliminari
studi
canin
patient
ibd
suggest
fecal
bile
acid
concentr
alter
typifi
increas
primari
bile
acid
decreas
secondari
bile
acid
compar
healthi
control
purpos
studi
determin
effect
cholestyramin
fecal
bile
acid
profil
healthi
dog
baselin
fecal
sampl
collect
healthi
beagl
dog
n
two
week
administr
cholestyramin
addit
fecal
sampl
collect
two
week
daili
cholestyramin
administr
two
week
later
washout
period
dog
maintain
mainten
diet
studi
fed
gday
cholestyramin
powder
g
activ
ingredi
suspend
ml
water
cholestyramin
administr
period
fecal
concentr
primari
bile
acid
ie
cholic
acid
chenodeoxychol
acid
secondari
bile
acid
ie
lithochol
acid
deoxychol
acid
ursodeoxychol
acid
evalu
use
ga
chromatographi
coupl
mass
spectrometri
data
assess
normal
use
shapirowilk
test
differ
bile
acid
concentr
compar
use
friedman
test
dunn
posttest
use
appropri
statist
signific
set
p
total
bile
acid
concentr
significantli
increas
two
week
cholestyramin
administr
median
minmax
lgmg
lgmg
compar
baselin
valu
median
minmax
lgmg
lgmg
p
total
secondari
bile
acid
concentr
significantli
increas
two
week
cholestyramin
administr
median
minmax
lgmg
lgmg
compar
baselin
valu
median
minmax
lgmg
lgmg
p
two
week
washout
paramet
remain
significantli
differ
compar
origin
baselin
valu
conclus
fecal
bile
acid
profil
alter
healthi
dog
cholestyramin
administr
studi
need
understand
potenti
clinic
util
cholestyramin
therapeut
option
canin
patient
gastrointestin
diseas
exocrin
pancreat
insuffici
epi
diseas
character
insuffici
synthesi
secret
pancreat
enzym
exocrin
pancrea
result
malassimil
macronutri
exampl
insuffici
pancreat
lipas
prevent
normal
digest
dietari
fat
consequ
epi
would
expect
associ
excess
fat
eg
fatti
acid
remain
fece
treatment
epi
includ
oral
supplement
pancreat
digest
enzym
often
effect
decreas
sever
clinic
sign
unclear
assimil
normal
concomitantli
studi
evalu
fecal
fatti
acid
fa
concentr
dog
epi
undergo
enzym
supplement
hypothesi
studi
fecal
fatti
acid
concentr
would
increas
dog
epi
compar
healthi
dog
even
treat
enzym
supplement
fatti
acid
concentr
quantifi
fecal
sampl
dog
diagnos
epi
treat
pancreat
enzym
supplement
healthi
control
dog
use
inhous
ga
chromatographymass
spectrometri
gcm
assay
target
analyt
includ
palmit
acid
stearic
acid
oleic
acid
linol
acid
alinolen
acid
gondoic
acid
eruc
acid
mannwhitney
u
test
use
comparison
group
pvalu
adjust
multipl
comparison
statist
signific
set
p
fecal
fa
significantli
increas
fece
dog
epi
p
fecal
fatti
acid
concentr
increas
dog
epi
even
treat
pancreat
enzym
supplement
data
consist
malassimil
fat
patient
hypersensit
prolifer
tcell
play
key
role
pathogenesi
ibd
human
medicin
indic
cell
growth
studi
canin
medicin
aim
studi
investig
relat
tcell
marker
canin
ibd
accord
clinic
sign
histopatholog
result
eleven
privat
own
dog
group
ibd
ibd
six
healthi
beagl
serv
control
co
dog
clinic
assess
use
canin
chronic
enteropathi
activ
index
ccecai
score
system
duoden
mucos
biopsi
sampl
endoscop
retriev
histopatholog
examin
use
world
small
anim
veterinari
associationschem
wsava
doublemark
immunofluoresc
microscopi
use
investig
identifi
prolifer
cell
combin
detect
tcell
differ
area
epithelium
e
lamina
propria
lp
villi
crypt
respect
ibdpati
signific
increas
clinic
score
ae
vs
co
constant
p
furthermor
doubleposit
cell
significantli
increas
lp
crypt
region
ibddog
ae
cellsmm
vs
co
ae
cellsmm
p
area
signific
correl
found
ccecai
index
r
summari
index
signific
upregul
lp
specif
crypt
area
ibd
dog
indic
metabol
activ
region
conclus
could
use
marker
canin
ibd
activ
peopl
lower
esophag
sphincter
le
disord
caus
function
obstruct
identifi
rare
caus
megaesophagu
obstruct
le
disord
identifi
dog
lack
clear
diagnost
criteria
condit
may
respond
target
therapi
correct
diagnosi
critic
videofluoroscop
swallow
studi
vfss
goldstandard
diagnosi
dysphagia
dog
object
character
vfss
featur
le
achalasialik
syndrom
dyssynchroni
dog
hypothes
le
achalasialik
syndrom
lesa
le
dyssynchroni
lesd
could
distinguish
normal
dog
use
standard
vfss
criteria
retrospect
studi
sixti
dog
present
univers
missouri
veterinari
health
center
april
vfss
use
freefeed
stand
protocol
use
least
consist
iohexol
barium
impregn
food
thin
liquid
pure
kibbl
dog
function
le
obstruct
n
evalu
use
subject
object
metric
presenc
distal
esophag
bolu
height
rel
maxim
le
open
esophag
contractil
face
physiolog
distent
propuls
abor
bolu
movement
primari
secondari
peristalsi
bird
beak
time
le
openingclosur
use
vfss
dog
determin
healthi
n
lesa
n
lesd
n
primari
esophag
dysmotilitygerd
n
dog
lesa
dog
lesd
ratio
esophag
bolu
column
height
height
vertebr
bodi
significantli
greater
lesa
compar
healthi
dog
p
dog
lesa
significantli
lower
ratio
distal
esophag
column
height
le
open
height
compar
normal
p
lesd
p
dog
subject
contractil
esophagu
normal
n
lesd
hypocontractil
n
lesd
n
lesa
acontractil
n
lesa
propuls
complet
effect
n
lesd
ineffect
n
lesd
presenc
primari
andor
secondari
peristalt
wave
observ
dog
lesd
n
compar
lesa
n
birdbeak
sign
seen
dog
lesa
dog
lesd
abnorm
time
le
open
close
function
obstruct
le
due
lesa
lesd
repres
discret
diseas
state
distinguish
vfss
variou
option
elimin
diet
avail
veget
dri
food
one
altern
dietari
intervent
thought
alter
gut
microbi
commun
healthi
individu
resolut
dysbiosi
expect
diseas
anim
concurr
remiss
clinic
sign
therefor
aim
studi
evalu
chang
fecal
microbiota
dog
fre
elimin
dietari
trial
veget
diet
veget
diet
trial
perform
healthi
control
dog
hc
evalu
chang
fecal
microbiota
trial
compar
fre
dog
dog
fre
n
hc
n
fed
veget
diet
day
fecal
sampl
collect
dietari
trial
fecal
genom
dna
extract
use
illumina
sequenc
rrna
gene
sequenc
data
analyz
use
qiim
pipelin
dysbiosi
index
sequenc
data
calcul
use
publish
mathemat
model
score
consid
dysbiot
statist
signific
set
p
significantli
lower
alpha
divers
observ
dog
frebaselin
compar
hcbaselin
freafter
trial
distinct
microbi
commun
observ
dog
frebaselin
compar
hcbaselin
anosim
p
dog
freafter
trial
anosim
p
microbi
commun
still
differ
freafter
trial
compar
hcbaselin
anosim
p
calcul
dysbiosi
index
higher
dog
frebaselin
compar
hcbaselin
p
signific
differ
observ
freafter
trial
hcbaselin
fecal
microbiota
hc
show
signific
differ
vs
veget
dietari
trial
result
studi
suggest
fre
dog
treatment
veget
elimin
diet
led
partial
recoveri
fecal
microbiota
significantli
increas
microbiota
rich
significantli
closer
healthi
microbiota
treatment
contrast
chang
detect
fecal
microbiota
healthi
control
dog
fed
veget
diet
induct
emesi
ingest
toxin
challeng
cat
due
variabl
efficaci
advers
effect
associ
use
agonist
emet
hydromorphon
may
effect
altern
fewer
advers
effect
object
studi
compar
efficaci
hydromorphon
dexmedetomidin
induc
emesi
cat
prospect
blind
random
crossov
studi
util
healthi
purposebr
cat
cat
randomli
assign
receiv
hydromorphon
mgkg
mglb
subcutan
dexmedetomidin
mcgkg
mglb
intramuscularli
follow
administr
incid
emesi
number
emet
event
sign
nausea
temperatur
heart
rate
respiratori
rate
sedat
score
record
emesi
success
cat
treat
hydromorphon
cat
treat
dexmedetomidin
p
dexmedetomidin
like
caus
sedat
hydromorphon
p
heart
rate
cat
significantli
decreas
hour
posthydromorphon
p
respect
hour
postdexmedetomidin
p
respect
cat
like
develop
increas
bodi
temperatur
hydromorphon
administr
result
studi
indic
hydromorphon
effect
altern
dexmedetomidin
induct
emesi
cat
sedat
decreas
heart
rate
observ
less
hydromorphon
administr
investig
adequ
dose
hydromorphon
optim
emesi
warrant
imag
jejunum
dog
problemat
ultrasound
frequent
miss
mucos
lesion
tradit
endoscopi
typic
reach
jejunum
alicam
capsul
endoscopi
system
imag
entir
bowel
purpos
studi
retrospect
assess
frequenc
jejun
lesion
dog
given
alicam
gastrointestin
sign
andor
laboratori
abnorm
boardcertifi
internist
interpret
studi
eight
dog
complet
studi
lesion
identifi
jejunum
consid
signific
eight
dog
posit
studi
given
alicam
regen
anemia
sign
overt
gastrointestin
bleed
melena
five
dog
normal
gastrointestin
tract
ultrasound
prior
alicam
administr
one
dog
normal
gastroduodenoscopi
second
dog
normal
gastroduodenoscopi
laparoscopi
prior
alicam
alicam
find
includ
ulcer
mass
dog
larg
eros
ulcer
dog
focal
fluid
blood
mucos
abnorm
dog
follow
alicam
two
dog
underw
manual
push
enteroscopi
one
case
ulcer
lesion
seen
alicam
found
second
case
suspect
lesion
identifi
resect
third
dog
exploratori
laparotomi
subsequ
identif
resect
mass
seen
alicam
alicam
use
imag
jejunum
consid
import
diagnost
step
work
gastrointestin
diseas
especi
case
unexplain
anemia
tradit
endoscopi
ultrasound
fail
identifi
caus
purpos
studi
determin
effect
sustain
therapi
antiplatelet
drug
glucocorticoid
platelet
function
test
upper
gastrointestin
tract
fifteen
healthi
dog
random
group
aspirin
mgkgd
clopidogrel
mgkgd
c
prednison
mgkg
p
combin
prednison
aspirin
pa
prednison
clopidogrel
pc
therapi
po
day
platelet
count
analysi
collagenepinephrin
collagenadp
appropri
endoscopi
perform
baselin
day
platelet
test
day
presenc
hemorrhag
punctat
eros
invas
eros
ulcer
consid
clinicallysignific
bleed
dog
categor
antiplatelet
respond
closur
time
sec
aspirin
increas
compar
baselin
clopidogrel
gastrointestin
bleed
antiplatelet
respond
statu
compar
among
group
fisher
exact
test
p
consid
signific
one
pa
dog
remov
day
sever
weight
loss
invas
gastric
eros
identifi
via
capsul
endoscopi
endoscop
lesion
present
day
c
dog
dog
hemorrhag
hemorrhag
tract
p
dog
invas
eros
remain
pa
dog
invas
eros
pc
dog
invas
eros
diffus
hemorrhag
deep
ulcer
platelet
count
normal
c
dog
dog
pc
dog
pa
dog
classifi
respond
base
pfa
closur
time
day
respect
frequenc
bleed
differ
significantli
among
group
respond
statu
differ
significantli
among
group
day
p
p
clinic
signific
gastrointestin
bleed
occur
sustain
clopidogrel
therapi
occur
treatment
group
efficaci
antiplatelet
therapi
decreas
time
particularli
dog
receiv
concurr
steroid
therapi
evalu
larger
popul
dog
warrant
dog
hypoadrenocortic
ha
frequent
show
gastrointestin
sign
gi
howev
proport
dog
present
chronic
gi
main
complaint
ultim
suffer
ha
unknown
aim
studi
determin
preval
ha
dog
chronic
gi
identifi
clinic
laboratori
paramet
help
diagnos
ha
dog
standard
workup
perform
dog
gi
week
durat
present
one
specialist
german
gastroenterolog
work
group
novemb
decemb
includ
basal
serum
cortisol
measur
acth
stimul
test
acthst
basal
serum
cortisol
lgdl
dog
prospect
includ
basal
serum
cortisol
concentr
lgdl
lgdl
dog
dog
ha
diagnos
base
acthst
stimul
serum
cortisol
concentr
lgdl
repres
preval
hyperkalemia
hyponatremia
observ
dog
ha
ha
dog
melena
hematochezia
note
histor
inform
laboratori
paramet
abl
separ
ha
disord
caus
chronic
gi
conclus
preval
ha
amongst
dog
chronic
gi
consider
differenti
ha
caus
lead
chronic
gi
possibl
base
histori
physic
examin
baselin
blood
work
determin
basal
serum
cortisol
concentr
perform
screen
test
ha
follow
acthst
suspici
case
exocrin
pancreat
insuffici
epi
associ
decreas
product
intrins
factor
dog
cat
sinc
requir
cobalamin
cbl
absorpt
ileum
cbl
defici
preval
sequel
epi
dog
associ
neg
prognosi
current
supplement
protocol
cbl
dog
call
parenter
pe
supplement
human
sever
studi
report
equal
efficaci
pe
oral
po
supplement
cbl
recent
group
report
success
po
cbl
supplement
dog
ce
hypocobalaminemia
retrospect
observ
studi
prospect
studi
compar
oral
parenter
cbl
supplement
purpos
retrospect
studi
evalu
effect
po
cbl
supplement
dog
epi
subnorm
lownorm
serum
cbl
concentr
computer
databas
search
dog
treat
evidensia
specialist
anim
hospit
helsingborg
sweden
perform
inclus
criteria
dog
diagnos
epi
base
subnorm
serum
canin
trypsinlik
immunoreact
concentr
ctli
refer
rang
lg
l
initi
serum
cobalamin
concentr
ngl
refer
interv
ngl
daili
treatment
cbl
tablet
cyanocobalamin
mgtablet
dog
kg
kg
dog
kg
tablet
exclus
criteria
pe
cbl
supplement
parallel
po
failur
compli
treatment
protocol
ten
dog
age
median
year
match
inclus
criteria
serum
cbl
followup
analyz
median
day
start
supplement
use
autom
chemiluminesc
immunoassay
immulit
siemen
dog
advia
centaur
siemen
dog
common
breed
includ
german
shepherd
n
mix
breed
dog
n
median
serum
ctli
concentr
lgl
rang
lgl
inclus
median
rang
serum
cbl
concentr
ngl
ngl
increas
significantli
ngl
ngl
supplement
differ
statist
signific
p
wilcoxon
matchedpair
sign
rank
test
due
retrospect
natur
studi
metabol
marker
cbl
defici
could
analyz
despit
limit
result
suggest
oral
cbl
supplement
appear
effect
treat
dog
epi
subnorm
lownorm
serum
cobalamin
concentr
sinc
accord
manufactur
trace
present
pez
find
suggest
dog
demonstr
human
may
ifindepend
pathway
cbl
absorpt
whether
altern
pathway
exist
dog
requir
studi
addit
studi
compar
cellular
cobalamin
statu
po
pe
supplement
dog
epi
warrant
threedimension
organbud
organoid
novel
organ
mimick
vitro
model
base
stem
cell
show
realist
microanatomi
recent
intestin
organoid
cultur
variou
speci
includ
mice
human
describ
howev
canin
intestin
cryptderiv
organoid
yet
describ
sinc
organoid
infinit
expand
cultur
remain
genet
stabl
differenti
cell
type
intestin
repres
ideal
vitro
model
intestin
diseas
inflammatori
bowel
diseas
viru
infect
drug
screen
aim
studi
establish
small
intestin
colonbas
organoid
cultur
system
dog
follow
molecular
cellular
character
fresh
cadaver
sampl
obtain
duodenum
jejunum
colon
seven
individu
dog
follow
crypt
isol
organoid
propag
use
expans
media
differenti
achiev
remov
prolifer
induc
compon
establish
crypt
isol
protocol
kept
organoid
line
three
area
intestin
duodenum
jejunum
colon
seven
dog
cultur
least
passag
geneexpress
level
stem
cell
marker
stabl
expans
media
differenti
express
goblet
cell
marker
paneth
cell
marker
increas
wherea
express
level
stem
cell
marker
decreas
novel
robust
vitro
model
small
intestin
colon
organoid
appli
model
studi
canin
intestin
diseas
futur
claim
probiot
includ
colonis
gastrointestin
tract
support
stabilis
maintain
balanc
healthi
microbiota
evid
effect
administr
enterococcu
faecium
unhealthi
dog
inform
yet
effect
particularli
microbiota
healthi
dog
twelv
healthi
dog
histori
gastrointestin
diseas
normal
faecal
examin
receiv
week
cours
prepar
contain
x
cfu
enterococcu
faecium
ncimb
per
dose
taken
daili
normal
void
faec
collect
end
treatment
day
end
treatment
dna
extract
faecal
sampl
use
detect
quantifi
probiot
bacteria
qpcr
analys
faecal
microbiota
illumina
sequenc
probiot
bacteria
detect
faec
whilst
dog
receiv
product
detect
day
treatment
stop
effect
probiot
microbiota
faec
normal
dog
principl
coordin
analysi
show
microbiota
faec
similar
individu
dog
treatment
chang
speci
rich
divers
p
small
insignific
increas
lactobacillu
spp
p
effect
amount
e
coli
enterobacteriacea
cladogram
show
differ
faecal
sampl
dog
taken
trial
period
increas
amount
e
faecium
day
p
data
clearli
show
probiot
transient
colonis
gastrointestin
tract
healthi
dog
appear
affect
faecal
microbiota
day
administr
hypothes
maropit
superior
metoclopramid
prevent
vomit
regurgit
administ
prior
orogastr
tube
administr
polyethylen
glycol
solut
peg
dog
n
natur
occur
diseas
peg
administ
bowel
cleans
prior
colonoscopi
prospect
enrol
dog
randomli
assign
administ
maropit
metoclopramid
subcutan
minut
prior
orogastr
tube
administr
mlkg
peg
supervis
blind
author
peg
dose
repeat
hour
later
antiemet
incid
vomit
regurgit
respect
regurgit
occur
often
dog
lower
bodi
weight
kg
vs
kg
p
dog
rapid
administr
peg
dose
second
vs
second
p
dose
second
vs
second
p
femal
dog
vs
p
author
insert
orogastr
tube
vomit
occur
less
often
author
vs
p
differ
incid
vomit
dose
vs
p
dose
vs
p
regurgit
dose
vs
p
dose
vs
p
dog
receiv
maropit
metoclopramid
respect
vomit
regurgit
occur
commonli
follow
peg
administr
dog
natur
occur
larg
intestin
diseas
maropit
superior
prevent
peg
administr
techniqu
may
import
recent
novel
poreform
toxin
design
nete
netf
identifi
clostridium
c
perfringen
type
strain
isol
dog
acut
hemorrhag
diarrhea
poreform
toxin
cytotox
activ
could
respons
necrot
mucos
lesion
typic
present
dog
acut
hemorrhag
diarrhea
syndrom
ahd
thu
studi
aim
determin
preval
c
perfringen
encod
nete
netf
fece
dog
ahd
evalu
associ
sever
clinic
sign
presenc
toxin
gene
fecal
sampl
dog
ahd
dog
canin
parvoviru
cpv
infect
healthi
dog
test
realtim
pcr
nete
netfgen
sever
clinic
sign
time
recoveri
mortal
rate
select
laboratori
paramet
compar
toxin
geneposit
neg
dog
ahd
signific
differ
three
group
preval
poreform
toxin
nete
netf
dog
ahd
dog
cpvinfect
healthi
dog
p
dog
ahd
signific
differ
detect
paramet
evalu
neteand
netfposit
neteand
netf
neg
dog
result
suggest
overgrowth
c
perfringen
type
strain
encod
nete
netf
gener
sequel
acut
hemorrhag
diarrhea
sinc
gene
detect
dog
cpv
infect
primari
pathogen
role
toxin
ahd
like
peripher
eosinophilia
limit
marker
eosinophilmedi
diseas
measur
serum
report
serv
monitor
tool
eosinophilmedi
diseas
human
previou
studi
show
serum
concentr
increas
dog
eosinophil
gastroenter
well
lymphocyticplasmacyt
enter
howev
serum
concentr
previous
evalu
specif
dog
foodrespons
diarrhea
frd
steroidrespons
diarrhea
srd
therefor
object
studi
compar
peripher
eosinophil
count
dog
frd
srd
healthi
control
dog
evalu
compar
serum
concentr
dog
frd
srd
healthi
control
dog
associ
peripher
eosinophilia
group
frd
n
srd
n
healthi
control
dog
n
determin
use
fisher
exact
test
serum
concentr
measur
use
electron
impact
ioniz
ga
chromatographymass
spectrometri
serum
concentr
dog
frd
dog
srd
healthi
control
dog
compar
use
kruskalw
test
posttest
analysi
use
determin
differ
serum
concentr
among
group
signific
set
p
signific
associ
peripher
eosinophilia
group
dog
p
median
minmax
serum
concentr
dog
frd
srd
healthi
control
dog
lmoll
lmoll
lmoll
respect
serum
concentr
dog
srd
significantli
higher
dog
frd
p
healthi
control
dog
p
serum
concentr
dog
frd
also
significantli
higher
healthi
control
dog
p
conclus
serum
concentr
higher
dog
srd
frd
healthi
control
dog
also
dog
srd
higher
serum
concentr
dog
frd
suggest
eosinophilmedit
inflamm
play
role
pathogenesi
disord
especi
srd
research
need
determin
whether
measur
use
subclassifi
dog
chronic
enteropathi
frd
srd
previous
shown
monoclon
antibodi
eosinophil
peroxidas
epx
detect
intact
degranul
eosinophil
canin
jejun
mucosa
ajvr
januari
aim
present
studi
compar
epx
label
haematoxylin
eosin
h
e
stain
intact
degranul
eosinophil
endoscopicallyderiv
sampl
canin
duoden
mucosa
object
determin
whether
epx
could
improv
detect
intact
degranul
eosinophil
duoden
mucosa
dog
inflammatori
bowel
diseas
ibd
tissu
sampl
obtain
histopatholog
archiv
univers
bristol
school
veterinari
scienc
dog
includ
studi
met
wsava
standard
ibd
ie
clinic
sign
upper
gi
endoscop
imag
biopsi
histopatholog
sampl
divid
three
group
dog
affect
lymphocyticplasmacyt
enter
lpe
ii
eosinophil
enter
ee
iii
control
group
base
wsava
criteria
serial
section
paraffin
waxembed
tissu
immunolabel
epx
mab
stain
h
e
intact
degranul
eosinophil
consecut
microscop
field
magnif
upper
villu
tip
lower
musculari
mucosa
crypt
region
duoden
mucosa
count
manual
inflamm
classifi
mild
moder
sever
one
blind
investig
md
eosinophil
count
carri
two
investig
blind
ident
case
ib
ds
epx
mab
readili
detect
degranul
intact
eosinophil
duoden
mucosa
good
agreement
eosinophil
quantif
two
observ
epxmab
h
e
stain
section
h
e
stain
readili
detect
intact
eosinophil
duodenum
ineffect
detect
degranul
eosinophil
across
studi
group
epxmabihc
immunohistochemistri
detect
three
time
eosinophil
compar
h
estain
slide
term
diseas
sever
degranul
intact
eosinophil
number
twofold
greater
moder
vs
mild
diseas
conclud
h
e
stain
fail
detect
degranul
eosinophil
effect
grossli
underestim
eosinophil
count
duoden
mucosa
epx
ihc
detect
intact
degranul
eosinophil
result
present
studi
suggest
epx
ihc
may
serv
potenti
diagnost
method
identifi
ibd
monitor
diseas
activ
evalu
success
treatment
dog
may
constitut
first
step
toward
understand
role
eosinophil
degranul
pathogenesi
ibd
dog
proton
pump
inhibitor
administr
human
associ
increas
risk
enter
particularli
clostridium
difficil
infect
omeprazol
also
alter
canin
microbiom
howev
studi
explor
effect
felin
fecal
microbiom
metabolom
hypothes
prolong
oral
omeprazol
administr
would
alter
fecal
microbiom
metabolom
cat
withinsubject
studi
perform
wherebi
cat
receiv
day
consecut
treatment
placebo
mg
lactos
po
h
follow
mg
mgkg
po
h
omeprazol
day
placebo
omeprazol
therapi
free
catch
fecal
sampl
collect
cat
fecal
microbiom
character
use
rrna
gene
sequenc
qpcr
assay
also
use
specif
target
clostridium
perfringen
clostridium
hiranoni
bifidobacterium
spp
metabolom
character
untarget
mass
spectrometrybas
method
twoway
repeatedmeasur
anova
test
util
determin
effect
phase
treatment
time
interact
phase
time
global
chang
microbiom
metabolom
observ
base
multivari
analysi
anosim
p
howev
bacteri
genera
alter
follow
omeprazol
administr
includ
increas
rel
abund
streptococcu
lactobacillu
clostridium
faecalibacterium
spp
decreas
bifidobacterium
spp
cat
result
pilot
studi
suggest
omeprazol
might
littl
impact
felin
fecal
microbiom
metabolom
administ
day
less
larger
studi
need
confirm
result
evid
oxid
stress
play
import
role
pathogenesi
ibd
human
patient
particularli
initi
perpetu
inflamm
subsequ
tissu
damag
oxid
stress
occur
mark
imbal
product
reactiv
oxygen
speci
ro
remov
antioxid
recent
public
suggest
oxid
stress
could
also
repres
signific
factor
pathogenesi
ibd
dog
object
studi
compar
panel
variou
serum
biomark
evalu
antioxid
respons
oxid
damag
dog
inflammatori
bowel
diseas
ibd
healthi
control
dog
eighteen
dog
ibd
healthi
dog
enrol
studi
trolox
equival
antioxid
capac
teac
cupric
reduc
antioxid
capac
cuprac
ferric
reduc
abil
plasma
frap
total
thiol
concentr
paraoxonas
activ
evalu
serum
determin
antioxid
respons
evalu
oxid
statu
ferrou
oxidationxylenol
orang
fox
thiobarbitur
acid
reactiv
substanc
tbar
reactiv
oxygen
speci
product
ro
concentr
serum
determin
mean
concentr
antioxid
biomark
analyz
except
frap
significantli
lower
p
serum
dog
ibd
healthi
dog
oxid
marker
studi
significantli
higher
p
serum
dog
ibd
healthi
dog
find
support
hypothesi
oxid
stress
play
import
role
pathogenesi
ibd
dog
llactat
gener
pyruv
via
lactat
dehydrogenas
normal
cell
metabol
lactobacillal
lactic
acid
bacteria
intestin
tract
synthes
dand
llactat
current
serum
lactat
concentr
use
marker
tissu
hypoperfus
hypoxia
case
dlactic
acidemia
report
dog
human
intestin
diseas
fecal
lactat
also
shown
increas
human
short
bowel
syndrom
calv
diarrhea
fecal
lactat
concentr
might
serv
marker
microbi
activ
intestin
therefor
aim
studi
analyt
valid
enzymat
method
measur
dand
llactat
canin
fece
commerci
kit
adapt
use
fece
dllactic
acid
kit
rbiopharm
surplu
homogen
canin
fecal
sampl
seven
dog
use
method
valid
valid
variabl
includ
lower
limit
detect
dilut
parallel
spike
recoveri
interand
intraassay
variabl
lower
limit
detect
dand
llactat
concentr
mm
respect
observedtoexpect
ratio
dilut
parallel
rang
dlactat
llactat
recoveri
spike
sampl
extract
rang
dlactat
llactat
total
lactat
averag
intraassay
coeffici
variat
cv
l
total
lactat
respect
averag
interassay
cv
l
total
lactat
respect
assay
shown
linear
precis
accur
reproduc
futur
studi
underway
evalu
util
fecal
lactat
measur
dog
gastrointestin
diseas
report
dog
exocrin
pancreat
insuffici
epi
commonli
intestin
dysbiosi
howev
effect
epi
microbi
metabol
poorli
understood
aim
studi
compar
fecal
dysbiosi
well
fecal
lactat
bile
acid
concentr
dog
epi
healthi
control
dog
fecal
sampl
collect
eleven
dog
epi
receiv
antibiot
least
week
enzym
supplement
year
median
year
fecal
sampl
healthi
dog
n
collect
three
consecut
day
pool
serv
control
sampl
dna
extract
analyz
qpcr
select
bacteri
group
data
express
dysbiosi
index
previous
report
fecal
lactat
measur
enzymat
method
dllactic
acid
kit
rbiopharm
bile
acid
quantifi
ga
chromatographi
mass
spectrometri
lyophil
fece
mannwhitney
u
test
use
compar
dysbiosi
index
fecal
lactat
bile
acid
concentr
dog
epi
healthi
control
dog
correl
assess
use
spearman
correl
coeffici
signific
set
p
dog
epi
higher
dysbiosi
index
median
minmax
healthi
control
dog
p
total
fecal
lactat
concentr
increas
dog
epi
mm
mm
compar
healthi
control
dog
mm
mm
p
proport
secondari
bile
acid
lower
dog
epi
compar
healthi
control
dog
p
correl
measur
durat
enzym
therapi
conclus
studi
identifi
differ
fecal
microbiota
well
fecal
lactat
bile
acid
concentr
dog
epi
healthi
control
dog
also
known
receptor
kda
transmembran
cytokin
receptor
primarili
express
activ
cell
regulatori
cell
treg
type
cancer
cell
human
increas
express
membranebound
report
patient
autoimmun
inflammatori
diseas
transplant
reject
type
neoplasia
solubl
form
gener
proteolyt
cleavag
molecular
mass
kda
elev
serum
concentr
report
human
patient
aforement
condit
posit
correl
report
membran
express
serum
concentr
vitro
activ
cell
treg
shown
shed
therefor
high
concentr
serum
thought
reflect
sustain
immun
activ
moreov
use
biomark
help
character
diseas
progress
prognosi
treatment
human
thu
aim
studi
establish
analyt
valid
radioimmunoassay
measur
canin
serum
canin
specif
protein
antibodi
commerci
avail
use
establish
assay
competit
liquidphas
radioimmunoassay
ria
setup
analyt
valid
determin
lower
limit
detect
llod
dilut
parallel
spike
recoveri
intraand
interassay
variabl
surplu
canin
serum
sampl
pool
use
valid
addit
due
inabl
find
canin
serum
sampl
naturallyoccur
high
concentr
three
sampl
spike
differ
concentr
pure
canin
treat
unknown
sampl
test
assay
across
entir
work
rang
recoveri
evalu
spike
three
sampl
five
differ
concentr
ngml
llod
calcul
ngml
mean
ae
sd
observedtoexpect
ratio
oe
serial
dilut
ae
sampl
mean
ae
sd
oe
spike
recoveri
ae
mean
ae
sd
sampl
coeffici
variat
intraassay
variabl
serum
sampl
mean
ae
sd
ae
wherea
interassay
coeffici
variat
sampl
mean
ae
sd
ae
respect
conclus
ria
describ
linear
accur
precis
reproduc
measur
solubl
canin
serum
studi
warrant
evalu
clinic
util
measur
serum
concentr
evalu
dog
immunemedi
inflammatori
condit
intestin
microbiom
import
maintain
gastrointestin
health
alter
may
contribut
gastrointestin
diseas
current
unclear
whether
fecal
microbi
transplant
fmt
may
present
altern
approach
standard
therapi
gastrointestin
diseas
purpos
studi
evalu
fecal
microbiota
fmt
patient
present
chronic
diarrhea
fresh
frozen
stool
infect
free
donor
dog
hypoallergen
diet
administ
fmt
use
gkg
stool
dilut
ml
salin
administ
per
rectum
via
red
rubber
cathet
outpati
basi
unsed
patient
stool
sampl
collect
patient
gastrointestin
diseas
immedi
one
week
administr
fmt
microbi
dysbiosi
determin
use
previous
describ
dysbiosi
index
target
sever
key
bacteria
typic
associ
maintain
health
includ
univers
rrna
faecalibacterium
turicibact
streptococcu
e
coli
blautia
fusobacterium
clostridium
hiranoni
data
analyz
wilcoxon
sign
rank
test
match
pair
signific
set
p
dysbiosi
index
significantli
decreas
dog
post
fmt
median
minmax
compar
dog
fmt
median
minmax
p
studi
suggest
fmt
alter
abund
commonli
target
bacteri
group
typic
associ
gastrointestin
diseas
studi
warrant
investig
fmt
alter
fecal
microbiota
specif
enteropathi
longterm
effect
microbiom
ac
duchaussoy
kl
boedec
c
mansfield
uvet
hospit
faculti
veterinari
agricultur
scienc
univers
melbourn
moorabbin
victoria
australia
centr
hospitali
veterinair
fregi
arcueil
iledefr
franc
uvet
hospit
faculti
veterinari
agricultur
scienc
univers
melbourn
werribe
victoria
australia
genet
environment
defect
immun
system
dysbiosi
identifi
main
factor
involv
pathophysiolog
chronic
enteropathi
short
chain
fatti
acid
scfa
volatil
compound
directli
correl
quantit
qualit
bacteri
popul
gastrointestin
tract
increas
number
public
assess
gastrointestin
health
inflamm
includ
scfa
measur
fecal
matter
howev
scant
inform
repeat
reliabl
scfa
analysi
dog
cat
scfa
highli
volatil
unstabl
preliminari
result
fece
dog
cat
show
high
variabl
anim
healthi
anim
investig
repeat
variabl
scfa
measur
start
prospect
studi
healthi
dog
normal
bodi
condit
fecal
sampl
collect
upon
void
divid
aliquot
immedi
collect
aliquot
duplic
store
ambient
temperatur
freez
vs
also
vari
durat
time
collect
freez
sampl
scfa
measur
use
dilut
ga
chromatographymass
spectrometri
gcm
assay
previous
describ
sampl
thaw
batch
kept
ice
intern
standard
solut
ad
focus
three
preval
short
chain
fatti
acid
identifi
dog
name
propion
acid
butyr
acid
valer
acid
result
show
linear
increas
amount
scfa
time
collect
freez
process
left
room
temperatur
observ
sampl
store
signific
differ
sampl
store
result
next
compon
studi
obtain
fecal
sampl
healthi
dog
monthli
sampl
frozen
immedi
collect
scfa
measur
use
gcm
assay
result
show
wide
variabl
result
normal
dog
also
notic
degre
individu
variabl
overtim
potenti
caus
variabl
includ
variat
within
stool
sampl
well
possibl
presenc
undigest
debri
fecal
materi
conclus
show
high
degre
variabl
within
individu
dog
well
storag
method
data
improv
understand
scfa
analysi
potenti
interpret
scfa
studi
chronic
enteropathi
dog
beyond
role
digest
bile
acid
also
act
system
signal
modul
sever
pathway
involv
glucos
lipid
metabol
play
antiinflammatori
role
activ
nuclear
gprotein
coupl
receptor
ie
express
demonstr
mani
gastrointestin
tissu
human
laboratori
anim
aim
studi
evalu
immunohistochem
distribut
receptor
gastrointestin
tract
dog
sampl
collect
six
adult
dog
femal
male
median
year
rang
year
human
euthan
due
caus
relat
studi
dog
clinic
sign
histopatholog
lesion
suggest
gastrointestin
diseas
section
duodenum
jejunum
ileum
colon
cecum
rectum
liver
gallbladd
pancrea
fix
formalin
follow
routin
histolog
process
immunohistochemistri
heatinduc
antigen
retriev
perform
tissu
incub
polyclon
antibodi
direct
amino
acid
human
dilut
rabbit
igg
neg
control
hour
room
temperatur
intestin
mucosa
label
identifi
granular
stain
pattern
membran
goblet
cell
enterocyt
colonocyt
enteroendocrin
cell
crypt
small
larg
intestin
show
granular
label
cytoplasm
membran
resid
macrophag
lamina
propria
peyer
patch
granular
homogen
label
present
cytoplasm
membran
ganglion
cell
submucos
musculari
plexu
small
larg
intestin
musculari
layer
smooth
muscl
express
membran
liver
membran
biliari
epithelium
canalicular
surfac
hepatocellular
membran
posit
cytoplasm
membran
kupffer
cell
epithelium
gallbladd
show
granular
label
membran
cytoplasm
pancrea
membran
label
evid
epitheli
cell
duct
membranouscytoplasm
pattern
identifi
approxim
islet
cell
cytoplasm
membran
endotheli
cell
posit
examin
tissu
find
show
base
antigen
express
ubiquit
distribut
gastrointestin
tract
dog
express
predominantli
membran
epitheli
cell
membran
cytoplasm
ganglia
histiocyt
enteroendocrin
cell
canin
chronic
enteropathi
ce
suspect
multifactori
etiolog
interplay
genet
environment
factor
alter
gut
microbiota
host
immun
system
dog
ce
alter
serum
fecal
metabolom
includ
chang
fecal
bile
acid
bile
acid
import
signal
molecul
act
interact
receptor
g
proteincoupl
bile
acid
receptor
farnesoid
x
receptor
fxr
agonist
shown
suppress
tnfa
product
macrophag
lamina
propria
human
patient
crohn
diseas
aim
studi
compar
antigen
express
receptor
colon
sampl
well
fecal
concentr
bile
acid
dog
ce
control
dog
ce
group
compris
seven
dog
femal
male
median
year
rang
month
year
histori
gastrointestin
sign
three
week
mild
moder
inflammatori
infiltr
colon
mucosa
identifi
caus
gastrointestin
gi
inflamm
control
group
consist
six
adult
dog
femal
male
median
year
rang
year
human
euthan
due
caus
relat
studi
dog
gi
sign
histopatholog
lesion
none
dog
studi
receiv
antibiot
corticosteroid
therapi
within
week
colon
fecal
sampl
formalinfix
paraffinembed
section
colon
use
immunohistochemistri
heatinduc
antigen
retriev
perform
block
tissu
incub
polyclon
antibodi
direct
amino
acid
human
dilut
rabbit
igg
neg
control
hour
room
temperatur
concentr
fecal
bile
acid
measur
ga
chromatographymass
spectrometri
mannwhitney
utest
use
test
statist
signific
p
group
immunolabel
identifi
membran
colonocyt
goblet
cell
smooth
muscl
cell
musculari
membran
cytoplasm
enteroendocrin
cell
crypt
resid
macrophag
ganglion
cell
endotheli
cell
infiltr
inflammatori
cell
ce
dog
mainli
compos
lymphocyt
plasma
cell
neither
express
immunohistochem
express
colon
differ
control
ce
dog
howev
dog
ce
increas
proport
primari
bile
acid
fece
p
although
dog
ce
show
alter
proport
fecal
bile
acid
differ
express
colon
sampl
could
detect
immunohistochemistri
investig
use
techniqu
includ
gene
array
need
might
contribut
understand
bile
acid
dysmetabol
dog
ce
estim
foster
kitten
die
euthan
due
ill
age
reportedli
clinic
sign
postmortem
evid
gastrointestin
diseas
children
enteropathogen
ecoli
epec
common
caus
diarrhea
associ
higher
hazard
death
proven
difficult
detect
experiment
model
anim
previous
report
epec
seri
kitten
die
diarrhea
purpos
studi
determin
preval
epec
infect
kitten
associ
diarrhea
diarrheaassoci
mortal
specif
intestin
tract
patholog
possibl
risk
factor
live
kitten
n
without
diarrhea
deceas
kitten
n
euthan
appar
good
health
euthanizeddi
due
sever
diarrhea
obtain
differ
shelter
facil
kitten
age
kg
bodi
weight
fecal
cultur
epec
extract
fecal
dna
qpcr
amplif
epec
enterocyteattachingeffac
gene
eae
perform
deceas
kitten
underw
autopsi
section
stomach
small
intestin
colon
obtain
histopatholog
score
lesion
fluoresc
insitu
hybrid
fish
detect
enteroadher
e
coli
medic
record
examin
variabl
potenti
associ
epec
infect
base
fecal
cultur
preval
epec
infect
live
deceas
kitten
base
qpcr
amplif
eae
fece
preval
live
kitten
deceas
kitten
epec
observ
kitten
without
diarrhea
howev
kitten
die
euthan
due
sever
diarrhea
harbor
significantli
greater
quantiti
live
epec
eae
compar
kitten
without
diarrhea
kitten
diagnos
epec
significantli
greater
sever
inflammatori
infiltr
small
intestin
colon
increas
epitheli
injuri
small
intestin
enteroadher
e
coli
observ
mean
fish
kitten
live
deceas
kitten
popul
examin
basi
epec
diagnosi
signific
associ
observ
epec
infect
medic
histori
subcutan
fluid
administr
find
identifi
epec
preval
infect
kitten
implic
epec
signific
primari
contribut
caus
intestin
inflamm
dehydr
diarrheaassoci
mortal
kitten
high
preval
epec
healthi
kitten
children
complic
interpret
epec
infect
patient
diarrhea
futur
effort
identifi
mechan
respons
suscept
epecinduc
diarrhea
lead
advanc
understand
epec
pathogenesi
kitten
children
gut
microbiota
import
maintain
intestin
health
bile
acid
increasingli
appreci
play
role
regul
gut
microbi
composit
intestin
health
bile
acid
synthes
cholesterol
conjug
liver
secret
gastrointestin
tract
git
undergo
modif
certain
member
intestin
microbiota
numer
bile
acid
receptor
eg
farnesoid
x
receptor
g
proteincoupl
membran
receptor
identifi
along
git
respons
regul
metabol
maintain
antiinflammatori
environ
gut
aim
studi
develop
analyt
valid
ga
chromatographi
mass
spectrometri
gcm
assay
identif
quantif
bile
acid
canin
fece
fecal
ursodeoxychol
acid
udca
measur
unconjug
form
undergo
butyl
esterif
chromatograph
separ
capillari
ms
ultra
inert
column
use
split
sampl
inject
ratio
valid
paramet
includ
lower
upper
limit
quantif
lloq
uloq
respect
addit
precis
assay
calcul
assay
aliquot
taken
singl
fecal
sampl
dog
runday
follow
calcul
intraassay
coeffici
variat
cv
reproduc
assay
determin
analyz
aliquot
taken
singl
fecal
sampl
dog
consecut
day
follow
calcul
interassay
variat
cv
lloq
uloq
lgml
follow
compound
cholic
acid
chenodeoxychol
acid
lithochol
acid
deoxychol
acid
ursodeoxychol
acid
intraassay
variabl
averag
cv
ca
cdca
lca
dca
udca
respect
interassay
variabl
averag
cv
ca
cdca
lca
dca
udca
respect
conclus
present
assay
found
reproduc
precis
quantif
select
bile
acid
canin
fece
howev
evid
lack
gi
inflamm
ongo
microbi
dysbiosi
affect
metabolit
longterm
patient
undergo
immunosuppress
therapi
therefor
purpos
studi
character
fecal
metabolom
dog
ibd
upon
initi
diagnosi
therapi
use
untarget
approach
nine
dog
nonrespons
dietari
antibiot
therapi
histolog
confirm
intestin
inflamm
enrol
fecal
sampl
collect
baselin
week
week
patient
receiv
immunosuppress
therapi
initi
diagnosi
clinic
sign
score
accord
canin
ibd
activ
index
cibdai
fecal
sampl
also
collect
healthi
dog
n
serv
control
fecal
sampl
analyz
untarget
metabolom
platform
use
ga
chromatographi
coupl
mass
spectrometri
data
found
nonparametr
therefor
comparison
made
across
time
point
use
friedman
test
repeat
measur
dunn
posttest
use
appropri
pvalu
adjust
multipl
comparison
use
benjamini
hochberg
fals
discoveri
rate
signific
set
p
multivari
test
consist
princip
compon
analysi
reveal
signific
differ
healthi
control
dog
ibd
baselin
week
week
therapi
median
cibdai
score
patient
week
follow
initi
diagnosi
compar
median
cibdai
score
enrol
univari
analysi
reveal
metabolit
measur
sinapin
acid
glycin
acid
stearic
acid
heptadecano
acid
myoinositol
dehydroabiet
acid
found
significantli
differ
among
repeat
time
point
sampl
dog
ibd
p
conclus
distinct
chang
metabol
profil
observ
healthi
dog
dog
ibd
despit
improv
clinic
activ
score
sever
metabolit
remain
alter
week
follow
sterol
fatti
acid
play
essenti
role
build
block
structur
compon
signal
molecul
energi
metabol
yet
also
toxic
cell
increas
concentr
increas
cholesterol
decreas
phytosterol
concentr
fece
dog
chronic
enteropathi
previous
report
studi
aim
explor
concentr
fecal
sterol
fatti
acid
dog
exhibit
wide
varieti
gastrointestin
diseas
phenotyp
baselin
fecal
sampl
collect
dog
acut
hemorrhag
diarrhea
syndrom
ahd
n
foodrespons
diarrhea
frd
n
steroidrespons
diarrhea
srd
n
healthi
control
dog
n
subset
diseas
dog
followup
sampl
collect
month
baselin
sampl
ahd
n
frd
n
srd
n
diagnos
frd
srd
base
respons
therapi
dog
frd
success
manag
vegetarian
diet
fece
analyz
ga
chromatographymass
spectrometri
gcm
use
inhous
assay
two
timepoint
kruskalw
test
benjaminihochberg
stepup
method
adjust
multipl
comparison
use
identifi
significantli
alter
compound
dunn
test
use
compar
group
statist
signific
set
p
baselin
dog
ahd
exhibit
decreas
fecal
phytosterol
ie
bsitosterol
campesterol
sitostanol
fucosterol
stigmasterol
p
increas
cholesterol
p
increas
fatti
acid
ie
stearic
eruc
gondoic
palmit
alinolen
p
concentr
compar
healthi
control
dog
statist
signific
differ
compound
frd
srd
dog
baselin
sever
signific
differ
observ
dog
srd
healthi
control
dog
baselin
decreas
bsitosterol
sitostanol
campesterol
fucosterol
p
p
p
p
respect
increas
eruc
gondoic
stearic
acid
p
p
p
respect
howev
month
followup
sever
sterol
alter
dog
srd
frd
sitostanol
bsitosterol
fucosterol
decreas
srd
p
p
p
respect
alinolen
eruc
gondoic
acid
also
decreas
dog
srd
p
p
p
month
followup
campesterol
stigmasterol
cholesterol
stearic
acid
palmit
acid
longer
significantli
differ
dog
ahd
healthi
control
dog
profound
chang
fecal
sterol
observ
baselin
dog
ahd
healthi
control
dog
mani
chang
normal
rapidli
observ
differ
dog
srd
frd
followup
month
may
larg
due
effect
diet
futur
studi
requir
evalu
util
compound
marker
diseas
phenotyp
respons
therapi
cholesterol
abund
sterol
mammalian
tissu
play
critic
role
cell
membran
function
serv
precursor
molecul
hormon
vitamin
bile
acid
structur
similar
cholesterol
phytosterol
associ
antiinflammatori
effect
rodent
model
coliti
previou
studi
shown
alter
fecal
sterol
concentr
dog
chronic
enteropathi
fatti
acid
import
sourc
energi
along
sterol
also
critic
intestin
epitheli
cell
membran
structur
function
aim
studi
analyt
valid
ga
chromatographymass
spectrometri
gcm
assay
measur
sever
sterol
ie
cholesterol
coprostanol
cholestanol
bsitosterol
stigmasterol
campesterol
sitostanol
fucosterol
fatti
acid
ie
palmit
oleic
linol
alinolen
stearic
gondoic
eruc
acid
canin
fecal
sampl
fecal
sampl
collect
eight
dog
lyophil
use
assess
intraand
interassay
variabl
cv
sampl
standard
prepar
adapt
publish
method
use
deuter
analog
cholesterol
sitostanol
stearic
acid
intern
standard
valid
paramet
also
includ
lower
upper
limit
quantit
lloq
uloq
respect
qualiti
control
procedur
sampl
run
consist
blank
continu
calibr
verif
standard
laboratori
control
sampl
pool
fece
intraand
interassay
variabl
median
cv
cholesterol
coprostanol
cholestanol
bsitosterol
stigmasterol
campesterol
sitostanol
fucosterol
palmit
acid
oleic
acid
linol
acid
alinolen
acid
stearic
acid
gondoic
acid
eruc
acid
limit
quantit
compound
lgml
lloquloq
follow
palmit
acid
linol
acid
alinolen
acid
oleic
acid
stearic
acid
conclus
gcm
method
valid
precis
reproduc
sensit
quantif
sever
sterol
fatti
acid
canin
fecal
sampl
previou
studi
identifi
dysbiosi
dog
idiopath
ibd
ibd
dog
acut
hemorrhag
diarrhea
syndrom
ahd
aim
studi
evalu
whether
dysbiosi
pattern
differ
diseas
group
time
fecal
sampl
analyz
healthi
dog
n
dog
ibd
n
dog
ahd
n
followup
sampl
collect
multipl
timepoint
week
dog
group
none
dog
treat
antibiot
microbiota
analyz
pcr
e
coli
streptococcu
turicibact
faecalibacterium
fusobacterium
blautia
c
perfringen
data
express
individu
numer
combin
dysbiosi
index
di
kruskalw
friedman
test
use
compar
data
group
time
signific
set
p
baselin
dog
ibd
p
ahd
p
higher
di
compar
healthi
dog
cibdai
score
decreas
dog
sre
significantli
p
di
remain
significantli
increas
compar
healthi
dog
even
week
dog
ahd
di
significantli
increas
day
p
day
p
differ
dysbiosi
pattern
also
observ
ibd
ahd
primari
increas
c
perfringen
dog
ahd
ibd
conclus
although
dog
sre
improv
clinic
di
remain
increas
contrast
dog
ahd
show
rapid
normal
microbiota
within
day
suggest
differ
dysbiosi
pattern
due
underli
diseas
sever
human
anim
studi
report
gut
microbiota
gm
alter
adult
obes
compar
nonobes
subject
studi
conduct
grow
one
aim
studi
identifi
differ
gm
homogen
popul
grow
dog
identifi
alter
occur
evalu
composit
fecal
microbiota
grow
femal
beagl
dog
time
month
age
illumina
sequenc
quantit
pcr
rrna
gene
popul
dog
homogen
term
age
age
neuter
month
environment
feed
condit
fed
diet
ad
libitum
hour
daili
month
age
fed
puppi
growth
diet
fat
total
dietari
fiber
crude
protein
dri
matter
basi
dm
subsequ
adult
mainten
diet
fat
total
dietari
fiber
crude
protein
dm
basi
dog
allot
posteriori
group
accord
fatfre
mass
fat
mass
percentag
pelvic
circumfer
month
optim
bodi
weight
iw
n
moder
overweight
n
overweight
n
data
analyz
linear
mixedeffect
model
anim
random
term
correct
multipl
comparison
abund
phyla
firmicut
bacteroidet
fusobacteria
proteobacteria
account
sequenc
preneut
period
proteobacteria
significantli
less
abund
p
group
iw
group
howev
throughout
studi
rel
abund
proteobacteria
increas
significantli
group
iw
group
p
without
signific
differ
abund
month
group
result
suggest
earli
low
increas
abund
proteobacteria
could
relat
overweight
develop
howev
proteobacteria
highli
divers
metabol
analys
genu
level
andor
metagenom
analys
may
explain
underli
link
microbiota
modul
excess
weight
gain
gastrointestin
gi
microbiota
consid
play
crucial
role
onset
progress
respons
treatment
outcom
mani
diseas
process
includ
chronic
enteropathi
ce
cat
howev
limit
inform
fecal
microbi
composit
cat
ce
avail
aim
studi
character
fecal
microbiota
cat
histolog
confirm
ce
treatment
fecal
sampl
collect
clinic
healthi
cat
n
cat
ce
n
week
medic
treatment
chronic
enteropathi
defin
display
sign
gastrointestin
diseas
week
cat
receiv
antibiot
steroid
within
week
prior
endoscopi
fecal
sampl
exclud
studi
cat
ce
underw
standard
medic
workup
collect
intestin
biopsi
endoscop
fecal
dna
evalu
use
quantit
pcr
qpcr
analysi
total
bacteria
fusobacteria
streptococcu
spp
blautia
spp
e
coli
faecalibacterium
spp
turicibact
spp
clostridium
hiranoni
differ
bacteri
abund
among
healthi
cat
cat
ce
treatment
evalu
use
mann
whitney
test
sampl
collect
treatment
affect
cat
compar
use
wilcoxon
sign
rank
test
felin
chronic
enteropathi
activ
index
fceai
compar
cat
ce
treatment
use
wilcoxon
sign
rank
test
statist
signific
set
p
histolog
evalu
intestin
biopsi
consist
ibd
n
small
cell
lymphoma
n
treatment
consist
prednisolon
chlorambucil
variou
antibiot
cyanocobalamin
combin
treatment
abund
faecalibacterium
spp
turicibact
spp
significantli
decreas
cat
ce
p
respect
compar
healthi
control
cat
streptococcu
spp
fusobacteria
significantli
increas
cat
ce
p
respect
signific
differ
abund
bacteri
group
total
bacteri
count
group
fceai
significantli
decreas
treatment
cat
ce
median
rang
compar
treatment
p
howev
signific
differ
found
abund
bacteri
group
treatment
cat
ce
conclus
fecal
dysbiosi
present
cat
ce
although
fceai
decreas
significantli
week
medic
treatment
abund
select
bacteri
group
chang
significantli
result
might
suggest
longer
period
treatment
differ
approach
medic
therapi
ie
preor
probiot
may
need
cat
recov
fecal
dysbiosi
associ
ce
human
medicin
recent
studi
shown
individu
inflammatori
bowel
diseas
ibd
statist
signific
decreas
mean
platelet
volum
mpv
platelet
distribut
width
pdw
increas
platelet
crit
pct
compar
healthi
control
remiss
pdw
pct
found
significantli
greater
control
studi
date
investig
associ
platelet
indic
dog
ibd
compar
healthi
control
determin
platelet
indic
could
use
predictor
diseas
presenc
sever
therefor
purpos
retrospect
studi
determin
platelet
indic
significantli
differ
dog
diagnos
ibd
healthi
match
control
dog
indic
predict
sever
base
canin
chronic
enteropathi
clinic
activ
index
ccecai
score
assign
retrospect
dog
diagnos
ibd
dog
histopatholog
diagnosi
inflammatori
bowel
diseas
ibd
concurr
ill
receiv
immunosuppress
therapi
elig
inclus
studi
twenti
dog
diagnos
ibd
healthi
match
control
dog
includ
analysi
variabl
compar
two
group
includ
mpv
pdw
pct
well
mean
platelet
number
plt
mean
platelet
compon
concentr
mpc
mean
platelet
compon
concentr
distribut
width
pcdw
mean
platelet
mass
mpm
platelet
dri
mass
distribut
width
pmdw
signific
differ
dog
diagnos
ibd
healthi
control
evalu
use
ttest
report
mean
ae
standard
deviat
receiv
oper
characterist
roc
curv
addit
correl
platelet
indic
ccecai
score
evalu
use
bivari
scatterplot
linear
regress
model
determin
variabl
predict
diseas
sever
result
indic
none
variabl
compar
two
group
statist
signific
pvalu
predict
presenc
diseas
although
signific
variabl
close
pvalu
trend
toward
signific
could
repres
possibl
predict
indic
diseas
mean
plt
pct
notic
higher
ibd
dog
mean
pcdw
notic
lower
ibd
dog
healthi
control
roc
analysi
perform
determin
predict
valu
variabl
use
area
curv
auc
base
auc
valu
platelet
indic
strongli
correl
diseas
howev
plt
pct
pcdw
mpm
pmdw
auc
valu
indic
may
somewhat
predict
diseas
presenc
bivari
scatterplot
move
averag
demonstr
plt
pvalu
pct
pvalu
statist
signific
predict
diseas
sever
linear
regress
show
mild
correl
ccecai
score
two
indic
plt
r
valu
pct
conclus
strong
correl
platelet
indic
presenc
sever
diseas
dog
inflammatori
bowel
diseas
statist
support
spite
mani
indic
show
potenti
valu
predictor
diseas
patient
ibd
larger
studi
popul
like
need
determin
true
signific
felin
hepat
lipidosi
fhl
character
excess
accumul
lipid
within
hepatocyt
lead
intrahepat
cholestasi
sever
hepat
dysfunct
hypothes
cat
fhl
show
alter
serum
lipoprotein
profil
due
intens
lipolysi
adipos
tissu
alter
hepatocellular
lipid
metabol
aim
studi
compar
serum
lipoprotein
profil
well
serum
cholesterol
triglycerid
concentr
cat
fhl
healthi
control
cat
analysi
serum
lipoprotein
profil
use
densiti
gradient
ultracentrifug
perform
cat
fhl
confirm
cytolog
andor
histolog
find
healthi
control
cat
area
curv
triglyceridesrichlipoprotein
trl
ldl
hdl
calcul
addit
serum
cholesterol
triglycerid
concentr
measur
use
clinic
chemistri
analyz
data
analyz
use
wilcoxon
rank
sum
test
signific
set
p
ldl
content
significantli
higher
cat
fhl
healthi
control
cat
p
hdl
content
significantli
lower
cat
fhl
healthi
control
cat
p
trl
content
significantli
differ
two
group
p
also
serum
cholesterol
triglycerid
concentr
significantli
differ
two
group
p
p
respect
studi
serum
lipoprotein
profil
alter
cat
fhl
even
though
serum
cholesterol
triglycerid
concentr
significantli
differ
compar
healthi
control
cat
clinic
import
lipoprotein
profil
cat
hepat
lipidosi
warrant
studi
exact
aetiolog
inflammatori
chronic
enteropathi
dog
remain
unknown
accumul
evid
suggest
pivot
role
intestin
dysbiosi
diseas
pathogenesi
mani
studi
evalu
alter
faecal
microbiota
canin
chronic
gastrointestin
gi
diseas
less
research
focus
mucos
microbiota
especi
ileum
colon
object
current
studi
evalu
ileal
colon
mucos
microbiota
dog
steroid
respons
enteropathi
sre
month
treatment
compar
control
dog
cd
total
dog
diagnos
sre
enrol
complet
gi
endoscopi
perform
sampl
collect
cytolog
brush
diagnosi
srebaselin
n
month
treatment
sreafter
n
oral
lax
water
enema
perform
endoscopi
total
cd
euthan
reason
unrel
studi
gi
diseas
includ
sampl
cd
obtain
necropsi
within
hour
death
mucos
genom
dna
extract
use
illumina
sequenc
rrna
gene
sequenc
data
analys
use
qiim
pipelin
statist
signific
set
p
clinic
sign
improv
significantli
month
treatment
sre
improv
seen
endoscop
histolog
evalu
signific
differ
microbi
commun
srebaselin
cd
observ
colon
anosim
p
ileum
anosim
p
dog
sre
ileal
colon
microbi
commun
remain
similar
month
treatment
anosim
p
p
respect
differ
cd
anosim
p
p
respect
result
studi
suggest
mucos
microbiota
colon
dog
sre
differ
cd
although
clinic
sign
improv
colon
mucos
dysbiosi
still
present
month
treatment
canin
pancreat
lipas
immunoreact
cpli
concentr
consid
specif
biomark
diagnosi
canin
pancreat
one
report
week
oral
administr
prednison
mgkgday
six
healthi
dog
signific
effect
serum
cpli
concentr
steiner
et
al
aim
studi
determin
effect
highdos
prednisolon
mgkgday
pancreat
tissu
serum
cpli
concentr
healthi
dog
six
healthi
beagl
receiv
prednisolon
mgkgday
subcutan
week
measur
cpli
concentr
ultrasonograph
examin
pancrea
perform
treatment
laparoscop
biopsi
liver
right
pancreat
lobe
also
perform
treatment
serum
cpli
concentr
compar
treatment
use
wilcoxon
signedrank
test
serum
cpl
concentr
significantli
higher
treatment
posttreat
cpli
concentr
classifi
normal
lgl
five
dog
abnorm
lgl
one
dog
ultrasonograph
examin
pancrea
show
signific
chang
treatment
histolog
evid
pancreat
right
pancreat
lobe
treatment
administr
prednisolon
mgkgday
week
increas
serum
cpli
concentr
six
healthi
dog
although
clinic
signific
increas
lgl
observ
one
dog
histolog
evid
pancreat
observ
six
dog
examin
human
acut
pancreat
ap
treatment
within
hour
onset
import
profoundli
influenc
prognosi
dog
ap
efficaci
corticosteroid
treatment
unknown
purpos
studi
investig
respons
initi
corticosteroid
therapi
prognosi
dog
ap
sixtyf
dog
includ
studi
dog
divid
prednisolon
pdl
nonprednisolon
npdl
group
prednisolon
administ
dose
mgkgday
pdl
group
enrofloxacin
maropit
famotidin
fentanyl
iv
fluid
use
treatment
group
number
day
crp
level
mgdl
clinic
sign
score
apc
durat
hospit
mortal
relaps
rate
analyz
treatment
effect
assess
use
rel
absolut
risk
reduct
rrr
arr
number
need
treat
nnt
crp
valu
significantli
lower
pdl
group
npdl
group
day
hospit
vs
mgdl
p
day
taken
crp
level
mgdl
apc
durat
hospit
significantli
shorter
pdl
group
npdl
group
vs
day
vs
day
vs
day
p
respect
mortal
pdl
group
significantli
lower
npdl
group
vs
therapeut
effect
rrr
arr
nnt
conclus
initi
corticosteroid
therapi
may
effect
dog
ap
exocrin
pancreat
insuffici
epi
syndrom
character
inadequ
synthesi
secret
pancreat
digest
enzym
result
maldigest
dietari
trial
dog
epi
demonstr
benefit
specif
diet
determin
fecal
composit
use
determin
nutrient
digest
aim
studi
evalu
fecal
composit
dri
matter
dm
organ
matter
om
ash
crude
protein
cp
total
lipid
content
acid
hydrolyz
fat
ahf
dog
natur
occur
epi
surplu
fecal
sampl
dog
dog
receiv
enzym
supplement
enrol
unrel
clinic
trial
involv
dog
epi
util
includ
studi
dog
least
year
age
clinic
sign
epi
ie
polyphagia
weight
loss
steatorrhea
andor
loos
volumin
andor
malodor
stool
serum
ctli
concentr
lgl
free
clinic
appar
diseas
epi
twelv
healthi
dog
enrol
healthi
control
three
natur
void
fecal
sampl
collect
owner
home
store
frozen
shipment
upon
receipt
sampl
pool
aliquot
store
shipment
anim
scienc
laboratori
depart
anim
scienc
divis
nutrit
scienc
univers
illinoi
fecal
sampl
analyz
dm
om
ash
cp
ahf
fecal
composit
paramet
compar
three
group
healthi
control
dog
dog
epi
enzym
supplement
epi
dog
epi
without
enzym
supplement
epin
use
kruskalw
test
signific
differ
identifi
posthoc
test
perform
use
dunn
multipl
comparison
test
signific
set
p
median
dm
content
fece
minmax
healthi
epi
epin
dog
respect
median
om
content
fece
dm
basi
minmax
healthi
epi
epin
dog
respect
median
ash
content
fece
dm
basi
minmax
healthi
epi
epin
dog
respect
median
cp
content
fece
dm
basi
minmax
healthi
epi
epin
dog
respect
median
ahf
content
fece
dm
basi
minmax
healthi
epi
epin
dog
respect
dm
om
ash
ahf
significantli
differ
healthi
dog
dog
epi
howev
signific
differ
observ
fecal
composit
epi
dog
regardless
whether
treat
enzym
supplement
studi
show
fecal
composit
alter
dog
natur
occur
epi
even
manag
enzym
supplement
larger
prospect
clinic
studi
necessari
elucid
mechan
lead
alter
fecal
composit
despit
enzym
replac
therapi
aim
present
studi
identifi
singl
nucleotid
polymorph
use
genom
wide
associ
studi
gwa
may
confer
genet
suscept
resist
ibd
genom
dna
extract
edta
blood
saliva
sampl
case
control
genotyp
case
control
perform
canin
illumina
hd
snp
array
data
gener
analyz
use
plink
use
fst
logist
associ
analys
identifi
candid
gene
previous
report
associ
human
ibd
involv
pathway
link
diseas
eight
gene
one
ptprc
protein
tyrosin
phosphatas
receptor
type
c
chromosom
seven
coloni
stimul
factor
solut
carrier
member
interferon
regulatori
factor
chromosom
identifi
approach
conclus
identifi
gene
associ
ibd
gsd
result
suggest
cytokin
could
implic
pathogenesi
ibd
gsd
target
resequenc
gene
identifi
studi
help
identifi
caus
snp
consequ
function
analysi
causal
snp
reveal
insight
mechan
involv
pathogenesi
canin
ibd
purpos
studi
analyz
capsul
endoscopi
ce
find
hypoalbuminem
dog
record
dog
given
alicam
gastrointestin
sign
andor
laboratori
abnorm
retrospect
assess
seventeen
dog
hypoalbuminem
complet
studi
mean
ae
sd
albumin
ae
gdl
mean
ae
sd
age
ae
year
mean
ae
sd
weight
ae
kg
eight
dog
concurr
anemia
prior
ce
dog
ultrasound
examin
gastrointestin
tract
stomach
small
intestin
si
colon
normal
n
character
nonspecif
wall
thicken
n
seventeen
ce
studi
abnorm
find
consist
irregularthicken
mucosa
without
eros
n
numer
dilat
lacteal
n
sever
eros
ulcer
activ
bleed
n
mass
n
hookworm
n
si
nodul
n
lesion
consist
colon
vascular
ectasia
n
lesion
seen
ce
dilat
lacteal
colon
vascular
ectasia
confirm
two
dog
subsequ
underw
tradit
endoscopi
third
dog
gastroduodenoscopi
prior
ce
show
si
hemorrhag
miss
si
nodul
later
identifi
ce
diagnosi
strongyloid
made
base
endoscop
biopsi
fecal
baermann
test
fourth
dog
sever
melena
neg
gastroduodenoscopi
laparoscopi
yet
ce
subsequ
identifi
sever
gastrointestin
eros
ulcer
thought
secondari
nsaid
administr
ce
inform
dog
hypoalbuminemia
even
lesion
identifi
tradit
endoscopi
surgeri
ultrasound
sever
acut
pancreat
sap
associ
system
complic
high
mortal
rate
dog
mesenchym
stem
cell
msc
investig
therapeut
potenti
sever
inflamm
model
studi
investig
effect
canin
adipos
tissuederiv
cat
msc
rat
model
sap
induc
retrograd
inject
sodium
taurochol
solut
pancreat
duct
catmsc
label
tetramethylindocarbocyanin
perchlor
cellskg
system
administ
rat
pancreat
tissu
collect
day
later
histopatholog
quantit
realtim
pcr
immunocytochem
analys
greater
number
infus
catmsc
detect
pancrea
sap
compar
shamoper
rat
catmsc
infus
reduc
pancreat
edema
inflammatori
cell
infiltr
acinar
cell
necrosi
decreas
pancreat
express
proinflammatori
cytokin
tumor
necrosi
factora
interleukin
il
interferonc
stimul
express
antiinflammatori
cytokin
sap
rat
moreov
catmsc
decreas
number
cluster
differenti
cell
increas
forkhead
box
cell
injur
pancrea
result
indic
catmsc
effect
cellbas
therapeut
strategi
treatment
sap
dog
limit
inform
regard
likelihood
outcom
esophag
perfor
secondari
esophag
foreign
bodi
efb
dog
medic
record
databas
two
veterinari
hospit
identifi
dog
efb
jan
bone
fishhook
predomin
fifteen
dog
diagnos
perfor
base
radiographi
n
esophagoscopi
n
surgic
explor
n
ten
fishhook
efb
five
bone
esophag
perfor
influenc
patient
size
esophag
perfor
like
dog
fishhook
v
odd
ratio
p
type
efb
fishhook
bone
efb
median
time
ingest
present
substanti
longer
dog
perfor
hr
hr
respect
without
hr
p
hr
p
respect
endoscop
efb
remov
attempt
dog
eight
recov
without
surgic
intervent
one
euthan
esophag
necrosi
six
dog
treat
surgic
five
surviv
one
euthan
intraop
two
nonsurvivor
longstand
bone
efb
surviv
rate
dog
esophag
perfor
esophag
perfor
secondari
efb
rel
uncommon
howev
ingest
fishhook
markedli
increas
likelihood
perfor
delay
efb
ingest
present
hospit
ten
dog
perfor
secondari
fishhook
discharg
aliv
major
survivor
requir
surgic
intervent
research
involv
fecal
collect
clientown
cat
challeng
due
time
differ
defec
collect
well
owner
complianc
refriger
freez
sampl
immedi
follow
collect
studi
examin
effect
prolong
ambient
temperatur
exposur
felin
fecal
microbiota
composit
fecal
sampl
collect
within
minut
defec
healthi
cat
board
facil
guelph
canada
sampl
aliquot
first
aliquot
frozen
within
one
hour
defec
time
point
remain
aliquot
maintain
ambient
temperatur
frozen
hour
collect
dna
extract
aliquot
region
rrna
gene
amplifi
use
polymeras
chain
reaction
pcr
pcr
product
sequenc
nextgener
sequenc
illumina
miseq
mothur
softwar
use
bioinformat
analysi
total
sequenc
pass
filter
median
sequenc
per
sampl
rang
sequencessampl
rel
abund
differ
taxa
calcul
compar
time
point
signific
differ
p
taxa
time
point
follow
benjaminihochberg
adjust
alphadivers
index
shannon
divers
simpson
divers
use
evalu
even
divers
rich
respect
signific
differ
identifi
p
comparison
betadivers
measur
appli
assess
similar
commun
membership
structur
phylogenet
tree
creat
visual
present
commun
membership
structur
jaccard
yue
clayton
index
respect
time
cat
signific
differ
identifi
parsimoni
unifracunweight
test
p
princip
coordin
analys
perform
show
sampl
cluster
mainli
cat
signific
differ
time
point
amova
p
homova
p
linear
discrimin
analysi
lda
effect
size
lefs
method
perform
identifi
genom
featur
enrich
taxa
time
point
lefs
analysi
fail
detect
differ
group
random
forest
algorithm
analysi
identifi
error
rate
indic
homogen
across
time
point
contradictori
evid
exist
human
studi
regard
effect
storag
differ
temperatur
fecal
microbiota
recent
studi
wees
jalali
show
limit
impact
refriger
day
felin
canin
microbiota
concur
current
studi
demonstr
maintain
felin
fecal
sampl
ambient
temperatur
hour
day
demonstr
effect
bacteri
membership
structur
result
lefs
random
forest
analysi
also
provid
support
evid
lack
differ
time
point
current
research
suggest
use
mesenchym
stem
cell
msc
therapi
treat
clinic
diseas
chronic
enteropathi
may
optim
donor
select
precondit
strategi
therefor
investig
effect
sever
precondit
method
donor
sex
vitro
cytokin
product
adiposederiv
canin
msc
cmsc
passag
cmsc
gener
cryopreserv
subcutan
adipos
tissu
healthi
adult
intact
dog
femal
male
cmsc
subject
differ
condit
control
poli
c
ifnc
tgfb
serumfre
media
mix
hypox
environ
supernat
cmsc
harvest
hour
level
tgfb
vegf
determin
elisa
level
detect
sampl
tgfb
measur
well
treat
tgfb
gener
otherwis
undetect
detect
rel
low
level
sampl
one
male
one
femal
donor
cmsc
produc
small
moder
amount
constitut
reach
peak
level
hour
alter
precondit
cmsc
produc
larg
amount
vegf
alter
precondit
gener
serumfre
mix
hypox
environ
decreas
product
measur
cytokin
sampl
male
donor
show
signific
donor
variabl
compar
femal
suggest
treatment
success
might
influenc
care
donor
select
well
pretreat
condit
depend
desir
outcom
purpos
studi
compar
incid
antibioticassoci
gastrointestin
sign
aag
alter
fecal
microbiom
metabolom
healthi
cat
random
receiv
mg
clindamycin
capsul
placebo
synbiot
proviabledc
daili
day
reevalu
day
antibiot
discontinu
daili
food
consumpt
occurr
vomit
fecal
score
record
fecal
sampl
collect
day
baselin
sequenc
rrna
gene
perform
mass
spectrometri
use
determin
metabolom
profil
p
consid
signific
benjamini
hochberg
fals
discoveri
rate
fdr
use
adjust
multipl
comparison
cat
develop
aag
vomit
less
cat
receiv
synbiot
differ
signific
alpha
beta
divers
chang
significantli
treatment
decreas
actinobacteria
bifidobacterium
collinsella
slackia
bacteriodet
bacteroid
lachnospiracea
blautia
coprococcu
roseburia
ruminococcacea
faecilobacterium
ruminococcu
erysipelotrichacea
bulleidia
eubacterium
increas
clostridiacea
clostridium
proteobacteria
aeromonadal
enterobacteriacea
occur
incomplet
normal
day
derang
shortchain
fatti
acid
bile
acid
indol
sphingolipid
polyamin
cinnamin
acid
profil
occur
persist
day
differ
group
cat
aag
accompani
shortand
longterm
dysbiosi
alter
metabolom
profil
metabolom
profil
aag
bacteri
abund
differ
group
time
investig
warrant
determin
whether
antibioticinduc
dysbiosi
associ
increas
risk
aag
cat
whether
prior
synbiot
administr
amelior
risk
purpos
studi
compar
fecal
microbiom
metabolom
healthi
cat
random
receiv
mg
clindamycin
food
follow
hour
later
capsul
placebo
synbiot
proviabledc
daili
day
reevalu
week
treatment
fecal
sampl
collect
day
baselin
sequenc
rrna
gene
perform
mass
spectrometri
use
determin
metabolom
profil
p
consid
signific
benjamini
hochberg
fals
discoveri
rate
use
adjust
multipl
comparison
alpha
beta
divers
alter
significantli
treatment
alter
shannon
dysbiosi
indic
persist
day
age
significantli
associ
shannon
dysbiosi
indic
rel
bacteri
abund
decreas
actinobacteria
adlercreutzia
bifidobacterium
collinsella
slackia
bacteriodet
bacteroid
prevotella
ruminococcacea
faecilobacterium
ruminococcu
veillonellacea
megamona
megasphaera
phascolarctobacterium
erysipelotrichacea
eubacterium
increas
clostridiacea
clostridium
proteobacteria
enterobacteriacea
occur
incomplet
normal
day
metabolit
profil
differ
significantli
time
group
time
x
group
metabolit
respect
microbiom
chang
accompani
derang
shortchain
fatti
acid
bile
acid
indol
sphingolipid
cinnamin
acid
profil
persist
day
differ
group
cat
antibiot
administr
caus
sustain
dysbiosi
ageassoci
chang
microbiom
could
affect
sensit
antibioticinduc
gastrointestin
effect
metabolom
profil
differ
treatment
group
time
suggest
potenti
mechan
decreas
antibioticinduc
gastrointestin
effect
cat
administ
synbiot
canin
immun
mediat
hemolyt
anemia
imha
high
mortal
rate
despit
aggress
immunosuppress
therapi
support
care
develop
immunemedi
diseas
like
multifactori
process
lead
loss
normal
immun
selftoler
human
affect
autoimmun
hemolyt
anemia
show
sever
cytokin
derang
includ
newli
defin
subset
cell
cell
secret
appear
critic
role
pathogenesi
aiha
peopl
work
mous
model
diseas
indic
potenti
treatment
target
hypothes
dog
imha
would
display
signific
elev
concentr
compar
healthi
control
serum
measur
thirti
dog
primari
imha
diagnosi
day
initi
immunosuppress
therapi
well
clinic
healthi
dog
significantli
increas
time
present
dog
imha
p
compar
healthi
dog
well
p
cours
hospit
significantli
decreas
p
p
discharg
patient
n
chang
level
observ
among
dog
euthan
hospit
correl
concentr
bilirubin
level
lactat
cbc
paramet
time
present
throughout
hospit
elev
dog
imha
seem
decreas
respons
therapi
observ
oxid
stress
play
consider
role
pathophysiolog
multipl
diseas
well
document
contributor
diseas
human
veterinari
literatur
oxid
stress
result
product
reactiv
oxygen
speci
caus
cellular
injuri
direct
indirect
mechan
one
atrisk
cell
type
erythrocyt
howev
role
oxid
stress
canin
anemia
investig
oxid
stress
primarili
assess
activ
antioxid
enzym
concentr
endogen
antioxid
byproduct
oxid
damag
purpos
studi
determin
oxid
stress
present
anem
dog
hypothes
anem
dog
would
alter
activ
glutathion
peroxidas
gpx
reduct
total
antioxid
capac
tac
increas
concentr
urinari
byproduct
lipid
peroxid
compar
healthi
dog
prospect
crosssect
studi
recruit
clientown
dog
anemia
pcv
due
caus
clientown
agematch
healthi
control
dog
dog
evalu
whole
blood
gpx
activ
plasma
tac
urinari
concentr
anem
dog
stratifi
hemolyt
caus
nonhemolyt
caus
anem
dog
significantli
lower
gpx
activ
x
ul
x
dog
control
group
x
ul
x
p
indic
inactiv
gpx
activ
deplet
antioxid
defens
mechan
dog
hemolyt
anemia
lower
mean
gpx
activ
compar
dog
nonhemolyt
anemia
differ
reach
signific
p
howev
may
suggest
degre
oxid
stress
may
sever
hemolysi
tac
concentr
p
urinari
p
significantli
differ
group
first
studi
veterinari
medicin
demonstr
glutathion
peroxidas
defici
subsequ
oxid
stress
anem
dog
studi
warrant
determin
antioxid
supplement
would
improv
surviv
overal
outcom
part
therapeut
regimen
anem
state
especi
hemolysi
yunnan
baiyao
popular
chines
herbal
medicin
agent
use
antiinflammatori
properti
hemostat
properti
wound
heal
properti
peopl
approxim
centuri
recommend
use
dog
control
hemorrhag
epistaxi
splenic
hemangiosarcoma
howev
studi
evalu
safeti
yunnan
baiyao
use
dog
vivo
studi
effect
yunnan
baiyao
coagul
paramet
healthi
dog
object
studi
evalu
effect
yunnan
baiyao
kinet
hemostasi
determin
advers
effect
associ
administr
yunnan
baiyao
healthi
dog
studi
use
six
healthi
purpos
bred
dog
baselin
evalu
includ
complet
blood
count
serum
biochemistri
profil
urinalysi
prothrombin
time
partial
thromboplastin
time
hemostat
kinet
use
rotem
thromboelastrometri
extem
intem
fibtem
rotem
paramet
assess
includ
clot
time
clot
format
clot
stabil
clot
lysi
dog
administ
oral
yunnan
baiyao
dose
mgkg
oral
daili
day
day
day
day
rotem
thromboelastometri
perform
dog
day
complet
blood
count
serum
biochemistri
profil
urinalysi
prothrombin
time
partial
thromboplastin
time
also
perform
dog
signific
chang
note
treatment
paramet
monitor
signific
chang
clot
time
p
clot
format
time
p
clot
format
rate
p
note
pretreat
rotem
valu
post
treatment
rotem
valu
compar
result
studi
conclud
yunnan
baiyao
safe
administr
dog
result
signific
chang
baselin
health
paramet
coagul
paramet
healthi
dog
hypothes
net
form
storag
canin
rbc
prestorag
lr
reduc
netosi
applic
supernat
store
nonleukoreduc
nlr
rbc
unit
would
induc
netosi
healthi
canin
neutrophil
blood
unit
collect
healthi
dog
process
divid
two
equal
subunit
rbc
one
leukoreduc
commerci
filter
unit
store
day
sampl
biweekli
net
marker
citrullin
histon
cellfre
dna
quantifi
unit
supernat
via
western
blot
fluoresc
dna
dye
respect
supernat
appli
ex
vivo
neutrophil
healthi
dog
releas
extracellular
dna
repres
netosi
assess
data
analyz
repeat
measur
anova
treatment
time
fix
variabl
marker
net
increas
rbc
storag
higher
nlr
lr
unit
figur
isol
neutrophil
form
net
respons
supernat
store
canin
rbc
netosi
occur
store
canin
nlr
rbc
unit
attenu
prestorag
lr
net
may
mediat
transfus
reaction
clinic
benefit
prestorag
lr
explor
purpos
studi
describ
length
time
glucocorticoid
util
treatment
autoimmun
hemolyt
anemia
aiha
immunemedi
thrombocytopenia
itp
evan
syndrom
canin
treat
author
institut
retrospect
analysi
perform
patient
achiev
remiss
wean
glucocorticoid
treatment
full
treatment
data
avail
seventyseven
case
includ
analyz
median
dosag
taper
timelin
length
glucocorticoid
therapi
collect
data
present
alongsid
anecdot
data
obtain
survey
diplom
american
colleg
veterinari
intern
medicin
specialti
intern
medicin
median
start
glucocorticoid
dose
mgkgday
prednison
equival
case
start
secondari
immunosuppress
median
time
taper
step
day
median
taper
origin
dose
step
median
length
glucocorticoid
treatment
day
rang
thirteen
case
experienc
relaps
within
studi
period
two
occur
within
month
discontinu
prednison
secondari
immunosuppress
two
within
month
discontinu
secondari
immunosuppress
therapi
remaind
occur
month
discontinu
secondari
immunosuppress
therapi
survey
data
indic
respond
initi
glucocorticoid
treatment
mgkgd
begin
taper
glucocorticoid
week
addit
step
week
interv
respond
decreas
origin
dose
step
respons
indic
glucocorticoid
treatment
greater
three
month
estim
relaps
rate
within
six
month
discontinu
immunosuppress
therapi
respond
result
studi
indic
success
maintain
remiss
use
rapid
glucocorticoid
taper
schedul
use
secondari
immunosuppress
data
similar
anecdot
achiev
prolong
treatment
glucocorticoid
presum
decreas
sever
side
effect
prolong
glucocorticoid
therapi
one
explan
report
decreas
rbc
surviv
transfus
increas
shear
stress
damag
rbc
blood
forc
inlin
microaggreg
filter
goal
studi
determin
blood
pass
microaggreg
filter
via
syring
pump
would
damag
canin
rbc
hypothesi
time
filter
would
becom
clog
fibrin
cellular
debri
requir
increas
forc
maintain
prefer
flow
rate
therebi
caus
increas
damag
rbc
whole
blood
ml
collect
healthi
dog
use
syring
pump
blood
pass
standard
microaggreg
filter
three
standard
rate
use
clinic
set
mlhr
preand
postfilt
blood
sampl
collect
begin
end
simul
transfus
sampl
analyz
determin
erythrocyt
osmot
fragil
mean
corpuscular
fragil
mcf
rbc
count
hemoglobin
concentr
rbc
distribut
width
rdw
rbc
morpholog
forc
requir
pass
blood
microaggreg
filter
also
measur
continu
simul
transfus
regardless
transfus
rate
chang
mcf
rbc
count
hemoglobin
concentr
rdw
preand
postfilt
sampl
addit
dog
signific
chang
pressur
within
filter
seen
time
echinocyt
common
abnorm
erythrocyt
morpholog
note
mlhr
rate
end
simul
transfus
preand
postfilt
sampl
schistocyt
identifi
one
sampl
postfilt
mlhr
studi
suggest
regardless
transfus
rate
microaggreg
filter
alter
fragil
canin
rbc
may
alter
morpholog
rbc
morpholog
alter
could
contribut
decreas
rbc
surviv
administr
blood
via
syring
pump
circul
platelet
microparticl
pmp
subcellular
vesicl
releas
platelet
possibl
megakaryocyt
membran
peopl
alter
pmp
concentr
associ
prothrombot
inflammatori
neoplast
cardiovascular
condit
canin
studi
exist
bloodprocess
preanalyt
influenc
pmp
concentr
studi
purpos
analyt
valid
pmp
quantif
dog
perspect
clinic
applic
use
flow
cytometri
dualli
annexin
posit
pmp
lm
quantifi
citrat
whole
blood
wb
plateletpoor
plasma
centrifug
g
minut
coeffici
varianc
cv
duplic
intraassay
parallel
interassay
pmp
analys
detect
limit
dl
calcul
accept
maxim
variat
data
obtain
healthi
dog
demonstr
accept
intraassay
cv
wb
median
rang
plasma
accept
interassay
cv
wb
plasma
plasma
pmp
concentr
equal
nois
level
neg
control
antibodi
centrifug
plasma
protocol
markedli
reduc
nois
dl
pmpll
antibodi
centrifug
implement
anoth
seven
dog
result
demonstr
accept
wb
intraassay
interassay
cv
except
one
dog
interassay
cv
unfortun
hemolysi
andor
lipidemia
interf
plasma
pmp
quantif
five
seven
dog
conclus
pmp
concentr
quantifi
reliabl
wb
accept
analyt
precis
suggest
applic
clinic
set
plasma
pmp
concentr
invalid
unobtain
due
dl
overlap
hemolysi
andor
lipidemia
respect
cardiogen
embol
ce
cat
devast
condit
primarili
associ
cardiomyopathi
hypercoagul
may
pose
risk
thrombu
format
howev
singl
test
predict
develop
ce
platelet
microparticl
pmp
subcellular
vesicl
releas
platelet
membran
associ
thrombosi
human
purpos
studi
analyt
valid
flow
cytometr
pmp
quantif
cat
ii
pilot
studi
evalu
concentr
procoagul
pmp
healthi
cat
cat
cardiomyopathi
cat
underw
physic
examin
hematolog
serum
biochemistri
extend
coagul
screen
full
cardiac
examin
includ
blood
pressur
measur
electrocardiographi
echocardiographi
use
flow
cytometri
dualli
annexin
posit
pmp
lm
quantifi
citrat
whole
blood
wb
plateletpoor
plasma
coeffici
varianc
cv
duplic
intraassay
parallel
interassay
pmp
analys
calcul
six
healthi
cat
five
cat
mild
hypertroph
cardiomyopathi
examin
pmp
concentr
could
quantifi
accept
intraassay
cv
wb
median
rang
plasma
accept
interassay
cv
wb
plasma
groupwis
comparison
wb
pmp
concentr
demonstr
differ
healthi
cat
pmpul
pmpul
cat
mild
cardiomyopathi
pmpul
pmpul
p
conclus
wb
pmp
concentr
could
reliabl
quantifi
cat
clinic
set
pmp
concentr
howev
differ
healthi
cat
cat
mild
cardiomyopathi
purpos
studi
review
caus
outcom
leukemoid
respons
dog
computer
search
dog
seen
last
year
neutrophil
count
cellsll
univers
missouri
complet
demograph
data
hemogram
diagnos
clinic
outcom
extract
record
base
record
diagnosi
leukemoid
respons
deem
due
focal
system
infect
inflamm
immunemedi
diseas
neoplast
diseas
tissu
damagenecrosi
caus
undetermin
total
dog
identifi
includ
male
intact
castrat
unknown
statu
femal
intact
spay
dog
mean
age
year
minimum
maximum
nine
mix
breed
german
shepherd
dog
chi
squar
p
overrepres
median
neutrophil
count
cellsll
iqr
maximum
cellsll
definit
diagnosi
avail
dog
presumpt
diagnosi
fortytwo
infectioninflamm
neoplast
diseas
lymphoma
leukemia
immunemedi
diseas
tissu
damag
dog
went
undiagnos
fortyfour
dog
surviv
discharg
euthan
die
hospit
median
segment
neutrophil
count
differ
diseas
group
base
kruskalw
one
way
analysi
varianc
rank
similarli
surviv
relat
neutrophil
count
magnitud
leukemoid
respons
alon
may
predict
diseas
caus
prognosi
use
infus
syring
pump
canin
blood
transfus
controversi
pump
potenti
damag
red
blood
cell
rbc
render
transfus
less
effect
previou
studi
healthi
dog
report
complet
absenc
detect
biotinyl
rbc
hour
posttransfus
mani
anim
blood
given
syring
infus
pump
complet
loss
transfus
rbc
within
one
day
transfus
howev
inconsist
anecdot
clinic
experi
object
current
studi
confirm
whether
number
differ
transfus
method
one
syring
one
infus
pump
brand
compar
graviti
drip
result
prematur
loss
transfus
cell
explor
time
earli
rbc
loss
occur
eight
healthi
hound
dog
phlebotom
ml
whole
blood
blood
centrifug
supernat
plasma
collect
store
remain
rbc
incub
nhsbiotin
dissolv
dmso
wash
salin
rbc
resuspend
store
autolog
plasma
ml
retain
posit
biotinyl
control
sampl
remaind
transfer
either
ml
dri
blood
bag
infus
pump
graviti
drip
ml
syring
syring
pump
assign
transfus
treatment
follow
graviti
drip
dog
infus
pump
heska
vet
iv
dog
syring
pump
inlin
filter
medfus
hemon
blood
filter
dog
autolog
whole
blood
transfus
perform
rate
ml
per
hour
blood
sampl
collect
sodium
citrat
anticoagul
time
pretransfus
use
neg
nonbiotinyl
control
hour
day
posttransfus
sampl
label
phycoerythrinstreptavidin
percentag
biotinyl
rbc
analyz
flow
cytometri
rbc
gate
accord
forward
side
light
scatter
gate
event
per
sampl
immedi
posttransfus
hour
percent
biotinyl
rbc
percent
total
rbc
mean
ae
sem
ae
graviti
ae
infus
ae
syring
consist
minim
loss
rbc
transfus
sinc
estim
posttransfus
mean
target
percent
biotinyl
rbc
rang
first
hour
subsequ
day
signific
differ
transfus
techniqu
approxim
biotinyl
cell
present
day
follow
transfus
figur
studi
found
accept
posttransfus
surviv
label
rbc
regardless
method
find
discrep
prior
studi
document
unmeasur
level
biotinyl
rbc
one
day
transfus
use
variou
pump
subsequ
explor
reason
discrep
result
suggest
sever
possibl
dmso
standard
solvent
use
biotin
sinc
biotin
insolubl
aqueou
solut
biotin
precipit
dmso
solut
less
high
dmso
concentr
therefor
need
biotin
label
studi
inadvert
dilut
dmso
residu
plasma
rbc
label
therefor
potenti
render
biotinyl
ineffect
addit
found
differ
concentr
dmso
caus
variabl
lysi
rbc
dmso
dilut
pb
caus
mark
hemolysi
caus
moder
hemolysi
caus
mild
hemolysi
caus
hemolysi
find
suggest
transfus
studi
use
biotinyl
rbc
may
suscept
techniqu
artifact
subtl
variat
dmso
concentr
lead
either
failur
biotinyl
inadvert
rbc
damag
biochem
immunolog
chang
consist
erythrocyt
storag
lesion
describ
felin
pack
red
blood
cell
prbc
unit
oxid
damag
occur
store
human
erythrocyt
evidenc
decreas
glutathion
concentr
yet
investig
cat
purpos
studi
determin
effect
storag
glutathion
osmot
fragil
methemoglobin
reductas
activ
felin
prbc
whole
blood
ml
collect
five
healthi
cat
blood
bag
contain
bag
split
half
prbc
unit
prepar
cat
addit
solut
ad
one
unit
prbc
store
aliquot
unit
sampl
day
storag
assay
glutathion
osmot
fragil
methemoglobin
reductas
activ
friedman
test
use
assess
chang
time
glutathion
decreas
significantli
time
untreat
prbc
osmot
fragil
increas
significantli
time
untreat
prbc
chang
baselin
prbc
treat
methemoglobin
reductas
activ
unchang
treat
untreat
sampl
storag
felin
prbc
day
lead
glutathion
deplet
increas
osmot
fragil
find
evid
storag
lesion
felin
prbc
howev
addit
mitig
chang
consid
develop
futur
blood
product
protocol
fresh
frozen
plasma
use
treat
varieti
condit
critic
ill
plasma
transfus
potenti
caus
advers
reaction
limit
resourc
current
evidencebas
plasma
transfus
recommend
dog
cat
includ
document
coagulopathi
bleed
plan
invas
procedur
dc
warfarin
revers
wr
massiv
transfus
mt
factor
defici
fd
aim
studi
determin
plasma
transfus
anim
met
guidelin
use
human
medicin
medic
record
system
retrospect
search
dog
cat
receiv
plasma
transfus
indic
transfus
record
percentag
categori
record
well
case
clear
indic
surviv
record
dog
n
cat
n
identifi
seventysix
percent
n
patient
plasma
transfus
could
classifi
indic
propos
guidelin
human
patient
patient
indic
could
classifi
multipl
categori
common
indic
dc
n
mt
n
wr
n
fd
n
twentyfour
percent
n
anim
administ
plasma
reason
frequent
hypoproteinemia
surviv
discharg
dog
n
cat
n
major
plasma
transfus
consid
indic
base
guidelin
human
patient
howev
transfus
consid
indic
similar
guidelin
consid
companion
anim
cat
hypertroph
cardiomyopathi
hcm
increas
risk
format
aortic
thromboembol
ate
due
blood
stasi
platelet
hyperreact
enlarg
cardiac
chamber
among
prothrombot
factor
antiplatelet
medic
commonli
use
cat
consid
risk
develop
thromboembol
clopidogrel
bisulf
thienopyridin
drug
caus
irrevers
inhibit
platelet
aggreg
respons
adp
collagen
common
initi
clot
format
trade
name
clopidogrel
plavix
previous
investig
healthi
cat
associ
signific
inhibit
platelet
activ
fda
approv
gener
form
clopidogrel
inhibitori
effect
platelet
aggreg
investig
hypothes
gener
clopidogrel
associ
equal
antiplatelet
effect
associ
trade
name
clopidogrel
healthi
cat
formul
associ
minim
oralgastrointestin
advers
event
random
doubleblind
crossov
studi
five
skelet
matur
cat
determin
healthi
base
physic
examin
diagnost
includ
cbc
serum
chemistri
profil
urinalysi
coagul
time
cat
particip
three
treatment
phase
randomli
assign
receiv
either
trade
name
clopidogrel
mg
po
sid
day
gener
clopidogrel
mg
po
sid
day
placebo
cellulos
po
sid
day
day
prior
start
treatment
baselin
platelet
aggreg
assess
multipl
platelet
aggregomet
briefli
blood
collect
lithium
heparin
tube
platelet
activ
assay
use
adp
platelet
aggreg
repeat
day
determin
percentag
platelet
inhibit
achiev
inform
regard
potenti
advers
effect
record
daili
cat
phase
minimum
fourweek
washout
period
occur
phase
cat
maintain
normal
platelet
count
time
point
studi
advers
effect
note
administr
trade
name
gener
clopidogrel
cat
two
cat
reliabl
show
signific
inhibit
platelet
aggreg
respons
trade
name
gener
clopidogrel
full
respond
one
cat
show
slight
inhibit
platelet
aggreg
respons
gener
clopidogrel
trade
name
clopidogrel
partial
respond
two
cat
show
inhibit
platelet
aggreg
respons
trade
name
gener
clopidogrel
nonrespond
determin
trade
name
gener
formul
clopidogrel
safe
administ
cat
reliabl
inhibit
platelet
aggreg
cat
cat
tend
similar
respons
formul
clopidogrel
impli
intrins
factor
affect
efficaci
drug
oppos
human
assay
error
variabl
respons
treatment
may
due
alter
cytochrom
gene
code
enzym
respons
clopidogrel
metabol
sever
polymorph
identifi
human
first
studi
investig
effect
gener
formul
clopidogrel
platelet
aggreg
due
low
sampl
size
meaning
conclus
made
vari
respons
drug
studi
aim
increas
sampl
size
investig
metabol
genet
intrins
factor
could
affect
drug
efficaci
object
studi
evalu
effect
hyperton
salin
solut
hss
whole
blood
coagul
healthi
dog
compar
effect
vivo
vitro
dilut
hss
prospect
control
experiment
studi
includ
twelv
healthi
beagl
twelv
dog
includ
treatment
group
five
randomli
select
serv
control
group
dog
treatment
group
n
given
ml
kg
hss
iv
mlkgmin
follow
washout
period
dog
control
group
n
receiv
mlkg
normal
salin
solut
subsequ
blood
sampl
collect
immedi
infus
min
infus
thromboelastographi
teg
measur
vitro
studi
perform
dilut
sampl
blood
sampl
collect
baselin
diffus
hss
ratio
equival
mlkg
infus
vivo
situat
measur
use
anova
carri
repeatedli
analysi
vivo
studi
statist
signific
chang
p
teg
variabl
treatment
group
control
group
comparison
vivo
vitro
studi
pair
ttest
use
comparison
vitro
vivo
dilut
perform
point
time
immedi
infus
similar
situat
vitro
dilut
hss
immedi
diffus
vivo
signific
chang
maximum
amplitud
p
g
valu
p
suggest
hss
affect
whole
blood
coagul
differ
accord
studi
design
unlik
previou
vitro
studi
reveal
hss
anticoagul
effect
clinic
relev
dose
mlkg
hss
effect
whole
blood
coagul
compar
normal
salin
vivo
purpos
studi
evalu
abil
two
human
complement
inhibitor
inhibit
canin
complementmedi
hemolyisi
vitro
valid
use
elisa
detect
canin
complement
activ
dog
human
complement
inhibitor
compstatin
human
recombin
inhibitor
evalu
use
vitro
hemolyt
assay
antibodyco
sheep
erythrocyt
expos
canin
complement
without
inhibitor
dose
curv
gener
plot
percentag
hemolysi
inhibitor
concentr
complement
activ
sampl
healthi
dog
imha
determin
use
elisa
detect
termin
complement
complex
tcc
concentr
tcc
patient
sampl
extrapol
standard
curv
gener
use
suppli
protein
standard
sampl
treat
snake
venom
use
posit
control
complement
activ
show
dosedepend
inhibit
canin
complementmedi
hemolysi
compstatin
minim
effect
tcc
concentr
tend
higher
control
sampl
compar
dog
imha
inhibit
canin
complement
activ
vitro
compstatin
show
minim
inhibit
canin
complementmedi
hemolysi
dose
evalu
elisa
test
consist
detect
complement
activ
novel
thrombogen
examin
whole
blood
total
thrombusform
analysi
system
dog
iwanaga
yamada
r
fukushima
nagasato
maruyama
n
miura
kagoshima
univers
kagoshima
kagoshima
japan
anim
cardiovascular
thorac
surgeri
fuchuu
tokyo
japan
tokyo
univers
agricultur
technolog
fuchuu
tokyo
japan
blood
clot
control
platelet
activ
coagul
system
virchow
three
condit
must
met
form
clot
vivo
howev
current
blood
coagul
examin
fragmentari
total
thrombusform
analysi
system
tta
new
laboratori
procedur
evalu
blood
clot
abil
whole
blood
flow
microflow
chamber
imit
blood
vessel
tta
util
two
microchip
plchip
archip
plchip
predominantli
evalu
platelet
function
archip
evalu
platelet
activ
coagul
simultan
blood
clot
abil
evalu
measur
intern
pressur
chip
rise
clot
format
measur
valu
occlus
start
time
ost
time
reach
kpa
occlus
time
ot
time
reach
kpa
area
pressur
curv
auc
studi
assess
reproduc
chip
healthi
dog
establish
refer
rang
dog
pl
n
ar
n
confirm
effect
aspirin
dog
reproduc
chip
confirm
base
coeffici
variat
cv
pl
cv
ost
cv
ot
cv
auc
ar
cv
ost
cv
ot
cv
auc
refer
rang
ost
ot
plchip
averag
ae
standard
deviat
ae
ae
min
respect
auc
ae
archip
ae
ae
respect
auc
ae
dog
graph
shift
right
plchip
aspirin
administr
archip
thu
appar
extens
pl
observ
indic
success
evalu
platelet
suppress
aspirin
result
studi
indic
evalu
blood
coagul
dog
use
tta
use
blood
clot
abil
dog
variou
diseas
might
evalu
subtli
tta
futur
purpos
studi
describ
frequenc
dog
treat
primari
immunemedi
hemolyt
anemia
imha
veterinari
teach
hospit
vaccin
diagnosi
investig
whether
associ
exist
vaccin
vaccin
reaction
includ
limit
relaps
imha
popul
retrospect
descript
observ
studi
perform
involv
dog
veterinari
teach
hospit
colorado
state
univers
oregon
state
univers
medic
record
databas
search
case
meet
inclus
exclus
criteria
primari
imha
owner
refer
veterinarian
identifi
dog
contact
survey
via
postal
mail
gather
inform
regard
vaccin
dog
follow
diagnosi
refer
veterinarian
contact
phone
regard
vaccin
histori
dog
prior
diagnosi
imha
least
one
survey
return
case
result
indic
dog
receiv
vaccin
diagnosi
dog
receiv
vaccin
diagnosi
remaind
dog
survey
return
survey
exclud
inconsist
inform
vaccin
dog
possibl
vaccin
reaction
report
vomit
urticaria
dog
worsen
anemia
dog
date
vaccin
prior
diagnosi
avail
dog
mean
number
day
vaccin
initi
diagnosi
imha
day
result
indic
vaccin
occur
among
nearli
half
dog
diagnos
imha
rabi
common
vaccin
administ
dog
may
reflect
legal
requir
rabi
vaccin
locat
advers
event
uncommon
overal
comparison
rate
advers
event
gener
popul
perform
final
studi
document
tempor
relationship
vaccin
initi
diagnosi
imha
although
comparison
control
popul
necessari
confirm
find
canin
heartworm
diseas
due
dirofilaria
immiti
import
diseas
caus
hemostat
disord
although
sever
studi
show
relationship
coagul
pathway
heartworm
infect
studi
use
convent
method
laboratori
assess
hemostasi
limit
use
convent
coagul
test
evalu
hypercoagul
state
heartworm
infect
dog
thromboelastographi
teg
provid
truth
reflect
vivo
hemostasi
compar
convent
coagul
test
diagnosi
monitor
patient
studi
describ
teg
find
dog
heartworm
infect
compar
coagul
statu
determin
teg
clinic
present
heartworm
grade
convent
coagul
test
studi
consist
fifteen
healthi
dog
twentyf
dog
heartworm
infect
heartworm
infect
diagnos
use
commerci
elisa
test
kit
dog
heartworm
infect
grade
four
group
accord
blood
work
radiographi
echocardiographi
platelet
count
prothrombin
time
activ
partial
thromboplastin
time
plasma
ddimer
concentr
plasma
fibrinogen
concentr
thromboelastographi
perform
dog
result
valu
alpha
show
tendenc
increas
grade
increas
tabl
p
indic
higher
level
fibrinogen
activ
advanc
grade
rank
coeffici
correl
convent
coagul
test
teg
platelet
significantli
posit
coeffici
correl
g
valu
heartworm
infect
grade
interest
result
dog
diagnos
femor
arteri
thromboembol
show
significantli
hypercoagul
state
teg
compar
convent
test
figur
also
serial
teg
analysi
dog
dissemin
intravascular
coagul
repres
hypocoagul
state
time
figur
studi
suggest
applic
teg
help
diagnosi
treatment
heartworm
infect
dog
ehrlichia
cani
infect
dog
manifest
clinic
sign
relat
bleed
also
commonli
caus
thrombocytopenia
exact
mechan
bleed
thrombocytopenia
unknown
thought
relat
process
vascul
immun
nonimmun
process
platelet
also
unknown
dog
show
sign
bleed
dog
despit
signific
thrombocytopenia
possibl
platelet
becom
activ
infect
andor
blood
clot
becom
resist
fibrinolysi
could
prevent
bleed
phenotyp
purpos
studi
assess
platelet
indic
activ
platelet
function
via
whole
blood
imped
platelet
aggregometri
percentag
immunoglobulin
associ
platelet
percent
igg
thromboelastographi
teg
measur
includ
veloc
curv
variabl
dog
experiment
infect
e
cani
six
healthi
laboratori
beagl
experiment
infect
e
cani
via
needl
inocul
four
dog
inocul
one
natur
infect
dog
two
dog
inocul
second
natur
infect
dog
four
dog
becam
posit
e
cani
via
serolog
pcr
remain
two
dog
never
becam
posit
despit
repeat
test
result
four
dog
design
posit
two
dog
design
neg
platelet
indic
platelet
count
mean
platelet
volum
mpv
plateletcrit
pct
platelet
volum
distribut
width
pdw
mean
platelet
mass
mpm
mean
platelet
compon
concentr
mpc
platelet
compon
distribut
width
pcdw
measur
platelet
aggregometri
area
curv
auc
record
use
salin
control
auc
salin
agonist
adenosin
diphosph
adp
auc
adp
arachidon
acid
aa
auc
aa
percent
igg
assess
direct
flow
cytometri
tissu
factor
tf
activ
teg
tfactiv
teg
tissu
plasminogen
tpa
perform
teg
variabl
reaction
time
r
clot
time
k
rate
clot
format
maximum
amplitud
percent
clot
lysi
minut
clot
lysi
minut
percent
clot
lysi
minut
clot
lysi
minut
record
addit
veloc
curv
variabl
maxim
rate
thrombu
gener
mrtg
time
maximum
rate
thrombu
gener
tmrtg
total
thrombu
gener
tg
maximum
rate
lysi
mrl
time
maxim
rate
lysi
tmrl
total
lysi
l
test
perform
posit
neg
dog
prior
inocul
week
due
clinic
sign
weight
loss
hyporexia
lethargi
fever
posit
dog
administ
doxycyclin
mgkg
po
daili
week
week
variabl
repeat
measur
analysi
anova
posthoc
analysi
perform
compar
posit
neg
dog
analysi
p
consid
signific
signific
differ
group
posit
vs
neg
variabl
pdw
mpc
pcdw
auc
salin
r
k
tmrtg
mrl
infect
platelet
count
pct
auc
adp
auc
aa
significantli
lower
mpv
mpm
percent
igg
mrtg
tg
tmrl
l
significantli
higher
posit
group
overt
sign
bleed
note
studi
posit
dog
significantli
lower
platelet
count
evid
activ
platelet
base
increas
mpv
mpm
evid
decreas
platelet
function
posit
dog
could
relat
degre
thrombocytopenia
posit
dog
also
show
evid
antiplatelet
antibodi
infect
overal
posit
dog
appear
hypercoagul
base
increas
mrtg
tg
hypofibrinolyt
base
lower
higher
tmrl
characterist
hemostasi
experiment
e
cani
infect
complic
platelet
indic
activ
evid
hypercoagul
hypofibrinolyt
state
may
explain
lack
bleed
phenotyp
dog
despit
signific
thrombocytopenia
whole
blood
imped
platelet
aggregometri
healthi
greyhound
compar
healthi
beagl
shropshir
c
olver
colorado
state
univers
fort
collin
co
usa
whole
blood
imped
platelet
aggregometri
affect
hematocrit
platelet
count
human
sought
evalu
whether
phenomenon
exist
dog
compar
blood
greyhound
breed
known
high
hematocrit
low
platelet
count
beagl
breed
normal
hematocrit
platelet
count
hypothes
aggregometri
greyhound
may
result
erron
interpret
platelet
function
purpos
studi
compar
whole
blood
imped
platelet
aggregometri
hemostat
assay
healthi
greyhound
healthi
beagl
whole
blood
imped
platelet
aggregometri
tissu
factoractiv
thromboelastographi
tfteg
perform
six
healthi
clientown
greyhound
six
healthi
laboratori
beagl
platelet
aggregometri
area
curv
record
agonist
adenosin
diphosph
adp
arachidon
acid
aa
salin
control
tfteg
reaction
time
r
clot
time
k
rate
clot
format
maximum
amplitud
percent
clot
lysi
minut
reach
amount
clot
lysi
minut
reach
percent
clot
lysi
minut
reach
amount
clot
lysi
minut
reach
record
hematocrit
platelet
count
fibrinogen
also
record
unpair
ttest
perform
adp
aa
hematocrit
platelet
count
fibrinogen
r
mannwhitney
u
test
perform
salin
control
k
pearson
correl
also
assess
hematocrit
adp
aa
platelet
count
adp
aa
fibrinogen
test
p
consid
signific
adp
aa
platelet
count
fibrinogen
significantli
lower
hematocrit
significantli
higher
greyhound
statist
differ
salin
control
r
k
group
twelv
dog
correl
hematocrit
r
adp
r
aa
r
platelet
count
adp
r
aa
r
r
fibrinogen
r
agreement
previou
studi
healthi
greyhound
significantli
higher
hematocrit
lower
platelet
count
base
teg
trace
greyhound
appear
significantli
hypocoagul
decreas
hyperfibrinolyt
increas
decreas
futur
studi
investig
whether
hyperfibrinolysi
contribut
propens
bleed
greyhound
platelet
aggregometri
result
significantli
lower
agonist
greyhound
compar
beagl
could
erron
interpret
decreas
platelet
function
breed
therefor
hematocrit
platelet
count
affect
teg
trace
consider
appli
whole
blood
imped
platelet
aggregometri
high
hematocrit
low
platelet
count
healthi
greyhound
potenti
contribut
lower
aggregometri
read
due
suspect
vitro
effect
rather
reflect
true
vivo
effect
sinc
studi
demonstr
normal
platelet
function
greyhound
therefor
recommend
compar
whole
blood
imped
platelet
aggregometri
measur
greyhound
nongreyhound
subjectbas
populationbas
refer
interv
establish
breed
accur
interpret
result
object
studi
compar
thaw
time
warm
water
bath
wwb
run
water
bath
rwb
plasmatherm
compar
hemostat
protein
function
canin
fresh
frozen
plasma
ffp
thaw
wwb
plasmatherm
thaw
time
measur
ml
bag
ffp
thaw
wwb
rwb
plasmatherm
time
fresh
canin
donor
plasma
sampl
split
ml
bag
ml
control
aliquot
prior
freez
bag
thaw
wwb
plasmatherm
aliquot
equilibr
room
temperatur
concentr
hemostat
protein
albumin
ddimer
prothrombin
time
pt
partial
thromboplastin
time
ptt
obtain
repeat
measur
anova
friedman
appropri
correspond
post
test
use
compar
group
alpha
set
overal
differ
thaw
time
three
group
p
post
test
reveal
significantli
shorter
thaw
time
rwb
compar
plasmatherm
p
signific
differ
ptt
note
overal
p
post
test
reveal
longer
ptt
plasmatherm
wwb
group
compar
control
p
p
respect
overal
signific
differ
factor
vii
concentr
p
post
test
reveal
decreas
factor
vii
plasmatherm
wwb
group
compar
control
p
p
respect
signific
differ
factor
x
concentr
seen
overal
p
post
test
reveal
decreas
factor
x
plasmatherm
compar
control
p
rwb
fastest
thaw
time
signific
differ
detect
hemostat
protein
function
differ
consid
clinic
signific
object
prospect
studi
evalu
autom
felin
cartridg
blood
type
method
quickvet
rapidvet
qvrv
smb
farum
denmark
comparison
result
slide
tube
refer
method
commerci
avail
sampl
discord
result
addit
test
alvedia
quick
test
ab
alvedia
limonest
franc
determin
precis
blood
type
b
sampl
repeat
time
within
hour
consecut
day
edtaanticoagul
blood
sampl
routin
collect
diagnost
purpos
provid
outsid
laboratori
avail
one
sampl
sever
hemolysi
could
type
qvrv
slidetub
test
yield
result
sampl
sampl
blood
type
b
ab
qvrv
identifi
b
sampl
three
sampl
low
hematocrit
could
type
dilut
six
ab
sampl
gave
discord
result
compar
refer
method
ab
sampl
type
blood
type
qvrv
alvedia
b
qvrv
ab
alvedia
repeat
yield
result
base
sampl
run
qvrv
agre
refer
method
exclus
b
cat
agreement
blood
sampl
type
b
confirm
back
type
sampl
type
ab
tube
method
thrombocytosi
uncommon
hematolog
abnorm
canin
patient
associ
variou
neoplast
metabol
inflammatori
condit
aim
studi
character
thrombocytosi
dog
sever
diseas
associ
medic
record
dog
thrombocytosi
review
thrombocytosi
patient
character
primari
secondari
classifi
sever
diagnosi
diagnost
categori
includ
neoplasia
endocrin
diseas
inflammatori
diseas
miscellan
inflammatori
diseas
classifi
bodi
system
involv
serum
plasma
potassium
concentr
avail
evalu
possibl
pseudohyperkalemia
total
complet
blood
count
thrombocytosi
dog
includ
studi
median
platelet
count
popul
x
x
correl
sever
thrombocytosi
diagnosi
identifi
secondari
caus
includ
neoplasia
endocrin
diseas
inflammatori
diseas
dog
neoplasia
carcinoma
lymphoma
common
diagnos
immunemedi
diseas
common
associ
frequent
glucocorticoid
administr
significantli
higher
median
platelet
count
compar
bodi
system
p
thrombocytosi
commonli
associ
neoplasia
immunemedi
diseas
diagnos
dog
research
warrant
investig
role
thrombocytosi
hepatobiliari
renal
diseas
oxid
stress
play
signific
role
canin
liver
diseas
main
intracellular
antioxid
reduc
glutathion
rgsh
decreas
dog
natur
occur
liver
diseas
unknown
whether
circul
rgsh
level
correl
liver
concentr
aim
studi
determin
whether
circul
rgsh
correl
liver
rgsh
dog
natur
occur
liver
diseas
evalu
whether
marker
system
oxid
stress
plasma
vitamin
e
urin
correl
liver
rgsh
dog
liver
diseas
present
liver
biopsi
part
clinic
evalu
includ
urin
blood
collect
within
hour
liver
biopsi
plasma
erythrocyt
liver
rgsh
measur
use
high
perform
liquid
chromatographi
hplc
vitamin
e
measur
hplc
measur
ga
chromatographymass
spectrometri
thirtyon
dog
target
enrol
complet
studi
median
rgsh
liver
plasma
erythrocyt
mm
lm
mm
respect
correl
found
liver
rgsh
erythrocyt
rgsh
vitamin
e
modest
neg
correl
liver
plasma
rgsh
q
p
dog
liver
diseas
significantli
higher
urin
compar
healthi
control
vs
pg
mg
cr
p
initi
result
studi
demonstr
dog
natur
occur
liver
diseas
plasma
rgsh
correl
liver
rgsh
albeit
neg
addit
dog
natur
occur
liver
diseas
evid
increas
system
oxid
stress
compar
healthi
control
canin
cholang
appear
common
previous
thought
yet
understand
diseas
remain
incomplet
studi
aim
therefor
describ
popul
dog
biopsi
confirm
cholang
medic
record
biopsi
fiftyfour
dog
cholang
cholangiohepat
confirm
via
histopatholog
januari
decemb
retrospect
review
present
clinic
sign
includ
vomit
lethargi
inappet
major
dog
liver
enzym
elev
hyperbilirubinemia
hypercholesterolemia
ultrasonograph
abnorm
liver
andor
biliari
tree
seen
case
histopatholog
reveal
case
neutrophil
cholangitischolangiohepat
case
lymphocyt
cholang
major
chronic
histopatholog
reveal
concurr
gallbladd
diseas
case
biliari
tract
obstruct
case
seventeen
biliari
liver
cultur
posit
bacteri
growth
escherichia
coli
enterococcu
spp
common
median
patient
surviv
day
ci
control
age
dog
cholecystectomi
greater
hazard
ratio
death
p
ci
compar
dog
cholecystectomi
control
cholecystectomi
dog
greater
year
age
increas
risk
death
p
ci
compar
less
year
popul
dog
chronic
neutrophil
cholang
cholangiohepat
common
gallbladd
diseas
specif
cholecyst
biliari
tract
obstruct
occur
often
conjunct
cholang
studi
dog
cholang
biliari
tract
diseas
underw
cholecystectomi
reduc
risk
death
thu
cholecystectomi
may
improv
patient
outcom
chronic
hepat
common
condit
dog
fibrosi
import
compon
diseas
process
human
patient
chronic
hepat
prognosi
relat
stage
hepat
fibrosi
therefor
aim
studi
determin
relationship
stage
hepat
fibrosi
surviv
time
dog
chronic
hepat
dog
histolog
diagnos
chronic
hepat
januari
januari
veterinari
medic
teach
hospit
texa
univers
retrospect
enrol
dog
suffici
detail
followup
medic
record
avail
includ
studi
dog
time
liver
biopsi
surviv
time
caus
death
euthanasia
record
hepat
fibrosi
stage
boardcertifi
veterinari
pathologist
arh
use
score
system
adapt
ishak
score
system
absent
mild
moder
mark
mark
surviv
dog
absent
moder
mark
mark
hepat
fibrosi
compar
use
kaplanmey
surviv
curv
analysi
mantelcox
test
statist
signific
set
p
medic
record
dog
chronic
hepat
review
suffici
detail
follow
record
avail
dog
median
surviv
time
day
dog
absent
mild
fibrosi
n
day
dog
mark
mark
hepat
fibrosi
n
p
median
surviv
time
dog
absent
mild
fibrosi
significantli
longer
patient
mark
mark
fibrosi
chronic
hepat
common
caus
morbid
mortal
dog
identif
protein
differenti
express
dog
chronic
hepat
could
contribut
develop
diagnost
marker
diseas
provid
insight
pathogenesi
object
studi
identifi
protein
differenti
express
liver
dog
chronic
hepat
hepat
tissu
collect
healthi
dog
ovariohysterectomi
also
dog
histolog
confirm
chronic
hepat
proteom
liver
tissu
extract
mechan
disrupt
deterg
base
cell
lysi
analyz
fluoresc
differ
gel
electrophoresi
protein
separ
first
dimens
isoelectr
focus
nonlinear
immobil
ph
gradient
sodium
dodecyl
sulfatepolyacrylamid
gel
electrophoresi
second
dimens
decyd
differenti
analysi
softwar
util
data
analysi
protein
absolut
fold
chang
valu
select
analysi
protein
identif
achiev
nanoflow
liquid
chromatographi
tandem
mass
spectrometri
nano
lcmsm
posthoc
test
perform
use
bonferroni
multipl
comparison
test
signific
set
p
twentyeight
protein
spot
show
increas
abund
show
decreas
abund
liver
tissu
dog
chronic
hepat
compar
liver
tissu
healthi
control
dog
sixteen
protein
select
analysi
protein
significantli
increas
liver
dog
chronic
hepat
includ
protein
disulfideisomeras
carbamoylphosph
synthas
senesc
marker
protein
formimidoyltransferasecyclodeaminas
complement
protein
involv
varieti
process
includ
inflamm
redox
homeostasi
well
detoxif
studi
need
determin
whether
protein
identifi
may
prove
use
biomark
chronic
hepat
dog
canin
chronic
hepat
present
diagnost
challeng
variou
etiolog
lead
similar
clinic
sign
laboratori
find
histopatholog
assess
liver
biopsi
specimen
often
requir
definit
diagnosi
made
prognost
marker
exist
emerg
scienc
metabolom
use
detect
chang
endogen
low
molecular
weight
metabolit
biolog
sampl
offer
possibl
identifi
nonor
minimallyinvas
surrog
marker
diseas
object
studi
character
metabolit
chang
urin
dog
chronic
hepat
use
untarget
methodolog
urin
sampl
collect
cystocentesi
adult
dog
chronic
hepat
healthi
adult
control
dog
urin
sampl
analyz
ga
chromatographi
timeofflight
mass
spectrometri
gctof
data
found
nonparametr
principl
compon
analysi
use
make
multivari
comparison
dog
chronic
hepat
healthi
control
dog
wilcoxon
ranksum
test
use
make
univari
comparison
group
pvalu
adjust
multipl
comparison
use
benjamini
hochberg
fals
discoveri
rate
signific
set
p
principl
compon
analysi
reveal
signific
differ
dog
chronic
hepat
healthi
control
dog
univari
analysi
demonstr
statist
signific
differ
dog
chronic
hepat
healthi
control
dog
name
metabolit
clinic
relev
includ
glutamin
glycylprolin
putrescin
ornithin
import
stimul
macrophag
play
role
tissu
repair
prolifer
signific
differ
urin
metabolit
dog
chronic
hepat
healthi
control
dog
identifi
target
assess
alter
metabolit
need
valid
observ
leptospir
infect
infecti
diseas
seen
dog
shown
caus
dysfunct
multipl
organ
system
typic
demonstr
predilect
liver
kidney
report
chronic
hepat
caus
leptospira
spp
absenc
renal
involv
confin
small
case
seri
individu
kennel
date
role
organ
idiopath
chronic
hepat
remain
unknown
howev
recent
avail
fluoresc
insitu
hybridis
fish
accur
identif
spirochaet
liver
sampl
possibl
consequ
may
help
elucid
role
organ
case
chronic
canin
hepat
aim
studi
describ
clinicohistopatholog
present
case
hepat
leptospirosi
diagnos
fish
absenc
renal
involv
case
includ
studi
consist
case
present
queen
veterinari
school
hospit
univers
cambridg
case
consult
telephon
advic
dog
includ
studi
histolog
diagnosi
hepat
presenc
leptospir
identifi
fish
cluster
suggest
live
reproduc
organ
liver
histolog
case
review
singl
pathologist
case
without
histopatholog
diagnosi
exclud
presenc
clinic
evid
renal
involv
azotaemia
serum
creatinin
mmollbas
iri
guidelin
glycosuria
criteria
exclus
ten
dog
includ
studi
age
present
rang
year
year
median
year
six
ten
spaniel
breed
repres
includ
cavali
king
charl
spaniel
n
labrador
retriev
n
cocker
spaniel
n
english
springer
spaniel
n
west
highland
white
terrier
n
jack
russel
terrier
n
eight
case
femal
two
male
clinic
sign
vari
commonli
includ
anorexia
n
abdomin
pain
n
vomit
n
lethargi
n
gingiv
n
pyrexia
n
polydipsiapolyuria
n
two
dog
sibl
live
togeth
develop
clinic
sign
time
three
dog
asymptomat
persist
elev
liver
enzym
mild
thrombocytopenia
report
four
case
case
elev
liver
enzym
histopatholog
liver
document
chronic
hepat
case
granulomat
hepat
seven
case
one
show
sheet
macrophag
three
case
demonstr
lymphoplasmacyt
neutrophil
hepat
three
dog
underw
repeat
liver
biopsi
month
follow
initi
diagnosi
respect
fibrosi
vacuolar
hepatopathi
diagnos
first
case
cirrhosi
second
case
case
remain
posit
leptospira
fish
case
rebiopsi
month
diagnos
granulomat
hepat
becom
neg
fish
one
patient
histopatholog
diagnosi
neutrophil
lymphoplasmacyt
gingiv
vascul
demonstr
presenc
leptospira
fish
leptospirosi
speciat
one
case
granulomat
hepat
document
presenc
leptospira
interrogan
dog
treat
minimum
mgkg
doxycyclin
po
sid
day
clinic
outcom
known
case
six
dog
aliv
time
write
four
dog
euthanis
result
progress
liver
diseas
studi
suggest
presenc
leptospir
organ
within
liver
may
associ
chronic
hepat
often
granulomat
without
clinic
evid
renal
involv
intend
undertak
studi
perform
sequenc
leptospira
spp
organ
well
perform
fish
control
liver
biopsi
absenc
hepat
state
univers
fort
collin
co
usa
liver
diseas
associ
abnorm
hepatocyt
copper
cu
concentr
occur
commonli
dog
excess
hepat
cu
result
hepatocyt
damag
oxid
stress
result
cell
death
subsequ
necroinflammatori
chang
genet
mutat
cu
metabol
impair
biliari
excret
cu
increas
dietari
cu
thought
contribut
excess
hepat
cu
aim
studi
document
trend
age
sex
breed
dog
abnorm
elev
hepat
cu
correl
abnorm
copper
content
degre
histopatholog
inflammatori
chang
hypothes
abnorm
hepat
cu
concentr
would
common
middl
age
older
femal
dog
certain
breed
repres
also
hypothes
higher
cu
content
sever
inflammatori
liver
chang
would
examin
diagnost
laboratori
record
case
liver
histopatholog
hepat
cu
quantit
year
fresh
liver
tissu
analyz
cu
via
flame
atom
absorpt
spectroscopi
express
lgg
dri
weight
liver
dwl
normal
elect
evalu
subset
dog
hepat
cu
lgg
case
would
like
reflect
primari
copper
storag
disord
histopatholog
diagnos
group
inflammatori
noninflammatori
inflammatori
sampl
subclassifi
mild
moder
sever
noninflammatori
sampl
character
hepatocellular
swell
hyperplasia
lipidosi
nonspecif
reactiv
hepatopathi
fibrosi
neoplasia
case
met
criteria
liver
histolog
cu
quantit
case
hepat
cu
median
lgg
dwl
age
rang
year
median
year
femal
differ
breed
repres
labrador
retriev
doberman
pinscher
west
highland
white
terrier
standard
poodl
four
common
pure
breed
median
age
labrador
retriev
compar
year
doberman
pinscher
labrador
retriev
doberman
pinscher
standard
poodl
none
west
highland
white
terrier
femal
case
normal
copper
level
labrador
retriev
chihuahua
maltes
standard
poodl
shih
tzu
yorkshir
terrier
compris
case
case
hepat
cu
also
inflammatori
chang
histopatholog
inflamm
classifi
mild
moder
sever
dog
inflammatori
chang
far
like
elev
hepat
cu
p
specif
cu
dog
moder
sever
inflamm
significantli
higher
hepat
cu
concentr
p
labrador
retriev
breed
repres
moder
sever
group
find
indic
labrador
retriev
common
breed
copper
associ
liver
diseas
howev
may
overrepresent
due
popular
breed
femal
case
elev
hepat
cu
breed
except
west
highland
white
terrier
male
case
identifi
affect
dog
studi
averag
year
old
time
diagnosi
except
doberman
pinscher
averag
younger
higher
level
hepat
cu
like
associ
sever
inflammatori
chang
histopatholog
coagul
abnorm
common
human
veterinari
patient
hepatobiliari
diseas
due
liver
complex
vari
influenc
hemostasi
derang
result
multitud
outcom
patient
includ
propens
toward
bleed
andor
thrombosi
hepat
biopsi
commonli
indic
diagnost
workup
hepatobiliari
diseas
dog
increasingli
perform
via
laparoscopi
knowledg
patient
hemostat
statu
prior
biopsi
consid
essenti
assess
bleed
risk
howev
convent
test
alway
accur
predictor
clinic
bleed
addit
newer
techniqu
evalu
coagul
system
recent
becom
avail
object
studi
evalu
convent
modern
test
coagul
system
group
dog
undergo
laparoscop
liver
biopsi
diagnost
workup
hepatobiliari
diseas
result
test
correl
use
intervent
control
clinic
bleed
laparoscop
liver
biopsi
dog
undergo
laparoscop
liver
biopsi
colorado
state
univers
prospect
enrol
blood
collect
prior
procedur
chemistri
profil
platelet
count
platelet
aggregometri
multipl
analyz
thromboelastographi
prothrombin
time
activ
partial
thromboplastin
time
antithrombin
activ
fibrinogen
ddimer
fibrin
degrad
product
bleed
score
base
whether
gelfoam
absorb
gelatin
spong
usp
util
laparoscopist
aid
control
bleed
gelfoam
appli
activ
bleed
persist
second
one
biopsi
site
histolog
confirm
hepat
diseas
dog
idiopath
chronic
hepat
n
copperassoci
hepatopathi
n
hydropicvacuolar
n
nonspecif
reactiv
n
vascular
n
lymphoma
n
dog
least
one
coagul
abnorm
dog
gelfoam
place
aid
hemostasi
one
biopsi
site
hypoalbuminemia
p
decreas
antithrombin
activ
p
older
age
p
associ
use
gelfoam
dog
abnorm
platelet
aggregometri
includ
dog
receiv
gelfoam
abnorm
platelet
aggregometri
associ
use
gelfoam
aid
hemostasi
p
prolong
pt
aptt
associ
use
gelfoam
hypofibrinogenemia
also
associ
gelfoam
use
correl
hypoalbuminemia
p
bleed
control
gelfoam
intervent
alon
dog
one
dog
sustain
splenic
lacer
entri
abdomen
hemostasi
achiev
quickli
otherwis
signific
complic
occur
thrombocytopathia
may
contribut
clinic
bleed
laparoscop
liver
biopsi
group
dog
hepatobiliari
diseas
addit
dog
low
antithrombin
gelfoam
place
biopsi
site
aid
hemostasi
low
antithrombin
may
reflect
decreas
liver
function
andor
due
consumpt
consequ
lowgrad
dissemin
intravascular
coagul
hypofibrinogenemia
correl
hypoalbuminemia
possibl
fibrinogen
could
assess
addit
marker
hepat
function
dog
laparoscop
liver
biopsi
safe
adequ
sampl
achiev
histolog
diagnosi
obtain
case
hepat
biopsi
often
necessari
definit
diagnosi
liver
diseas
liver
play
central
role
hemostasi
bleed
biopsi
procedur
concern
aim
studi
determin
risk
factor
bleed
follow
percutan
ultrasoundguid
liver
biopsi
record
dog
cat
percutan
ultrasoundguid
liver
biopsi
retrospect
review
base
human
guidelin
bleed
blood
loss
classifi
minor
moder
sever
absolut
decreas
hematocrit
respect
complic
defin
physiolog
compromis
necessit
intervent
transfus
resuscit
fluid
death
relationship
chang
hematocrit
complic
initi
hematocrit
pt
aptt
platelet
count
serum
paramet
liver
enzym
bilirubin
well
number
biopsi
biopsi
needl
gaug
final
histolog
diagnosi
ultrasonograph
find
focal
vs
diffus
nodular
ascit
assess
use
chi
squar
test
one
way
analysi
varianc
pearson
correl
coeffici
p
valu
consid
signific
mild
moder
sever
bleed
occur
dog
respect
complic
dog
dog
higher
initi
hematocrit
greater
decreas
hematocrit
dog
neoplasia
like
complic
mild
moder
sever
bleed
occur
cat
respect
complic
cat
moderatesever
bleed
like
cat
nodular
liver
cat
higher
initi
platelet
count
greater
decreas
hematocrit
complic
associ
lower
prebiopsi
hematocrit
cat
dog
cat
correl
chang
hematocritcompl
pt
aptt
bilirubin
serum
liver
enzym
activ
number
biopsi
biopsi
needl
gaug
histolog
diagnosi
vitamin
k
administr
presenc
ascit
focal
diffus
diseas
ultrasoundguid
liver
biopsi
rel
safe
procedur
risk
complic
higher
cat
associ
lower
prebiopsi
hematocrit
reason
paradox
find
higher
platelet
number
hematocrit
cat
dog
respect
associ
greater
decreas
hematocrit
requir
investig
typic
indic
hypocoagul
prolong
pt
aptt
low
platelet
count
predict
occurr
complic
magnitud
chang
hematocrit
postbiopsi
like
reflect
complex
state
coagul
exist
liver
diseas
hepat
fibrosi
result
chronic
hepat
injuri
lead
loss
function
hepat
mass
portal
hypertens
thu
import
event
progress
chronic
hepat
pathogenesi
hepat
fibrosi
dog
yet
fulli
character
aim
studi
identifi
differenti
express
gene
dog
chronic
hepat
elucid
molecular
mechan
involv
develop
regul
hepat
fibrosi
rna
extract
highthroughput
rna
sequenc
perform
liver
biopsi
specimen
collect
dog
chronic
hepat
healthi
control
dog
undergo
ovariohysterectomi
sequenc
data
analyz
use
clc
genom
softwar
clc
bio
qiagen
includ
empir
analysi
differenti
gene
express
gene
absolut
fold
changevalu
group
multipl
comparison
adjust
pvalu
consid
differenti
express
differenti
express
gene
transcript
potenti
relat
pathogenesi
hepat
fibrosi
select
subcategor
use
genecardsorg
databas
genecard
pathcard
geneanalyt
sixhundredandfiftyon
gene
transcript
differenti
express
dog
chronic
hepat
connect
hepat
fibrosi
relat
pathway
identifi
gene
transcript
onehundredandsixtyf
gene
transcript
upregul
transcript
downregul
group
follow
subcategori
extracellular
matrix
degrad
extracellular
matrix
organ
hepat
stellat
cell
activ
apoptosi
detoxif
reactiv
oxygen
speci
compon
fibrot
mechan
mention
human
literatur
larg
number
gene
found
differenti
express
dog
chronic
hepat
compar
healthi
control
dog
gene
may
potenti
relat
pathogenesi
hepat
fibrosi
studi
dataset
confirmatori
test
subset
identifi
gene
quantit
rtpcr
might
provid
insight
pathogenesi
canin
hepat
fibrosi
hypovitaminosi
identifi
dog
sepsi
peopl
calcitriol
revers
immunopatholog
sepsi
yet
littl
known
effect
calcitriol
innat
immun
function
dog
hypothes
calcitriol
reduc
canin
leukocyt
tnf
product
increas
product
augment
pmn
phagocytosi
reduc
express
blood
collect
eight
healthi
adult
dog
incub
calcitriol
control
h
follow
incub
lpsstimul
leukocyt
product
tnf
measur
use
caninespecif
multiplex
assay
pmn
phagocytosi
opson
e
coli
constitut
express
evalu
use
flow
cytometri
three
dog
concentr
respons
curv
perform
evalu
cytokin
modul
concentr
depend
comparison
made
use
pair
ttest
wilcoxon
sign
rank
test
p
consid
signific
calcitriol
significantli
reduc
lpsstimul
leukocyt
tnf
product
meanaesd
calcitriol
ae
control
ae
pgml
p
tnf
ratio
median
calcitriol
control
p
product
calcitriol
ae
control
ae
pgml
p
blunt
tnf
product
concentr
depend
concentr
rang
phagocytosi
express
significantli
alter
calcitriol
data
indic
calcitriol
induc
antiinflammatori
shift
leukocyt
expos
lp
without
alter
phagocytosi
express
vitro
may
due
alter
postreceptor
signal
protein
translat
thu
calcitriol
could
novel
candid
immunomodulatori
therapi
sepsi
dog
urban
environ
exposur
air
pollut
associ
human
autoimmun
diseas
includ
system
lupu
erythematosu
multipl
sclerosi
specif
environment
trigger
canin
immunemedi
diseas
remain
larg
undiscov
identif
would
improv
manag
highrisk
individu
aim
studi
determin
dog
live
urban
area
increas
odd
immunemedi
diseas
compar
rural
area
case
record
referr
hospit
american
midwest
retrospect
review
identifi
dog
meet
prespecifi
criteria
immunemedi
hemolyt
anemia
imha
andor
thrombocytopenia
itp
immunemedi
polyarthr
impa
meningoenceph
unknown
origin
muo
breedmatch
control
without
immunemedi
diseas
randomli
select
censu
tract
dog
live
popul
densiti
retriev
govern
databas
urban
environ
classifi
peopl
per
squar
mile
defin
us
censu
bureau
case
control
meet
inclus
criteria
odd
ratio
immun
mediat
diseas
confid
interv
p
urban
vs
rural
dog
specif
immunemedi
diseas
odd
ratio
p
n
case
imhaitp
p
n
case
impa
p
n
case
muo
studi
reveal
signific
associ
urban
environ
canin
immunemedi
diseas
larger
studi
studi
geograph
area
might
still
reveal
relationship
current
studi
suggest
exposur
common
rural
urban
dog
merit
investig
trigger
immunedysregul
nasal
lavag
oropharyng
swab
use
obtain
resid
cell
healthi
adult
cat
cell
popul
phenotyp
enumer
use
flow
cytometri
baselin
sampl
collect
cat
treat
intranas
oral
administr
liposometlr
mucos
immun
stimul
mucosimmun
chang
immun
cell
popul
assess
nasal
lavag
oral
swab
obtain
h
h
h
treatment
found
normal
cat
nasal
passag
contain
mix
popul
cell
monocyt
rel
abund
neutrophil
contrast
oropharynx
contain
numer
cell
monocyt
neutrophil
follow
administr
mucosimmun
sustain
influx
neutrophil
nose
h
neutrophil
increas
oropharynx
h
treatment
signific
increas
monocyt
site
h
gradual
declin
h
site
transient
disappear
lymphocyt
h
rebound
normal
number
h
data
indic
nasal
passag
oropharynx
cat
contain
rel
abund
popul
immun
cell
capabl
respond
rapidli
tlr
activ
oropharynx
contain
dens
cell
popul
nose
contain
neutrophil
like
b
cell
site
respond
rapidli
mucos
deliveri
tlr
agonist
earli
appear
innat
immun
cell
disappear
reappear
lymphocyt
result
indic
mucos
administr
liposometlr
agonist
rapidli
activ
local
immun
respons
felin
upper
respiratori
tract
may
associ
nonspecif
protect
viral
bacteri
pathogen
idiopath
immunemedi
polyarthr
impa
inflammatori
noninfecti
joint
diseas
caus
immunecomplex
deposit
synovium
due
typeiii
hypersensit
reaction
oral
administr
immunosuppress
drug
standard
treatment
condit
commonli
use
drug
prednisolon
often
combin
immunosuppress
agent
benefit
combin
immunosuppress
therapi
introduc
time
diagnosi
previous
evalu
aim
retrospect
studi
compar
outcom
dog
impa
treat
prednisolon
alon
combin
immunosuppress
drug
introduc
time
diagnosi
hypothesis
use
combin
immunosuppress
would
improv
outcom
canin
impa
medic
record
singl
tertiari
referr
centr
review
januari
may
dog
diagnos
idiopath
impa
basi
consist
joint
fluid
analysi
case
exclud
underli
diseas
identifi
thirtysix
dog
met
inclus
criteria
femal
male
variou
breed
median
age
year
rang
median
bodyweight
kg
kg
case
present
lame
reduc
mobil
dog
display
system
sign
eg
lethargi
decreas
appetit
pyrexia
manifest
mobil
issu
prior
diagnosi
median
time
diagnosi
day
rang
season
bia
group
dog
receiv
prednisolon
whilst
group
dog
receiv
prednisolon
azathioprin
ciclosporin
outcom
data
compar
use
nonparametr
test
dog
group
relaps
taper
medic
compar
group
p
three
dog
group
euthanas
due
suspect
complic
aris
impa
therapi
one
dog
die
develop
pyothorax
exclud
calcul
dog
group
still
aliv
p
group
median
treatment
durat
day
compar
median
day
group
p
signific
differ
group
durat
therapi
relaps
rate
mortal
thu
hypothesi
accept
observ
dog
start
multidrug
protocol
outset
requir
shorter
treatment
durat
lower
mortal
lower
relaps
rate
may
reflect
type
ii
error
due
low
group
number
prospect
studi
greater
number
ongo
investig
previou
studi
demonstr
abil
liposometlr
ligand
complex
ltlc
potent
activ
innat
immun
respons
sever
speci
fulli
evalu
activ
cat
current
unmet
need
broad
spectrum
immun
stimul
prevent
earli
treatment
viral
bacteri
respiratori
tract
pathogen
cat
purpos
present
studi
investig
vitro
respons
cat
lymphocyt
monocyt
stimul
ltlc
cat
peripher
blood
mononuclear
cell
pbmc
obtain
healthi
cat
use
assess
immun
activ
ltlc
pbmc
incub
ltlc
hour
immun
activ
assess
cytokin
releas
assay
rtpcr
flow
cytometri
found
ltlc
trigger
ifng
product
pbmc
within
h
incub
addit
upregul
express
tnfa
mrna
demonstr
use
rtpcr
companion
abstract
demonstr
mucos
immun
stimulatori
properti
ltlcbase
immun
stimul
administ
healthi
cat
therefor
taken
togeth
vitro
find
present
result
suggest
ltlc
may
use
effect
nonspecif
immun
stimul
induct
antivir
antibacteri
immun
cat
tumor
necrosi
factoralpha
tnfa
cytokin
releas
mainli
macrophag
respons
contact
infecti
agent
tissu
injuri
tumor
growth
autoimmun
condit
thu
measur
tnfa
warrant
evalu
diagnost
prognost
marker
cat
inflammatori
diseas
howev
current
analyt
valid
assay
commerci
avail
measur
cytokin
cat
aim
studi
develop
analyt
valid
electrochemiluminesc
immunoassay
measur
tnfa
cat
serum
use
commerci
avail
platform
uplex
meso
scale
diagnost
felin
tnfa
electrochemiluminesc
assay
develop
recombin
felin
tnfa
polyclon
rabbit
antifelin
tnfa
antibodi
valid
variabl
includ
lower
limit
detect
dilut
parallel
spike
recoveri
intraassay
variabl
interassay
variabl
lower
limit
detect
ngl
observedtoexpect
ratio
dilut
parallel
n
rang
mean
aesd
ae
recoveri
spike
tnfa
serum
sampl
n
rang
mean
ae
sd
ae
intraassay
coeffici
variat
cv
n
mean
ae
sd
ae
interassay
coeffici
variat
n
mean
ae
sd
ae
assay
shown
sensit
precis
accur
measur
tnfa
cat
serum
howev
assay
linear
suboptim
studi
need
determin
whether
linear
improv
current
assay
system
also
clinic
implic
serum
tnfa
concentr
need
evalu
speci
canin
atop
dermat
cad
common
chronic
geneticallypredispos
relaps
inflammatori
skin
diseas
cad
multifacet
diseas
result
complex
interact
environment
genet
factor
factor
shape
skin
barrier
function
immunolog
respons
predispos
patient
regulatori
cell
treg
becom
known
prevent
excess
immun
respons
immunoregulatori
properti
therefor
play
lead
role
mainten
immunolog
homeostasi
research
perform
analyz
relationship
cad
proport
treg
peripheri
blood
present
studi
aim
assess
proport
circul
treg
healthi
atop
dog
analyz
implic
treg
cad
investig
correl
treg
cad
sever
age
anim
analysi
consist
eight
healthi
dog
nine
atopi
dog
never
treat
diagnosi
cad
made
fulfil
clinic
criteria
farvot
criteria
exclus
differenti
diagnosi
includ
ectoparasit
infecti
dermatos
express
treg
peripher
blood
evalu
flow
cytometri
treg
identifi
cell
cell
statist
signific
increas
proport
cell
cell
peripheri
blood
atop
dog
compar
healthi
dog
mean
vers
p
mean
vers
p
circul
regulatori
cell
treg
atop
dog
neg
correl
diseas
sever
p
also
neg
age
p
treg
treg
may
relev
pathogenesi
cad
cours
atop
dermat
studi
demonstr
neg
associ
treg
frequenc
diseas
sever
number
circul
treg
atop
dog
decreas
got
older
francisella
tularensi
pathogen
gram
neg
intracellular
bacteria
caus
pneumonia
skin
lesion
system
ill
known
tularemia
affect
cat
certain
region
unit
state
lipoxygenas
lo
enzym
util
arachidon
acid
produc
antiinflammatori
mediat
delet
would
expect
produc
increas
sever
diseas
sinc
role
regul
inflamm
hypothesi
pneumon
tularemia
mice
would
produc
increas
morbid
mortal
francisella
tularensi
live
vaccin
strain
ft
lv
pathogen
mice
peopl
wild
type
wt
lo
knock
ko
mice
infect
intratrach
subleth
dose
ft
lv
weight
monitor
day
day
postinfect
mice
euthan
lung
spleen
liver
collect
analysi
cellular
phenotyp
infiltr
inflammatori
cell
leukotrien
kc
level
determin
lung
tissu
histopatholog
assess
lung
liver
splenic
weight
determin
lo
ko
mice
increas
morbid
compar
wt
mice
indic
signific
weight
loss
kc
chemoattract
neutrophil
significantli
p
higher
lung
tissu
ko
mice
inflammatori
cell
neutrophil
cell
macrophag
pulmonari
histopatholog
score
significantli
higher
p
ko
mice
contrast
assist
host
defens
significantli
decreas
p
lo
ko
mice
splenic
weight
significantli
p
higher
wt
spleen
correl
sever
diseas
given
inform
lo
play
role
regul
inflamm
pneumon
tularemia
eicosanoid
highli
conserv
among
speci
possibl
lo
agonist
may
use
natur
therapeut
aid
resolut
pneumonia
domest
anim
studi
need
mesenchym
stem
cell
msc
immunomodulatori
function
differenti
capac
confer
variou
clinic
use
although
msc
appli
treatment
variou
inflammatori
diseas
mechanist
research
felin
msc
lack
accordingli
studi
aim
analys
immunomodulatori
mechan
msc
isol
felin
adipos
tissu
fatmsc
cytokin
express
murin
macrophag
allogen
felin
peripher
blood
mononuclear
cell
fpbmc
measur
use
quantit
realtim
polymeras
chain
reaction
qrtpcr
compar
accord
presenc
fatmsc
also
extract
rna
collect
supernat
fatmsc
measur
solubl
factor
express
level
qrtpcr
enzymelink
immunosorb
assay
level
proinflammatori
cytokin
eg
tumour
necrosi
factora
tnfa
induc
nitric
oxid
synthas
interleukin
il
significantli
decreas
cocultur
mitogenstimul
cell
fatmsc
compar
cell
addit
express
immunomodulatori
factor
fatmsc
includ
transform
growth
factor
tgf
b
ido
hepatocyt
growth
factor
increas
presenc
cell
express
proinflammatori
tnfa
interferonc
decreas
express
antiinflammatori
increas
cocultur
mitogenstimul
allogen
fpbmc
fatmsc
tgfb
ido
express
prostaglandin
product
fatmsc
increas
presenc
allogen
fpbmc
data
suggest
solubl
factor
secret
fatmsc
play
import
role
immunomodulatori
effect
cell
find
may
help
applic
fatmsc
felin
patient
immunerel
diseas
gene
therapi
emerg
treatment
modal
human
medicin
anim
model
includ
dog
cat
often
use
preclin
studi
demonstr
efficaci
safeti
research
gene
therapi
condit
anim
start
well
adenoassoci
viru
aav
base
vector
among
common
deliveri
mechan
well
establish
antibodi
aav
vector
impact
success
gene
transfer
primari
object
studi
determin
pet
popul
circul
antibodi
two
aav
vector
use
gene
therapi
elisa
techniqu
util
assess
titer
level
circul
antibodi
serotyp
canin
felin
patient
present
univers
hospit
result
variabl
mean
valu
canin
felin
mean
valu
weak
posit
correl
serotyp
within
speci
base
twosid
pearson
productmo
correl
test
canin
r
felin
r
base
result
appear
dog
cat
pet
popul
circul
antibodi
capabl
bind
particl
howev
without
concurr
neutral
antibodi
level
clinic
signific
find
unknown
correl
circul
antibodi
titer
neutral
antibodi
titer
exist
would
suggest
potenti
candid
gene
therapi
drawn
pet
popul
might
requir
screen
antibodi
immunosuppress
therapi
prior
receiv
aav
vector
base
treatment
increas
interest
gene
therapi
potenti
treatment
modal
varieti
human
diseas
larg
anim
model
includ
dog
cat
often
use
preclin
studi
also
interest
use
techniqu
treat
diseas
affect
pet
popul
adenoassoci
viru
aav
base
vector
among
common
util
deliveri
mechan
circul
antibodi
capabl
bind
particl
identifi
pet
dog
cat
primari
object
studi
identifi
whether
pet
might
neutral
antibodi
titer
transduct
serum
sampl
seven
pet
dog
seven
pet
cat
vari
level
circul
antibodi
util
neutral
antibodi
assay
perform
use
selfcomplementari
csmcbamcherri
report
packag
either
permiss
cell
respect
multipl
infect
vgcell
posit
control
serum
sampl
dog
research
coloni
previous
treat
vector
neg
control
serum
vector
preincub
seri
serum
dilut
infect
cell
three
day
post
infect
transduct
assess
measur
mcherrymedi
fluoresc
neutral
transduct
greater
rel
serum
control
lowest
dilut
identifi
cat
dog
cat
dog
obviou
posit
correl
circul
antibodi
titer
neutral
titer
trend
presenc
felin
serum
posit
impact
transduct
effici
vector
clinic
signific
result
remain
unknown
suggest
need
evalu
determin
candid
gene
therapi
pet
popul
might
requir
screen
test
immunosuppress
therapi
prior
receiv
aav
vector
base
treatment
improv
understand
bartonella
spp
serolog
pattern
dog
may
aid
clinic
decis
make
enhanc
current
understand
naturallyoccur
arthropod
vector
transmiss
analyz
larg
diagnost
laboratori
databas
better
understand
bartonella
seroepidemiolog
dog
north
america
identifi
demograph
group
bartonella
exposur
may
like
describ
variat
chronolog
geograph
pattern
bartonella
seroreact
examin
coexposur
vectorborn
pathogen
hypothes
signific
demograph
risk
factor
bartonella
exposur
bartonella
exposur
common
region
season
high
vector
preval
among
dog
canin
vectorborn
diseas
cvbd
exposur
cvbd
serolog
result
diagnost
submiss
gener
januari
decemb
north
carolina
state
univers
colleg
veterinari
medicin
vector
born
diseas
diagnost
laboratori
retrospect
review
bartonella
hensela
b
vinsonii
subsp
berkhoffii
andor
b
koehlera
seroreact
determin
indirect
immunofluoresc
antibodi
ifa
test
subset
access
comprehens
diagnost
cvbd
serolog
panel
ehrlichia
spp
anaplasma
spp
rickettsia
spp
borrelia
spp
dirofilaria
immiti
perform
use
snap
idexx
laboratori
ifa
overal
access
bartonella
spp
seroreact
percentag
compar
seroreact
cvbd
among
us
canin
populationwid
serosurvey
seroreact
b
hensela
b
koehlera
antigen
detect
frequent
seroreact
b
vinsonii
subsp
berkhoffii
p
antigen
intact
male
dog
like
seroreact
neuter
male
p
ci
p
intact
spay
femal
p
ci
p
mix
nonakc
breed
dog
like
seroreact
purebr
dog
p
ci
p
season
seroreact
trend
three
bartonella
spp
geograph
pattern
seroreact
correspond
region
cvbd
pattern
rather
seroreact
distribut
broadli
across
north
america
area
appar
higher
exposur
risk
b
hensela
wa
ct
b
koehlera
mo
coexposur
vectorborn
pathogen
common
associ
b
hensela
b
vinsonii
subsp
berkhoffii
multipl
cvbd
pathogen
b
koehlera
seroreact
associ
ehrlichia
spp
ci
p
rickettsia
spp
ci
p
exposur
associ
pathogen
transmit
predominantli
ixodesscapulari
b
burgdorferi
anaplasma
spp
conclud
bartonella
spp
exposur
may
occur
throughout
north
america
may
seen
time
year
dog
expos
cvbd
male
intact
dog
mix
breed
dog
higher
risk
bartonella
exposur
flea
multipl
tick
speci
propos
vector
canin
bartonellosi
seroepidemiolog
analys
suggest
may
multipl
vector
bartonella
infect
dog
major
vector
may
depend
local
geograph
environment
host
factor
cours
doxycyclin
recommend
treatment
ehrlichia
cani
infect
dog
although
studi
report
clearanc
infect
antibiot
therapi
other
document
persist
infect
even
treatment
therefor
concern
recrudesc
diseas
aris
immunosuppress
drug
treatment
immun
mediat
diseas
dog
previous
infect
e
cani
purpos
studi
determin
whether
administr
prednisolon
cyclosporin
standard
dose
would
induc
clinic
laboratori
evid
reactiv
e
cani
dog
previous
treat
infect
seven
beagl
experiment
infect
e
cani
administ
doxycyclin
mgkg
po
daili
week
includ
studi
three
dog
also
infect
anaplasma
plati
babesia
voge
administ
two
dose
imidocarb
mgkg
im
week
apart
prior
enrol
dog
administ
prednisolon
dose
rang
mgkg
po
hour
conjunct
cyclosporin
whose
dosag
adjust
base
trough
level
final
dose
rang
mgkg
po
hour
week
clinic
sign
fever
lethargi
anorexia
complet
blood
count
cbc
polymeras
chain
reaction
pcr
dna
e
cani
plati
b
voge
blood
antiecani
indirect
fluoresc
antibodi
ifa
titer
flow
cytometri
antiplatelet
antibodi
monitor
dog
neg
pcr
posit
ifa
prior
immunosuppress
complet
immunosuppress
protocol
recrudesc
e
cani
infect
detect
base
clinic
sign
result
cbc
pcr
ifa
flow
cytometri
antiplatelet
antibodi
antiecani
ifa
titer
neg
dog
end
immunosuppress
protocol
neg
month
protocol
dog
dog
neg
via
pcr
e
cani
plati
b
voge
throughout
immunosuppress
cours
doxycyclin
without
supplement
imidocarb
clear
e
cani
infect
least
month
immunosuppress
week
risk
reactiv
e
cani
infect
immun
suppress
previous
treat
dog
consid
minimum
heartworm
antigen
test
routin
perform
diagnos
heartworm
infect
dog
origin
diagnost
test
employ
immun
complex
dissoci
icd
method
releas
antigen
bound
endogen
canin
antibodi
howev
icd
method
discontinu
major
commerci
avail
assay
due
improv
assay
technolog
oconnor
et
al
immunoassay
applic
veterinari
diagnost
wild
ed
immunoassay
handbook
ed
great
britain
elsevi
interfer
immun
complex
uniqu
heartworm
diagnost
variou
method
avail
icd
purpos
studi
evalu
differ
method
icd
detect
free
heartworm
antigen
microtit
plate
elisa
evalu
perform
icd
pet
dog
origin
usda
licens
petchek
heartworm
test
idexx
laboratori
inc
util
pepsin
acid
ph
icd
prior
antigen
test
use
set
experiment
sampl
pepsin
method
compar
heat
treatment
acid
treatment
method
found
releas
complex
antigen
produc
posit
result
posttreat
sampl
test
heartworm
antigen
microtit
plate
elisa
heat
treatment
requir
minimum
either
serum
plasma
pepsin
acid
method
need
patient
sampl
extend
field
popul
sampl
patient
submit
idexx
laboratori
investig
discrep
heartworm
result
sampl
evalu
without
pepsin
icd
use
petchek
heartworm
total
patient
becam
antigen
posit
icd
protocol
posit
without
icd
demonstr
least
increas
plate
absorb
od
posit
without
icd
minim
chang
plate
od
follow
icd
remain
patient
detect
antigen
without
icd
prospect
studi
dog
receiv
preadulticid
heartworm
treatment
consist
macrocycl
lacton
combin
doxycyclin
evalu
way
serial
sampl
dog
reveal
reduct
free
circul
antigen
within
week
initi
treatment
case
free
antigen
level
could
recov
icd
heartworm
antigen
test
icd
valuabl
adjunct
diagnost
patient
discrep
result
intermitt
use
macrocycl
lacton
receiv
treatment
inform
fecal
shed
felin
panleukopenia
viru
fpv
cat
modifiedl
vaccin
aim
studi
provid
inform
parvoviru
dnashed
recent
vaccin
adult
healthi
cat
assess
relat
factor
use
chisquar
fisher
exact
test
forti
cat
includ
studi
vaccin
commerci
fpv
modifiedl
vaccin
fece
cat
test
presenc
parvoviru
dna
day
quantit
realtim
pcr
preand
postvaccin
serum
antibodi
titer
measur
hemagglutin
inhibit
day
almost
onethird
cat
ci
shed
parvoviru
dna
postvaccin
period
parvoviru
dna
detect
day
immun
parvoviru
dnashed
significantli
associ
lack
protect
prevaccin
antibodi
titer
p
oddsratio
ci
postvaccin
titer
increas
p
ci
vaccin
cat
shed
parvoviru
dna
least
week
vaccin
shed
occur
commonli
cat
without
protect
titer
postvaccin
shed
thu
interfer
diagnosi
recent
vaccin
cat
present
clinic
sign
suspici
panleukopenia
felin
herpesviru
common
felin
infecti
diseas
cat
cat
hous
group
set
infect
liposometlr
ligand
complex
ltlc
shown
mice
enhanc
innat
immun
induc
nonspecif
protect
viral
bacteri
diseas
new
formul
ltlc
use
mucos
immun
stimul
mucosimmun
shown
safe
capabl
stimul
local
immun
cat
object
studi
determin
whether
mucosimmun
administ
prior
experiment
inocul
first
sign
clinic
ill
postinocul
kitten
could
lessen
clinic
sign
shed
compar
untreat
control
total
femal
male
purposebr
kitten
neg
antibodi
serum
dna
cell
collect
oropharynx
swab
divid
three
group
hous
three
separ
room
thirteen
kitten
random
group
n
prevent
group
b
n
treatment
kitten
assign
group
c
serv
untreat
control
group
administ
mucosimmun
ml
nostril
ml
oropharynx
hour
prior
inocul
day
kitten
sedat
administ
tcid
divid
nare
oropharynx
group
b
kitten
administ
one
dose
mucosimmun
first
day
clinic
sign
note
second
dose
administ
hour
later
two
train
mask
observ
appli
standard
clinic
score
system
detail
ocular
respiratori
clinic
sign
room
minut
day
total
day
mucos
cell
collect
caudal
pharynx
kitten
group
c
day
kitten
group
b
clinic
sign
recogn
prior
first
mucosimmun
dose
day
first
treatment
day
inocul
total
dna
extract
oropharyng
swab
quantit
pcr
assay
perform
dna
gapdh
result
present
compar
amongst
group
ratio
wilcoxon
ranksum
test
use
comparison
amongst
group
within
time
period
day
day
day
time
resolut
ill
total
score
also
compar
amongst
group
signific
differ
found
total
combin
score
group
compar
group
c
kitten
compar
group
c
total
ocular
score
group
kitten
significantli
lower
day
p
lower
conjunct
score
detect
period
p
p
p
compar
group
total
respiratori
score
group
c
kitten
significantli
lower
day
p
day
p
clinic
ill
shorter
durat
group
kitten
median
day
rang
day
compar
group
c
kitten
median
rang
day
result
significantli
differ
p
day
ratio
group
significantli
lower
p
group
c
group
b
result
compar
group
c
signific
differ
found
total
combin
score
total
ocular
score
total
respiratori
score
time
resolut
howev
group
b
kitten
significantli
less
pyrexia
day
p
compar
group
c
administr
mucosimmun
lessen
clinic
sign
experi
model
decreas
shed
administ
hour
prior
inocul
sporotrichosi
frequent
subcutan
mycosi
detect
urban
area
caus
zoonot
pathogen
speci
sporothrix
schenckii
complex
affect
especi
cat
brazil
due
larg
outbreak
sporotrichosi
citi
guarulho
state
paulo
diseas
becom
notifi
clinic
diseas
character
subcutan
mycosi
papular
lesion
nodular
featur
ulcerogummi
definit
diagnosi
obtain
isol
fungu
cultur
howev
result
take
week
result
delay
start
appropri
treatment
diseas
could
spread
commun
member
aim
studi
standard
diagnosi
felin
sporotrichosi
cell
block
cytolog
cb
cb
consist
immedi
wet
cell
fixat
preserv
liquid
base
cytolog
solut
surepath
bd
histolog
process
compar
two
collect
method
fine
needl
aspir
fna
exfoli
brush
eb
endocerv
brush
ten
sampl
skin
lesion
nine
suspect
cat
collect
five
sampl
method
eb
allow
cell
thick
sediment
product
sever
histolog
section
slide
stain
period
acid
schiff
method
sampl
collect
method
show
posit
result
fungal
structur
fna
case
reveal
low
cellular
imposs
histolog
process
standard
show
cb
process
possibl
eb
lesion
fixat
cytolog
preserv
solut
allow
storag
month
harvest
test
immunohistochemistri
cb
altern
sporotrichosi
diagnosi
canin
leptospirosi
diseas
worldwid
distribut
signific
zoonot
potenti
acut
bacteri
infect
dog
caus
pathogen
spirochet
belong
genu
leptospira
time
diagnosi
canin
leptospirosi
import
earli
initi
antibiot
therapi
provid
greatest
opportun
success
patient
outcom
howev
diagnosi
hinder
vagu
clinic
sign
diagnost
method
difficult
interpret
requir
lag
time
result
report
later
flow
test
wit
lepto
zoeti
develop
detect
igm
antibodi
leptospira
offer
advantag
result
minut
pointofcar
without
need
special
equip
expertis
hypothesi
wit
lepto
detect
igm
four
signific
leptospira
serovar
yield
posit
result
earlier
concurr
microscop
agglutin
test
mat
serolog
refer
method
diagnosi
leptospirosi
thirtytwo
beagl
dog
approxim
six
month
age
experiment
infect
day
zero
one
two
serovar
canicola
grippotyphosa
icterohaemorrhagia
pomona
n
dogsserovar
sera
collect
evalu
leptospir
antibodi
wit
lepto
mat
three
four
day
interv
minimum
fourfold
increas
antibodi
titer
serovar
mat
panel
indic
seroconvers
studi
approv
zoeti
institut
anim
care
use
committe
seroconvers
detect
dog
day
wit
lepto
mat
respect
earli
day
method
day
wit
lepto
yield
posit
result
dog
wherea
mat
yield
posit
result
dog
conclus
wit
lepto
detect
igm
four
serovar
includ
studi
detect
seroconvers
earlier
concurr
mat
pointofcar
wit
lepto
may
use
screen
test
acut
ill
dog
suspect
leptospirosi
infect
histoplasma
capsulatum
routin
diagnos
cat
use
quantit
enzym
immunoassay
eia
perform
urin
serum
level
antigenuriaantigenemia
consid
indic
activ
infect
urin
eia
sensit
object
studi
determin
urin
eia
result
time
diagnosi
prior
administr
antifung
agent
predict
outcom
ie
surviv
month
cat
histoplasmosi
pretreat
urin
eia
result
avail
cat
examin
four
institut
april
decemb
cat
aliv
day
die
median
surviv
time
day
rang
day
three
lost
follow
statist
purpos
posit
result
level
quantif
ngml
list
ngml
median
eia
time
diagnosi
cat
aliv
month
ngml
rang
similar
find
nonsurvivor
median
ngml
rang
p
figur
surviv
cat
significantli
younger
mean
age
yr
nonsurvivor
mean
age
yr
p
median
bodi
weight
kg
v
kg
rate
pulmonari
involv
v
similar
find
indic
urin
eia
result
time
diagnosi
predict
outcom
cat
histoplasmosi
use
prognost
indic
methicillin
resist
staphylococcu
spp
mr
carriag
rate
companion
anim
well
describ
north
america
europ
investig
australia
aim
studi
quantifi
overal
carriag
rate
mr
companion
anim
present
two
major
veterinari
hospit
brisban
area
identifi
geograph
differ
carriag
rate
risk
factor
mr
carriag
rural
r
urban
u
veterinari
hospit
nasal
rectal
swab
taken
anim
within
h
hospit
admiss
follow
growth
select
media
brillianc
staph
agar
tm
pcr
meca
nuc
gene
perform
confirm
methicillin
resist
differenti
aureu
mrsa
pseudintermediu
mrsp
medic
data
collect
includ
residenti
address
signal
previou
drug
use
surgic
procedur
veterinari
visitshospitalis
prior
year
risk
factor
evalu
use
stata
corp
tm
geograph
variat
carriag
analysi
use
semivariogram
openbug
tm
overal
preval
dog
cat
hors
carri
mr
mrsp
carriag
found
dog
none
cat
mrsa
carriag
identifi
one
dog
also
mrsp
carrier
one
cat
found
statist
signific
differ
mrsp
carriag
rate
site
r
site
u
signific
spatial
variat
found
mrsp
carrier
dog
explain
clinic
histori
contextu
factor
dog
resid
conclus
major
differ
canin
mrsp
carriag
rate
may
exist
urban
rural
area
leishmania
spp
neorickettsia
spp
bartonella
spp
presumpt
healthi
dog
present
oklahoma
state
univers
vth
annual
well
evalu
secondari
object
correl
pcr
result
histor
inform
physic
examin
clinicopatholog
result
dog
enrol
studi
client
survey
complet
snap
plu
idexx
cbc
chemistri
panel
vectorborn
diseas
pcr
one
hundr
twelv
dog
femal
male
median
age
year
rang
year
enrol
studi
juli
novemb
snap
plu
result
show
dog
posit
ehrlichia
spp
ehrlichia
pcr
posit
eight
dog
pcr
posit
vectorborn
pathogen
infect
candidatu
mycoplasma
haematoparvum
mycoplasma
haemocani
ehrlichia
ewingii
four
infect
dog
normal
cbc
chemistri
result
dog
clinicopatholog
abnorm
potenti
attribut
vectorborn
diseas
thrombocytopenia
hyperglobulinemia
g
dl
anemia
document
dog
infect
mycoplasma
spp
preval
vectorborn
diseas
healthi
dog
present
oklahoma
state
univers
vth
fairli
low
mycoplasma
spp
infect
common
anaplasma
phagocytophilum
infect
commonli
associ
clinic
diseas
human
dog
howev
phagocytophilum
infect
routin
associ
clinic
diseas
cat
recent
report
shown
anaplasma
infect
caus
signific
ill
cat
object
studi
determin
preval
phagocytophilum
infect
adult
feral
cat
massachusett
endem
area
phagocytophilum
tick
vector
ixod
scapulari
blood
sampl
collect
june
decemb
appar
healthi
adult
feral
cat
present
trap
releas
spayneut
center
massachusett
complet
blood
count
blood
smear
evalu
snap
idexx
phagocytophilum
pcr
perform
sampl
document
acut
infect
pcr
posit
andor
inclus
observ
blood
smear
exposur
phagocytophilum
snap
posit
phagocytophilum
antibodi
preval
exposur
phagocytophilum
feral
cat
massachusett
wherea
preval
acut
infect
blood
smear
neg
anaplasma
inclus
therefor
acut
infect
defin
test
posit
pcr
analysi
preval
phagocytophilum
exposur
feral
cat
approach
significantli
higher
previous
report
preval
unit
state
p
phagocytophilum
infect
may
emerg
infecti
diseas
felin
research
need
determin
preval
clinic
ill
associ
phagocytophilum
infect
cat
live
endem
area
howev
incid
ofi
risk
factor
develop
dog
undergo
immunosuppress
treatment
unknown
aim
studi
determin
proport
dog
diagnos
certain
immunemedi
diseas
treat
immunosuppress
drug
develop
ofi
followup
determin
particular
drug
risk
factor
ofi
medic
record
dog
present
texa
univers
veterinari
teach
hospit
januari
decemb
diagnos
imha
impa
itp
andor
evan
syndrom
retrospect
review
age
sex
breed
patient
evalu
dog
exclud
euthan
die
lost
follow
within
day
initi
immunosuppress
treatment
dog
immunosuppress
agent
treat
whether
develop
ofi
follow
record
multivari
logist
regress
use
determin
associ
particular
immunosuppress
agent
develop
ofi
statist
signific
set
p
two
hundr
fortysix
dog
diagnos
select
immunemedi
diseas
retrospect
includ
studi
immun
mediat
hemolyt
anemia
immun
mediat
thrombocytopenia
immun
mediat
polyarthr
evan
syndrom
sixteen
patient
diagnos
ofi
multivari
logist
regress
analysi
show
odd
develop
ofi
significantli
higher
among
dog
receiv
cyclosporin
ci
p
rel
dog
receiv
cyclosporin
ofi
significantli
like
male
dog
femal
dog
ci
p
ofi
import
complic
dog
select
immunemedi
diseas
patient
significantli
like
develop
ofi
treat
cyclosporin
male
propos
similar
correl
exist
antigen
concentr
purpos
studi
util
nextgener
microtit
plate
elisa
quantifi
antigen
concentr
compar
realtim
pcr
result
popul
sampl
obtain
field
total
felin
sampl
submit
idexx
laboratori
realpcr
tm
test
includ
felv
util
studi
match
plasma
store
frozen
test
use
petchek
felv
elisa
idexx
laboratori
inc
antigen
recombin
protein
use
gener
standard
curv
quantifi
result
felv
pcr
posit
sampl
cross
point
cp
less
equal
concentr
greater
ngml
averag
ngml
twentyeight
pcr
posit
sampl
cp
greater
concentr
less
ng
ml
detect
antigen
pcr
neg
sampl
sampl
antigen
concentr
ngml
studi
demonstr
potenti
correl
provir
dna
load
concentr
circul
antigen
result
combin
diagnost
methodolog
may
provid
object
inform
stage
progress
regressivelat
regressivefoc
monitor
felv
infect
felin
immunodefici
viru
fiv
felin
leukemia
viru
felv
global
distribut
retrovirus
capabl
induc
fatal
diseas
cat
felv
spread
primarili
via
saliva
among
cat
close
casual
contact
wherea
fiv
commonli
transmit
comb
cat
deep
bite
wound
rapid
test
method
detect
fiv
antibodi
felv
antigen
blood
well
establish
standard
practic
among
veterinarian
screen
cat
diseas
purpos
observ
studi
evalu
macrogeograph
trend
fiv
felv
test
result
pet
cat
period
data
mine
comprehens
intern
databas
snap
felin
tripl
snap
fivfelv
combo
snap
fivfelv
combo
plu
field
result
use
assess
frequenc
singular
coinfect
retrovirus
cat
result
obtain
million
sampl
distribut
across
uniqu
postal
code
countri
countri
group
geograph
global
region
north
america
countri
n
caribbean
countri
n
latin
america
countri
n
northern
europ
countri
n
southern
europ
countri
n
middl
eastafrica
countri
n
sampl
asiapacif
countri
n
weight
averag
rang
fiv
posit
rate
region
north
america
avg
rang
caribbean
latin
america
northern
europ
southern
europ
middl
eastafrica
asiapacif
weight
averag
rang
frequenc
felv
posit
region
north
america
avg
rang
caribbean
latin
america
northern
europ
southern
europ
middl
eastafrica
asiapacif
weight
averag
rang
incid
fivfelv
coinfect
region
north
america
avg
rang
caribbean
latin
america
northern
europ
southern
europ
middl
eastafrica
asiapacif
studi
repres
broadest
worldwid
felin
retrovir
serolog
survey
report
date
util
data
singl
test
platform
result
along
futur
monitor
data
may
use
develop
global
view
efficaci
variou
control
erad
strategi
employ
felv
fiv
across
differ
region
world
lower
urinari
tract
sign
cat
lut
frequent
due
steril
inflamm
rather
infect
practition
may
forgo
microbiolog
cultur
due
cost
prescrib
antimicrobi
agent
empir
incur
unnecessari
select
pressur
side
effect
patient
therefor
rapid
screen
test
detect
bacteria
cat
urin
could
direct
appropri
therapi
dipstick
style
immunoassay
detect
bacteria
perform
felin
urin
n
submit
routin
bacteri
cultur
veterinari
teach
hospit
immunoassay
perform
accord
manufactur
instruct
cultur
perform
quantit
columbia
agar
sheep
blood
maximum
hour
incub
time
ambient
air
bacteria
identifi
use
matrixassist
laserdesorpt
timeofflight
mass
spectrometri
eleven
sampl
yield
cfuml
cultur
ten
posit
immunoassay
consist
e
coli
n
enterococcu
spp
n
staphylococcu
feli
n
three
sampl
yield
cfuml
one
posit
immunoassay
consist
e
coli
n
staphylcoccu
feli
e
coli
n
immunoassay
posit
two
cultur
neg
sampl
immunoassay
correctli
categor
bacteria
gramneg
gramposit
eleven
concord
sampl
sampl
cfuml
consid
neg
sensit
specif
immunoassay
respect
posit
neg
predict
valu
given
low
preval
bacteri
cystiti
cat
data
suggest
immunoassay
use
screen
tool
cat
present
lut
entercoccu
faecium
efm
cultur
commerci
avail
probiot
effect
tf
prolifer
evalu
throughout
log
phase
growth
potenti
efm
reduc
tf
adhes
intestin
epithelium
analyz
cocultur
model
use
porcin
intestin
epitheli
cell
tf
pretreat
efm
prior
cocultur
evalu
prophylact
postinfect
treatment
efm
tf
adhes
cytotox
evalu
use
fluoresc
microscopi
crystal
violet
spectrophotometr
analysi
data
analyz
use
sigmastat
efminduc
inhibit
tf
growth
observ
concentr
low
tf
ef
p
determin
larg
ph
depend
p
tfinduc
cytopathogen
cocultur
efm
prior
infect
ipec
unalt
howev
pretreat
ipec
monolay
efm
reduc
tf
adhes
p
suggest
benefit
pretreat
efm
cat
risk
tf
infect
result
demonstr
efm
inhibit
tf
growth
pretreat
intestin
epitheli
cell
efm
treatment
time
tf
infect
inhibit
adhes
tf
intestin
epitheli
cell
vitro
studi
investig
enterococcu
spp
well
multistrain
probiot
combin
ronidazol
warrant
gammaherpesvirus
ghv
member
emerg
subfamili
herpesvirida
two
major
human
ghv
epsteinbarr
viru
ebv
kaposi
sarcomaassoci
herpesviru
kshv
clinic
import
pathogen
virus
possess
tumorigenesi
potenti
especi
immunecompromis
patient
felin
practic
often
experi
tumor
case
especi
lymphoma
felin
leukemia
viru
felv
major
caus
develop
lymphoma
past
day
howev
major
lymphoma
case
shift
felvfre
cat
mechan
tumorigenesi
spontan
develop
lymphoma
well
understood
situat
ghv
becam
candid
explain
lymphomagenesi
domest
cat
recent
studi
identifi
novel
ghv
domest
cat
feli
catu
ghv
fcaghv
epidemiolog
survey
found
fcaghv
distribut
sever
countri
includ
unit
state
australia
singapor
germani
austria
present
studi
nationwid
molecular
epidemiolog
studi
conduct
investig
preval
ghv
japan
ghvderiv
dna
blood
sampl
detect
degener
nest
panghv
pcr
target
gb
gene
previous
report
nucleotid
sequenc
obtain
dna
fragment
determin
blast
analysi
carri
phylogen
analysi
also
conduct
risk
factor
relat
ghv
infect
clinic
paramet
includ
age
sex
statu
retroviru
infect
bite
wound
histori
clinic
sign
statist
analyz
use
univari
fisher
exact
test
multivari
logist
regress
model
analys
ghvderiv
dna
detect
japanes
domest
cat
blast
analysi
reveal
show
high
similar
fcaghv
isol
domest
cat
unit
state
phylogen
analysi
also
reveal
japanes
isol
form
one
cluster
fcaghv
univari
analysi
older
age
ci
p
male
ci
p
fiv
infect
ci
p
felv
infect
ci
p
sick
cat
ci
p
statist
select
risk
factor
ghv
infect
follow
multivari
analysi
older
age
ci
p
fiv
infect
ci
p
found
signific
independ
risk
factor
ghv
infect
studi
preval
ghv
japanes
domest
cat
survey
risk
factor
ghv
infect
determin
fcaghv
preval
japan
lower
previous
report
preval
countri
area
us
europ
unabl
determin
caus
differ
howev
japanes
isol
identifi
close
genet
relationship
domest
cat
deriv
fcaghv
find
suggest
viru
highli
conserv
anim
speci
ghv
harbor
host
specif
manner
well
herpesvirus
risk
factor
ghv
infect
japanes
cat
fiv
infect
previous
report
clarifi
fiv
enhanc
ghv
infect
andor
viremia
clinic
import
ghv
infect
felin
practic
still
unknown
investig
necessari
identifi
pathogen
ghv
domest
cat
zoeti
conduct
ongo
surveil
program
evalu
suscept
trend
antimicrobi
agent
canin
felin
escherichia
coli
e
coli
pathogen
isol
urinari
tract
infect
uti
sinc
data
analyz
annual
first
five
year
suscept
data
amoxicillinclavulan
acid
ampicillin
cefovecin
cefpodoxim
ceftiofur
enrofloxacin
marbofloxacin
orbifloxacin
trimethoprimsulfamethoxazol
cephalexin
present
total
e
coli
strain
isol
etiolog
agent
cat
dog
present
natur
occur
uti
seen
primarygener
care
practic
submit
surveil
program
veterinari
diagnost
laboratori
throughout
unit
state
us
canada
minim
inhibitori
concentr
mic
isol
test
use
broth
microdilut
system
thermo
fisher
scientif
oakwood
villag
oh
conform
clinic
laboratori
standard
institut
clsi
standard
data
collect
first
year
program
show
mode
mic
valu
remain
stabl
within
one
doubl
dilut
antimicrobi
test
e
coli
dog
cat
year
test
mic
valu
stabl
year
test
except
amoxicillin
clavulan
acid
ampicillin
mode
mic
valu
remain
lgml
mic
valu
rang
lgml
time
vitro
test
cefovecin
cefpodoxim
ceftiofur
steadi
mode
mic
mic
valu
rang
lgml
singl
drug
singl
year
mic
valu
test
outsid
rang
mode
mic
valu
fluoroquinolon
enrofloxacin
marbofloxacin
orbifloxacin
test
lgml
mic
valu
rang
lgml
trimethoprimsulfamethoxazol
mode
mic
valu
stabl
lgml
mic
valu
rang
lgml
vitro
test
cephalexin
includ
mode
mic
valu
singl
year
test
e
coli
dog
cat
lgml
mic
valu
lgml
cat
lgml
dog
screen
phenotyp
confirm
extendedspectrum
blactamas
esbl
product
e
coli
done
follow
clsi
standard
year
test
e
coli
isol
dog
e
coli
isol
cat
confirm
esblproduc
strain
overal
antimicrobi
suscept
data
stabl
show
progress
resist
time
frame
effect
doxycyclin
administr
antibodi
differ
borrelia
burgdorferi
peptid
mr
lappin
moroff
colorado
state
univers
fort
collin
co
usa
antech
laboratori
lake
success
ny
usa
borrelia
burgdorferi
transmit
ixod
spp
associ
inflammatori
arthriti
nephriti
dog
lyme
diseas
number
diagnost
modal
evalu
aid
diagnosi
lyme
diseas
dog
serolog
test
prove
benefici
antibodi
outer
surfac
protein
ospa
ospc
ospf
antibodi
peptid
current
use
frequent
commerci
avail
serolog
assay
antibodi
ospc
often
first
detect
serum
new
exposur
b
burgdorferi
human
ixod
spp
infest
doxycyclin
treatment
shown
block
progress
b
burgdorferi
infect
whether
occur
dog
unknown
purpos
studi
report
effect
doxycyclin
administr
serolog
respons
ospa
ospc
ospf
peptid
dog
experiment
infest
wildcaught
scapulari
total
young
adult
dog
infest
femal
male
scapulari
wild
caught
rhode
island
b
burgdorferi
carriag
rate
dog
multipl
fed
tick
present
remov
chamber
day
serum
collect
prior
infest
weekli
infest
assay
commerci
avail
clinic
assay
idexx
laboratori
peptid
commerci
laboratori
accuplex
antech
diagnost
ospa
ospc
ospf
first
dog
posit
ospc
antibodi
neg
antibodi
peptid
administ
doxycyclin
approxim
mgkg
daili
day
week
scapulari
infest
dog
develop
serolog
evid
b
burgdorferi
infect
dog
ospc
antibodi
alon
administ
doxycyclin
day
dog
never
develop
antibodi
peptid
neg
ospc
antibodi
week
week
start
doxycyclin
administr
treat
dog
becam
posit
peptid
alon
week
doxycyclin
administr
posit
next
model
induc
serolog
evid
b
burgdorferi
infect
dog
untreat
dog
develop
serolog
evid
chronic
infect
character
antibodi
ospf
peptid
dog
may
spontan
limit
antibodi
product
peptid
dog
administ
doxycyclin
acut
phase
limit
antibodi
product
result
confirm
larger
number
dog
may
suggest
treatment
ospc
antibodi
first
detect
may
block
develop
antibodi
respons
associ
chronic
b
burgdorferi
infect
natur
resist
cat
leishmaniosi
primarili
due
cellular
immun
respons
wide
suggest
leishmanin
skin
test
lst
success
use
human
dog
posit
lst
result
indic
exposur
leishmania
state
cell
mediat
immun
total
cat
seroneg
felv
fiv
present
veterinari
teach
hospit
endem
area
brazil
evalu
lst
leishmania
infect
confirm
cat
bone
marrow
qpcr
noninfect
cat
compos
control
group
among
infect
cat
present
clinic
sign
asymptomat
cat
intraderm
inject
suspens
l
chagasi
promastigot
inactiv
thimeros
solut
inner
surfac
right
thigh
thimeros
solut
inject
opposit
limb
control
infect
cat
test
neg
lst
time
read
h
inocul
expect
least
part
asymptomat
seroneg
cat
present
posit
lst
canin
leishmaniosi
canl
lst
detect
high
proport
asymptomat
dog
although
neg
lst
even
presenc
cellular
immun
respons
method
employ
previous
use
canl
potenti
immunogen
confirm
promot
posit
lst
five
natur
infect
asymptomat
dog
endem
area
howev
lst
test
seem
adequ
tool
diagnosi
felin
leishmaniosi
transport
blood
remot
area
problemat
dna
gener
stabl
number
studi
evalu
dna
extract
dri
blood
mammal
minim
inform
determin
sensit
differ
techniqu
use
dog
blood
object
studi
determin
optim
techniqu
extract
dna
filter
paper
dri
blood
spot
use
ehrlichia
cani
dna
target
blood
sampl
dog
collect
owner
permiss
use
vector
born
agent
preval
studi
mexico
collect
aliquot
blood
place
edta
blot
onto
filter
paper
vwr
grade
allow
dri
store
individu
steril
bag
filter
paper
sampl
store
room
temperatur
edta
blood
store
assay
central
laboratori
glyceraldehyd
dehydrogenas
gapdh
quantit
pcr
use
estim
dna
yield
differ
experi
differ
buffer
incub
period
assess
experi
use
entir
filter
paper
differ
wash
procedur
determin
overnight
pb
wash
gave
best
result
method
method
commerci
avail
kit
qiaamp
dna
blood
mini
kit
dri
blood
spot
db
protocol
perform
per
manufactur
instruct
method
optim
sampl
previous
shown
posit
e
cani
dna
blood
convent
pcr
assay
known
neg
sampl
thaw
use
make
filter
paper
blot
allow
dri
overnight
subject
dna
extract
method
whole
blood
filter
paper
deriv
dna
extract
assay
gapdh
qpcr
ehrlichia
spp
pcr
assay
total
whole
blood
sampl
pcr
posit
band
character
strong
n
medium
n
weak
n
one
sampl
use
method
exclud
due
wash
incorrect
blot
gapdh
qpcr
result
whole
blood
compar
filter
paper
extract
method
shown
method
fold
method
fold
lower
dna
yield
ehrlichia
cani
dna
amplifi
whole
blood
posit
sampl
use
method
sampl
use
method
filter
paper
sampl
dri
sever
month
gave
result
filter
paper
sampl
dri
hour
specif
dna
extract
blood
dri
filter
paper
sensit
decreas
compar
whole
blood
techniqu
use
commerci
kit
like
sensit
overnight
pb
wash
e
ewingii
preval
ticktransmit
ehrlichia
spp
identifi
dog
southern
us
fever
lame
neutrophil
polyarthr
neurolog
abnorm
consid
common
clinic
find
dog
naturallyinfect
e
ewingii
howev
nonclin
dog
pcr
assess
clinicopatholog
featur
e
ewingii
pcr
case
analyz
medic
record
naturallyinfect
dog
includ
studi
dog
clinic
data
archiv
whole
blood
avail
north
carolina
state
universitycolleg
veterinari
medicin
e
ewingii
pcr
pcr
vectorborn
pathogen
includ
ehrlichia
spp
e
cani
e
chaffeensi
panola
mountain
ehrlichia
anaplasma
spp
babesia
spp
bartonella
spp
hemotrop
mycoplasma
spp
rickettsia
spp
base
upon
diagnost
andor
retrospect
research
test
dog
satisfi
inclus
criteria
frequent
report
physic
exam
find
includ
joint
pain
effus
heart
murmur
organomegali
vomit
fever
e
ewingii
pcr
dog
correspond
cbc
biochemistri
panel
urinalys
respect
hematolog
biochem
abnorm
includ
increas
abnorm
lymphocyt
neutrophilia
character
left
shift
anemia
character
regen
monocytosi
lymphopenia
thrombocytopenia
elev
alp
alt
two
dog
receiv
corticosteroid
hypoalbuminemia
elev
creatinin
urinalys
abnorm
includ
albuminuria
proteinuria
inact
sediment
bilirubinuria
dog
urineproteincreatinin
ratio
greater
rang
canin
vectorborn
diseas
ifa
serolog
result
avail
dog
sera
submit
dog
e
cani
ifa
seroreact
titer
r
rickettsii
spot
fever
group
rickettsia
ifa
seroreact
titer
dog
babesia
spp
bartonella
spp
seroneg
use
snap
plu
test
kit
serum
blood
sampl
ehrlichia
lyme
dog
anaplasma
antibodi
dirofilaria
immiti
antigen
frequent
medic
record
diagnos
includ
renal
diseas
imha
neurolog
diseas
polyarthr
hepat
diseas
cancer
undiagnos
ill
ehrlichiosi
sole
diagnosi
dog
list
concurr
diagnos
dog
hypothes
infect
e
ewingii
may
contribut
comorbid
function
precipit
factor
spectrum
clinic
syndrom
dog
hypothesi
test
use
inferenti
statist
larg
diagnost
data
set
idexx
laboratori
inc
caus
prolif
urethr
pu
elucid
chronic
bacteri
infect
immunemedi
process
propos
aerob
bacteri
urin
cultur
abuc
often
posit
diagnosi
whether
caus
consequ
pu
unknown
object
retrospect
studi
describ
clinicopatholog
data
case
pu
util
fluoresc
situ
hybrid
fish
determin
whether
mucos
associ
bacteria
present
describ
whether
associ
exist
type
inflamm
presenc
absenc
bacteria
fish
evalu
twentytwo
case
biopsyconfirm
pu
identifi
mean
age
year
rang
year
femal
male
breed
repres
four
dog
posit
abuc
periop
posit
mucos
bacteri
cultur
neg
abuc
urin
cultur
unavail
perform
dog
fish
analysi
perform
case
adherentinvas
bacteria
note
dog
tissueassoci
bacteria
dog
dog
posit
abuc
time
biopsi
fish
analys
neg
bacteria
also
neg
abuc
one
dog
adherentinvas
bacteria
visual
lymphoplasmacyt
histiocyt
urethr
remain
neutrophil
lymphoplasmacyt
mix
inflamm
report
histopatholog
result
suggest
primari
secondari
bacteri
invas
may
associ
pu
despit
neg
abuc
knowledg
may
alter
treatment
diseas
aim
studi
measur
vitamin
metabolit
dog
without
histori
caox
urolithiasi
twenti
miniatur
schnauzer
bichon
frise
shih
tzu
includ
studi
case
consist
dog
histori
caox
urolithiasi
fast
urinari
calcium
creatinin
ratio
ucacr
control
consist
age
sex
breedmatch
dog
without
urolithiasi
determin
screen
radiographi
ucacr
oh
vitamin
total
oh
vitamin
measur
commerci
laboratori
heartland
assay
ame
iowa
statist
signific
differ
case
control
compar
oh
oh
total
oh
ratio
total
oh
oh
howev
case
significantli
higher
ratio
oh
oh
compar
control
median
respect
p
nine
highest
ratio
found
case
substanti
overlap
half
case
fall
within
rang
observ
control
moder
posit
correl
ratio
oh
oh
ucacr
r
p
data
suggest
decreas
convers
oh
vitamin
inact
oh
vitamin
occur
subset
dog
caox
urolithiasi
abnorm
vitamin
metabol
may
contribut
stone
risk
dog
ureter
stent
bypass
commonli
use
manag
benign
ureter
obstruct
object
casecontrol
studi
determin
postop
rate
urinari
tract
infect
uti
cat
undergo
procedur
identifi
risk
factor
associ
uti
develop
fortytwo
clientown
cat
undergo
renal
decompress
surgeri
includ
cat
includ
urin
cultur
perform
prior
surgeri
variabl
compar
statist
identifi
risk
factor
median
durat
followup
day
rang
day
postop
urin
cultur
posit
cat
one
uti
nine
differ
bacteria
identifi
enterococcu
faecium
n
e
coli
n
predomin
cat
undergo
bilater
surgeri
like
ci
p
develop
uti
postop
compar
cat
unilater
surgeri
anur
cat
also
like
develop
uti
compar
nonanur
cat
ci
p
preexist
chronic
kidney
diseas
postop
urinari
cathet
abdomin
drain
placement
significantli
associ
infect
either
prior
discharg
longterm
followup
postop
uti
occur
rel
commonli
cohort
cat
postop
urethr
catheter
specul
increas
uti
risk
evid
cohort
cat
greater
case
number
requir
definit
conclus
made
futur
work
focu
gather
greater
case
number
clinic
signific
infect
uropathogen
ecoli
upec
common
bacteria
involv
lower
urinari
tract
infect
dog
studi
test
hypothesi
acid
dilut
urin
promot
upec
growth
author
obtain
earli
morn
urin
sampl
nine
healthi
bitch
follow
urin
filtrat
lm
biofilt
obtain
matrix
three
level
ph
three
level
urin
specif
graviti
usg
titrat
urin
hcl
naoh
inocul
urin
known
quantiti
three
upec
strain
incub
four
hour
made
serial
dilut
plate
nutrient
agar
hour
subsequ
count
number
coloni
form
unit
cfu
count
plate
dilut
grew
cfu
experi
neg
posit
control
number
upec
cfu
analyz
mix
linear
model
includ
fix
effect
strain
ph
concentr
interact
three
random
effect
dog
inocul
dose
upec
covari
least
squar
mean
obtain
use
comparison
comparison
alpha
probabl
error
p
signific
differ
mean
aes
log
cfu
differ
ph
usg
least
bacteria
grew
ph
usg
acid
neutral
dilut
urin
strain
upec
signific
effect
growth
differ
strain
substanti
concentr
alkalin
urin
impact
acidifi
pet
food
diet
may
upec
infect
determin
recent
demonstr
urineproteincreatinin
upc
ratio
higher
canin
urin
sampl
collect
hospit
ih
set
collect
home
ah
stress
associ
inhospit
procedur
travel
hospit
could
play
role
higher
upc
observ
purpos
studi
evalu
urin
cortisolcreatinin
ratio
uccr
metric
stress
correl
upc
urin
sampl
obtain
home
hospit
prospect
nonmask
studi
client
obtain
freecatch
urin
sampl
home
offcampu
hour
prior
appoint
time
urin
collect
total
hospit
visit
time
record
second
urin
sampl
obtain
conclus
dog
appoint
hospit
urin
creatinin
protein
cortisol
level
full
urinalysi
measur
urin
sampl
urin
protein
creatinin
ratio
uccr
compar
ah
ih
set
via
wilcoxon
sign
rank
test
correl
uccr
upc
set
effect
travelhospit
time
chang
uccr
upc
evalu
spearman
analysi
thirtysix
dog
enrol
major
dog
nonproteinur
upc
urin
sampl
uccr
significantli
lower
p
urin
sampl
obtain
ah
median
rang
compar
ih
median
rang
upc
statist
differ
p
urin
sampl
obtain
ah
median
rang
compar
ih
median
rang
uccr
significantli
associ
upc
sampl
collect
set
travel
time
time
hospit
total
time
prior
ih
urin
collect
associ
chang
uccr
upc
patient
borderlin
proteinur
upc
proteinur
upc
statist
differ
upc
set
p
howev
uccr
significantli
higher
p
sampl
collect
ih
median
rang
compar
ah
median
rang
contrari
earlier
studi
data
demonstr
upc
higher
measur
urin
sampl
collect
ih
compar
ah
dog
higher
uccr
ih
compar
ah
howev
uccr
associ
upc
stress
estim
uccr
affect
proteinuria
patient
periton
dialysi
pd
renal
replac
therapi
commonli
use
human
veterinari
medicin
treatment
kidney
insuffici
object
studi
assess
renal
function
anim
renal
failur
pd
renal
case
present
veterinari
teach
hospit
ankara
univers
treat
pd
june
june
total
case
consist
dog
acut
renal
failur
ethylen
glycol
toxic
n
ingest
unknown
plant
n
remain
one
dog
one
cat
chronic
renal
failur
pd
appli
daili
rang
day
concentr
serum
urea
patient
significantli
decreas
second
attempt
pd
serum
creatinin
pd
procedur
complet
concentr
serum
urea
creatinin
significantli
lower
case
howev
valu
still
refer
rang
except
one
dog
acut
renal
failur
complic
identifi
pd
periton
n
hypoalbuminemia
n
hypokalemia
n
dialys
retent
leakag
cathet
site
n
edema
n
pleural
effusionchylothorax
n
first
report
pd
procedur
success
appli
lifesav
easili
applic
cost
effect
clinic
procedur
companion
anim
renal
failur
could
adapt
veterinari
practition
turkey
total
calcium
tca
correct
tca
consid
unreli
predictor
calcium
homeostasi
especi
dog
renal
azotemia
unfortun
measur
ioniz
calcium
mica
truli
reflect
calcium
homeostasi
readili
avail
practic
dog
renal
azotemia
ie
creatininemia
mgdl
urin
specif
graviti
retrospect
identifi
record
inclus
studi
includ
dog
tca
correct
total
protein
albumin
concentr
use
publish
equat
predict
ioniz
calcium
pica
calcul
routin
biochem
valu
age
via
canin
ioniz
calcium
calcul
websit
avail
http
vetmedillinoisedu
studymarsmodelvetmedphp
sensit
specif
pica
compar
tca
correct
tca
true
hypercalcemia
hypocalcemia
determin
mica
mcnemar
test
azotem
dog
includ
studi
hypercalcem
hypocalcem
base
mica
sensit
pica
tca
correct
tca
equival
detect
hypercalcemia
p
specif
pica
tca
statist
differ
p
specif
pica
significantli
higher
specif
correct
tca
diagnos
hypercalcemia
p
furthermor
sensit
pica
significantli
higher
sensit
tca
correct
tca
detect
hypocalcemia
p
specif
pica
tca
correct
tca
equival
diagnos
hypocalcemia
p
dog
renal
azotemia
pica
seem
accur
diagnos
true
hypercalcemia
sensit
detect
true
hypocalcemia
correct
tca
adsorpt
protein
surfac
polym
plastic
glass
could
affect
urin
protein
creatinin
ratio
homopolym
polypropylen
specimen
contain
mitig
protein
adsorpt
urin
sampl
collect
owner
sometim
store
propylen
copolym
plastic
food
storag
glass
contain
either
room
temperatur
refriger
frozen
primari
aim
studi
determin
whether
protein
creatinin
ratio
upc
affect
storag
condit
urin
collect
hour
period
one
mildli
proteinur
one
sever
proteinur
dog
neg
urin
cultur
unremark
urin
sediment
store
homopolym
propylen
collect
jug
design
urin
protein
analysi
human
five
aliquot
urin
sampl
subject
nine
storag
condit
three
type
contain
glass
propylen
copolym
homopolym
propylen
either
hour
hour
hour
addit
five
aliquot
store
homopolym
control
follow
experiment
storag
sampl
store
homopolym
analysi
determin
minimum
size
studi
group
power
analysi
perform
priori
power
alpha
standard
deviat
sever
proteinur
anim
mildli
proteinur
anim
base
pilot
studi
sampl
would
need
detect
approxim
decreas
upc
sever
proteinur
sampl
approxim
decreas
upc
mildli
proteinur
anim
latter
chosen
would
alter
recommend
base
acvim
guidelin
shapirowilk
test
indic
valu
normal
distribut
urin
sampl
ratio
compar
use
oneway
anova
storag
condit
factor
model
ratio
compar
among
treatment
posthoc
bonferroni
correct
experimentwis
type
error
ratio
differ
slightli
significantli
p
among
aliquot
store
differ
condit
urin
sampl
mildli
proteinur
urin
upc
valu
slightli
higher
mean
vs
aliquot
store
copolym
contain
slightli
lower
vs
aliquot
store
glass
contain
differ
control
sever
proteinur
urin
upc
higher
aliquot
store
copolym
glass
control
nevertheless
storag
condit
affect
ratio
detect
differ
would
led
differ
clinic
recommend
base
acvim
consensu
statement
iri
guidelin
result
suggest
collect
store
urin
clean
commonli
use
household
contain
propylen
copolym
food
storag
contain
glass
jar
unlik
lead
chang
suffici
magnitud
clinic
import
howev
studi
would
need
determin
might
specif
circumst
variabl
ie
patient
dysproteinemia
differ
amount
surfac
area
contact
contain
type
might
still
caus
clinic
signific
chang
measur
upc
advanc
ckd
associ
hyporexia
vomit
sign
typic
attribut
urem
toxin
gastric
hyperacid
underli
iri
recommend
acid
suppress
use
advanc
ckd
cat
howev
gastric
ph
measur
cat
ckd
accordingli
central
object
studi
determin
cat
moder
sever
ckd
decreas
gastric
ph
compar
agematch
healthi
cat
base
previous
publish
work
demonstr
associ
hypergastrinemia
ckd
hypothes
cat
ckd
would
reduc
gastric
ph
compar
healthi
agedmatch
cat
cat
concurr
diseas
exclud
basi
histori
physic
examin
cbc
serum
chemistri
profil
urinalysi
urin
cultur
serum
total
thyroxin
sdma
control
obtain
within
hour
ph
monitor
assess
serum
gastrin
concentr
ten
cat
iri
stage
iiiv
ckd
meanaesd
age
ae
yr
nine
healthi
matur
adult
cat
mean
age
ae
yr
prospect
enrol
continu
hr
gastric
ph
monitor
perform
oral
administr
ph
capsul
serum
gastrin
concentr
mean
gastric
ph
mean
percentag
time
gastric
ph
strongli
acid
ph
compar
group
use
independ
ttest
ph
paramet
includ
mean
gastric
ph
ckd
ae
healthi
ae
significantli
differ
cat
ckd
healthi
cat
mean
serum
gastrin
concentr
ckd
ae
healthi
ae
ngdl
higher
highli
variabl
cat
ckd
previous
describ
significantli
differ
group
ph
data
suggest
cat
ckd
gastric
hyperacid
compar
agedmatch
healthi
cat
thu
studi
investig
benefit
acid
suppress
cat
ckd
warrant
increas
urin
volum
decreas
urin
specif
graviti
usg
consid
import
manag
dog
crystalassoci
lower
urinari
tract
diseas
object
studi
evalu
impact
increas
dietari
salt
sodium
chlorid
water
intak
urin
volum
usg
miner
excret
dog
two
diet
ident
except
salt
content
fed
healthi
adult
dog
use
crossov
design
control
diet
con
contain
g
kcal
high
sodium
diet
hna
contain
g
kcal
dog
fed
con
week
baselin
randomli
alloc
receiv
con
hna
week
follow
washout
dog
fed
con
final
week
feed
period
use
dog
fed
altern
diet
phase
water
consumpt
measur
daili
total
void
urin
collect
day
phase
determin
volum
usg
miner
excret
gener
linear
mix
model
detect
differ
among
diet
p
consid
statist
signific
increas
water
consumpt
reach
statist
signific
howev
urin
volum
mlkgday
increas
usg
decreas
p
dog
fed
hna
ae
ae
respect
vs
conf
dog
ae
ae
respect
total
daili
excret
calculogen
compon
calcium
magnesium
oxal
phosphat
increas
dog
fed
hna
p
urin
concentr
miner
differ
baselin
con
p
total
excret
citrat
increas
hna
dog
p
vs
baselin
urin
concentr
differ
reach
signific
p
vs
baselin
differ
vs
con
among
urin
concentr
na
cl
increas
k
decreas
hna
vs
baselin
con
p
conclus
increas
sodium
intak
result
greater
urin
volum
lower
usg
without
chang
urin
concentr
calculogen
compon
moder
increas
dietari
sodium
could
viabl
way
increas
urin
dog
lower
urinari
tract
condit
preval
function
impair
injuri
kidney
high
cancer
patient
significantli
diagnos
use
creatinin
studi
lymphoma
patient
compris
kidney
function
cohort
identifi
use
creatinin
remaind
need
kidney
biopsi
diagnosi
common
caus
compromis
kidney
includ
infiltr
nephrotox
chemotherapeut
volum
deplet
tumor
lysi
syndrom
obstruct
sepsi
ineffect
creatinin
like
due
reduc
product
result
cachexia
reduc
protein
intak
therapeut
mention
french
epidemiolog
studi
human
cancer
patient
differ
type
solid
tumor
report
reduc
gfr
stage
detail
inform
nonexist
veterinari
patient
time
reason
think
situat
differ
asid
increas
rate
cancer
due
longev
mani
chemotherapeut
nephrotox
signific
need
effect
sensit
biomark
diagnos
kidney
diseas
effect
manag
intervent
understand
effect
sdma
creatinin
diagnos
kidney
impair
cancer
patient
perform
retrospect
studi
cat
dog
use
bank
sampl
correl
result
histopatholog
studi
includ
patient
dog
cat
varieti
malign
sdma
rang
lgdl
patient
upper
refer
limit
necropsi
histopatholog
perform
patient
patient
increas
sdma
histopatholog
find
indic
kidney
diseas
neoplast
infiltr
find
observ
patient
normal
sdma
patient
creatinin
upper
refer
limit
rang
mgdl
addit
retrospect
evalu
use
cat
dog
neoplasia
increas
sdma
elev
creatinin
conclus
increas
sdma
correl
histopatholog
find
patient
neoplasia
thu
sdma
reliabl
estim
kidney
function
cat
dog
cancer
studi
investig
water
intak
hydrat
healthi
cat
evalu
nutrientenrich
water
hydrat
domest
shorthair
cat
n
mean
age
yrsaesd
bc
scale
receiv
either
tapwat
w
n
testwat
contain
whey
protein
glycerol
tw
n
day
prior
treatment
baselin
establish
daili
w
food
consumpt
use
monitor
system
ad
libitum
water
dri
food
blood
urin
sampl
collect
day
urin
specif
graviti
usg
creatinin
osmol
measur
endogen
creatininebas
glomerular
filtrat
rate
gfr
calcul
sampl
collect
day
baselin
w
calori
intak
similar
group
although
differ
observ
group
treatment
phase
tw
group
daili
liquid
increas
median
intak
across
day
rang
increas
varianc
control
post
hoc
cat
character
respond
r
consumpt
nonrespond
nr
w
versu
tw
p
daili
urin
volum
mlkg
bw
higher
p
tw
ae
se
versu
w
treat
cat
ae
se
differ
p
group
gfr
ae
se
versu
ae
se
respect
baselin
usg
similar
group
gml
declin
anova
p
tw
gml
aes
versu
w
gml
aes
serum
osmol
similar
group
entir
trial
studi
suggest
specif
nutrient
ad
cat
water
improv
liquid
intak
significantli
improv
overal
hydrat
determin
greater
urin
output
dilut
may
offer
health
benefit
cat
need
greater
water
consumpt
progress
interstiti
nephriti
primari
caus
felin
chronic
kidney
diseas
ckd
affect
mani
elderli
cat
preval
increas
age
vaccin
shown
risk
factor
develop
felin
ckd
crandel
ree
felin
kidney
crfk
cell
line
commonli
use
grow
virus
use
felin
vaccin
product
repeat
administr
vaccin
contain
crfk
remnant
model
interstiti
nephriti
shown
induc
strong
antibodi
respons
crfk
lysat
alphaenolas
immunodomin
glycolyt
pathway
enzym
found
mammalian
cell
studi
marker
inflammatori
diseas
peopl
primari
object
studi
evalu
potenti
model
assess
sampl
cat
cellmedi
immun
respons
alphaenolas
evalu
serum
cytokin
concentr
use
commerci
avail
kit
describ
chang
renal
alphaenolas
stain
pattern
model
serum
urin
peripher
blood
mononuclear
cell
renal
biopsi
collect
six
one
year
old
healthi
purpos
bred
unvaccin
kitten
three
male
three
femal
sampl
collect
week
week
cat
administ
commerci
avail
parenter
fvrcp
vaccin
shown
previous
induc
anticrfk
antienolas
antibodi
second
renal
biopsi
collect
week
avoid
previou
biopsi
site
blood
urin
sampl
collect
sampl
date
singl
lymphocyt
prolifer
assay
perform
hyperinocul
cat
unvaccin
healthi
control
cat
use
antigen
kidney
spleen
alphaenolas
crfk
sera
assay
use
commerci
avail
kit
detect
sfa
ligand
gmcsf
ifngamma
kc
pdgfbb
rant
scf
tnfalpha
milliplex
map
cytokinechemokin
felin
panel
millipor
darmstadt
germani
alphaenolas
immunohistochem
stain
perform
kidney
biopsi
sampl
week
week
evalu
score
boardcertifi
pathologist
mask
time
biopsi
lymphocyt
hyperinocul
cat
prolifer
significantli
presenc
alphaenolas
compar
three
antigen
confirm
induct
cellmedi
immun
respons
toward
alphaenolas
contain
vaccin
glomerular
tubular
alphaenolas
express
significantli
p
greater
week
mean
score
respect
compar
week
respect
increas
cytokin
concentr
hyperinocul
period
note
gmcsf
cat
ifngamma
cat
cat
cat
cat
cat
cat
cat
cat
pdgfbb
cat
rant
cat
cat
tnfalpha
cat
hyperinocul
market
lead
fvrcp
parenter
vaccin
induc
antibodi
cellmedi
immun
respons
toward
alphaenolas
increas
alphaenolas
express
renal
tubul
glomeruli
led
elev
select
inflammatori
cytokin
chemokin
within
model
although
direct
link
made
parenter
fvrcp
vaccin
felin
interstiti
nephriti
date
result
urinari
cytokin
assess
alphaenolas
express
within
felin
kidney
use
continu
evalu
potenti
model
tammhorsfal
protein
thp
exclus
synthes
distal
nephron
physiolog
condit
therefor
expect
larger
amount
protein
urin
healthi
individu
chronic
kidney
diseas
ckd
dog
investig
report
quantiti
thp
urin
lower
urinari
excret
thp
ckd
dog
might
associ
distal
tubular
injuri
andor
loss
renal
mass
thp
may
act
marker
diseas
progress
aim
studi
assess
role
thp
marker
ckd
progress
dog
nine
clinic
healthi
dog
recruit
control
group
forti
ckd
dog
enrol
iri
stage
stage
n
stage
n
stage
n
stage
n
western
blot
thp
perform
result
densitometri
express
mean
ae
sem
urinari
immunodetect
thp
ae
control
dog
ae
ae
ae
ae
ckd
dog
stage
respect
differ
among
group
observ
particularli
stage
p
like
progress
reduct
urinari
excret
thp
may
contribut
detect
gradual
loss
nephron
may
act
marker
diseas
progress
ckd
dog
infect
angiostrongylu
vasorum
av
emerg
diseas
dog
wide
rang
clinic
sign
date
clear
whether
av
abl
caus
glomerular
immun
complex
deposit
renal
damag
aim
studi
evalu
kidney
dog
experiment
infect
av
sixteen
beagl
dog
year
age
oral
infect
third
stage
larva
eight
dog
treat
anthelmint
av
day
eight
left
untreat
dog
euthan
day
infect
renal
sampl
obtain
fix
neutralbuff
formalin
glutaraldehyd
light
lm
electron
microscopi
em
analysi
untreat
dog
show
signific
chang
lm
occasion
fetal
glomeruli
dog
multifoc
granuloma
observ
cortex
treat
dog
show
signific
chang
lm
occasion
fetal
glomeruli
focal
segment
mesangi
sclerosi
mild
increas
mesangi
cell
associ
occasion
mesangi
interposit
overal
em
confirm
histolog
diagnosi
glomerular
immun
deposit
found
demonstr
kidney
dog
infect
av
day
mild
lm
chang
immun
mediat
diseas
studi
obes
human
anim
model
obes
reveal
complex
interact
metabol
inflammatori
hemodynam
factor
result
alter
renal
perfus
vascular
dysfunct
histolog
chang
kidney
earli
detect
renal
dysfunct
crucial
reduc
morbid
mortal
contrastenhanc
ultrasound
ceu
suggest
sensit
method
studi
renal
microvascular
perfus
therefor
object
studi
assess
effect
weight
gain
dog
kidney
function
perfus
use
ceu
sixteen
healthi
lean
adult
beagl
year
ideal
bodi
weight
bw
averag
ae
kg
ideal
bodi
condit
score
bc
rang
median
equal
divid
control
group
group
c
treatment
group
group
base
age
sex
four
week
adapt
commerci
adult
mainten
diet
group
receiv
mainten
energi
requir
induc
weight
gain
week
wherea
group
c
fed
maintain
ideal
bw
bc
week
dog
weigh
bc
assess
weekli
basi
end
adapt
week
week
systol
blood
pressur
serum
urea
creatinin
albumin
urinari
specif
graviti
urinari
protein
creatinin
ratio
upc
measur
glomerular
filtrat
rate
gfr
measur
plasma
clearanc
exoiohexol
intraven
bolu
inject
iohexol
omnipaqu
mgkg
bw
sedat
butorphanol
mlkg
ceu
left
kidney
perform
use
bolu
inject
sonovu
time
intens
curv
reflect
tissu
perfus
gener
base
manual
drawn
region
interest
renal
cortex
medulla
perfus
paramet
risefal
time
area
curv
auc
time
peak
washinout
rate
wirwor
washinout
auc
washin
perfus
index
wipi
mean
transit
time
peak
enhanc
pe
calcul
evalu
parametr
nonparametr
test
use
compar
group
pair
data
signific
set
p
week
signific
differ
group
c
group
found
week
group
gain
averag
weight
consequ
higher
bc
p
group
c
despit
weight
gain
signific
effect
blood
pressur
gfr
observ
group
week
howev
significantli
higher
median
upc
p
observ
week
compar
week
group
ceu
perfus
paramet
cortex
significantli
differ
two
group
week
medulla
howev
pe
measur
relat
blood
volum
significantli
higher
group
group
c
week
p
furthermor
wir
wipi
wor
medulla
paramet
relat
blood
veloc
also
significantli
higher
close
signific
compar
group
c
week
p
respect
week
wir
p
wor
p
weight
gain
dog
appear
affect
routin
marker
kidney
function
gfr
increas
upc
suggest
weight
gain
result
higher
urinari
excret
protein
seen
human
addit
ceu
abl
detect
differ
blood
volum
veloc
renal
medulla
may
indic
structur
function
chang
may
occur
result
weight
gain
studi
util
noninvas
marker
techniqu
local
abnorm
kidney
function
injuri
obes
dog
warrant
addit
studi
also
requir
evalu
whether
chang
revers
weight
loss
fibroblast
growth
factor
bonederiv
hormon
regul
phosphoru
p
vitamin
metabol
recent
shown
dog
chronic
kidney
diseas
ckd
increas
concentr
increas
urinari
fraction
excret
phosphoru
ufep
order
limit
increas
serum
phosphoru
phosphatur
activ
base
suppress
renal
p
reabsorpt
proxim
tubul
recent
human
studi
show
ratio
may
reflect
function
nephron
phosphatur
action
use
prognost
marker
ckd
low
ratio
may
indic
reduct
number
function
nephron
andor
impair
signal
klotho
coreceptor
express
goal
studi
evalu
whether
ratio
reflect
sever
ckd
could
predict
prognosi
ckd
dog
sixteen
ckd
dog
followedup
month
death
iri
stage
n
stage
n
urinari
serum
phosphoru
well
serum
measur
first
visit
ratio
determin
fifteen
healthi
dog
mean
ae
sem
ae
normophosphatemia
ae
mgdl
rang
mgdl
detect
ckd
dog
stage
time
followup
hyperphosphatemia
detect
dog
stage
ae
mgdl
rang
mgdl
ratio
ae
stage
ckd
ae
stage
ckd
p
serum
concentr
higher
stage
even
though
increas
increment
phosphaturia
ckd
dog
stage
lower
ratio
poorer
prognosi
decreas
surviv
predict
ratio
less
surviv
day
worst
prognosi
occur
ratio
less
day
surviv
conclus
low
ratio
associ
normal
high
serum
concentr
support
reduct
function
nephron
andor
impair
signal
renal
injuri
sinc
increas
promot
suffici
phosphaturia
evalu
klotho
serum
urin
renal
tissu
valuabl
question
studi
larger
popul
dog
variou
iri
ckd
stage
confirm
prognost
valu
ufep
dog
spontan
chronic
kidney
diseas
alphaenolas
ubiquit
glycolyt
enzym
known
catalyz
convers
phosphoenolpyruv
implic
selfantigen
variou
autoimmun
diseas
autoantibodi
serum
capabl
elicit
renal
injuri
ultim
contribut
patient
morbid
mortal
furthermor
endogen
renal
alphaenolas
shown
overexpress
human
patient
system
lupu
nephriti
mix
cryoglobulinemia
chronic
kidney
diseas
ckd
common
companion
anim
affect
signific
proport
geriatr
cat
antibodi
alphaenolas
shown
present
sera
cat
pattern
alphaenolas
protein
express
kidney
determin
healthi
diseas
cat
purpos
studi
identifi
character
alphaenolas
express
renal
tissu
cat
without
ckd
none
cat
tissu
collect
euthan
studi
renal
tissu
collect
cat
iri
stage
ii
iv
ckd
mean
age
year
rang
year
age
cat
creatinin
concentr
mgdl
urin
specif
graviti
cat
normal
creatinin
concentr
divid
year
age
n
cat
year
age
n
cat
interstiti
nephriti
predomin
histopatholog
find
ckd
group
minim
absent
cat
normal
creatinin
concentr
immunohistochemistri
techniqu
semiquantit
measur
alphaenolas
protein
express
felin
tissu
optim
util
commerci
avail
monoclon
alphaenolas
antibodi
section
kidney
evalu
posit
immunoreact
assign
score
base
signal
intensityimmunoreactivityrang
score
defin
follow
stain
light
browntan
moder
brown
stain
dark
brown
may
obscur
nucleu
mean
score
young
geriatr
ckd
compar
use
kruskalw
dunn
post
hoc
analysi
nonazotem
cat
year
age
moder
alphaenolas
express
tubular
epithelium
median
score
rang
stain
absent
mild
glomeruli
median
score
rang
contrast
alphaenolas
express
moder
high
tubular
epithelium
median
score
rang
glomeruli
median
score
rang
nonazotem
cat
year
age
lastli
evalu
kidney
cat
ckd
show
alphaenolas
express
decreas
tubul
degen
atroph
median
score
rang
similar
group
cat
normal
tubul
median
score
rang
moder
highli
express
glomeruli
median
score
rang
statist
differ
found
tubular
immunoreact
score
signific
differ
glomerular
immunoreact
score
nonazotem
cat
year
age
nonazotem
cat
year
age
p
ckd
cat
nonazotem
cat
year
age
p
alphaenolas
express
decreas
damag
tubul
increas
glomeruli
older
cat
prior
develop
detect
ckd
compar
young
nonazotem
cat
studi
requir
determin
whether
find
relat
pathogenesi
ckd
could
use
earli
diagnost
test
ckd
metabolom
may
use
provid
descript
endogen
metabolit
present
biolog
sampl
respons
pathophysiolog
extern
stimuli
purpos
present
studi
use
metabolom
compar
cat
felin
idiopath
cystiti
fic
struvit
plug
sp
healthi
cat
male
cat
present
either
sp
n
fic
n
healthi
n
recruit
veterinari
practic
urin
sampl
collect
cystocentesi
nmr
spectra
acquir
bruker
avanc
spectromet
oper
mhz
h
reson
frequenc
equip
cryoprob
data
reduct
normalis
bucket
rmn
analys
multivari
statist
analys
inspect
spectra
reveal
variat
urin
composit
three
group
enabl
identif
metabolit
respons
peak
osc
filtrat
valid
robust
plsda
model
explain
variabl
three
group
built
urin
fic
cat
contain
higher
concentr
indoxylsulf
hippur
creatinin
felinin
betain
tmao
compar
sp
healthi
cat
urin
sp
cat
contain
guanidinoacet
dimethylamin
compar
fic
healthi
cat
creatin
tmao
healthi
cat
urin
healthi
cat
contain
higher
quantiti
carnitin
less
tmao
creatinin
studi
use
metabolom
abl
describ
biochem
variat
urin
healthi
cat
cat
present
fic
sp
novel
applic
metabolom
open
new
hypothesi
pathophysiolog
treatment
cat
monitor
urin
protein
creatinin
upc
ratio
dog
proteinlos
nephropathi
pln
determin
respons
therapi
challeng
due
daytoday
variat
upc
valu
purpos
studi
determin
singl
sampl
averag
sampl
pool
sampl
compar
determin
upc
ratio
regardless
degre
proteinuria
pln
dog
receiv
medic
therapi
twentyf
clientown
dog
diagnos
pln
current
receiv
ace
inhibitor
andor
arb
treatment
proteinuria
enrol
studi
dog
upc
ratio
less
dog
upc
ratio
upc
ratio
measur
dog
util
three
separ
method
singl
sampl
day
averag
sampl
day
pool
sampl
equal
pool
urin
day
blandaltman
analysi
perform
evalu
singl
upc
versu
pool
upc
singl
upc
versu
averag
upc
pool
upc
versu
averag
upc
correl
coeffici
three
analys
also
calcul
follow
simpl
linear
regress
blandaltman
analysi
also
perform
subgroup
upc
upc
compar
method
differ
degre
proteinuria
evalu
dog
strong
correl
singl
upc
compar
pool
upc
r
p
singl
upc
averag
upc
r
p
pool
upc
averag
upc
r
p
bland
altman
comparison
limit
agreement
time
differ
two
methodolog
fall
within
rang
describ
good
agreement
three
method
particularli
dog
upc
poorer
agreement
seen
singl
upc
pool
averag
upc
singl
day
upc
typic
higher
pool
averag
upc
result
studi
show
upc
ratio
singl
sampl
averag
sampl
pool
sampl
compar
pln
dog
receiv
medic
therapi
upc
pln
dog
upc
variabl
method
exist
previou
studi
xlink
nephropathi
dog
receiv
medic
therapi
show
degre
variabl
may
clinic
relev
howev
futur
studi
need
verifi
true
dog
pln
receiv
medic
therapi
purpos
retrospect
studi
gain
insight
effect
three
oral
potassium
supplement
potassium
glucon
tablet
pgt
potassium
glucon
powder
pgp
potassium
citrat
granul
pcg
hypokalemia
serum
bicarbon
colorado
state
univers
veterinari
teach
hospit
medic
record
retrospect
search
cat
prescrib
oral
potassium
supplement
manag
ckdassoci
hypokalemia
data
collect
includ
signal
bodyweight
age
supplement
type
dose
direct
concurr
medic
diet
indic
owner
unabl
give
supplement
serum
chemistri
urinalysi
valu
inclus
laboratori
work
avail
time
hypokalemia
diagnosi
recheck
within
one
six
week
treatment
respons
defin
three
way
increas
potassium
increas
potassium
within
normal
refer
rang
increas
greater
meql
data
normal
distribut
thu
wilcoxon
sign
rank
test
use
compar
pre
postsupplement
valu
spearman
rank
use
assess
correl
dose
chang
serum
potassium
bicarbon
total
cat
identifi
search
inelig
met
inclus
criteria
includ
cat
given
pgt
given
pgp
given
pcg
chang
dose
supplement
chang
supplement
type
dose
rang
meqkg
mgkg
pgt
meqkg
mgkg
pgp
meqkg
mgkg
pcg
cat
increas
potassium
supplement
pgt
pgp
pcg
cat
increas
within
potassium
refer
rang
pgt
pgp
pcg
cat
increas
potassium
meql
pgt
pgp
pcg
presupplement
potassium
mean
sd
pgt
postsupplement
presupplement
potassium
mean
sd
pgp
postsupplement
presupplement
potassium
mean
sd
pcg
postsupplement
statist
signific
differ
serum
potassium
post
supplement
three
medic
pgt
p
pgp
p
pcg
p
posit
correl
pgt
dose
chang
potassium
level
p
signific
correl
pgp
pcg
signific
differ
pre
post
supplement
serum
bicarbon
correl
potassium
supplement
dose
serum
bicarbon
level
enough
data
assess
effect
urin
ph
three
potassium
supplement
effect
treat
hypokalemia
secondari
ckd
major
cat
despit
quit
variabl
dose
treatment
respons
depend
definit
respons
use
indic
alkalin
effect
seen
prospect
studi
need
thorough
assess
symmetr
dimethylarginin
sdma
neutrophil
gelatinaseassoci
lipocalin
ngal
suggest
use
biomark
evalu
renal
diseas
object
studi
assess
circul
sdma
ngal
concentr
dog
correct
dehydr
sixtynin
clientown
dog
dehydr
healthi
dog
includ
casecontrol
observ
studi
dog
dehydr
divid
group
base
presenc
azotemia
addit
dog
dehydr
divid
group
accord
sever
dehydr
dehydr
dog
rehydr
within
hour
standard
fluid
therapi
serum
concentr
sdma
ngal
measur
correct
dehydr
signific
differ
concentr
sdma
ngal
measur
measur
correct
dehydr
dog
azotemia
dog
without
azotemia
addit
sdma
ngal
concentr
show
signific
decreas
correct
dehydr
dog
moder
sever
dehydr
dog
mild
dehydr
notabl
dog
serum
sdma
concentr
correct
dehydr
higher
refer
interv
normal
refer
interv
rehydr
correl
serum
sdma
creatinin
concentr
signific
regardless
presenc
azotemia
wherea
serum
ngal
concentr
significantli
correl
creatinin
concentr
dog
azotemia
studi
found
circul
sdma
concentr
affect
hydrat
statu
indic
measur
sdma
concentr
dehydr
dog
might
need
repeat
correct
dehydr
howev
studi
need
clarifi
result
oxid
stress
central
pathogenesi
mani
system
diseas
human
antioxid
deplet
lipid
peroxid
correl
diseas
sever
outcom
previous
shown
ill
dog
experi
oxid
stress
includ
decreas
glutathion
vitamin
e
increas
urinari
shortterm
nacetylcystein
supplement
impact
clinic
score
outcom
prevent
glutathion
deplet
purpos
studi
evalu
longerterm
combin
antioxid
supplement
marker
oxid
stress
clinic
score
surviv
ill
dog
hospit
clientown
dog
elig
inclus
dog
random
supplement
ns
oral
denamarin
vitamin
e
supplement
day
antioxid
glutathion
cystein
vitamin
e
selenium
clinic
score
determin
enrol
day
glutathion
cystein
vitamin
e
quantifi
highperform
liquid
chromatographi
selenium
measur
use
atom
absorpt
spectroscopi
ga
chromatographymass
spectrometri
respect
thirtytwo
ill
dog
target
enrol
complet
studi
date
n
ns
n
ill
dog
significantli
elev
versu
healthi
control
vs
pg
mgcr
p
antioxid
supplement
result
signific
differ
median
endogen
glutathion
cystein
vitamin
e
selenium
concentr
score
day
surviv
interestingli
ns
group
significantli
decreas
plasma
cystein
concentr
day
compar
baselin
lm
p
preliminari
find
suggest
heterogen
popul
ill
dog
combin
antioxid
supplement
alter
redox
state
clinic
outcom
eat
intestin
surgeri
dog
variabl
human
earli
enter
feed
shown
decreas
morbid
reduc
durat
postop
ileu
poi
poi
increas
length
hospit
studi
evalu
durat
anorexia
time
discharg
dog
follow
simpl
enterotomi
sa
multipl
enterotomi
linear
foreign
bodi
lfb
resect
anastomosi
r
addit
prokinet
use
evalu
medic
record
search
conveni
sampl
fifti
case
identifi
data
record
includ
signal
first
time
voluntari
consumpt
food
occur
use
prokinet
time
discharg
time
eat
tue
time
discharg
tud
follow
surgeri
calcul
time
extub
incomplet
record
dog
histori
previou
intestin
surgeri
case
dehisc
occur
exclud
multivari
regress
perform
model
effect
variabl
adjust
popul
characterist
nineteen
dog
sa
seventeen
lfb
fourteen
r
mean
age
year
respect
dog
receiv
opioid
receiv
full
muagonist
n
fortytwo
per
cent
n
receiv
metoclopramid
six
sa
nine
lfb
six
r
dog
remain
hospit
thirti
hour
longer
averag
compar
dog
receiv
metoclopramid
p
reason
metoclopramid
use
clearli
document
dog
surviv
discharg
mean
tue
hour
respect
tue
significantli
extend
tud
independ
surgeri
type
addit
hour
noteat
delay
discharg
hour
p
mean
tud
hour
respect
r
dog
discharg
averag
thirti
hour
later
sa
p
r
dog
receiv
metoclopramid
discharg
sixti
hour
later
compar
sa
dog
receiv
metoclopramid
eat
decreas
time
hospit
follow
intestin
surgeri
dog
earli
enter
feed
encourag
metoclopramid
associ
prolong
hospit
use
suggest
real
anticip
poi
studi
use
prokinet
poi
contest
human
medicin
consist
decreas
hospit
though
may
improv
feed
toler
resect
anastomosi
expect
lengthen
hospit
period
birth
wean
repres
critic
period
puppi
develop
bodi
composit
prewean
period
wellstudi
sedat
previous
requir
analysi
quantit
magnet
reson
qmr
noninvas
technolog
requir
anesthesia
valid
method
assess
bodi
fat
lean
total
bodi
water
tbw
companion
anim
object
studi
determin
qmr
use
measur
bodi
composit
puppi
prewean
period
healthi
newborn
puppi
labrador
retriev
beagl
n
select
studi
bodi
weight
collect
qmr
scan
perform
awak
unrestrain
puppi
within
hour
birth
week
age
differ
weight
percent
lean
bodi
fat
tbw
lean
mass
hydrat
assess
bodi
weight
higher
labrador
retriev
timepoint
p
bodi
fat
percentag
significantli
higher
beagl
puppi
birth
week
age
p
although
lean
mass
percentag
similar
breed
birth
labrador
retriev
significantli
higher
proport
week
p
breed
differ
observ
tbw
percentag
time
period
beagl
significantli
higher
lean
mass
hydrat
birth
p
result
indic
qmr
use
detect
differ
bodi
composit
critic
prewean
period
research
evalu
differ
bodi
composit
among
dog
breed
growth
requir
retrospect
studi
perform
describ
underli
diseas
clinicopatholog
abnorm
prognosi
associ
hypocholesterolemia
popul
cat
present
tertiari
referr
hospit
case
inclus
criteria
hypocholesterolemia
physic
exam
cbc
serum
biochemistri
urinalysi
avail
serum
total
retrovir
test
imag
report
necropsi
report
review
analysi
cat
categor
accord
diseas
bodi
system
etiolog
neoplast
infecti
steril
inflammatori
hepatobiliari
cardiac
gastrointestin
malnutrit
toxin
neurolog
unknown
fortyeight
cat
met
inclus
criteria
neuter
male
compris
cat
intact
male
spay
femal
intact
femal
median
age
year
rang
year
domest
mix
breed
cat
compris
studi
popul
unknown
breed
diagnosi
categori
distribut
follow
infecti
gastrointestin
neoplast
hepatobiliari
malnutrit
inflammatori
unknown
cardiac
neurolog
toxin
anemia
common
cbc
abnorm
present
cat
common
biochem
abnorm
hyperglycemia
increas
bun
hyperproteinemia
increas
alt
median
cholesterol
concentr
mgdl
rang
mgdl
comorbid
present
cat
renal
cardiac
diseas
preval
respect
signific
differ
found
serum
cholesterol
concentr
diagnosi
categori
signific
differ
found
serum
cholesterol
concentr
survivor
nonsurvivor
hypocholesterolemia
appear
associ
surviv
studi
previou
studi
enterococcu
faecium
strain
fortiflora
purina
fed
puppi
wean
year
age
differ
immun
respons
detect
compar
control
group
studi
first
data
collect
point
week
supplement
unknown
potenti
benefici
effect
may
occur
earlier
addit
whether
probiot
induc
chang
immun
respons
adult
dog
unknown
sinc
first
studi
perform
advanc
techniqu
evalu
immun
system
dog
object
current
studi
evalu
select
immun
respons
adult
dog
supplement
e
faecium
strain
total
agematch
clinic
healthi
laboratori
rear
young
adult
beagl
hous
research
facil
chosen
studi
blood
edta
serum
collect
dog
prior
supplement
monthli
week
flow
cytometri
use
measur
percentag
b
cell
express
surfac
bound
igg
mhcii
percentag
cell
express
mhcii
percentag
cell
express
mhcii
molecul
amount
surfac
express
also
determin
calcul
geometr
mean
fluoresc
index
gmfi
lymphocyt
prolif
respons
dog
nonspecif
mitogen
concanavalin
assess
flow
cytometri
ratio
prolifer
unstimul
cell
stimul
cell
determin
sera
assess
panel
cytokin
use
commerci
avail
kit
milliplex
map
canin
cytokinechemokin
magnet
bead
panel
emd
millipor
differ
group
assess
signific
defin
p
lymphocyt
prolif
respons
mitogen
activ
dog
week
rang
median
statist
greater
p
week
median
compar
week
statist
signific
increas
b
cell
express
surfac
bound
igg
mhcii
increas
b
cell
mhcii
gmfi
first
note
week
maintain
week
compar
week
numer
increas
percentag
cell
express
mhcii
percentag
cell
express
mhcii
increas
cell
mhc
gmfi
increas
cell
mhcii
gmfi
detect
week
differ
statist
signific
compar
week
cell
cell
gmfi
significantli
greater
week
effect
appar
week
cytokineschemokin
least
sera
assess
concentr
within
rang
assay
kclike
statist
signific
differ
supplement
probiot
note
supplement
adult
beagl
enterococcu
faecium
strain
induc
immunomodul
earli
week
dog
addit
studi
ongo
detail
clinic
benefit
jewel
hill
pet
nutrit
inc
topeka
ks
usa
two
pet
parent
feed
older
pet
ageappropri
food
aaha
publish
guidelin
care
older
dog
recommend
focu
area
client
educ
includ
well
care
nutrit
oxid
stress
free
radic
inflammatori
process
consid
lead
caus
degen
diseas
cellular
age
therefor
purpos
studi
evalu
efficaci
food
design
counter
chang
senior
dog
compar
nonnutrit
control
cohort
studi
review
approv
anim
care
use
committe
veterinarian
owner
mask
studi
sponsor
enrol
small
medium
breed
dog
must
year
age
larg
breed
dog
must
year
age
overt
evid
major
organ
diseas
dog
north
american
veterinari
hospit
screen
physic
examin
cbc
serum
chemistri
urinalysi
attend
veterinarian
dog
random
test
control
group
control
group
could
consum
dri
nontherapeut
food
exclud
raw
food
owner
choos
abl
switch
food
discret
test
food
contain
control
miner
ad
antioxid
includ
vitamin
e
ascorb
acid
beta
caroten
lipoic
acid
sourc
fatti
acid
includ
chicken
fat
fish
oil
flax
seed
carnitin
phytonutri
suppli
inclus
carrot
citru
pulp
spinach
tomato
pomac
plant
extract
histori
physic
examin
form
medic
record
dietari
inform
owner
questionnair
fill
electron
month
blood
urin
sampl
obtain
screen
month
month
blood
work
result
questionnair
result
previous
report
hall
et
al
plo
one
test
group
significantli
decreas
blood
urea
nitrogen
bun
vs
significantli
lower
control
group
bun
significantli
lower
test
compar
control
group
three
hundr
dog
screen
enrol
studi
test
mean
age
rang
control
mean
age
rang
test
control
dog
complet
studi
statist
analysi
repeat
measur
regress
model
valu
interest
depend
variabl
diet
time
point
diet
interact
time
point
independ
variabl
differ
least
squar
mean
use
test
signific
differ
p
valu
less
use
determin
signific
previou
food
consum
enrol
dog
includ
dri
can
brand
food
major
food
label
indic
specif
senior
pet
pet
owner
report
dog
test
group
exhibit
significantli
posit
respons
greater
improv
vital
seek
owner
attent
coat
shine
coat
soft
decreas
stiff
improv
abil
rise
rest
compar
control
group
compar
baselin
month
studi
design
use
standard
control
food
therefor
may
captur
bia
toward
andor
away
test
food
due
loyalti
owner
chosen
food
novelti
test
food
improv
bun
consist
control
studi
pet
transit
onto
mask
senior
control
food
studi
provid
real
world
scenario
reflect
pet
parent
overal
posit
experi
transit
current
food
test
food
dog
benefit
test
food
shown
decreas
bun
posit
chang
appear
agingassoci
behavior
rise
rest
increas
activ
interact
famili
member
jewel
hill
pet
nutrit
inc
topeka
ks
usa
two
pet
parent
feed
older
pet
ageappropri
food
aaha
publish
guidelin
care
older
cat
recommend
focu
area
client
educ
includ
well
care
nutrit
oxid
stress
free
radic
inflammatori
process
consid
lead
caus
degen
diseas
cellular
age
therefor
purpos
studi
evalu
efficaci
food
design
counter
chang
senior
cat
compar
nonnutrit
control
cohort
studi
review
approv
anim
care
use
committe
veterinarian
owner
mask
studi
sponsor
enrol
cat
must
year
age
overt
evid
major
organ
diseas
cat
north
american
veterinari
hospit
screen
physic
examin
cbc
serum
chemistri
urinalysi
attend
veterinarian
cat
random
age
test
control
group
control
food
could
dri
nontherapeut
food
exclud
raw
food
owner
choos
abl
switch
food
discret
test
food
contain
control
miner
ad
antioxid
includ
vitamin
e
ascorb
acid
beta
caroten
sourc
fatti
acid
includ
chicken
fat
fish
oil
carnitin
phytonutri
suppli
inclus
broccoli
tomato
pomac
plant
extract
histori
physic
examin
form
medic
record
dietari
inform
owner
questionnair
fill
electron
month
blood
urin
sampl
obtain
screen
month
month
blood
work
result
questionnair
result
previous
report
hall
et
al
ploson
test
group
significantli
decreas
creatinin
blood
urea
nitrogen
bun
vs
significantli
lower
control
group
one
hundr
twentynin
cat
screen
enrol
studi
test
mean
age
rang
control
mean
age
rang
test
control
cat
complet
studi
statist
analysi
repeat
measur
regress
model
valu
interest
depend
variabl
diet
time
point
diet
interact
time
point
independ
variabl
differ
least
squar
mean
use
test
signific
differ
p
valu
less
use
determin
signific
previou
food
consum
includ
dri
can
brand
food
major
label
indic
specif
senior
pet
month
test
group
pet
owner
report
significantli
improv
score
vital
coat
textur
less
mat
increas
interact
famili
member
improv
abil
run
play
control
group
compar
baselin
studi
design
use
standard
control
food
therefor
may
captur
bia
toward
andor
away
test
food
due
loyalti
owner
chosen
food
novelti
test
food
improv
bun
creatinin
consist
control
studi
pet
transit
onto
mask
senior
control
food
studi
provid
real
world
scenario
reflect
pet
parent
experi
transit
current
food
test
food
cat
benefit
senior
food
shown
improv
bun
creatinin
concentr
posit
chang
appear
age
associ
behavior
increas
abil
run
play
increas
activ
greater
interact
famili
success
placement
iv
cathet
essenti
treatment
ill
injur
pet
veterinari
student
often
struggl
gain
skill
iv
insert
purpos
prospect
studi
evalu
factor
student
success
surround
placement
iv
cathet
student
ask
complet
survey
follow
cathet
placement
attempt
er
respons
anonym
irb
review
studi
student
particip
student
ask
selfassess
level
experi
high
medium
low
characterist
patient
restrain
cathet
locat
type
record
well
success
failur
cathet
placement
degre
coach
also
record
chisquar
test
use
evalu
differ
insert
dog
cat
univari
logist
regress
analysi
use
assess
relationship
success
variabl
one
hundr
thirtyf
cathet
attempt
dog
cat
student
report
low
moder
prior
experi
percent
success
veterinari
technician
restrain
major
cathet
placement
provid
coach
attempt
relationship
success
cathet
placement
prior
experi
speci
indic
catheter
brand
cathet
vessel
restrain
student
success
faculti
member
restrain
patient
although
signific
due
small
sampl
size
catheter
vital
clinic
skill
ongo
effort
improv
teach
clinic
instruct
still
necessari
n
licht
ea
rozanski
je
rush
tuft
univers
north
grafton
usa
cum
school
veterinari
medicin
tuft
univers
grafton
usa
prolong
hypotens
may
neg
impact
surviv
critic
ill
cat
hypotens
refractori
fluid
therapi
indic
continu
rate
infus
cri
vasoact
medic
vm
purpos
studi
review
indic
outcom
cat
receiv
vm
electron
medic
record
databas
search
use
term
cat
dopamin
epinephrin
norepinephrin
vasopressin
record
review
cat
exclud
receiv
vm
cpr
immedi
follow
rosc
receiv
vm
anesthesia
immedi
postop
underli
diseas
initi
bp
vm
use
rate
durat
vm
use
outcom
record
descript
statist
use
fisher
exact
test
compar
group
fortyon
cat
met
inclus
criteria
studi
enrol
initi
bp
detect
mmhg
doppler
cat
sepsi
neoplasia
dka
common
underli
condit
vm
use
commonli
dopamin
cat
typic
receiv
mcgkgmin
norepinephrin
second
common
vm
cat
typic
receiv
mcgkgmin
sixteen
cat
surviv
cat
receiv
one
vm
cat
surviv
cat
receiv
vasopressor
cat
surviv
p
thirti
cat
receiv
vm
hour
surviv
receiv
vm
hour
surviv
p
advers
affect
attribut
vm
vasopressor
may
use
cat
critic
ill
eustachian
tube
obstruct
eto
one
lead
caus
inflamm
middl
ear
undiagnos
untreat
otiti
media
progress
result
seriou
patholog
chang
purpos
studi
assess
middl
ear
cat
eto
studi
materi
consist
total
tempor
bone
cat
eto
progress
time
interv
day
result
reveal
moder
hyperplasia
equal
develop
throughout
epitheli
layer
surround
neutrophilrich
mild
inflammatori
cell
infiltr
pronounc
one
week
obstruct
compar
day
moreov
major
cleft
fill
serou
effus
postobstruct
hyperplasia
edema
hyper
vascular
epitheli
layer
sever
increas
number
inflammatori
cell
within
serou
effus
week
transit
effus
serou
mucoid
increas
infiltr
plasma
mononuclear
cell
well
sever
epitheli
hyperplasia
addit
granul
tissu
appear
origin
extracellular
matrix
caviti
round
window
nich
epitheli
hyperplasia
characterist
effus
directli
proport
durat
eto
therefor
patient
present
longlast
complaint
ocular
nasal
discharg
epistaxi
sneez
otorrhea
ear
itch
head
tilt
facial
nerv
paralysi
noisi
difficult
breath
examin
dysfunct
blockag
eustachian
tube
diagnost
techniqu
tympanometri
purpos
studi
assess
effect
age
bodi
condit
score
bc
muscl
condit
score
mc
indirect
radial
coccyg
doppler
systol
arteri
blood
pressur
sap
measur
dog
sixtytwo
privatelyown
dog
enrol
june
juli
bc
mc
determin
investig
blood
pressur
measur
per
publish
guidelin
use
headphon
order
measur
site
random
dog
posit
right
later
recumb
radial
measur
sternal
recumb
stand
coccyg
measur
associ
sap
variabl
assess
correl
coeffici
analysi
covari
radial
coccyg
sap
measur
moder
correl
r
p
radial
sap
significantli
higher
coccyg
sap
mean
differ
mmhg
p
discord
occur
direct
differ
observ
first
measur
taken
averag
measur
averag
measur
either
radial
mmhg
p
coccyg
mmhg
p
site
associ
found
sap
measur
either
site
age
weight
bc
mc
anxieti
score
cuff
size
heart
rate
decreas
significantli
start
acclim
end
first
data
collect
seri
regardless
site
p
measur
site
base
patient
oper
prefer
given
lack
associ
patient
variabl
site
use
serial
sap
measur
given
discord
result
site
variabl
evalu
studi
heart
rate
hr
respiratori
rate
rr
noninvas
blood
pressur
nibp
cardiac
output
co
cardiac
index
ci
arteri
oxygen
satur
end
tidal
temperatur
arteri
pressur
carbon
dioxid
arteri
pressur
oxygen
bicarbon
ph
total
carbon
dioxid
presenc
lactat
blood
also
evalu
order
assess
influenc
medic
cardiorespiratori
function
hemodynam
function
acidbas
statu
measur
taken
two
differ
time
point
time
point
one
correspond
anesthesia
isofluran
time
point
two
correspond
anesthesia
isofluran
continu
infus
offlk
lgkgmin
statist
signific
differ
effect
medic
temperatur
acidbas
statu
p
contrast
statist
signific
differ
effect
medic
cardiorespiratori
hemodynam
variabl
p
use
flk
continu
infus
dosag
lgkgmin
patient
anesthet
isofluran
gener
statist
signific
chang
blood
ph
bodi
temperatur
p
regard
cardiovascular
hemodynam
variabl
statist
signific
differ
chang
p
differ
time
point
although
possibl
observ
tendenc
improv
tissu
perfus
hemodynam
stabil
keyword
anesthesia
blood
gase
cardiac
output
multimod
analgesia
mycophenol
acid
activ
form
mycophenol
mofetil
mmf
effect
control
dysregul
lymphocyt
respons
associ
immunemedi
diseas
drug
shown
promis
treatment
multipl
autoimmun
diseas
dog
cat
human
dose
optim
plasma
drug
concentr
monitor
tdm
recommend
order
maxim
mpa
effect
particularli
patient
requir
sustain
immunosuppress
human
mpa
highli
protein
bound
drug
recommend
monitor
free
drug
plasma
concentr
free
unbound
mpa
correl
immunosuppress
effect
like
dog
cat
would
also
need
tdm
optim
dosag
regimen
howev
extent
mpa
plasma
protein
bind
dog
cat
unknown
importantli
extent
mpa
protein
bind
extrapol
speci
due
inher
differ
albumin
structur
drug
bind
capac
hypothes
extent
plasma
protein
bind
dog
cat
furthermor
consid
mmf
like
coadminist
corticosteroid
also
evalu
effect
prednisolon
dexamethason
plasma
protein
bind
mpa
extent
plasma
protein
bind
mpa
lgml
potenti
interact
dexamethason
prednisolon
plasma
evalu
use
high
throughput
equilibrium
dialysi
devic
valid
chromatograph
method
concentr
drug
use
studi
correspond
plasma
concentr
report
clinic
patient
treat
therapeut
dose
determin
plasma
protein
bind
use
individu
plasma
sampl
clinic
healthi
dog
n
cat
n
evalu
impact
corticosteroid
mpa
plasma
protein
bind
pool
plasma
healthi
dog
cat
experi
run
triplic
repeat
differ
day
data
group
analyz
student
ttest
p
consid
signific
extent
plasma
protein
bind
mean
rang
dog
cat
respect
unbound
plasma
concentr
lgml
rang
dog
cat
respect
mean
unbound
plasma
concentr
mpa
statist
differ
p
two
speci
result
effect
corticosteroid
plasma
protein
bind
mpa
present
tabl
mean
unbound
plasma
concentr
mpa
higher
combin
prednisolon
p
dexamethason
p
conclus
result
studi
suggest
mpa
highli
bound
plasma
protein
furthermor
prednisolon
appar
vitro
effect
extent
bind
mpa
plasma
dog
cat
result
necessarili
reflect
higher
unbound
plasma
concentr
mpa
vivo
due
effect
drug
distribut
elimin
plasma
concentr
purpos
determin
pharmacokinet
pk
toler
cannabidiol
cbd
healthi
dog
hypothes
oral
transderm
deliveri
would
well
toler
provid
measur
system
level
cbd
thirti
healthi
beagl
dog
randomli
assign
receiv
one
three
cbd
formul
capsul
oil
transderm
cream
twice
daili
total
dose
mgday
approxim
mgkgday
week
blood
collect
hour
follow
first
dose
cbd
pk
blood
collect
cbc
chemistri
panel
bile
acid
cbd
plasma
level
daili
observ
note
weekli
physic
examin
also
perform
pharmacokinet
analysi
demonstr
oil
formul
result
higher
plasma
concentr
system
exposur
less
variabl
cannabidiol
exposur
dose
proport
elimin
halflif
oil
formul
follow
dose
mg
ae
ae
minut
respect
twicedaili
administr
maintain
plasma
cbd
level
studi
complet
signific
abnorm
cbc
urinalysi
preand
postprandi
bile
acid
mild
elev
serum
alkalin
phosphatas
alp
occur
week
frequent
capsul
oil
formul
mgday
dog
experienc
diarrhea
presenc
onset
sever
correl
formul
dose
cannabidiol
appear
well
toler
dog
exposur
proport
dose
oil
formul
provid
favor
pk
result
provid
framework
futur
efficaci
studi
cbd
dog
mycophenol
mofetil
mmf
prodrug
mycophenol
acid
mpa
potent
immunosuppress
agent
mpa
inhibit
inosin
monophosph
dehydrogenas
impdh
enzym
de
novo
purin
nucleotid
synthesi
pathway
lymphocyt
lack
purin
salvag
pathway
altern
sourc
nucleotid
therefor
especi
suscept
effect
mpa
mmf
report
inhibit
b
cell
prolifer
mmf
origin
develop
use
human
transplant
patient
sinc
inexpens
gener
version
becom
avail
drug
becom
popular
veterinari
medicin
treatment
immunemedi
disord
dog
assum
mmf
effect
dog
similar
establish
effect
human
date
limit
data
avail
regard
effect
mpa
canin
lymphocyt
object
current
project
evalu
concentrationdepend
effect
mpa
canin
lymphocyt
function
util
cell
activ
assay
b
cell
lymphocyt
prolifer
assay
peripher
blood
mononuclear
cell
pbmc
isol
six
healthi
hound
dog
use
histopaqu
densiti
gradient
centrifug
isol
pbmc
plate
incub
escal
concentr
mpa
ngml
vehicl
dmso
control
media
control
stimul
either
pokewe
mitogen
pwm
concanavalin
cona
cell
activ
assay
model
commerci
avail
human
assay
activ
posit
cell
atp
synthesi
market
nonspecif
test
efficaci
immunosuppress
agent
briefli
posit
cell
magnet
sort
pbmc
follow
activ
cona
cell
lyse
releas
intracellular
atp
luminesc
reagent
luciferinluciferas
activ
atp
ad
result
bioluminesc
measur
use
luminomet
b
cell
prolifer
evalu
measur
incorpor
tritiat
thymidin
via
scintil
betacount
follow
activ
pwm
cona
respect
studi
reveal
mpa
concentrationdepend
effect
cell
activ
assay
signific
differ
dmso
vehicl
control
ae
mean
rel
fluoresc
unit
ae
sem
even
highest
mpa
concentr
evalu
ngml
ae
lymphocyt
prolifer
assay
contrast
reveal
mpa
reliabl
inhibit
b
cell
prolifer
concentrationdepend
manner
ic
half
maxim
inhibitori
concentr
ngml
assay
figur
studi
confirm
mpa
reliabl
inhibit
canin
b
cell
prolifer
concentrationdepend
fashion
ic
achiev
mpa
concentr
readili
achiev
standard
mmf
dose
rate
base
result
vitro
studi
oral
mmf
would
anticip
potenti
inhibit
b
cell
prolifer
dog
base
result
studi
cell
activ
assay
significantli
affect
exposur
mpa
suggest
assay
although
market
human
medicin
nonspecif
test
druginduc
suppress
posit
cell
may
clinic
valu
dog
receiv
mmf
mycophenol
mofetil
mmf
attract
altern
commerci
avail
immunosuppress
rapid
onset
action
minim
sideeffect
goal
studi
evalu
pharmacokinet
pk
variou
clinic
paramet
week
oral
dose
mmf
healthi
cat
pk
mycophenol
acid
mpa
activ
form
mmf
evalu
follow
oral
administr
mgkg
po
bid
n
mgkg
po
bid
n
mgkg
po
tid
n
mmf
cellcept
oral
suspens
roch
lab
inc
week
healthi
popul
cat
plasma
sampl
taken
prior
first
administr
mmf
hs
first
mmf
administr
addit
plasma
sampl
taken
hs
first
administr
next
dose
concentr
mpa
deriv
plasma
determin
use
valid
chromatograph
method
noncompartment
analysi
done
estim
pk
paramet
mpa
cat
biotransform
mmf
mpa
result
suggest
cat
biotransform
mmf
mpa
rel
fast
observ
intraven
pk
experi
done
laboratori
signific
variat
absorpt
phase
concentr
time
profil
drug
reflect
dispers
tmax
valu
addit
signific
interindividu
variabl
mpa
exposur
shape
concentr
vs
time
profil
mpa
first
dose
mmf
suggest
mpa
undergo
enterohepat
recycl
follow
multipl
administr
trough
mpa
level
reflect
signific
accumul
drug
plasma
bid
dosag
regimen
evalu
small
accumul
time
mpa
tid
administr
mmf
three
metabolit
mpa
detect
cat
phenol
glucuronid
phenol
glucosid
acyl
glucuronid
administr
mgkg
acyl
glucuronid
metabolit
identifi
mgkg
po
bid
group
cat
vomit
studi
cat
mgkg
tid
group
hyporex
recov
discontinu
mmf
mild
reduct
serum
protein
level
pcv
platelet
count
occur
day
day
studi
valu
alter
mmf
use
cat
studi
describ
clinic
paramet
pk
oral
mmf
administr
healthi
cat
futur
studi
evalu
pharmacodynam
mpa
patient
receiv
dose
mmf
purpos
studi
use
limit
sampl
strategi
determin
pharmacokinet
oral
mirtazapin
alter
cat
liver
diseas
compar
healthi
age
match
control
cat
amc
twenti
cat
enrol
liver
diseas
appar
healthi
agematch
control
cat
liver
diseas
evid
chronic
kidney
diseas
hyperthyroid
base
complet
blood
count
serum
biochemistri
urinalysi
total
well
recent
exposur
mirtazapin
appar
healthi
amc
cat
screen
physic
examin
complet
blood
count
serum
biochemistri
urinalysi
total
blood
drawn
cat
hour
hour
follow
one
mg
oral
dose
mirtazapin
subset
cat
group
blood
also
obtain
hour
postadministr
mirtazapin
concentr
measur
liquid
chromatographi
coupl
tandem
mass
spectrometri
drug
exposur
auc
halflif
predict
use
limit
sampl
approach
base
multipl
linear
regress
analysi
previou
full
sampl
studi
estim
use
noncompartment
method
data
normal
distribut
mann
whitney
test
use
compar
paramet
two
group
spearman
rank
use
analyz
correl
liver
valu
pharmacokinet
paramet
statist
signific
differ
max
liver
diseas
cat
amc
cat
p
max
hour
liver
cat
versu
amc
cat
hour
liver
cat
versu
amc
cat
auc
significantli
differ
two
group
howev
calcul
halflif
liver
diseas
cat
significantli
increas
p
compar
healthi
amc
cat
correl
serum
alp
p
r
alt
p
r
total
bilirubin
p
r
compar
serum
halflif
mirtazapin
liver
diseas
cat
prolong
halflif
mirtazapin
dose
decreas
frequenc
consid
cat
liver
diseas
effect
quit
variabl
addit
work
need
done
determin
cat
effect
esomeprazol
senantiom
omeprazol
report
favour
pharmacokinet
efficaci
antacid
properti
human
howev
littl
inform
dosag
esomeprazol
pharmacokinet
properti
consciou
dog
aim
evalu
efficaci
intraven
esomeprazol
h
compar
efficaci
mgkg
mgkg
healthi
dog
six
healthi
adult
coloni
beagl
dog
enrol
random
crossov
design
group
dog
receiv
mgkg
mgkg
respect
intraven
h
hour
continu
intragastr
ph
measur
bravo
ph
monitor
system
record
mean
percentag
time
mpt
ph
hour
group
comparison
group
analys
repeat
measur
analysi
varianc
posthoc
bonferroni
method
mpt
valu
ph
first
hour
ae
ae
mgkg
group
ae
ae
mgkg
group
respect
statist
differ
mpt
group
group
show
critic
advers
effect
first
studi
evalu
intraven
esomeprazol
twice
daili
nonanesthet
healthi
dog
result
suggest
mgkg
iv
h
administr
esomeprazol
efficaci
mgkg
iv
h
healthi
dog
jh
hwang
jg
cho
lim
koo
kw
seo
veterinari
intern
medicin
chungnam
nation
univers
daejeon
taejonjikhalsi
korea
graduat
school
new
drug
discoveri
develop
chungnam
nation
univers
daejeon
taejonjikhalsi
korea
chungnam
nation
univers
daejeon
taejonjikhalsi
korea
esomeprazol
senantiom
omeprazol
report
favour
pharmacokinet
efficaci
antacid
properti
human
howev
pharmacokinet
effect
intragastr
ph
esomeprazol
dog
report
determin
pharmacokinet
esomeprazol
administ
via
variou
rout
pk
studi
investig
effect
esomeprazol
intragastr
ph
use
bravo
ph
monitor
system
pd
studi
twelv
healthi
adult
male
beagl
dog
includ
studi
studi
use
open
random
crossov
design
pk
studi
dog
receiv
intraven
iv
subcutan
sc
oral
dose
po
esomeprazol
mgkg
treatment
period
separ
washout
period
least
day
esomeprazol
plasma
concentr
measur
hplcmsm
efficaci
studi
intragastr
ph
record
without
medic
baselin
ph
follow
iv
sc
po
esomeprazol
dose
regimen
mgkg
dog
bioavail
esomeprazol
administ
po
entericco
granul
sc
inject
respect
halflif
approxim
hour
mean
percent
time
intragastr
ph
significantli
increas
result
indic
esomeprazol
administr
increas
intragastr
ph
regardless
dose
rout
p
pk
paramet
po
sc
esomeprazol
administr
favour
esomeprazol
significantli
increas
intragastr
ph
follow
iv
po
sc
administr
iv
sc
administr
esomeprazol
may
use
po
administr
possibl
signific
advers
effect
observ
acetylsalicyl
acid
asa
commonli
known
aspirin
cyclooxygenas
inhibitor
frequent
use
inhibit
platelet
function
format
thromboemboli
risk
patient
potenti
phenomenon
resist
antiplatelet
effect
document
peopl
potenti
dog
aspirin
resist
may
contribut
factor
develop
life
threaten
thrombi
thu
increas
rate
morbid
mortal
sever
canin
diseas
understand
phenomenon
aspirin
resist
develop
method
predict
could
lead
improv
surviv
patient
caus
aspirin
resist
remain
unclear
individu
variabl
esteras
activ
therefor
hydrolysi
aspirin
suggest
potenti
caus
poor
bioavail
aspirin
blood
peopl
object
studi
determin
whether
asa
concentr
need
caus
inhibit
platelet
aggreg
vitro
healthi
dog
predict
valu
measur
dog
administr
oral
aspirin
vivo
furthermor
want
evalu
whether
addit
fluorid
known
caus
nonspecif
esteras
inhibit
alter
concentr
asa
metabolit
salicyl
acid
sa
blood
sampl
collect
oral
aspirin
administr
twentyon
healthi
clientown
dog
enrol
first
vitro
test
perform
twice
trial
least
week
apart
determin
individu
repeat
whole
blood
sampl
drawn
incub
differ
aspirin
concentr
aggreg
measur
auc
area
curv
unit
use
multipl
electrod
imped
aggregomet
multipl
vivo
test
dog
given
singl
oral
dose
mgkg
aspirin
aggreg
assess
prior
aspirin
administr
minut
administr
time
point
sampl
also
collect
edta
edtafluorid
blood
tube
measur
asa
sa
plasma
concentr
use
liquid
chromatographi
mass
spectrometri
base
calcul
vitro
dog
separ
differ
respons
group
eighteen
dog
consist
aspirin
respond
vitro
valu
umol
median
umol
rang
one
dog
show
consist
poor
respons
vitro
valu
umol
trial
two
dog
mark
variat
vitro
valu
trial
classifi
variabl
respond
dog
found
aspirin
nonrespond
consist
trial
trial
variat
vitro
dog
dog
valu
umol
mean
rang
respect
administr
mgkg
aspirin
oral
dog
show
platelet
inhibit
hour
vivo
valu
remain
dog
sampl
collect
edta
edta
fluorid
median
rang
umol
umol
respect
three
dog
identifi
poor
variabl
respond
vitro
inhibit
platelet
aggreg
vivo
addit
fluorid
blood
sampl
result
mean
percent
reduct
sa
concentr
mean
percent
increas
asa
concentr
studi
suggest
individu
variat
aspirin
respons
exist
dog
assess
multipl
electrod
aggregometri
singl
low
dose
mgkg
aspirin
suffici
caus
measur
inhibit
platelet
aggreg
dog
result
asa
concentr
substanti
less
use
vitro
aspirin
respons
vitro
correl
respons
vivo
scenario
use
edta
fluorid
anticoagul
result
inhibit
convers
asa
sa
suggest
success
inhibit
esteras
activ
store
dog
plasma
sampl
contain
aspirin
use
edta
contain
fluorid
may
prevent
esteras
hydrolysi
asa
investig
effect
esteras
activ
caus
aspirin
resist
dog
warrant
sildenafil
citrat
highli
select
phosphodiesteras
type
v
inhibitor
use
treat
pulmonari
hypertens
ph
veterinari
medicin
sometim
patient
ph
experi
respiratori
distress
oral
administr
type
drug
patient
fatal
patient
rectal
rout
care
consid
altern
mean
administ
drug
object
studi
compar
pharmacokinet
characterist
oral
disintegr
film
odf
formul
sildenafil
convent
filmcoat
tablet
fct
formul
healthi
dog
addit
pharmacokinet
profil
odf
formul
sildenafil
analyz
rectal
administr
twelv
healthi
beagl
dog
divid
four
group
given
sildenafil
per
follow
specif
fct
formul
mgkg
po
per
oral
odf
formul
mgkg
po
odf
formul
mgkg
dilut
distil
water
administ
rectal
odf
formul
mgkg
dissolv
water
administ
rectal
blood
sampl
collect
cours
h
concentr
sildenafil
assay
signific
differ
max
across
four
arm
c
max
rectal
administ
mgkg
dose
differ
significantli
oral
administ
mgkg
dose
contrast
c
max
rectal
administ
mgkg
dose
significantli
lower
oral
administ
mgkg
dose
rectal
administ
mgkg
dose
auc
rectal
administ
mgkg
dose
significantli
smaller
obtain
sildenafil
administ
oral
auc
rectal
administ
mgkg
dose
significantli
higher
oral
administr
arm
notabl
system
advers
effect
group
emerg
may
help
sildenafil
administ
rectal
respiratori
distress
patient
except
increas
auc
pharmacokinet
characterist
rectal
administ
mgkg
dose
shown
compar
oral
administ
mgkg
dose
mirtazapin
transderm
ointment
mzp
achiev
clinic
relev
serum
concentr
cat
result
increas
bodi
weight
dose
mgkg
purpos
studi
evalu
safeti
profil
exagger
dose
unmask
studi
mzp
appli
topic
inner
pinna
five
healthi
adult
intact
femal
cat
two
intact
femal
cat
chronic
kidney
diseas
ckd
serum
creatinin
mgdl
mgdl
urin
specif
graviti
respect
daili
consecut
day
mgkg
cat
rang
age
year
mzp
volum
split
equal
ear
administr
behavior
observ
conduct
twice
daili
throughout
studi
score
interact
activ
vocal
tremor
physic
examin
ecg
doppler
blood
pressur
conduct
studi
day
scan
echocardiogram
abdomin
ultrasound
conduct
studi
day
hematolog
serum
chemistri
conduct
studi
day
bodi
weight
measur
studi
day
bodi
weight
blood
pressur
serum
alt
compar
time
point
use
wilcoxon
sign
rank
test
pair
sampl
sum
predos
mean
behavior
score
compar
mean
behavior
score
day
use
wilcoxon
sign
rank
test
pair
sampl
statist
signific
set
p
test
erythema
inner
pinna
common
find
multipl
cat
variou
time
point
one
cat
show
excori
one
ear
day
subsequ
heal
unev
one
cat
ckd
exhibit
vomit
studi
day
recov
without
treatment
cat
show
intermitt
bout
sec
spasm
ataxia
tail
curl
back
day
cat
gain
signific
amount
weight
day
day
p
blood
pressur
analyz
healthi
cat
singl
time
point
signific
differ
compar
baselin
time
point
hematolog
serum
chemistri
show
clinic
signific
chang
either
appar
healthi
cat
two
cat
ckd
clinic
signific
chang
cardiac
find
signific
differ
behavior
score
begin
end
studi
despit
dose
mirtazapin
mirtazapin
transderm
ointment
well
toler
cat
administ
mgkg
consecut
day
studi
multicent
doubleblind
placebocontrol
random
studi
cat
least
year
age
weigh
kg
document
medic
histori
bodi
weight
loss
deem
clinic
signific
enrol
cat
could
serum
creatinin
mgdl
diagnos
neoplasia
random
mirtazapin
placebo
mzp
dose
mg
per
cat
equival
ml
volum
ointment
regardless
bodi
weight
placebo
ointment
ident
treatment
ointment
without
activ
ingredi
mirtazapin
dose
volum
ointment
administ
inner
pinna
daili
ae
day
effect
demonstr
comparison
mean
percent
chang
bodi
weight
day
week
visit
use
twosampl
ttest
signific
set
p
percent
chang
bodi
weight
mzp
group
greater
equal
clinic
patholog
data
case
receiv
mzp
placebo
includ
safeti
analysi
variabl
analyz
use
analysi
covari
treatment
fix
effect
baselin
valu
covari
advers
event
safeti
analysi
includ
observ
whether
consid
product
relat
unfavor
unintend
occur
use
studi
drug
day
studi
termin
twohundr
thirtyon
clientown
cat
enrol
studi
administ
least
one
dose
mzp
placebo
includ
safeti
analysi
onehundr
eightyseven
cat
determin
evalu
effect
analysi
cat
mzp
group
cat
placebo
group
result
summar
tabl
differ
mean
percent
chang
bodi
weight
ci
mzp
group
placebo
group
statist
signific
p
clinic
relev
statist
signific
chang
clinic
patholog
paramet
seen
advers
event
report
cat
safeti
popul
mild
common
applic
site
reaction
observ
placebo
treat
cat
mzp
treat
cat
nine
cat
seriou
advers
event
studi
relat
underli
diseas
cat
receiv
mzp
cat
receiv
placebo
mirtazapin
transderm
ointment
effect
manag
weight
loss
cat
use
mzp
result
mean
weight
gain
compar
placebo
two
week
transderm
treatment
product
gener
well
toler
mirtazapin
shown
increas
bodi
weight
cat
purpos
studi
evalu
singl
dose
pharmacokinet
pk
mirtazapin
novel
formul
mirtazapin
transderm
ointment
mzp
cat
studi
random
mask
crossov
pk
studi
eight
appar
healthi
adult
cat
year
age
studi
cat
healthi
determin
daili
clinic
observ
day
acclim
period
physic
examin
cbcserum
chemistri
cat
wore
elizabethan
collar
throughout
cours
studi
day
four
cat
treat
mgkg
mzp
appli
inner
pinna
right
ear
four
cat
treat
mgkg
mzp
given
oral
syring
back
mouth
day
cat
cross
opposit
treatment
plasma
collect
predos
hour
administr
frozen
prior
ship
analysi
plasma
mirtazapin
concentr
measur
use
valid
lcmsm
method
pk
paramet
calcul
use
standard
method
winnonlin
profession
pk
paramet
statist
compar
treatment
use
wilcoxon
sign
rank
test
signific
set
p
pk
paramet
summar
tabl
pk
paramet
significantli
differ
oral
transderm
administ
mzp
max
p
c
max
p
halflif
p
except
auc
p
transderm
applic
mzp
inner
pinna
achiev
measur
plasma
concentr
cat
absorpt
mzp
faster
consist
follow
oral
administr
compar
topic
applic
addit
mean
extent
absorpt
follow
oral
administr
higher
follow
topic
applic
mzp
longer
appar
termin
halflif
observ
follow
topic
compar
oral
administr
vs
hr
suggest
presenc
flipflop
pharmacokinet
rate
absorpt
significantli
slower
rate
elimin
mirtazapin
shown
increas
bodi
weight
cat
transderm
absorb
purpos
studi
evalu
multipl
dose
pharmacokinet
pk
mirtazapin
transderm
ointment
mzp
cat
studi
mask
random
threearm
parallel
studi
determin
plasma
pk
two
dosag
mgkg
mzp
appli
topic
daili
day
healthi
adult
cat
year
old
determin
cbcserum
chemistri
physic
exam
twenti
cat
random
eight
mg
kg
eight
mgkg
four
cat
treatment
cat
underw
acclim
day
dose
phase
day
postdos
phase
day
pk
sampl
cat
wore
elizabethan
collar
durat
studi
cat
assess
daili
gener
health
applic
site
abnorm
physic
examin
bodi
weight
record
begin
end
studi
plasma
sampl
mirtazapin
concentr
collect
within
one
hour
prior
treatment
last
dose
day
h
post
final
dose
analyz
use
valid
lcmsm
method
noncompartment
pharmacokinet
analysi
perform
winnonlin
profession
ver
pk
profil
summar
tabl
mean
ae
sd
bodi
weight
cat
receiv
mgkg
mzp
kg
ae
kg
prior
treatment
ae
kg
day
treatment
mean
ae
sd
bodi
weight
cat
receiv
mgkg
mzp
kg
ae
kg
prior
treatment
ae
kg
day
treatment
mean
ae
sd
bodi
weight
control
cat
kg
ae
kg
baselin
ae
kg
day
mild
red
pinna
applic
site
note
follow
administr
pinnal
excori
ulcer
observ
cat
daili
dose
day
mirtazapin
transderm
ointment
achiev
clinic
relev
serum
concentr
cat
mycophenol
mofetil
mmf
purin
synthesi
inhibitor
immunosuppress
agent
origin
develop
use
human
organ
transplant
recent
increasingli
use
veterinari
medicin
treatment
canin
immunemedi
disord
dog
howev
limit
experiment
data
avail
enabl
establish
effect
dose
rate
dose
rate
vari
wide
publish
case
seri
anecdot
clinic
report
advers
effect
particularli
diarrhea
frequent
report
human
canin
patient
often
lead
either
dose
reduct
drug
discontinu
object
studi
util
dose
escal
studi
healthi
dog
determin
maximum
toler
dose
mtd
mmf
anim
determin
effect
dose
pharmacodynam
assay
b
cell
prolifer
focus
establish
drug
mechan
action
eight
adult
hound
dog
given
oral
mmf
three
differ
escal
dose
rate
mgkg
bid
mgkg
bid
mgkg
bid
one
week
dose
week
washout
period
dose
monitor
signific
diarrhea
vomit
inappet
mtd
determin
dog
administ
dose
rate
week
blood
collect
day
b
cell
prolifer
assay
measur
incorpor
tritiat
thymidin
follow
activ
pokewe
mitogen
concanavalin
respect
complet
blood
count
cbc
serum
biochemistri
urinalysi
also
perform
begin
end
studi
dog
toler
oral
mmf
dose
rate
mgkg
bid
one
week
without
signific
side
effect
three
dog
develop
signific
diarrhea
one
also
develop
vomit
mgkg
bid
one
week
lead
final
start
mtd
mgkg
bid
dog
mgkg
bid
dog
subsequ
week
trial
howev
dog
mgkg
bid
develop
signific
diarrhea
start
second
week
drug
administr
necessit
dose
reduct
mgkg
bid
therefor
end
second
week
dog
mgkg
dog
mgkg
dog
mgkg
bid
signific
chang
cbc
serum
biochemistri
urinalysi
result
studi
period
b
cell
prolifer
result
one
week
oral
mmf
mtd
significantli
differ
day
result
pretreat
baselin
figur
howev
week
oral
mmf
b
cell
prolifer
significantli
reduc
b
cell
prolifer
countsmin
averag
reduc
baselin
cell
prolifer
baselin
interestingli
dog
reduc
mmf
dose
b
cell
prolifer
still
decreas
studi
confirm
oral
mmf
maxim
toler
dose
rate
significantli
inhibit
b
cell
prolifer
dog
effect
howev
appear
delay
sever
week
suggest
mmf
may
ideal
treatment
choic
dog
sever
emerg
immunemedi
diseas
requir
rapid
immunosuppress
mechan
delay
immunosuppress
effect
mmf
elucid
although
anoth
purin
synthesi
inhibitor
azathioprin
also
report
delay
effect
caus
also
yet
determin
diarrhea
previous
report
common
doselimit
side
effect
studi
exact
mechan
mmfassoci
diarrhea
determin
either
human
dog
interestingli
dog
druginduc
diarrhea
drug
effect
lymphocyt
prolifer
appear
delay
first
week
therapi
sinc
lower
oral
dose
rate
mgkg
bid
mmf
still
caus
signific
suppress
lymphocyt
prolifer
dog
without
associ
diarrhea
reduc
dose
rate
warrant
explor
futur
pharmacodynam
studi
enzym
cytochrom
b
reductas
encod
detoxifi
reactiv
metabolit
sulfonamid
antibiot
singl
nucleotid
polymorph
snp
g
recent
associ
sulfonamid
hypersensit
dog
synonym
code
snp
may
partial
explain
risk
idiosyncrat
drug
reaction
howev
function
signific
variant
unknown
base
silico
predict
hypothes
g
snp
would
decreas
protein
synthesi
total
cellular
cytochrom
b
reductas
activ
without
decreas
mrna
express
vitro
model
cell
transfect
express
vector
contain
either
wildtyp
variant
g
cdna
incub
hour
cell
harvest
mrna
protein
function
measur
qrtpcr
immunoblot
cytochrom
c
reduct
assay
respect
signific
differ
protein
express
g
allel
mrna
quantif
cytochrom
b
reductas
activ
assay
underway
preliminari
result
support
g
function
variant
lead
decreas
cytochrom
b
reductas
express
howev
immunoreact
semiquantit
measur
protein
express
result
mrna
enzym
activ
assay
may
better
inform
mechanist
signific
g
snp
sulfonamid
hypersensit
dog
cyclosporin
potent
immunosuppress
agent
commonli
use
treat
immunemedi
disord
dog
cyclosporin
target
lymphocyt
decreas
cytokin
express
ifnc
activ
cell
unfortun
signific
complic
lifethreaten
secondari
infect
sometim
aris
result
cyclosporin
administr
necessit
cessat
therapi
cyclosporin
stop
expect
patient
immun
system
complet
recov
commenc
function
appropri
current
unknown
quickli
immun
system
tcell
function
recov
follow
cessat
cyclosporin
therapi
object
studi
util
pharmacodynam
bioassay
quantifi
averag
time
take
tcell
function
return
pretreat
level
healthi
dog
cessat
immunosuppress
dose
cyclosporin
six
healthi
adult
dog
given
cyclosporin
mgkg
bid
po
day
whole
blood
gene
express
ifnc
evalu
treatment
day
drug
administr
two
hour
give
medic
use
quantit
revers
transcript
polymeras
chain
reaction
qrtpcr
sampl
activ
hour
phorbol
ionomycin
rna
extract
rel
gene
quantif
perform
compar
gene
express
drug
administr
pretreat
level
addit
one
week
cessat
cyclosporin
daili
blood
sampl
collect
evalu
ifnc
gene
express
day
oral
cyclosporin
ifnc
markedli
suppress
reach
pretreat
valu
respect
mean
ifnc
express
remain
decreas
pretreat
level
day
washout
wo
wo
day
sem
pretreat
valu
respect
wo
day
mean
ifnc
express
pretreat
valu
respect
result
suggest
follow
cessat
immunosuppress
dose
cyclosporin
tcell
express
ifnc
begin
return
pretreat
valu
within
initi
hour
dog
ifnc
express
return
pretreat
valu
within
day
stop
cyclosporin
dog
may
requir
addit
recoveri
day
interestingli
upon
recoveri
ifnc
express
exceed
pretreat
valu
suggest
potenti
rebound
effect
follow
cessat
cyclosporin
therapi
addit
studi
requir
determin
time
postcyclosporin
recoveri
tcell
function
dog
natur
occur
immunemedi
disord
hemostat
efficaci
safeti
yunnan
baiyao
yb
demonstr
across
multipl
speci
despit
widespread
anecdot
use
yb
veterinari
medicin
dog
bleed
tendenc
studi
evalu
efficaci
dog
primari
object
studi
evalu
effect
yb
clinic
hemorrhag
follow
nasal
biopsi
dog
measur
blood
loss
time
stop
bleed
secondari
object
evalu
effect
yb
measur
coagul
includ
buccal
mucos
bleed
time
bmbt
thromboelastographi
teg
nineteen
clientown
dog
present
utvmc
intern
medicin
servic
nasal
biopsi
march
august
enrol
prospect
dog
random
treatment
yb
placebo
control
group
owner
statistician
primari
investig
blind
treatment
dog
receiv
dog
receiv
dose
drug
one
dose
pm
even
one
dose
morn
procedur
accord
bodi
weight
dog
baselin
blood
pressur
platelet
count
prothrombin
time
activ
partial
thromboplastin
time
perform
present
bmbt
perform
capsul
administr
dog
exclud
studi
systol
blood
pressur
mmhg
platelet
count
sec
ptt
sec
bmbt
minut
addit
bmbt
teg
blood
loss
measur
perform
teg
perform
blood
loss
measur
perform
measur
blood
loss
includ
total
blood
loss
blood
loss
percentag
bodi
weight
time
stop
bleed
standard
anesthet
protocol
follow
final
diagnosi
determin
histopatholog
evalu
biopsi
sampl
ct
find
andor
cytolog
exam
individu
case
basi
statist
analysi
blood
loss
measur
perform
use
twoway
ancova
repeat
measur
mix
effect
ancova
use
analyz
bmbt
teg
variabl
alpha
angl
k
r
backward
variabl
elimin
perform
evalu
effect
covari
p
valu
consid
statist
signific
time
stop
bleed
significantli
shorter
yb
group
ae
sec
compar
control
group
ae
sec
influenc
underli
diseas
signific
effect
bodi
weight
weight
biopsi
weight
biopsi
percentag
bodi
weight
time
stop
bleed
age
presenc
epistaxi
present
significantli
associ
longer
time
stop
bleed
blood
pressur
biopsi
number
significantli
associ
shorter
time
stop
bleed
treatment
effect
remain
signific
even
effect
covari
consid
total
blood
loss
blood
loss
percentag
bodi
weight
significantli
differ
group
effect
yb
measur
coagul
includ
bmbt
teg
advers
effect
note
treatment
either
group
studi
preprocedur
oral
administr
yb
dog
undergo
nasal
biopsi
result
significantli
shorter
time
stop
bleed
follow
biopsi
result
studi
support
use
yb
prior
nasal
biopsi
dog
addit
studi
need
determin
clinic
use
yb
procedur
medic
condit
associ
hemorrhag
dog
furthermor
pharmacokinet
studi
need
determin
optim
oral
dose
yb
dog
purpos
studi
determin
incid
posit
pathogen
prestent
poststent
cultur
dog
tracheal
collaps
tc
retrospect
studi
review
record
traditionaltyp
tc
malformationtyp
tc
dog
receiv
tracheal
stent
anim
medic
center
dog
tracheal
stent
placement
concurr
endotrach
cultur
includ
prestent
cultur
subsequ
cultur
obtain
consid
poststent
cultur
posit
pathogen
cultur
defin
posit
bacteriolog
cultur
compat
cytolog
andor
radiograph
evid
infect
posit
pathogen
cultur
occur
prestent
poststent
dog
traditionaltyp
tc
dog
posit
pathogen
prestent
poststent
cultur
respect
malformationtyp
tc
dog
posit
pathogen
prestent
poststent
cultur
respect
common
isol
includ
escherichia
spp
pseudomona
spp
staphylococcu
spp
prestent
patient
escherichia
spp
pseudomona
spp
poststent
patient
posit
pathogen
cultur
present
similar
major
dog
tracheal
collaps
prior
follow
tracheal
stent
placement
malformationtyp
tc
dog
higher
incid
pathogen
poststent
cultur
compar
traditionaltyp
tc
dog
risk
posit
poststent
cultur
increas
malformationtyp
tc
decreas
traditionaltyp
tc
patient
tracheal
stent
may
increas
risk
airway
infect
tracheal
collaps
patient
bacteri
cultur
tc
dog
may
reflect
poor
clearanc
pharyng
enter
organ
probiot
may
benefici
alter
gastrointestin
microbiota
studi
cat
determin
oral
probiot
affect
composit
airway
microbiota
use
rrna
amplicon
sequenc
bacteri
dna
extract
oropharyng
op
swab
bronchoalveolar
lavag
bal
fece
blood
object
character
oral
probiot
chang
composit
upper
lower
airway
fecal
blood
microbiota
hypothes
probiot
would
modul
respiratori
microbiota
healthi
cat
demonstr
detect
probiot
bacteri
speci
present
fecal
sampl
alter
core
airway
microbiom
commun
respiratori
tract
six
healthi
research
cat
op
bal
fecal
blood
sampl
collect
baselin
week
receiv
oral
probiot
extract
dna
underw
pcr
rrna
gene
sequenc
coverag
number
readssampl
rich
rel
abund
repres
oper
taxonom
unit
otu
determin
princip
compon
analysi
pca
demonstr
related
sampl
receiv
probiot
coverag
bal
mean
ae
sd
ae
ae
readssampl
p
blood
ae
ae
readssampl
p
significantli
increas
signific
differ
coverag
op
fecal
swab
p
p
respect
rich
upper
ae
ae
p
lower
airway
ae
ae
p
blood
ae
ae
p
significantli
increas
fece
valu
express
mean
standard
deviat
follow
rang
parenthes
total
loss
total
blood
loss
loss
bw
blood
loss
percentag
bodi
weight
bleed
time
time
stop
bleed
p
valu
categori
diseas
repres
differ
paramet
regard
underli
diseas
categori
neoplast
vs
inflammatori
p
valu
categori
treatment
repres
differ
paramet
yb
control
group
p
valu
consid
statist
signific
rich
significantli
differ
probiot
p
probiot
capsul
resolv
otu
level
consist
follow
taxa
genu
bifidobacterium
bifidobacterium
animali
genu
streptococcu
lactobacillu
zeae
genu
lactobacillu
b
animali
l
zeae
detect
sampl
site
baselin
l
zeae
detect
site
posttreat
b
animali
detect
op
bal
fece
blood
overal
composit
upper
lower
airway
microbiota
underw
chang
regard
rel
abund
predomin
otu
otu
chang
significantli
op
bal
sampl
respect
contrast
otu
fece
chang
significantli
baselin
pca
reveal
distinct
microbiom
site
sampl
cluster
tightli
baselin
variat
probiot
administr
first
studi
describ
effect
oral
probiot
respiratori
microbiota
healthi
cat
find
bacteri
speci
present
oral
probiot
upper
lower
airway
provid
pilot
data
suggest
oral
probiot
could
investig
tool
target
dysbiosi
occur
inflammatori
airway
diseas
felin
asthma
histoplasmosi
common
fungal
infect
potenti
result
sever
clinic
diseas
major
cat
pulmonari
involv
purpos
studi
evalu
thorac
radiograph
find
cat
diagnos
histoplasmosi
medic
record
cat
present
oklahoma
state
univers
vth
review
cat
includ
studi
orthogon
thorac
radiograph
perform
complet
medic
record
definit
diagnosi
histoplasmosi
base
identif
h
capsulatum
posit
urin
antigen
andor
posit
fungal
cultur
radiologist
blind
clinic
sever
patient
evalu
radiograph
determin
predomin
pulmonari
pattern
sever
score
lung
lobe
fortyseven
cat
femal
male
includ
studi
median
age
year
rang
year
presum
aliv
time
abstract
predomin
pulmonari
pattern
bronchial
cat
cat
mix
pulmonari
pattern
combin
bronchial
interstiti
andor
alveolar
three
cat
bilater
pleural
effus
cat
normal
radiograph
lung
lobe
abnorm
major
cat
median
sever
score
lung
lobe
moder
felin
histoplasmosi
result
pulmonari
abnorm
major
cat
infect
predomin
pulmonari
pattern
moder
bronchial
pattern
without
interstiti
compon
retrospect
evalu
presenc
hemosiderin
canin
felin
bronchoalveolar
lavag
bal
sampl
possibl
associ
signal
prebal
treatment
diagnosi
blood
paramet
transthorac
fineneedl
aspir
bal
procedur
time
prior
immunemedi
diseas
neoplasia
medic
record
dog
cat
respiratori
diseas
underw
bal
ontario
veterinari
colleg
review
record
dog
cat
met
inclus
criteria
hemosiderin
report
bal
cytolog
dog
cat
p
cat
higher
risk
bal
hemosiderosi
dog
dog
histori
cancer
higher
risk
bal
hemosiderosi
none
factor
associ
bal
hemosiderosi
except
prolong
bal
procedur
dog
p
increas
proport
bal
eosinophil
cat
associ
absenc
hemosiderin
p
hemosiderin
identifi
bal
dog
pneumonia
dog
bronchiti
dog
neoplasia
one
nondiagnost
bal
sampl
dog
contain
hemosiderin
hemosiderin
identifi
bal
cat
asthma
cat
pneumonia
cat
bronchiti
cat
neoplasia
hemosiderin
present
dog
cat
underw
transthorac
fine
needl
aspir
prior
bal
hemosiderosi
common
bal
sampl
cat
dog
appear
associ
specif
respiratori
condit
lung
lobe
torsion
dog
cat
k
benavid
ea
rozanski
oura
tuft
univers
north
grafton
usa
cum
school
veterinari
medicin
tuft
univers
grafton
usa
lung
lobe
torsion
llt
uncommon
pulmonari
diseas
lung
twist
around
pedicl
result
necrosi
lobe
primari
object
studi
evalu
characterist
anim
identifi
llt
secondari
object
evalu
prognost
indic
medic
record
system
search
use
lung
lobe
torsion
individu
case
review
confirm
llt
either
time
surgic
intervent
necropsi
data
record
includ
signal
larg
small
breed
imag
modal
i
presenc
preoper
pleural
effus
lobe
affect
outcom
fisher
exact
test
use
compar
group
thirtynin
case
identifi
includ
dog
cat
pug
n
common
remain
dog
small
breed
n
larg
breed
n
three
cat
dsh
one
minskin
one
small
breed
dog
one
cat
euthan
time
diagnosi
thorac
radiograph
perform
case
ct
bronchoscopi
lobe
affect
includ
right
middl
n
left
cranial
n
right
cranial
n
accessori
n
treat
surviv
discharg
treat
pug
small
breed
dog
cat
surviv
larg
breed
surviv
p
thirtyon
anim
preoper
pleural
effus
surviv
anim
preoper
effus
surviv
p
small
breed
cat
llt
excel
prognosi
surviv
discharg
prognosi
larg
dog
guard
limit
noninvas
method
avail
evalu
lung
mechan
hypothes
inspiratori
expiratori
chang
lung
area
assess
fluoroscopi
would
result
reproduc
measur
could
use
futur
evalu
lung
function
mechan
dog
respiratori
diseas
fortyfour
consciou
unsed
dog
evid
respiratori
diseas
minim
restrain
sternal
recumb
tidal
respir
record
fluoroscop
respiratori
cycl
maxim
inspiratori
expiratori
imag
respiratori
cycl
evalu
number
pixel
entir
thorac
caviti
measur
inspir
expir
averag
percent
chang
thorac
dimens
determin
dog
process
repeat
use
hemithorax
measur
exclud
mediastinum
cardiac
silhouett
refer
rang
confid
comput
use
nonparametr
percentil
distribut
median
percent
chang
thorac
dimens
total
thorax
measur
confid
interv
median
percent
chang
hemithorax
measur
significantli
differ
p
larger
confid
interv
render
respons
lung
area
chang
neither
measur
techniqu
correl
age
sex
thorac
conform
bc
breed
vari
bodi
weight
kg
conclus
fluoroscopi
provid
noninvas
reliabl
measur
lung
area
chang
respir
small
larg
dog
investig
lung
area
chang
requir
dog
respiratori
diseas
assess
util
detect
dysfunct
environment
tobacco
smoke
et
exposur
common
children
lower
socioeconom
class
et
exposur
link
varieti
health
risk
urin
cotinin
may
use
estim
et
exposur
purpos
studi
evalu
rate
et
exposur
dog
cat
differ
socioeconom
class
massachusett
urin
sampl
submit
leftov
routin
test
collect
two
univers
laboratori
sampl
anim
live
worcest
two
zip
code
websterwest
brookfield
westboroughwalpol
wellesleyweston
elig
inclus
repres
low
incom
lower
middl
incom
upper
middl
incom
high
incom
area
owner
inform
record
inform
consent
waiv
clinic
scienc
review
committe
urin
test
cotinin
classifi
posit
neg
result
compar
use
chisquar
analysi
one
hundr
seventyeight
dog
cat
enrol
seventeen
posit
urin
cotinin
worcest
lowincom
significantli
higher
rate
posit
anim
p
worcest
anim
rate
et
exposur
websterwest
brookfield
westboroughwalpol
wellesleyweston
dog
cat
similar
children
higher
rate
exposur
et
lower
socioeconom
set
may
risk
smokeassoci
diseas
object
studi
valid
use
twodimension
speckl
track
echocardiographi
assess
left
atrial
la
mechan
function
healthi
hors
aim
establish
testretest
reliabl
calcul
normal
refer
interv
healthi
warmblood
hors
includ
analys
la
wall
motion
perform
digit
store
cineloop
record
standard
rightparastern
view
focus
left
atrium
pwave
trigger
use
defin
start
cardiac
cycl
global
longitudin
strain
l
global
longitudin
strain
rate
sr
l
time
peak
left
atrial
contract
tplc
measur
character
la
contractil
reservoir
conduit
function
measur
randomli
select
hors
repeat
blind
fashion
observ
second
observ
differ
day
mean
sd
lower
upper
limit
refer
interv
calcul
use
refer
valu
advisor
softwar
wwwbio
statenvtfr
intraobserv
interobserv
measur
variabl
quantifi
use
coeffici
variat
cv
refer
interv
mean
ae
sd
lower
upper
limit
l
ae
sr
l
ae
la
contractil
function
l
ae
sr
l
ae
la
reservoir
function
l
ae
sr
l
ae
la
conduit
function
normal
tplc
ms
ae
daytoday
intraobserv
interobserv
variabl
cv
respect
la
contractil
function
l
sr
l
la
reservoir
function
l
sr
l
conduit
function
l
sr
l
tplc
studi
show
feasibl
reliabl
method
quantifi
left
atrial
wall
motion
low
low
daytoday
intraobserv
interobserv
variabl
refer
interv
healthi
warmblood
hors
report
futur
studi
focu
left
atrial
wall
motion
hors
cardiac
diseas
proof
concept
use
la
wall
motion
analysi
atrial
fibril
af
import
arrhythmia
equin
medicin
tradit
characterist
af
assess
intracardiac
measur
atrial
fibril
cycl
length
atrial
fibrillatori
rate
afr
retriev
surfac
ecg
howev
use
biomark
atrial
electr
remodel
aim
studi
studi
characterist
induc
af
modif
flecainid
healthi
hors
fourteen
hors
electr
stimul
af
multipolar
cathet
place
right
atrium
treat
either
isoton
salin
n
flecainid
mgkg
n
iv
singl
hors
spontan
persist
af
last
three
week
also
treat
flecainid
ecg
hors
analyz
use
spatiotempor
cancel
qrst
complex
calcul
afr
residu
atrial
signal
drug
administr
afr
ae
fibril
per
minut
fpm
flecainidetr
hors
ae
fpm
control
group
ns
flecainid
infus
follow
signific
p
afr
decreas
preced
restor
sinu
rhythm
induc
hors
fig
time
cardiovers
flecainid
infus
start
ae
min
control
anim
mean
af
durat
min
rang
min
alter
afr
observ
follow
salin
administr
last
min
spontan
cardiovers
gradual
decreas
afr
observ
p
fig
hors
spontan
persist
af
afr
decreas
fpm
fpm
follow
flecainid
administr
without
restor
sinu
rhythm
flecainid
caus
rapid
decreas
afr
result
restor
sinu
rhythm
afr
gradual
decreas
hors
spontan
cardiovert
afr
hors
natur
occur
af
markedli
higher
suggest
afr
noninvas
method
studi
atrial
remodel
effect
antiarrhythm
compound
atrial
fibril
af
common
patholog
arrhythmia
result
poor
perform
hors
purpos
studi
quantifi
impact
af
exercis
capac
nine
unfit
standardbr
mare
includ
studi
six
af
hors
three
timematch
control
hors
perform
maxim
exercis
treadmil
test
test
day
day
test
induct
af
pacemak
stimul
right
atrium
test
hors
equip
surfac
ecg
venou
cathet
blood
sampl
maximum
speed
af
group
ae
ms
slower
test
compar
test
wherea
control
hors
ran
ae
ms
faster
second
test
p
af
group
speed
hr
bpm
ae
ms
test
oppos
ae
ms
test
p
time
hr
reach
bmp
cessat
test
ae
ae
minut
test
respect
p
hors
af
maximum
hr
reach
ae
bpm
rang
bpm
exercis
compar
ae
bpm
rang
bpm
hors
sinu
rhythm
p
signific
differ
blood
paramet
found
test
exercis
capac
significantli
reduc
hors
develop
af
character
decreas
veloc
increas
hr
lower
speed
increas
maximum
hr
prolong
cardiac
recoveri
exercis
atrial
fibril
af
common
clinic
arrhythmia
hors
limit
number
drug
avail
pharmacolog
treatment
use
challeng
due
advers
reaction
flecainid
test
equin
af
variabl
efficaci
purpos
studi
test
whether
efficaci
flecainid
depend
af
durat
six
af
hors
three
control
includ
studi
studi
perform
period
day
day
hors
flecainid
mgkg
iv
administ
sinu
rhythm
baselin
measur
af
induc
af
group
mean
pacemak
stimul
right
atrium
day
flecainid
administ
hors
hors
af
cardiovert
sinu
rhythm
day
five
six
hors
cardiovert
day
wherea
hors
cardiovert
day
flecainid
infus
prolong
qr
durat
ae
ae
p
correct
qt
interv
ae
ae
p
four
six
hors
af
group
experienc
ventricular
arrhythmia
follow
flecainid
infus
day
andor
wherea
none
control
experienc
side
effect
flecainid
efficaci
decreas
length
af
durat
could
use
hors
af
recent
onset
drug
caus
ventricular
arrhythmia
use
caution
aim
quantifi
beattobeat
heart
rate
variabl
hrv
healthi
hors
standardis
ridden
exercis
test
sret
determin
level
fit
influenc
hrv
sret
perform
hors
use
pleasur
ride
group
p
use
medium
level
event
competit
group
e
veloc
hr
blood
lactat
concentr
ecg
record
ecg
correct
artefact
arrhythmia
note
hrv
analysi
perform
gallop
segment
per
cent
beattobeat
variabl
calcul
perform
indic
veloc
blood
lactat
mmoll
v
veloc
hr
min
v
calcul
group
p
lower
v
v
compar
group
e
mean
v
ae
sd
group
p
ae
ms
e
ae
ms
p
mean
v
ae
sd
group
p
ae
ms
e
ae
ms
p
four
group
p
group
e
hors
arrhythmia
gallop
phase
exercis
test
beat
beat
variat
gallop
phase
low
median
percentil
group
p
e
differ
group
p
hors
use
pleasur
ride
lower
perform
indic
v
v
hors
use
higher
level
event
competit
fit
level
influenc
low
beattobeat
variabl
seen
popul
hors
arrhythmia
detect
healthi
hors
ridden
exercis
infrequ
influenc
beattobeat
hrv
group
ridden
hors
similarbeat
tobeat
hrv
seen
addit
studi
use
differ
data
set
exercis
highspe
treadmil
dysfunct
hypothalamicpituitaryadren
axi
hpaa
manifest
rel
adren
insuffici
rai
critic
ill
relat
corticosteroid
insuffici
circi
associ
sepsi
mortal
newborn
foal
hpaa
dysfunct
adren
gland
cortisol
level
well
document
critic
ill
foal
inform
hypothalam
corticotropin
releas
hormon
crh
pituitari
adrenocorticotropin
acth
level
lack
hypothes
septic
foal
hpaa
activ
three
level
degre
activ
link
diseas
sever
mortal
propos
crh
acth
defici
occur
critic
ill
foal
associ
diseas
sever
mortal
blood
sampl
collect
admiss
septic
sepsi
score
sick
nonsept
sn
healthi
foal
day
age
blood
concentr
crh
acth
cortisol
determin
radioimmunoassay
crh
acth
defici
defin
valu
upper
level
confid
interv
valu
healthi
foal
hormon
valu
normal
rang
critic
ill
foal
consid
inappropri
crh
acth
cortisol
concentr
higher
septic
sn
healthi
foal
p
nonsurviv
foal
higher
crh
acth
concentr
survivor
p
twenti
one
percent
septic
foal
crh
acth
cortisol
defici
respect
septic
foal
hypocortisolemia
also
decreas
crh
acth
concentr
increas
crhacth
ratio
compar
septic
foal
adequ
cortisol
releas
p
compon
hpaa
activ
critic
ill
foal
septic
foal
demonstr
hpaa
dysfunct
hypocortisolemia
well
acth
crh
insuffici
high
crhacth
ratio
septic
foal
hypocortisolemia
suggest
pituitari
dysfunct
addit
adrenocort
insuffici
hyperinsulinemia
insulin
resist
associ
condit
hors
insulin
secret
increas
tissu
insulin
sensit
decreas
hypothes
insulinresist
ir
hors
would
increas
insulin
stain
pancreat
islet
compar
insulinsensit
hors
twentythre
hors
assign
n
ir
n
group
basi
frequentlysampl
intraven
glucos
toler
test
minim
model
analysi
fast
insulin
concentr
human
euthanasia
perform
reason
studi
pancrea
sampl
obtain
immunohistochem
analysi
pancrea
tissu
stain
insulin
glucagon
somatostatin
digit
imag
analyz
determin
express
hormon
rel
total
islet
area
signific
differ
insulin
stain
detect
group
hypothesi
support
ir
hors
significantli
less
glucagon
within
pancreat
islet
hors
median
interquartil
rang
percentag
total
islet
area
stain
posit
glucagon
total
islet
area
ir
hors
compar
hors
p
immunoreact
glucagon
insulin
somatostatin
present
approxim
total
islet
area
respect
conclud
insulin
express
differ
ir
group
evid
insulin
resist
increas
insulin
secret
within
pancreat
islet
lower
glucagon
express
ir
hors
may
result
compensatori
downregul
hormon
secret
respons
hyperinsulinemia
hyperglycemia
insulin
dysregul
id
specif
hyperinsulinemia
identifi
caus
lamin
certain
breed
seemingli
suscept
understand
breed
differ
insulin
respons
measur
lipid
metabolismadipokin
may
critic
identifi
truli
risk
individu
insulinmodifi
frequent
sampl
intraven
glucos
toler
test
fsigtt
n
oral
sugar
test
ost
n
perform
along
assess
marker
lipid
metabolismadipokin
n
breed
quarter
hors
qh
arabian
morgan
welsh
poni
wp
thoroughbr
minim
model
analys
fsigtt
insulin
sensit
si
acut
insulin
respons
glucos
airg
disposit
index
di
glucos
mediat
glucos
dispos
sg
lowest
glucos
valu
gmin
deflect
glucos
baselin
dgb
assess
ost
insulin
threshold
trajectori
area
curv
auc
assess
statist
includ
multilevel
regress
analysi
regress
model
time
trajectori
oneway
anova
kruskalw
test
roc
curv
analysi
signific
p
qh
higher
si
breed
lower
airg
wp
arabian
higher
di
morgan
arabian
higher
airg
morgan
lower
sg
wp
morgan
lower
airg
wp
arabian
morgan
wp
lower
gmin
thoroughbr
morgan
greater
dgb
qh
differ
ost
insulin
threshold
id
exist
breed
ost
glucos
insulin
trajectori
auc
lowest
qh
signific
breed
differ
exist
nonesterifi
fatti
acid
high
molecular
weight
adiponectin
leptin
triglycerid
breed
specif
differ
import
consid
evalu
metabol
health
insulin
dysregul
specif
hyperinsulinemia
identifi
caus
lamin
muscl
adipos
tissu
larg
role
insulin
regul
patholog
human
metabol
syndrom
role
well
interrog
hors
tailhead
adipos
tissu
n
middl
gluteal
muscl
n
biopsi
perform
equin
breed
quarter
hors
qh
arabian
morgan
welsh
poni
wp
relat
adipocyt
area
aa
muscl
fiber
type
percent
area
proport
bodi
condit
score
bc
total
bodi
fat
mass
tbfm
use
deuterium
dilut
techniqu
minim
model
paramet
frequent
sampl
intraven
glucos
toler
test
fsigtt
statist
includ
kolmogorovsmirnov
analysi
manova
spearman
correl
signific
set
p
overal
bc
weakli
moder
correl
insulin
sensit
si
acut
insulin
respons
glucos
airg
aa
tbfm
correl
si
weakli
correl
airg
aa
overal
moder
correl
aa
qh
qh
significantli
smaller
aa
arabian
wp
morgan
aa
weakli
relat
si
moder
airg
baselin
insulin
concentr
moder
correl
type
muscl
fiber
percent
area
proport
breed
differ
exist
muscl
fiber
type
area
proport
breed
differ
adipocyt
muscl
histolog
weak
correl
bc
tbfm
si
airg
suggest
adipos
may
key
factor
determin
metabol
fit
hors
equin
metabol
syndrom
em
cluster
metabol
disturb
result
insulin
dysregul
derang
fat
metabol
common
caus
lamin
previou
work
lab
confirm
pathophysiolog
em
complex
genet
environment
factor
contribut
phenotyp
variabl
metabol
trait
object
project
identifi
genom
region
contribut
em
perform
genomewid
associ
studi
gwa
cohort
welsh
poni
morgan
hors
phenotyp
metabol
trait
genotyp
perform
one
three
snp
array
snp
genotyp
imput
allow
gener
uniform
set
maker
across
platform
million
snp
gwa
perform
use
mix
linear
regress
model
sex
age
includ
covari
within
breed
total
welsh
poni
morgan
signific
loci
identifi
metabol
trait
share
breed
loci
defin
share
snp
pvalu
within
kb
window
specif
share
loci
identifi
insulin
level
post
oral
sugar
test
baselin
nonesterifi
fatti
acid
triglycerid
acth
respect
total
candid
gene
identifi
data
confirm
em
polygen
trait
risk
loci
uniqu
individu
breed
well
share
breed
futur
direct
includ
interrog
region
whole
genom
sequenc
relationship
insulin
dysregul
dietari
adapt
age
poorli
understood
yet
critic
make
dietari
recommend
hors
risk
insulin
dysregul
associ
lamin
studi
effect
age
diet
insulin
glucos
dynam
examin
healthi
thoroughbr
standardbr
hors
divid
two
group
adult
ae
year
mean
ae
sd
age
ae
year
four
concentr
isocalor
diet
base
low
starch
low
sugar
starch
base
plu
kibbl
corn
fiber
base
plu
beet
pulp
soybean
hull
sugar
base
plu
dextros
powder
fed
seven
week
balanc
fourway
crossov
hors
group
fed
low
nonstructur
carbohydr
hay
daili
individu
fed
concentr
meal
twice
daili
seventh
week
insulinmodifi
frequent
sampl
intraven
glucos
toler
test
oral
sugar
test
ost
mlkg
corn
syrup
perform
data
analyz
multivari
linear
mix
regress
signific
set
p
acut
insulin
respons
glucos
airg
ostpeak
insulin
insulin
area
curv
ostinsulin
minut
higher
age
adult
independ
diet
age
higher
airg
disposit
index
fiber
sugar
glucos
effect
sugar
adult
adapt
diet
adult
lower
ostinsulin
basal
fiber
compar
sugar
age
hors
higher
ostpeak
insulin
adult
fiber
age
diet
influenc
insulin
glucos
dynam
consid
evalu
hors
metabol
statu
diagnos
manag
hors
metabol
disord
includ
obes
challeng
due
poorli
understood
pathogenesi
lack
wellcharacter
risk
factor
therapeut
option
speci
differ
fecal
bile
acid
ba
fatti
acid
fa
sterol
recogn
metabol
diseas
howev
report
hors
thu
object
studi
compar
fecal
ba
sterol
fa
obes
nonobes
hors
fecal
sampl
collect
obes
hors
bodi
condit
score
bc
healthi
hors
bc
fecal
ba
fa
sterol
concentr
obtain
use
ga
chromatographi
coupl
mass
spectrometri
variabl
assess
normal
analyz
use
ttest
wilcoxon
rank
sum
test
assess
differ
group
total
sampl
analyz
includ
obes
hors
healthi
hors
signal
similar
group
seven
fa
sterol
ba
analyz
statist
differ
bile
acid
note
group
result
show
statist
significantli
lower
concentr
linol
acid
p
oleic
acid
p
stearic
acid
p
gondoic
acid
p
increas
cholesterol
concentr
p
obes
hors
understand
role
fecal
fa
sterol
hors
may
improv
understand
pathogenesi
metabol
diseas
lead
develop
diagnost
test
novel
therapeut
agent
eosinophil
periton
newli
describ
hypereosinophil
syndrom
hors
may
involv
abdomin
organ
infiltr
treatment
corticosteroid
may
result
remiss
antimicrobi
administr
consid
risk
factor
coliti
hors
subsequ
alter
resid
popul
gastrointestin
bacteria
may
result
dysmetabol
purpos
studi
investig
effect
metronidazol
commonli
prescrib
antibiot
anaerob
infect
cecal
fecal
microbiom
metabolom
hors
metronidazol
mgkg
po
h
administ
adult
hors
n
indwel
cecal
cannula
aup
fecal
cecal
sampl
taken
day
fecal
illumina
sequenc
rrna
gene
perform
extract
dna
data
analyz
use
quantit
insight
molecular
ecolog
qiim
analysi
similar
anosim
perform
univari
analysi
bacteri
group
perform
use
friedman
test
dunn
posttest
linear
discrimin
analysi
effect
size
lefs
use
find
bacteri
taxa
associ
studi
day
short
chain
fatti
acid
scfa
untarget
metabolom
analyz
use
mass
spectrometri
platform
alpha
divers
significantli
decreas
day
cecal
sampl
p
observ
otu
p
shannon
p
day
fecal
sampl
shannon
p
beta
divers
measur
weight
unifrac
distanc
show
signific
differ
day
cecal
fecal
sampl
anosim
p
lefs
analysi
reveal
sever
bacteri
taxa
christensenellacea
campylobacteriacea
spirochaetacea
significantli
alter
due
antibiot
administr
scfa
significantli
affect
metronidazol
metabolit
analyz
name
unnam
analysi
name
fecal
metabolit
found
significantli
differ
among
studi
day
metabolit
statist
signific
p
q
activ
biosynthesi
fatti
acid
steroid
protein
carbohydr
sucros
starch
name
cecal
metabolit
statist
differ
studi
day
p
fail
remain
signific
adjust
multipl
comparison
q
conclus
metronidazol
administr
chang
cecal
fecal
microbiom
metabolom
hors
effect
age
cortisol
equin
dendrit
cell
exposur
bacteria
ex
vivo
b
gorham
hurley
giguer
n
norton
giancola
k
hart
univers
georgia
athen
ga
usa
colleg
veterinari
medicin
univers
georgia
athen
ga
usa
dendrit
cell
dc
import
immun
respons
bacteria
foal
dc
function
well
character
monocytederiv
dc
modc
gener
foal
daysofag
adult
hors
modc
incub
hour
without
kill
escherichia
coli
staphlococc
aureu
antigen
presenc
absenc
cortisol
lgdl
modc
express
mhcii
measur
flow
cytometri
supernat
cytokin
concentr
ifngamma
ifnalpha
quantifi
fluoresc
beadbas
immunoassay
effect
age
cortisol
modc
variabl
determin
mixedeffect
linear
model
signific
p
percentag
cell
express
mhcii
lower
higher
modc
compar
hors
modc
p
bacteri
exposur
alon
alter
surfac
marker
express
foal
hors
cell
exposur
bacteria
cortisol
reduc
mhcii
express
foal
cell
p
follow
bacteri
exposur
modc
produc
significantli
less
ifngamma
ifnalpha
hors
modc
p
follow
bacteri
exposur
modc
produc
significantli
less
ifngamma
ifnalpha
hors
modc
p
foal
modc
exhibit
phenotyp
function
immatur
persist
first
month
life
compound
exposur
cortisol
thu
foal
dc
may
less
effect
activ
lymphocyt
respons
could
contribut
foal
increas
suscept
bacteri
sepsi
pulmonari
neutrophilia
characterist
find
sever
equin
asthma
sea
heav
also
common
moder
equin
asthma
mea
inflammatori
airway
diseas
mpxi
neutx
neuti
blood
neutrophil
activ
paramet
activ
myeloperoxidas
neutrophil
size
automat
provid
advia
hematolog
analyz
aim
studi
evalu
indic
healthi
asthmat
hors
corticosteroid
affect
retrospect
studi
mpxi
neutx
neuti
blood
mea
hors
sea
control
paramet
also
studi
hors
sea
control
administr
dexamethason
mgkg
po
sid
blood
collect
jugular
venipunctur
edta
vacutain
analyz
advia
hematolog
analyz
data
compar
use
student
ttest
one
way
anova
three
paramet
significantli
increas
blood
hors
sea
compar
control
mea
dexamethason
significantli
decreas
neutx
valu
sea
control
mpxi
neuti
significantli
reduc
sea
studi
describ
first
time
use
mpxi
neutx
neuti
equin
asthma
result
indic
neutrophil
activ
sea
mea
control
howev
diagnost
valu
paramet
equin
asthma
limit
due
data
overlap
group
furthermor
effect
dexamethason
mpxi
neutx
neuti
taken
account
monitor
paramet
hors
stallsid
serum
amyloid
saa
assay
recent
increas
avail
result
widespread
use
saa
identifi
diseas
process
requir
investig
diagnost
modal
treatment
decis
often
made
basi
high
chang
saa
valu
object
studi
improv
correl
serum
amyloid
plasma
fibrinogen
neutrophil
count
assess
use
saa
screen
tool
identifi
infecti
diseas
random
studi
equin
patient
present
uc
davi
veterinari
medic
teach
hospit
inclus
criteria
complet
blood
count
cbc
submiss
saa
sampl
run
whole
blood
use
stablelab
later
flow
immunoassay
hors
classifi
group
use
clinic
diagnost
modal
vmth
medic
record
refer
cbc
saa
result
aid
classif
group
includ
healthi
n
healthi
recent
vaccin
n
inflammatori
noninfecti
n
inflammatori
infecti
n
nonhealthi
noninflammatori
n
median
saa
valu
inflammatori
noninfecti
inflammatori
infecti
significantli
differ
mgml
mgml
respect
refin
model
saa
valu
categor
normal
low
medium
high
rang
saa
normal
healthi
group
nonhealthi
noninflammatori
group
high
elev
mgml
mainli
distribut
inflammatori
infecti
group
none
healthi
group
saa
valu
medium
high
rang
correl
well
abnorm
white
blood
cell
count
fibrinogen
data
set
statist
analyz
among
three
unhealthi
group
inflammatori
infecti
n
compar
two
group
noninfecti
n
compar
infecti
noninfecti
group
saa
valu
time
like
within
medium
rang
time
like
within
high
rang
mgml
sensit
saa
alon
overal
accuraci
combin
elev
saa
abnorm
neutrophil
count
hyperfibrinogenemia
improv
sensit
overal
accuraci
correctli
identifi
underli
infecti
inflammatori
process
conclus
serum
amyloid
perform
held
greater
overal
accuraci
compar
neutrophil
count
fibrinogen
individu
combin
defin
infecti
versu
noninfecti
diseas
use
conjunct
neutrophil
count
fibrinogen
saa
enhanc
accuraci
differenti
diseas
statu
stall
side
assay
found
excel
screen
tool
howev
normal
saa
rule
inflamm
high
saa
definit
infect
hematolog
paramet
high
variabl
among
individu
object
current
ongo
studi
investig
presenc
ecov
fece
hors
hospit
enter
diseas
n
orthoped
condit
n
fecal
sampl
collect
admiss
h
thereaft
presenc
ecov
evalu
use
electron
microscopi
em
revers
transcript
polymeras
rtpcr
categor
analys
perform
use
kruskalw
test
determin
associ
observ
age
breed
sex
clinic
sign
clinicopatholog
data
em
rtpcr
result
preliminari
data
show
hors
enter
diseas
posit
ecov
hospit
hors
follow
clinicopatholog
abnorm
fever
elev
liver
valu
hepat
lipidosi
sand
enteropathi
far
ecov
detect
orthoped
group
n
interestingli
discrep
em
rtpcr
result
note
ongo
studi
current
investig
result
current
studi
show
ecov
detect
small
percentag
hors
enter
diseas
common
find
hors
orthoped
condit
also
inconsist
agreement
em
rtpcr
result
emphas
diagnosi
ecov
confound
limit
sensit
specif
data
current
avail
diagnost
test
four
hors
experiment
infect
frozen
fece
contain
approxim
genom
equival
ecovg
fece
collect
intestin
lumen
hors
diagnos
ecov
necropsi
four
addit
hors
expos
daili
fece
experiment
challeng
hors
monitor
includ
twice
daili
physic
examin
daili
nasal
swab
blood
fecal
collect
quantit
molecular
detect
ecov
blood
collect
everi
day
hematolog
analysi
prior
experiment
infect
weekli
thereaft
serolog
analysi
eight
hors
show
evid
fecal
shed
ecov
qpcr
six
eight
hors
exhibit
mild
clinic
diseas
softform
manur
one
hors
exhibit
transient
pyrexia
hors
maintain
total
white
cell
count
within
normal
limit
though
hors
develop
mild
transient
lymphopenia
statist
signific
differ
p
quantiti
fecal
shed
experiment
infect
hors
hors
expos
ecovcontain
fece
experiment
infect
adult
hors
ecov
associ
mild
selflimit
clinic
sign
transient
lymphopenia
fecal
shed
ecov
experiment
infect
mimic
natur
infect
morbid
rate
vari
although
number
hors
group
rel
small
differ
experiment
infect
hors
hors
expos
ecovcontain
fece
studi
support
fecoor
rout
transmiss
hors
undergo
cem
quarantin
octob
june
veterinari
exam
nasal
secret
collect
time
entri
develop
acut
respiratori
sign
quarantin
sampl
assay
equin
influenza
viru
eiv
equin
herp
viru
equin
rhiniti
viru
b
erv
streptococcu
equi
subspeci
equi
use
qpcr
found
nasal
swab
respect
identifi
hors
n
detect
hors
hors
qpcr
posit
multipl
ehv
type
qpcr
posit
hors
symptomat
sampl
hors
qpcrposit
asymptomat
time
respect
clinic
respiratori
abnorm
seen
qpcr
neg
hors
eiv
erv
detect
sampl
howev
sampl
fail
qualiti
control
equi
recov
hors
clinic
sign
poorli
correl
qpcr
neg
qpcr
posit
posit
hors
clinic
affect
commonli
shed
signific
acut
respiratori
diseas
question
shed
hors
could
seriou
consequ
anim
introduc
larg
mix
popul
suscept
hors
upon
entri
usa
foal
immunolog
birth
mean
exposur
foreign
antigen
therefor
yet
mount
type
protect
immun
respons
accumul
signific
level
immunoglobulin
ig
ingest
absorpt
immunoglobulinrich
colostrum
sole
mean
passiv
transfer
foal
provid
temporari
protect
infect
first
month
life
current
recommend
optim
colostr
antibodi
transfer
mare
foal
includ
vaccin
mare
week
prior
parturit
practic
recommend
increas
serum
antibodi
level
dam
therefor
mare
would
concentr
higher
level
ig
colostrum
final
two
week
gestat
although
manag
practic
wide
accept
adequ
substanti
use
evidencedbas
medicin
adequ
control
studi
purpos
studi
determin
vaccin
pregnant
mare
approxim
week
prior
foal
increas
igg
antibodi
transfer
foal
specif
west
nile
viru
wnv
equin
influenza
viru
eiv
twentyseven
pregnant
adult
tennesse
walk
hors
twh
mare
rang
age
year
enrol
studi
mare
confirm
foal
via
rectal
palpat
confirm
via
ultrasound
mare
random
three
treatment
group
control
group
previou
vaccin
vaccin
administ
studi
vaccin
group
initi
vaccin
seri
revaccin
week
prior
foal
vaccin
group
initi
vaccin
seri
prefoal
revaccin
mare
administ
vetera
wnv
eastern
western
enceph
equin
influenza
clade
wnv
label
safe
use
pregnant
mare
follow
parturit
blood
collect
process
foal
determin
igg
level
passiv
immun
serum
aliquot
frozen
serum
ship
gluck
equin
research
center
lexington
ky
measur
serum
hemagglutinationinhibit
hi
equin
influenza
viru
antibodi
level
florida
clade
florida
clade
refer
strain
sampl
ship
cornel
anim
health
diagnost
center
ithaca
ny
analysi
wnv
igg
antibodi
level
measur
elisa
mean
antibodi
level
report
accompani
standard
deviat
confid
interv
serolog
titer
valu
quantifi
limit
report
valu
substitut
analys
provid
conserv
estim
null
hypothesi
vaccin
effect
test
mix
model
repeat
measur
methodolog
subject
random
effect
pairwis
comparison
report
vaccin
group
model
run
separ
refer
strain
p
valu
consid
statist
signific
foal
mare
initi
vaccin
seri
revaccin
week
prior
foal
significantli
higher
wnv
antibodi
level
p
compar
foal
nonvaccin
mare
foal
also
significantli
p
higher
elisa
wnv
antibodi
level
compar
foal
mare
administ
initi
two
vaccin
seri
signific
differ
p
elisa
wnv
antibodi
level
foal
mare
foal
unvaccin
mare
foal
mare
significantli
p
higher
eiv
florida
clade
antibodi
level
compar
foal
nonvaccin
mare
although
arithmet
mean
eiv
florida
clade
antibodi
level
greater
foal
mare
compar
foal
mare
signific
differ
p
signific
p
differ
eiv
florida
clade
antibodi
level
foal
mare
compar
foal
unvaccin
mare
foal
mare
significantli
p
higher
eiv
florida
clade
antibodi
level
compar
foal
nonvaccin
mare
although
arithmet
mean
eiv
florida
clade
antibodi
level
mare
greater
foal
mare
signific
differ
p
identifi
signific
p
differ
eiv
florida
clade
antibodi
level
foal
mare
compar
foal
unvaccin
mare
foal
mare
vaccin
initi
seri
revaccin
week
prior
parturit
significantli
higher
level
elisa
wnv
eiv
clade
passiv
transfer
antibodi
hour
follow
parturit
result
studi
support
import
recommend
vaccin
broodmar
week
foal
protect
importantli
maxim
concentr
immunoglobulin
colostrum
passiv
transfer
foal
purpos
pilot
studi
determin
creactiv
protein
crp
serum
amyloid
saa
increas
equin
protozo
myeloenceph
epm
compar
neurolog
diseas
accur
antemortem
epm
diagnosi
requir
evid
intrathec
antibodi
product
eg
serum
csf
titer
ratio
advoc
use
acut
phase
protein
addit
serolog
alon
result
substanti
fals
posit
serum
csf
crp
saa
measur
case
equin
neurolog
diseas
epm
cervic
vertebr
stenot
myelopathi
cvsm
neuroborreliosi
equin
motor
neuron
diseas
degen
myelopathi
leukoencephalomalacia
nine
epm
case
serum
csf
titer
ratio
untest
epm
case
confirm
postmortem
epm
case
nine
cvsm
case
confirm
postmortem
case
posit
myelogram
titer
ratio
remain
case
diagnos
postmortem
exam
serum
crp
elev
case
serum
saa
elev
two
case
neuroborreliosi
mgl
mgl
refer
mgl
suggest
saa
may
aid
diagnosi
test
warrant
neither
serum
crp
saa
increas
case
epm
cvsm
cerebrospin
fluid
crp
saa
also
fail
differenti
case
epm
crp
median
mgl
rang
mgl
saa
median
mgl
rang
mgl
cvsm
crp
median
mgl
rang
mgl
saa
median
mgl
rang
mgl
recurr
exert
rhabdomyolysi
rer
affect
race
thoroughbr
standardbr
potenti
quarter
hors
genet
basi
propos
substanti
dysregul
sarcoplasm
reticulum
calcium
cycl
suggest
caus
rer
hypothes
calcium
dysregul
rer
hors
could
impact
gene
encod
newli
discov
micropeptid
sarcolipin
sln
myoregulin
mrln
dworf
phospholamban
pln
modifi
activ
sarcoplasm
reticulum
calcium
atpas
serca
purpos
studi
determin
gene
express
sln
mrln
dworf
pln
equin
muscl
code
sequenc
micropeptid
potenti
differ
code
sequenc
control
rer
thoroughbr
rer
standardbr
rer
quarter
hors
gene
express
determin
gluteal
muscl
hors
use
next
gener
sequenc
sanger
sequenc
sln
mrln
dworf
perform
dna
isol
blood
muscl
tissu
minimum
rer
hors
per
gene
control
hors
select
neuromuscular
diagnost
laboratori
sln
predomin
regulatori
micropeptid
gluteal
muscl
sever
hundr
fold
higher
gene
express
plb
mrln
unlik
studi
mammalian
speci
equin
sln
encod
truncat
protein
vs
amino
acid
miss
key
regulatori
residu
propos
mediat
control
revers
serca
inhibit
contrast
equin
mln
one
conserv
amino
acid
substitut
dworf
nonconserv
amino
acid
substitut
pln
ortholog
speci
nonsynonym
mutat
sln
mln
dworf
identifi
rer
hors
compar
control
hors
conclud
sln
key
regul
serca
equin
muscl
conserv
sln
uniqu
regulatori
peptid
hors
suggest
evolutionari
advantageslightli
elev
myoplasm
calciumwhich
enhanc
muscl
power
output
rer
howev
appear
aris
distinct
mutat
sln
mrln
dworf
breed
total
phenotyp
varianc
explain
snp
test
snp
partit
base
estim
effect
size
tb
snp
small
moder
larg
effect
account
phenotyp
variabl
respect
similarli
stdb
small
moder
larg
effect
snp
explain
variabl
respect
genomewid
associ
studi
gwa
identifi
seven
genom
region
interest
roi
significantli
associ
rer
tb
n
stdb
n
hors
two
tb
four
stdb
one
share
locu
gene
within
roi
comput
predict
candid
gene
rhabdomyolysi
human
variant
roi
identifi
use
whole
genom
sequenc
rer
control
breed
total
variant
discov
roi
averag
variant
per
kb
variant
within
gene
put
function
effect
variant
priorit
base
segreg
rer
control
hors
predict
function
effect
highprior
variant
use
creat
assay
genotyp
entir
gwa
popul
sepsi
score
ss
use
diagnos
assum
presenc
sepsi
newborn
foal
last
thirti
year
howev
clinic
experi
recent
valid
studi
suggest
ss
accur
predict
sepsi
origin
studi
therefor
novel
score
methodth
foal
surviv
score
fss
recent
develop
predict
likelihood
surviv
sick
newborn
foal
base
sensit
specif
fss
good
abil
predict
surviv
howev
associ
fss
sever
ill
remain
determin
lower
fss
like
foal
die
high
ss
indic
sever
diseas
hypothes
fss
good
predictor
diseas
sever
compar
ss
outcom
hospit
foal
foal
day
age
classifi
type
diseas
group
base
clinic
laboratori
find
system
inflammatori
respons
syndrom
sir
n
sepsi
n
multipl
organ
dysfunct
syndrom
mod
n
healthi
foal
n
multinomi
regress
model
odd
ratio
calcul
predict
type
diseas
median
fss
invers
associ
ss
foal
mod
sepsi
sir
low
fss
compar
healthi
foal
p
probabl
sir
sepsi
mod
decreas
increas
fss
compar
healthi
foal
respect
p
increas
ss
associ
higher
likelihood
sir
sepsi
mod
compar
healthi
foal
p
foal
surviv
higher
fss
lower
ss
nonsurvivor
p
likelihood
surviv
increas
higher
fss
decreas
higher
ss
hospit
foal
p
studi
demonstr
fss
use
score
method
determin
diseas
sever
addit
predict
surviv
critic
ill
foal
futur
research
need
establish
specif
cutoff
valu
fss
diagnos
type
neonat
diseas
torsemid
loop
diuret
agent
potent
furosemid
oral
administr
demonstr
high
bioavail
across
speci
aim
studi
determin
pharmacokinet
profil
oral
torsemid
hors
torsemid
administ
intragastr
singl
dose
mgkg
six
healthi
adult
mare
blood
sampl
collect
predetermin
time
point
period
hour
plasma
torsemid
concentr
measur
use
high
perform
liquid
chromatographi
serum
biochem
profil
examin
student
ttest
bonferroni
correct
use
identifi
differ
pharmacokinet
biochem
paramet
baselin
pre
hour
post
drug
administr
post
statist
signific
set
p
pharmacokinet
analysi
reveal
peak
concentr
c
max
ae
lgml
time
maximum
concentr
max
ae
h
area
curv
auc
ae
lg
h
ml
elimin
halflif
ae
h
significantli
increas
concentr
creatinin
pre
median
mgdl
rang
mgdl
post
median
mgdl
rang
mgdl
p
bicarbon
pre
median
mmoll
rang
mmoll
post
median
mmoll
rang
mmoll
p
note
chlorid
concentr
markedli
decreas
pre
median
mmoll
rang
mmoll
post
median
mmoll
rang
mmoll
p
oral
torsemid
success
reach
therapeut
concentr
blood
result
mild
preren
azotemia
electrolyt
chang
result
suggest
oral
torsemid
may
employ
clinic
use
diuret
agent
manag
congest
heart
failur
fluid
retent
hors
diuret
therapi
limit
inject
formul
hors
due
poor
absorpt
oral
furosemid
purpos
studi
determin
whether
oral
torsemid
produc
clinic
signific
diuresi
healthi
hors
torsemid
administ
oral
mgkgday
healthi
adult
mare
day
fr
foley
urinari
cathet
urin
collect
bag
use
measur
urin
output
urin
specif
graviti
usg
hour
day
blood
sampl
collect
daili
serum
biochem
analysi
noninvas
mean
arteri
pressur
map
measur
daili
tail
cuff
student
ttest
bonferroni
correct
use
analyz
differ
laboratori
paramet
day
pre
day
post
urin
output
median
rang
significantli
increas
torsemid
torsemid
administ
oral
induc
clinic
signific
diuresi
mild
preren
azotemia
electrolyt
chang
result
suggest
oral
torsemid
therapi
could
help
overcom
current
therapeut
limit
hors
excess
fluid
retent
macrolid
antimicrobi
histor
associ
sever
advers
gastrointestin
effect
administ
adult
hors
howev
desir
antimicrobi
use
lower
respiratori
tract
diseas
recent
anecdot
result
suggest
efficaci
adult
hors
without
high
incid
advers
effect
object
studi
investig
associ
develop
diarrhea
adult
hors
foal
administ
macrolid
antimicrobi
versu
class
antimicrobi
treatment
lower
respiratori
tract
diseas
one
hundr
fiftyeight
hors
adult
foal
admit
referr
centr
diagnos
pneumonia
pleuropneumonia
pleuriti
administ
system
antimicrobi
includ
retrospect
studi
inform
obtain
medic
record
includ
age
admiss
breed
sex
antimicrobi
administ
hospit
clinic
diagnosi
clinic
outcom
presenc
absenc
diarrhea
macrolid
treatment
erythromycin
azithromycin
clarithromycin
without
rifampin
compar
treatment
combin
antimicrobi
relationship
age
antimicrobi
use
develop
diarrhea
investig
pearson
chisquar
fisher
exact
test
appli
p
includ
odd
ratio
confid
interv
macrolid
pharmacokinet
evalu
lithium
chlorid
licl
administ
healthi
adult
hors
intraven
iv
bolu
report
exist
valid
rapid
procedur
determin
plasma
lithium
li
concentr
hors
order
monitor
therapeut
level
avoid
toxic
goal
studi
determin
iv
bolu
pharmacokinet
paramet
li
healthi
adult
hors
compar
agreement
two
method
measur
plasma
li
concentr
spectrophotometr
enzymat
assay
sea
induct
coupl
plasma
mass
spectrometri
icpm
refer
method
lithium
chlorid
administ
mmolkg
bwt
iv
bolu
lithium
concentr
measur
time
pre
licl
administr
min
h
post
licl
administr
healthi
adult
hors
n
perform
outcom
sea
assess
use
follow
criteria
linearityofdilut
interday
coeffici
variat
cv
spikeandrecoveri
two
method
sea
icpm
plasma
li
concentr
measur
compar
agreement
pharmacokinet
paramet
determin
base
refer
icpm
data
iv
licl
bolu
well
toler
side
effect
observ
sea
show
accept
linear
r
interday
cv
recoveri
noncompartment
compartment
analys
tradit
twostag
nonlinear
mixedeffect
nlme
model
perform
geometr
mean
valu
noncompartment
paramet
plasma
li
concentr
time
zero
mm
termin
elimin
halflif
min
area
plasma
concentrationtim
curv
time
zero
infin
mm
min
clearanc
mlmin
kg
mean
resid
time
min
volum
distribut
steadi
state
mlkg
result
tradit
twostag
analysi
show
good
agreement
nlme
model
approach
blandaltman
analys
demonstr
poor
agreement
sea
icpm
method
therapeut
li
concentr
rang
limit
agreement
ae
mm
lithium
chlorid
dose
mmolkg
bwt
iv
bolu
well
toler
healthi
adult
hors
display
pharmacokinet
paramet
similar
report
speci
sea
display
accept
intern
valid
agre
well
icpm
result
studi
support
evalu
licl
clinic
use
previou
invitro
studi
use
voriconazolepoli
lacticcoglycol
acid
bpoli
ethylen
glycol
bpoli
lacticcoglycol
acid
thermogel
vorigel
demonstr
sustainedreleas
voriconazol
therapeut
concentr
equin
ocular
fungal
pathogen
object
evalu
safeti
voriconazol
concentr
ocular
tissu
aqueou
humor
ah
follow
subconjunctiv
inject
vorigel
hors
six
normal
hors
receiv
topic
voriconazol
voritop
everi
hour
day
subconjunctiv
inject
vorigel
washout
altern
eye
tear
ah
collect
day
voritop
day
vorigel
evalu
ocular
tissu
concentr
hors
receiv
subconjunctiv
inject
vorigel
day
hr
euthanasia
altern
eye
voriconazol
concentr
measur
high
perform
liquid
chromatographi
evalu
use
student
ttest
descript
statist
ocular
inflamm
assess
use
modifi
hackettmcdonald
score
system
neither
vorigel
voritop
caus
chang
ocular
inflammatori
score
voriconazol
concentr
tear
day
differ
treatment
voriconazol
concentr
ah
vorigel
detect
quantifi
day
voriconazol
concentr
ugg
detect
anterior
segment
tissu
hr
day
vorigel
inject
subconjunctiv
inject
vorigel
safe
normal
hors
low
ah
tear
concentr
like
due
intact
ocular
barrier
high
drug
lipophil
sustain
releas
therapeut
concentr
voriconazol
vorigel
anterior
segment
tissu
least
day
follow
inject
diagnosi
inflammatori
airway
diseas
iad
commonli
base
abnorm
bronchoalveolar
lavag
fluid
balf
cytolog
airway
hyperreact
ahr
hors
poor
perform
chronic
cough
studi
purpos
determin
whether
two
modal
noninvas
lung
function
test
fomforc
oscillatori
mechan
vs
riprespiratori
induct
plethysmographi
establish
clinic
diagnosi
ahr
use
histamin
bronchoprovoc
ahr
defin
histamin
dose
need
doubl
fom
baselin
resist
achiev
increas
rip
delta
flow
nineteen
hors
year
kg
clinic
sign
suggest
iad
randomli
assign
undergo
fom
rip
test
consecut
day
balf
subsequ
collect
stain
modifi
wright
toluidin
blue
stain
categor
data
compar
group
use
chisquar
analysi
abnorm
balf
cytolog
confirm
iad
hors
fom
rip
reveal
ahr
iad
hors
addit
hors
show
ahr
base
sole
rip
test
includ
hors
normal
balf
cytolog
diagnosi
ahr
often
associ
rip
fom
test
p
although
preval
ahr
significantli
higher
iad
vs
noniad
hors
regardless
test
methodolog
phase
angl
thorac
abdomin
compon
breath
differ
patient
group
conclus
rip
diagnos
ahr
frequent
fom
includ
hors
diagnost
evid
iad
without
evalu
two
test
modal
ahr
use
interchang
previou
studi
reveal
equin
commonli
isol
lung
hors
diagnos
equin
multinodular
pulmonari
fibrosi
empf
suggest
etiolog
link
current
studi
assess
impact
valacyclovir
treatment
viral
kinet
empf
case
object
studi
determin
effect
valacyclovir
treatment
viral
load
measur
quantiti
pcr
blood
nasal
swab
bronchoalveolar
lavag
fluid
four
hors
empf
treat
day
oral
valacyclovir
diagnosi
empf
base
histopatholog
find
detect
qpcr
lung
tissu
sequenti
blood
nasal
swab
bronchoalveolar
lavag
fluid
sampl
collect
analyz
viral
kinet
day
treatment
statist
differ
median
viral
load
two
time
point
three
sampl
type
test
viral
load
blood
day
rang
median
gb
gene
copiesmillion
cell
day
rang
median
gb
gene
copiesmillion
cell
viral
load
nasal
secret
day
rang
median
day
rang
median
viral
load
bronchoalveolar
lavag
fluid
day
rang
median
gb
gene
copiesmillion
cell
day
rang
median
gb
gene
copiesmillion
cell
valacyclovir
rel
expens
drug
routin
use
treat
hors
empf
studi
reveal
day
valacyclovir
treatment
significantli
alter
viral
kinet
measur
qpcr
nasal
swab
blood
bronchoalveolar
lavag
fluid
sampl
exerciseinduc
pulmonari
hemorrhag
eiph
diagnos
sever
assess
postexercis
tracheobronchoscop
examin
tbe
andor
enumer
erythrocyt
rbc
bronchoalveolar
lavag
fluid
balf
tbe
eiph
score
rang
indic
eiph
balf
rbc
indic
eiph
scant
inform
regard
relationship
tbe
eiph
score
balf
rbc
number
hypothes
balf
rbc
weakli
correl
r
tbe
score
tbe
follow
bal
perform
time
differ
hors
treadmil
hors
run
racetrack
hors
run
barrel
race
hors
run
exercis
tbe
eiph
score
rang
n
n
rbc
number
rang
eleven
tbe
score
despit
rbc
count
exam
tbe
score
balf
rbc
count
relationship
tbe
score
balf
rbc
number
signific
weak
p
r
spearman
evalu
tbe
eiph
score
weakli
correl
balf
rbc
number
larg
rang
balf
rbc
associ
tbe
score
eiph
score
rule
occurr
eiph
neither
balf
rbc
count
latter
find
unexpect
may
explain
fast
clearanc
respiratori
tract
lavag
airway
segment
one
bleed
possibl
technic
error
count
rbc
sampl
discount
exerciseinduc
pulmonari
hemorrhag
eiph
refer
presenc
blood
airway
caus
strenuou
exercis
document
race
polo
event
hors
littl
known
eiph
barrel
race
hors
purpos
studi
test
presenc
eiph
barrel
race
hors
estim
preval
pacif
northwest
determin
whether
relationship
eiph
perform
exist
studi
enrol
barrel
race
hors
compet
event
wa
id
mt
obtain
owner
consent
data
collect
includ
signal
illnessrespiratori
histori
race
divis
race
day
medic
tracheobronchoscopi
score
base
quantiti
blood
trachea
blood
larg
amount
throughout
trachea
erythrocyt
count
obtain
bronchoalveolar
lavag
fluid
statist
analysi
includ
logist
regress
chi
squar
fisher
exact
ttest
linear
regress
calcul
correl
coeffici
signific
set
p
preval
eiph
studi
hors
ran
faster
significantli
greater
likelihood
bleed
p
bleed
significantli
affect
perform
although
hors
bled
finish
lower
hors
nt
bleed
signific
p
posit
linear
relationship
tracheal
score
bal
erythrocyt
count
shown
correl
coeffici
test
poor
r
studi
show
eiph
present
barrel
race
hors
pacif
northwest
may
impact
perform
long
term
effect
eiph
variabl
requir
studi
cardiac
arrhythmia
notabl
atrial
fibril
link
poor
perform
recent
studi
draft
warmblood
breed
like
present
atrial
fibril
comparison
light
breed
except
standardbr
knowledg
data
describ
popul
competit
readi
draft
hors
object
determin
preval
silent
cardiac
arrhythmia
popul
draft
hors
conveni
sampl
draft
hors
studi
michigan
great
lake
intern
draft
hors
show
inform
gather
hors
includ
signal
histori
poor
perform
upper
airway
nois
myopathi
cardiac
arrhythmia
murmur
hors
auscult
side
thorax
second
electrocardiograph
ecg
record
taken
use
handheld
record
devic
transmit
smart
phone
alivecor
ecg
record
evalu
rhythm
heart
rate
pr
interv
rr
interv
measur
studi
popul
includ
percheron
belgian
clydesdal
belgian
mule
shire
percheron
mule
arrhythmia
found
four
hors
atrial
fibril
ventricular
prematur
depolar
second
degre
atrioventricular
block
none
hors
histori
poor
perform
known
cardiac
arrhythmia
conclud
preval
silent
arrhythmia
wellcondit
competit
draft
hors
low
frequent
measur
ventricular
volum
echocardiographi
hors
perform
use
paramet
obtain
mmode
teichholz
formula
appli
calcul
ventricular
volum
eject
fraction
american
societi
echocardiographi
recent
recommend
use
clinic
set
instead
simpson
method
disc
smod
recommend
updat
cardiac
chamber
quantif
guidelin
high
level
evid
veterinari
medicin
diagnost
superior
smod
versu
mmode
measur
similar
differ
breed
dog
doberman
pinscher
boxer
giant
breed
sighthound
aim
studi
establish
breedspecif
refer
interv
enddiastol
volum
edv
endsystol
volum
esv
biplanar
simpson
method
disc
smod
healthi
argentina
chair
hors
hypothes
hors
appar
diagnost
success
smod
similar
especi
high
perform
breed
sport
aptitud
studi
argentina
chair
hors
appropri
health
state
confirm
clinic
examin
ecg
echocardiographi
laboratori
test
recruit
hors
evid
system
diseas
cardiovascular
alter
exclud
hors
evalu
without
sedat
mmode
measur
perform
right
parastern
left
parastern
view
ventricular
volum
obtain
smod
mmode
index
bodi
surfac
area
bsa
refer
interv
smod
without
weight
normal
establish
use
right
parastern
left
parastern
view
volum
obtain
view
compar
well
gender
age
use
pair
ttest
normal
distribut
appar
volum
obtain
smod
mmode
compar
use
ttest
refer
interv
report
confidenti
pvalu
consid
statist
signific
index
volum
normal
distribut
accord
kolmogorovsmirnov
test
p
volum
obtain
smod
view
demonstr
modest
agreement
student
ttest
p
breedspecif
refer
interv
mlm
mlm
index
enddiastol
volum
edvi
index
endsystol
volum
esvi
respect
differ
index
volum
obtain
mare
male
p
well
age
group
p
howev
differ
volum
obtain
smod
method
onedimension
mmode
p
volum
deriv
mmode
signific
differ
left
right
parastern
view
p
conclus
studi
provid
echocardiograph
refer
interv
smodderiv
left
ventricular
volum
breed
aptitud
equestrian
sport
sport
stress
activ
cardiovascular
effort
athlet
hors
greater
indexedvolum
provid
studi
may
possibl
abil
recogn
earli
hors
diminish
athlet
perform
associ
cardiovascular
comorbid
ppid
well
character
endocrin
disord
temper
climat
northern
hemispher
howev
descript
tropic
subtrop
climat
southern
hemispher
scarc
analysi
review
case
ppid
report
southern
hemispher
describ
case
univers
queensland
reflect
differ
present
clinic
featur
diseas
variabl
associ
lamin
insulin
dysregul
surviv
report
ninetynin
case
includ
poni
hors
diagnos
ppid
either
basal
acth
dexamethason
suppress
test
common
clinic
sign
tachypnoea
anhidrosi
hypertrichosishirsut
weight
loss
polyuriapolydipsia
lame
common
clinicopatholog
abnorm
hypophosphataemia
investig
lamin
diagnos
case
insulin
dysregul
gastrointestin
parasit
pergolid
administ
case
dose
mgkg
increas
mgkg
period
month
eighti
percent
show
clinic
improv
surviv
factor
associ
lamin
younger
age
p
absenc
weight
loss
p
factor
associ
insulin
dysregul
younger
age
p
durat
clinic
sign
p
need
higher
dose
pergolid
p
factor
associ
surviv
clinic
improv
p
studi
show
commonli
describ
featur
ppid
found
southern
hemispher
unusu
find
also
warrant
investig
endocrin
disord
cortisol
commonli
use
indic
physiolog
stress
tradit
sampl
eg
blood
urin
saliva
measur
cortisol
secret
proven
adequ
assess
short
term
acut
respons
stress
hair
cortisol
concentr
hcc
increasingli
use
assess
longterm
stress
mammal
purpos
studi
analyz
hcc
whole
hair
hair
segment
investig
potenti
effect
bodi
locat
surgic
procedur
castrat
hcc
hors
mane
tail
hair
healthi
broodmar
n
collect
segment
analyz
addit
yearl
male
n
femal
hors
n
use
separ
mane
tail
hair
sampl
collect
begin
studi
castrat
month
male
femal
yearl
cortisol
extract
methanol
ground
hair
quantifi
use
elisa
hcc
mane
sampl
broodmar
greater
tail
sampl
studi
group
segment
away
hair
root
contain
lower
hcc
decreas
hair
cortisol
concentr
postcastr
significantli
lower
castrat
male
intact
femal
cortisol
accumul
month
castrat
could
explain
significantli
smaller
decreas
hcc
concentr
male
femal
time
period
result
suggest
hcc
analysi
hors
use
address
basal
elev
hpa
activ
hors
nevertheless
factor
segment
locat
collect
site
may
also
effect
measur
hcc
group
demonstr
equin
metabol
syndrom
em
phenotyp
variabl
explain
share
environ
howev
environment
variabl
explain
diet
exercis
season
suggest
environment
factor
play
role
em
endocrin
disrupt
chemic
edc
associ
metabol
syndrom
endocrin
abnorm
human
preliminari
data
demonstr
hors
farm
mile
edc
dispos
site
sf
like
lamin
higher
post
oralsugarchalleng
insulin
concentr
insost
data
suggest
edc
exposur
em
risk
factor
previous
report
measur
concentr
edc
capabl
activ
aryl
hydrocarbon
receptor
via
bioassay
ahredc
correl
edc
metabol
measur
hors
farm
extend
find
present
correl
edc
capabl
activ
estrogen
receptor
eredc
signific
p
mean
rang
eredc
concentr
pgml
plasma
edc
detect
limit
approxim
half
hors
aicc
statist
use
determin
best
linear
multivari
regress
model
edc
associ
em
phenotyp
variabl
eredc
associ
glucos
oral
sugar
test
ost
glucos
insulin
insulinost
overal
result
suggest
unexplain
environment
varianc
individu
em
due
edc
exposur
mediat
part
estrogen
arylhydrocarbon
receptor
pituitari
par
intermedia
dysfunct
ppid
describ
one
common
diseas
hors
poni
year
age
older
recent
clinic
sign
ppid
divid
earli
advanc
clinic
sign
establish
diagnosi
ppid
hors
earli
clinic
sign
current
difficult
challeng
face
equin
veterinarian
particularli
difficult
may
diagnosi
hors
ppid
equin
athlet
mani
clinic
sign
identifi
earli
advanc
ppid
may
recogn
sport
hors
along
tendon
suspensori
ligament
degener
suspensori
ligament
injuri
consid
common
caus
lame
equin
athlet
involv
competit
event
recent
histopatholog
studi
conclud
associ
exist
ppid
suspensori
ligament
sl
degener
object
studi
identifi
common
clinic
sign
associ
ppid
sport
hors
sport
hors
year
age
breed
sex
elig
studi
enrol
long
document
exhibit
one
earli
advanc
clinic
sign
ppid
includ
suspensori
ligament
desmiti
fortynin
hors
evalu
includ
final
data
analysi
least
one
clinic
sign
earli
advanc
ppid
demograph
data
signal
physic
examin
conduct
hors
test
ppid
use
trh
stimul
test
measur
acth
min
insulin
glucos
level
also
determin
normal
hors
exclud
studi
blood
sampl
ship
overnight
anim
health
diagnost
center
cornel
univers
ithaca
ny
analysi
associ
ppid
statu
base
acth
insulin
result
demograph
variabl
age
sex
breed
clinic
sign
two
test
result
variabl
insulin
glucos
statist
evalu
individu
use
pearson
chisquar
test
odd
ratio
signific
predictor
ppid
statu
comput
use
correspond
confid
interv
appli
multipl
logist
regress
analysi
hors
ppid
ir
ppid
hors
ppid
time
point
wherea
ppid
six
ppid
hors
hyperinsulinem
hors
age
rang
year
age
arithmet
mean
year
ppid
group
common
clinic
sign
observ
ppid
hors
delay
region
shed
loss
epaxi
muscl
mass
region
adipos
skelet
muscl
atrophi
suspensori
desmiti
ppid
significantli
p
associ
lame
suspensori
desmiti
tendon
laxiti
superfici
digit
flexor
tendon
hors
lame
ppid
base
result
studi
trh
stimul
procedur
requir
enrol
hors
laboratori
confirm
ppid
sport
hors
suspensori
desmiti
significantli
associ
ppid
statu
veterinarian
includ
ppid
list
differenti
diagnos
examin
sport
hors
suspensori
desmiti
along
earli
advanc
clinic
sign
ppid
assess
measur
prolactin
prl
concentr
screen
test
ppid
serum
prl
concentr
compar
hors
enrol
hors
fail
inclus
criteria
clinic
efficaci
studi
pergolid
enrol
requir
hors
hypertrichosi
score
either
elev
plasma
acth
concentr
pgml
abnorm
overnight
dexamethason
suppress
test
result
prl
measur
month
treatment
pergolid
hors
enrol
studi
prl
concentr
compar
rank
sum
analysi
anova
rank
repeat
measur
roc
curv
construct
assess
sensit
specif
prl
variou
cutoff
valu
screen
test
ppid
prl
greater
p
enrol
ae
ngml
mean
ae
sd
compar
exclud
ae
ngml
hors
area
roc
curv
ci
use
cutoff
valu
ngml
sensit
specif
respect
curious
prl
tend
decreas
month
pergolid
treatment
ae
ngml
signific
differ
higher
p
prl
day
pergolid
treatment
ae
ngml
compar
day
treatment
valu
cohort
hors
measur
prl
appear
use
screen
tool
ppid
treatment
ppidaffect
hors
pergolid
decreas
prl
pituitari
par
intermedia
dysfunct
ppid
consid
common
endocrinolog
disord
age
hors
diagnosi
ppid
typic
base
histori
clinic
sign
demonstr
endocrinolog
dysfunct
via
diagnost
assay
result
common
diagnost
test
util
veterinari
practition
diagnosi
ppid
current
measur
basal
plasma
adrenocorticotrop
hormon
acth
concentr
determin
rest
plasma
acth
concentr
practic
diagnost
test
ppid
like
due
eas
collect
avail
season
refer
rang
allow
test
time
year
multipl
recommend
exist
concern
vitro
stabil
acth
recommend
state
sampl
chill
promptli
collect
multipl
recommend
exist
time
centrifug
chill
sampl
sampl
collect
us
discord
exist
laboratori
recommend
concern
centrifug
time
sampl
collect
anywher
hour
hour
sampl
collect
realist
mani
equin
ambulatori
practition
abil
centrifug
sampl
within
hour
base
dilemma
purpos
studi
determin
stabil
acth
level
blood
sampl
increas
durat
collect
prior
centrifug
ten
hors
ppid
ppid
nonppid
hors
enrol
studi
autumn
timeperiod
day
ml
whole
blood
collect
hors
six
edta
tube
immedi
chill
one
tube
centrifug
within
minut
collect
time
follow
centrifug
one
tube
hors
hour
follow
collect
timepoint
plasma
centrifug
separ
ml
polypropylen
tube
store
plasma
ship
frozen
cold
pack
overnight
anim
health
diagnost
center
cornel
univers
ithaca
ny
analysi
percent
chang
baselin
pcfb
report
standard
data
due
differ
baselin
valu
mean
pcfb
standard
deviat
confid
interv
ci
report
null
hypothesi
time
effect
test
mix
model
repeat
measur
methodolog
subject
random
effect
pvalu
consid
statist
signific
absolut
chang
time
reveal
pattern
chang
time
mean
pfcb
ae
ci
signific
evid
pvalu
time
effect
use
repeat
measur
model
evid
signific
time
effect
level
acth
ppid
ppid
nonppid
hors
appear
systemat
degrad
acth
level
due
delay
measur
hour
post
collect
result
studi
support
recommend
immedi
chill
edta
blood
sampl
properli
store
may
centrifug
plasma
separ
within
hour
collect
shipment
respect
laboratori
analysi
without
degrad
acth
level
research
need
determin
acth
stabil
larger
number
hors
ppid
ppid
separ
site
differ
geograph
region
purpos
studi
investig
effect
system
corticosteroid
administr
circul
acth
cortisol
concentr
healthi
hors
hors
pituitari
par
intermedia
dysfunct
ppid
hypothesi
studi
administr
synthet
corticosteroid
would
decreas
circul
acth
cortisol
concentr
healthi
hors
signific
chang
would
detect
hors
ppid
seventeen
hors
meet
studi
inclus
criteria
test
ppid
use
endogen
acth
plasma
concentr
thyrotropin
releas
hormon
trh
stimul
test
studi
includ
six
healthi
hors
group
plasma
acth
concentr
pgml
post
trh
administr
hors
ppid
group
plasma
acth
concentr
season
refer
rang
pgml
post
trh
administr
subject
stabl
box
stall
free
choic
access
grass
hay
water
durat
studi
studi
conduct
accord
univers
missouri
anim
care
use
committe
februari
juli
acclim
period
blood
sampl
collect
measur
baselin
acth
cortisol
concentr
hors
dexamethason
mgkg
subsequ
administ
iv
next
hour
acth
cortisol
measur
everi
hour
repeat
measur
anova
analysi
follow
post
hoc
test
determin
signific
effect
dexamethason
treatment
acth
cortisol
concentr
time
group
hors
compar
differ
group
signific
chang
circul
acth
p
cortisol
concentr
p
detect
numer
time
point
dexamethason
treatment
group
hors
howev
signific
differ
group
evid
conclus
dexamethason
administr
appear
suppress
plasma
acth
concentr
hour
serum
cortisol
concentr
least
hour
healthi
hors
hors
affect
ppid
studi
larger
sampl
size
may
better
distinguish
differ
respons
endocrin
axi
dexamethason
treatment
healthi
hors
compar
hors
ppid
inflamm
key
develop
postop
ileu
poi
rodent
similar
pathogenesi
like
occur
speci
well
establish
dexamethason
reduc
inflamm
therefor
may
reduc
poi
hors
retrospect
studi
perform
determin
dexamethason
reduc
poi
hors
small
intestin
si
diseas
assess
effect
incision
health
shortterm
surviv
data
hors
underw
si
colic
surgeri
receiv
mgkg
dexamethason
intraven
surgeri
dex
extract
clinic
record
hors
thirtytwo
hors
underw
si
resect
data
hors
increas
preval
macrolideresist
rhodococcu
equi
lack
altern
antimicrobi
necessit
identifi
novel
therapi
stimul
host
innat
immun
respons
enhanc
clearanc
infecti
agent
object
studi
determin
whether
agonist
tolllik
receptor
tlr
viz
could
increas
kill
capac
adult
equin
monocytederiv
macrophag
mdm
macrolideresist
macrolidesuscept
r
equi
determin
whether
synergist
effect
clarithromycin
kill
capac
mdm
r
equi
null
hypothes
would
increas
kill
capac
mdm
either
strain
r
equi
would
synergist
effect
kill
capac
mdm
combin
clarithromycin
achiev
object
mdm
harvest
appar
healthi
universityown
adult
hors
mdm
hors
separ
infect
macrolideresist
macrolidesuscept
strain
r
equi
phagocytosi
bacteria
determin
count
coloni
form
unit
cfu
lyse
mdm
baselin
minut
postinfect
cfu
also
determin
hour
postinfect
treatment
treatment
neg
control
alon
pul
clarithromycin
alon
clr
combin
clarithromycin
pulc
percentag
cfu
reduct
determin
calcul
ratio
cfu
treatment
multipli
result
show
phagocytosi
vari
significantli
p
among
hors
addit
signific
differ
phagocytosi
ie
cfu
strain
p
macrolidesuscept
macrolideresist
r
equi
treatment
clr
pulc
mark
signific
p
reduct
cfu
rel
either
neg
control
treatment
pul
strain
differ
control
pul
clr
pulc
although
macrolideresist
strain
tend
less
effect
reduc
differ
signific
p
conclus
alon
effect
kill
either
macrolideresist
macrolidesuscept
strain
r
equi
equin
mdm
addit
detect
synergist
effect
combin
clarithromycin
similar
experi
use
adult
alveolar
macrophag
progress
determin
special
macrophag
affect
result
report
possibl
might
exert
indirect
effect
macrophag
stimul
respiratori
epitheli
cell
current
surgic
techniqu
cervic
stabil
technic
challeng
result
signific
complic
also
reli
sole
compress
provid
stabil
tension
result
micromot
potenti
catastroph
failur
implant
migrat
evalu
novel
techniqu
cervic
vertebr
interbodi
fusion
hors
cervic
vertebr
compress
myelopathi
cvcm
six
hors
diagnos
cvcm
preoper
ataxia
grade
rang
modifi
mayhew
scale
underw
novel
approach
two
hors
compress
site
compress
site
tabl
surgic
procedur
consist
creation
intervertebr
discspac
defect
placement
intervertebr
fusion
devic
ifd
titanium
polyaxi
pedicl
screw
connect
rod
secur
setscrew
figur
hors
reevalu
day
month
postop
procedur
approv
colorado
state
univers
institut
anim
care
use
committe
surgeri
perform
safe
postop
radiograph
show
good
placement
ifd
screw
rod
hors
implant
failur
ifd
displac
occur
postop
hors
improv
within
month
postop
ataxia
reduc
grade
use
novel
fusion
system
requir
less
disc
space
remov
provid
stabil
compress
tension
technic
straightforward
perform
surgeri
perform
success
improv
clinic
sign
hors
techniqu
promis
altern
current
surgic
procedur
treatment
cvcm
neuronavigationguid
intracrani
surgeri
increasingli
common
veterinari
medicin
although
use
yet
describ
equin
speci
object
studi
determin
accuraci
neuronavigationguid
intracrani
procedur
hors
use
standard
fiduci
array
compar
anatom
landmark
patient
registr
six
equin
cadav
head
use
studi
ct
imag
specimen
acquir
fiduci
array
rigidli
secur
frontal
bone
six
target
select
specimen
patient
registr
perform
separ
target
use
fiduci
array
target
use
anatom
landmark
lieu
biopsi
wire
seed
place
target
site
postop
imag
coregist
plan
scan
calcul
offset
tip
seed
target
statist
differ
accuraci
registr
techniqu
identifi
impact
surgeon
experi
examin
separ
techniqu
use
twosampl
ttest
experienc
surgeon
significantli
accur
mm
sd
novic
surgeon
mm
sd
use
fiduci
array
p
although
statist
signific
p
experienc
surgeon
mean
distanc
target
smaller
regist
fiduci
array
mm
natur
landmark
mm
conclus
surgeon
experi
impact
degre
accuraci
data
also
suggest
registr
use
anatom
landmark
feasibl
perhap
reserv
case
separ
plan
scan
fiduci
perform
caus
fatal
fei
threeday
event
comyn
bath
foot
c
marr
rossdal
llp
exn
uk
rossdal
llp
newmarket
uk
rossdal
llpequin
veterinari
journalunivers
glasgow
horserac
bet
levi
board
exn
uk
data
equin
death
threeday
event
lack
aim
report
preval
sudden
death
fatal
musculoskelet
injuri
describ
caus
sudden
death
number
start
fatal
deatheuthanasia
fatal
musculoskelet
injuri
obtain
intern
feder
equestrian
sport
fei
postmortem
report
review
sudden
death
classifi
use
categori
defin
thoroughbr
race
start
fatal
thu
preval
start
start
musculoskelet
injuri
start
sudden
death
case
detail
provid
consider
variat
avail
inform
postmortem
examin
definit
caus
death
identifi
sudden
death
case
central
nervou
system
trauma
blood
vessel
ruptur
presumpt
diagnos
propos
case
cardiopulmonari
failur
caus
sudden
death
unidentifi
distribut
musculoskelet
injuri
versu
sudden
death
similar
fatal
race
distribut
amongst
categori
also
similar
thoroughbr
race
fatal
definit
diagnos
reach
less
frequent
standardis
system
report
fatal
would
valuabl
lyle
c
h
et
al
sudden
death
race
thoroughbr
hors
intern
multicentr
studi
post
mortem
find
equin
veterinari
journal
endotheli
coloni
form
cell
ecfc
progenitor
cell
function
neovascular
may
use
therapeut
condit
poor
blood
suppli
distal
limb
wound
hors
inject
ecfchydrogel
scaffold
may
ensur
cell
surviv
local
improv
neovascular
heal
autolog
ecfc
isol
adult
hors
label
quantum
nanodot
qd
subset
cell
encapsul
poli
ethylen
glycol
fibrinogen
microspher
ms
fullthick
dermal
wound
creat
duplic
distal
limb
randomli
assign
inject
empti
ms
serum
ecfc
ecfc
encapsul
ms
ecfcm
wound
either
biopsi
weekli
week
analysi
includ
wound
surfac
area
wsa
granul
tissu
score
gs
thermographi
immunohistochem
stain
von
willebrand
factor
vwf
treatment
well
toler
hors
qd
label
cell
identifi
wound
biopsi
week
postinject
signific
effect
treatment
gs
wsa
influenc
treatment
p
ecfc
alon
smallest
wsa
week
gs
greater
wound
biopsi
p
hindlimb
p
thermograph
analysi
reveal
ecfcm
group
greatest
decreas
limb
temperatur
time
p
vwf
immunostain
densiti
lowest
ecfcm
group
treatment
effect
wound
temperatur
vessel
densiti
wound
size
may
indic
ecfc
affect
wound
heal
equin
distal
limb
despit
variabl
within
model
ecfc
treat
wound
asignificantlypositiveeffectonwoundh
septicemia
remain
common
clinic
entiti
neonat
foal
vari
degre
ill
associ
process
includ
cardiovascular
shock
instanc
clinic
paramet
heart
rate
blood
pressur
urin
output
may
unreli
late
indic
inadequ
tissu
perfus
poor
global
oxygen
statu
thu
provid
limit
guidanc
time
therapi
convers
invas
monitor
measur
cardiac
output
co
mix
venou
oxygen
satur
hemoglobin
advoc
studi
better
direct
therapi
ie
earli
goaldirect
therapi
improv
outcom
peopl
critic
ill
septic
shock
investig
evalu
global
oxygen
foal
despit
frequenc
equin
neonat
sepsi
consequ
equin
clinician
primarili
reli
physic
exam
paramet
blood
lactat
guid
therapi
placement
pulmonari
arteri
cathet
neonat
foal
measur
mix
venou
blood
v
clinic
impract
object
studi
evalu
paramet
associ
global
oxygen
central
venou
blood
healthi
neonat
foal
specif
studi
follow
paramet
measur
healthi
neonat
foal
central
venou
cv
arteri
blood
satur
hemoglobin
oxygen
cv
partial
pressur
oxygen
p
cv
p
partial
pressur
co
p
cv
co
p
co
ph
ph
cv
ph
llactat
lac
cv
lac
addit
follow
paramet
reflect
global
oxygen
calcul
venoustoarteri
co
gap
dco
oxygen
extract
ratio
er
ratio
p
fraction
inspir
oxygen
p
f
ratio
central
venou
arteri
bicarbon
hco
hco
base
excess
cv
hemoglobin
hb
cv
hb
oxygen
content
ct
cv
ct
complic
observ
cathet
placement
data
collect
studi
summari
studi
report
central
venou
arteri
blood
paramet
associ
global
oxygen
healthi
foal
establish
baselin
valu
differ
time
point
within
neonat
period
paramet
mani
util
human
critic
care
might
allow
better
hemodynam
monitor
critic
ill
foal
forthcom
object
compar
similar
global
oxygen
paramet
critic
ill
foal
hope
improv
patient
monitor
therapi
prognost
equin
neonat
sepsi
septic
shock
dipyron
welldescrib
antipyret
effect
studi
evalu
effect
dipyron
administ
intraven
control
fever
hors
compar
placebo
thirtyon
hors
fever
rectal
temperatur
natur
occur
diseas
random
two
group
fifteen
hors
treat
singl
dose
mgkg
dipyron
intraven
iv
sixteen
hors
treat
singl
dose
salin
placebo
iv
medic
procedur
may
affect
rectal
temperatur
prohibit
rectal
temperatur
assess
six
hour
follow
treatment
twentyfour
hour
follow
dose
administr
febril
hors
cross
treatment
group
procedur
treatment
respons
defin
temperatur
decreas
either
baselin
return
normothermia
six
hour
administr
dipyron
salin
statist
comparison
treatment
perform
use
fisher
exact
test
twosid
thirtyon
hors
complet
first
phase
hors
complet
second
phase
result
present
tabl
major
advers
event
due
infect
underli
diseas
three
hors
dipyron
group
episod
soft
manur
two
preexist
prior
treatment
one
hors
dipyron
group
sever
seriou
advers
event
relat
sever
pleuropneumonia
remov
studi
follow
first
phase
receiv
treatment
singl
administr
dipyron
iv
effect
control
fever
hour
post
administr
superior
placebo
dipyron
avail
inject
formul
europ
howev
oral
formul
develop
use
hors
commonli
accept
dose
dipyron
mgkg
administ
intraven
studi
evalu
clinic
safeti
high
dose
oral
formul
dipyron
hors
seven
hors
random
two
treatment
group
hors
dipyron
treatment
hors
salin
treatment
placebo
dipyron
group
treat
mgkg
dipyron
per
os
po
twice
daili
day
placebo
hors
receiv
salin
schedul
gastroscopi
perform
blood
sampl
hematolog
serum
chemistri
collect
baselin
day
day
hors
toler
high
dose
oral
dipyron
administr
well
two
dipyronetr
hors
one
placebo
hors
show
oral
mucos
trauma
relat
syring
dose
one
placebo
hors
mild
episod
colic
studi
day
gastroscopi
result
summar
tabl
one
dipyronetr
hors
clinic
signific
increas
creatin
kinas
ck
aspart
aminotransferas
ast
begin
day
remain
unchang
throughout
studi
one
dipyronetr
hors
clinic
signific
increas
ck
studi
termin
initi
assess
high
dose
dipyron
well
toler
hors
administ
twice
daili
day
neutrophil
particip
innat
immun
first
line
host
defens
microorgan
howev
exacerb
neutrophil
activ
harm
surround
tissu
import
rang
diseas
includ
allerg
asthma
chronic
obstruct
pulmonari
diseas
human
equin
asthma
tamoxifen
tx
nonsteroid
estrogen
receptor
modul
effect
cell
growth
surviv
tx
shown
induc
earli
apoptosi
peripher
blood
bronchoalveolar
lavag
bal
neutrophil
hors
acut
lung
inflamm
perez
et
al
studi
group
previous
show
neutrophil
respiratori
burst
chemotaxi
also
decreas
treatment
tx
confirm
direct
action
drug
cell
type
borlon
et
al
studi
pharmacolog
effect
tx
equin
neutrophil
obtain
jugular
venipunctur
healthi
hors
purifi
ficol
gradient
centrifug
respiratori
burst
evalu
chemoluminesc
induc
opson
zymosan
neutrophil
luminolemit
luminesc
measur
hour
use
luminomet
differ
concentr
tx
combin
select
estrogen
receptor
modul
serm
evalu
tx
lm
ici
high
affin
estrogen
receptor
antagonist
nm
select
gprotein
estrogen
receptor
antagonist
nm
bestradiol
nm
select
gprotein
estrogen
receptor
agonist
nm
ici
nm
tx
lm
nm
tx
lm
bestradiol
nm
tx
lm
nm
tx
lm
phosphatidylserin
express
quantifi
flow
cytometri
use
commerci
annexin
vfitc
kit
bd
bioscienc
cell
incub
humid
chamber
co
minut
dmso
vehicl
tx
lm
bestradiol
nm
ici
nm
nm
nm
result
show
tx
inhibit
neutrophil
respiratori
burst
induc
opson
zymosan
dose
depend
manner
nuclear
cell
membran
estrogen
receptor
agonist
antagonist
ici
respect
block
reproduc
tx
effect
thu
tx
inhibit
respiratori
burst
estrogen
receptor
tx
lm
also
produc
increas
phosphatidylserin
transloc
observ
serm
use
show
direct
proapoptot
effect
neutrophil
conclus
tx
inhibitori
proapoptot
effect
neutrophil
seem
independ
estrogen
receptor
hypothes
magnesium
sulfat
bronchodil
effect
sever
asthmat
hors
potenti
effect
inhal
salbutamol
six
sever
asthmat
hors
studi
use
crossov
experi
washout
period
treatment
clinic
score
lung
function
measur
impuls
oscillometri
io
record
administr
salbutamol
lg
mock
procedur
experi
ia
document
revers
paramet
also
record
mgso
infus
mgkgmin
iv
min
equival
volum
salin
adjust
osmolar
experi
ib
mgso
infus
salbutamol
compar
salbutamol
alon
experi
ii
salbutamol
significantli
improv
lung
function
studi
ia
ii
mgso
significantli
improv
clinic
score
administ
alon
salbutamol
p
trend
lung
function
improv
observ
administ
combin
salbutamol
p
mgso
also
increas
tidal
volum
experi
ii
salin
administr
mock
procedur
effect
lung
function
clinic
score
mgso
alon
combin
salbutamol
mild
posit
effect
clinic
score
sever
asthmat
hors
effect
clinic
score
io
paramet
could
due
undetect
bronchodilatori
effect
chang
breath
strategi
neonat
diarrhea
major
sourc
econom
loss
cattl
industri
lead
caus
calf
mortal
countri
major
goal
treatment
correct
dehydr
increas
blood
ph
restor
electrolyt
concentr
provid
nutrit
support
quit
possibl
use
oral
electrolyt
calv
moder
dehydr
acidosi
equal
perhap
even
greater
benefit
give
larg
volum
fluid
either
intraven
subcutan
object
studi
compar
abil
commerci
avail
oral
electrolyt
solut
oe
alon
combin
hyperton
salin
comparison
administr
intraven
subcutan
fluid
therapi
resuscit
calv
osmot
diarrhea
thirtytwo
holstein
bull
calv
day
age
use
studi
calv
acclim
hous
normal
diet
two
day
osmot
diarrhea
dehydr
induc
ad
sucros
milk
replac
addit
spironolacton
hydrochlorothiazid
given
oral
furosemid
intramuscularli
three
time
per
day
clinic
hydrat
score
depress
statu
fecal
consist
bodi
weight
record
feed
period
treatment
start
calf
hydrat
score
depress
score
fecal
score
calv
randomli
divid
four
treatment
group
calv
oe
alon
mix
accord
label
direct
oe
hyperton
salin
mlkg
iv
intraven
fluid
lr
liter
subcutan
fluid
lr
liter
treatment
administ
hour
chang
plasma
volum
acidbas
statu
electrolyt
concentr
physic
examin
paramet
record
fluid
therapi
hour
treatment
decreas
hematocrit
total
protein
albumin
concentr
well
increas
blood
ph
time
observ
group
oral
electrolyt
group
show
greater
increas
blood
ph
time
calv
show
improv
hydrat
score
plasma
volum
attitud
score
fecal
score
period
studi
fecal
score
appear
affect
treatment
conclus
oral
electrolyt
without
hyperton
salin
appear
excel
altern
resuscit
calv
moder
diarrhea
acidosi
often
perform
better
small
volum
iv
sc
fluid
bulk
tank
milk
btm
sampl
use
determin
infect
statu
estim
dairi
herd
preval
bovin
leukemia
viru
blv
use
antibodi
elisa
assay
blv
elisa
variabl
sampl
herd
differ
herd
investig
object
determin
withinherd
betweenherd
variabl
btm
blv
elisa
assay
sampl
interv
canadian
maritim
region
dairi
herd
n
contribut
bulk
tank
milk
sampl
particip
blv
antibodi
level
measur
three
btm
sampl
collect
interv
earli
well
two
btm
sampl
collect
interv
earli
randomeffect
model
use
estim
variabl
btm
sampl
herd
herd
sampl
interv
major
variabl
btm
sampl
seen
herd
unexplain
varianc
sampl
herd
squareroot
scale
greatest
ae
follow
ae
ae
interv
variabl
btm
sampl
antibodi
level
within
herd
present
much
smaller
variabl
herd
greatest
sampl
interv
sampl
interv
result
least
variabl
appropri
use
determin
baselin
level
withinherd
preval
blv
control
program
determin
effect
control
program
repeat
regular
interv
object
studi
describ
persist
speciesspecif
coagulas
neg
staphylococc
cn
intramammari
infect
imi
goat
larg
dairi
goat
herd
missouri
udderhalf
level
milk
sampl
asept
collect
bacteri
cultur
somat
cell
count
scc
milk
compon
fat
protein
determin
lactat
goat
n
commerci
goat
dairi
aerob
bacteri
cultur
perform
columbia
blood
agar
h
goat
least
one
udderhalf
yield
singl
coloni
morpholog
cn
enrol
two
addit
monthli
udderhalf
level
milk
sampl
staphylococc
isol
identifi
specieslevel
use
matrix
assist
laser
desorptionion
time
flight
malditof
mass
spectrometri
pcr
amplif
sequenc
tuf
gene
malditof
yield
indetermin
result
intramammari
infect
statu
defin
base
presenc
speci
cn
sampl
udder
half
differ
preval
chronic
imi
cnscnscn
versu
imi
first
sampl
assess
within
speci
use
chisquar
test
fisher
exact
test
applic
tabl
signific
declar
p
speci
imi
within
speci
data
combin
singl
categori
cn
analysi
bacteri
cultur
milk
sampl
initi
sampl
yield
udderhalv
cn
imi
goat
udderhalf
imi
lost
followup
st
sampl
addit
halv
exclud
due
unsuccess
identif
least
one
cn
isol
sampl
remain
imi
classifi
base
number
sampl
posit
cn
speci
tabl
commonli
identifi
speci
simulan
xylosu
capra
chromogen
epidermidi
major
imi
persist
sampl
period
hand
arletta
lentu
imi
persist
first
sampl
unlik
previou
studi
staphylococcu
simulan
found
associ
chronic
imi
goat
present
studi
herd
result
suggest
similar
cow
cn
speci
might
better
hostadapt
wherea
cn
speci
might
environment
nich
obstruct
urolithiasi
econom
signific
urolog
disord
male
goat
depend
urolith
type
present
medic
surgic
treatment
option
may
util
medic
therapi
alon
high
rate
recurr
surgic
option
costli
typic
requir
gener
anesthesia
alreadi
compromis
patient
low
cost
urin
divers
option
describ
howev
mani
associ
signific
complic
initi
descript
minim
invas
tube
cystostomi
techniqu
show
promis
manag
urolithiasi
small
rumin
follow
report
detail
implement
adapt
techniqu
patient
unit
state
mix
popul
boer
boercross
pygmi
buck
wether
n
present
oklahoma
state
univers
obstruct
urolithiasi
juli
octob
underw
minim
invas
tube
cystostomi
mitc
procedur
rang
age
month
year
mean
month
weight
kg
kg
mean
kg
briefli
mitc
procedur
perform
local
anesthesia
sedat
small
keyhol
incis
perform
upper
left
paralumbar
fossa
dorsal
aspect
bladder
punctur
trocar
silicon
jacksonpratt
drain
n
pigtail
latex
gastrostomi
tube
n
advanc
bladder
bodi
wall
close
standard
fashion
tube
secur
chines
finger
trap
ligatur
exit
bodi
wall
oneway
valv
place
end
tube
medic
therapi
includ
urin
acidif
antibiot
nonsteroid
antiinflammatori
drug
institut
cystostomi
tube
placement
depend
overal
health
statu
patient
budget
owner
avail
continu
care
monitor
patient
either
hospit
sent
home
follow
tube
placement
follow
mitc
resolut
urolithiasi
achiev
case
review
cystostomi
tube
place
averag
day
rang
day
complic
associ
presenc
calcium
carbon
urolith
n
displac
tube
bladder
accompani
uroabdomen
n
hemoabdomen
n
identifi
urolith
type
util
suitabl
tube
trocar
may
mitig
potenti
complic
base
case
mitc
show
promis
low
cost
yet
effect
method
manag
obstruct
urolithiasi
due
phosphat
urolith
male
goat
fructosamin
wide
use
long
term
hyperglycem
biomark
human
dog
clinic
use
fructosamin
hypoglycem
biomark
uncertain
primari
object
evalu
clinic
util
fructosamin
quantifi
magnitud
hypoglycemia
neg
energi
balanc
neb
earli
lactat
dairi
cattl
plasma
sampl
collect
weekli
holsteinfriesian
cattl
conclud
plasma
fra
suffici
sensit
specif
provid
clinic
use
method
quantifi
magnitud
hypoglycemia
neb
earli
lactat
low
cost
ionselect
electrod
ise
handheld
meter
laquatwin
horiba
us
recent
becom
avail
measur
sodium
concentr
na
biolog
fluid
object
studi
therefor
character
analyt
perform
ise
meter
measur
na
bovin
plasma
urin
milk
abomas
fluid
four
method
comparison
studi
complet
use
plasma
milk
urin
sampl
lactat
holsteinfriesian
cow
experimentallyinduc
free
water
electrolyt
acidbas
imbal
abomas
fluid
sampl
healthi
male
holsteinfriesian
calv
fed
fresh
milk
without
oral
electrolyt
solut
deme
regress
blandaltman
plot
use
character
meter
perform
refer
method
indirect
ise
hitachi
laquatwin
ise
meter
appli
directli
plasma
measur
na
meql
lower
indirect
ise
refer
method
consist
recommend
adjust
indirect
ise
method
use
analyz
plasma
laquatwin
ise
meter
run
indirect
mode
accur
measur
urin
na
laquatwin
ise
meter
run
direct
mode
measur
milk
na
meql
lower
indirect
tabl
associ
preval
given
coagulas
neg
staphylococcu
spp
cn
persist
imi
udderhalv
n
singl
imi
n
chronic
imi
parenthet
data
repres
within
column
percentag
imi
ise
refer
method
laquatwin
ise
meter
run
direct
mode
measur
abomas
fluid
na
meql
lower
indirect
ise
refer
method
conclud
laquatwin
ise
meter
provid
practic
low
cost
rapid
accur
pointofcar
instrument
farm
measur
na
plasma
milk
urin
abomas
fluid
sampl
cattl
sever
studi
examin
rate
backfat
mobil
periparturi
dairi
cattl
rate
intramuscular
fat
imf
mobil
rel
backfat
mobil
muscl
tissu
mobil
appear
studi
object
therefor
character
chang
imf
rel
chang
muscl
thick
backfat
thick
bft
physiolog
respons
neg
energi
balanc
periparturi
dairi
cattl
one
hundr
six
periparturi
holsteinfriesian
cattl
primipar
multipar
day
rel
parturit
examin
mhz
linear
ultrasound
probe
use
measur
bft
maximum
thick
imf
percentag
determin
use
thresholdingsegment
method
longissimu
dorsi
muscl
thorac
region
ldthorac
spearman
correl
coeffici
r
mix
model
analysi
use
statist
analysi
p
declar
signific
mean
decreas
bft
day
period
similar
primipar
multipar
cow
mean
decreas
imf
ldthorac
muscl
similar
primipar
multipar
cow
likewis
mean
decreas
ldthorac
muscl
thick
similar
primipar
multipar
cow
decreas
imf
associ
bft
decreas
r
associ
decreas
ldthorac
muscl
thick
r
p
conclud
ultrasonograph
measur
ldthorac
muscl
thick
imf
complement
ultrasonograph
measur
bft
quantifi
neg
energi
balanc
periparturi
dairi
cattl
hyperkalemia
frequent
observ
electrolyt
imbal
dehydr
acidem
calv
neonat
diarrhea
result
skelet
muscl
weak
lifethreaten
cardiac
conduct
abnorm
studi
aim
compar
plasma
potassiumlow
effect
hyperton
sodium
bicarbon
sodium
chlorid
glucos
infus
solut
initi
treatment
hyperkalem
calv
total
diarrheic
calv
age
day
plasma
potassium
concentr
ck
mmol
l
includ
studi
calv
randomli
receiv
one
follow
intraven
infus
period
minut
nahco
mlkg
bw
n
nacl
mlkg
bw
n
glucos
mlkg
bw
n
subsequ
allow
suckl
liter
electrolyt
solut
infus
nahco
nacl
provid
ident
sodium
load
mmolkg
bw
infus
hyperton
glucos
result
mark
hyperglycemia
hyperinsulinemia
ck
remain
unchang
first
minut
initi
treatment
min
start
treatment
mark
decrement
ck
observ
hyperton
nahco
valu
differ
significantli
p
hyperton
nacl
hyperton
glucos
min
observ
decrement
equival
ae
ae
ae
baselin
ck
group
nahco
nacl
glucos
respect
result
indic
treatment
advantag
hyperton
nahco
infus
use
hyperton
nacl
glucos
hyperkalem
diarrheic
calv
alkalin
provid
effect
potassiumlow
mechan
calfhood
diseas
major
econom
impact
beef
dairi
oper
due
cost
associ
mortal
treatment
long
term
effect
growth
perform
approv
drug
use
veal
calv
young
heifer
question
remain
distribut
effect
drug
young
anim
object
studi
compar
distribut
activ
drug
concentr
plasma
vs
differ
effector
compart
includ
interstiti
fluid
isf
pulmonari
epitheli
line
fluid
pelf
healthi
calv
calv
age
group
given
singl
subcutan
sc
dose
either
danofloxacin
mgkg
tulathromycin
mgkg
plasma
isf
bronchoalveolar
lavag
bal
fluid
collect
analyz
drug
concentr
plasma
protein
bind
measur
use
microcentrifug
system
individu
anim
day
week
month
age
old
calv
maintain
higher
isfplasma
concentr
ratio
throughout
studi
period
compar
observ
old
calv
danofloxacin
tulathromycin
nonlinear
mix
effect
model
reveal
age
signific
covari
plasma
concentr
differ
seen
calv
administ
tulathromycin
danofloxacin
treat
calv
plasma
protein
bind
assess
invitro
individu
dairi
calv
n
drug
includ
danofloxacin
tulathromycin
signific
differ
seen
calv
age
day
age
trend
toward
chang
old
calv
indic
need
assess
protein
bind
chang
futur
drug
approv
young
calv
conclus
administr
danofloxacin
tulathromycin
sc
label
dose
old
old
calv
demonstr
differ
distribut
affect
age
research
need
determin
impact
physiolog
differ
diseas
distribut
efficaci
commonli
use
drug
neonat
calv
object
project
describ
ecolog
hostadapt
staphylococcu
spp
teat
inguin
skin
dairi
heifer
crosssect
studi
includ
holstein
heifer
n
univers
missouri
foremost
dairi
conduct
heifer
randomli
select
base
hous
type
age
group
enrol
follow
group
prewean
heifer
n
wean
heifer
age
month
n
young
pastur
rais
heifer
age
month
n
pastur
rais
heifer
age
month
n
breed
age
heifer
month
n
bodi
site
swab
sampl
includ
composit
sampl
four
teat
second
composit
sampl
inguin
region
heifer
collect
swab
sampl
mix
ml
steril
salin
agit
plate
mannitol
salt
agar
incub
h
staphylococc
coloni
includ
least
one
morpholog
distinct
coloni
type
save
analysi
staphylococc
isol
speciat
use
matrixassist
laser
desorpt
ionizationtim
flight
malditof
mass
spectrometri
pcr
amplif
sequenc
rpob
tuf
gene
chi
squar
fisher
exact
test
applic
use
investig
whether
preval
staphylococc
speci
differ
inguin
teat
region
logist
regress
model
use
investig
relationship
heifer
age
continu
variabl
probabl
given
bodi
site
colon
certain
staphylococc
speci
total
staphylococc
isol
bodi
site
heifer
evalu
isol
elimin
data
analysi
due
replic
singl
speci
bodi
site
leav
isol
total
differ
staphylococc
speci
identifi
staphylococcu
aureu
preval
teat
skin
inguin
region
p
staphylococc
speci
equal
distribut
teat
inguin
region
speci
colon
inguin
teat
region
associ
age
heifer
staphylococcu
equorum
staphylococcu
lentu
staphylococcu
sciuri
staphylococcu
vitulinu
like
found
younger
heifer
staphylococcu
chromogen
staphylococcu
devriesei
staphylococcu
haemolyticu
like
found
older
heifer
divers
popul
staphylococc
speci
found
teat
inguin
region
heifer
staphylococc
popul
tend
chang
age
import
hostadapt
speci
frequent
associ
intramammari
infect
eg
chromogen
becom
preval
age
stress
neg
impact
health
product
lactat
dairi
cattl
primari
object
studi
determin
degre
stress
experienc
dairi
cattl
around
calv
whether
primipar
cattl
stress
multipar
cattl
periparturi
period
one
hundr
six
holsteinfriesian
cattl
primipar
multipar
studi
anim
move
indoor
separ
calv
pen
approxim
day
anticip
calv
date
heart
rate
respiratori
rate
mean
arteri
pressur
map
determin
daili
day
prepartum
day
postpartum
map
measur
use
indirect
oscillometri
applic
cuff
coccyg
arteri
pressur
correct
height
differ
scapulohumer
joint
plasma
sampl
collect
concentr
glucos
gluc
cortisol
cortisol
determin
mix
model
anova
use
statist
analysi
p
consid
signific
least
squar
mean
daili
heart
rate
consist
bpm
higher
primipar
bpm
multipar
cattl
bpm
p
least
squar
map
consist
higher
primipar
mmhg
multipar
cattl
mmhg
p
least
squar
mean
daili
respiratori
rate
consist
breathsmin
higher
primipar
breathsmin
multipar
cattl
breathsmin
p
primipar
cattl
higher
plasma
gluc
multipar
cattl
day
rel
parturit
plasma
cortisol
higher
p
primipar
ngml
multipar
ngml
cattl
day
parturit
conclud
primipar
cattl
stress
around
parturit
multipar
cow
human
veterinari
medicin
llactat
wellestablish
biomark
tissu
hypoxia
sepsi
diseas
sever
mortal
also
attract
increas
attent
bovin
medicin
due
avail
valid
cheap
portabl
llactat
analyz
aim
present
retrospect
analysi
therefor
assess
prognost
relev
increas
plasma
llactat
concentr
cllactat
larg
studi
popul
hospit
neonat
calv
purpos
data
neonat
calv
admit
clinic
rumin
lmu
munich
retrospect
analyz
llactat
determin
part
routin
perform
clinic
biochemistri
panel
admiss
overal
surviv
rate
studi
popul
increas
cllactat
mmoll
evid
calv
survivalr
calv
mmoll
decil
mmoll
cllactat
respect
oppos
calv
decil
cllactat
refer
rang
binari
logist
regress
analysi
indic
odd
nonsurviv
increas
factor
ci
everi
mmoll
increas
cllactat
p
area
roc
curv
cllactat
ci
conclus
increas
cllactat
associ
increas
risk
nonsurviv
hospit
neonat
calv
suffici
reliabl
predict
neg
outcom
work
howev
necessari
assess
whether
prognost
relev
depend
underli
disord
